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ABSTRACT 
Cystic fibrosis (CF) is the most common, genetically inherited, life-shortening 
condition in the Caucasian population, with ~11,000 people in the United 
Kingdom having the disease. The genetic defect responsible for CF results in 
accumulation of thick, sticky mucus that blocks the airways and digestive systems. 
As there is currently no cure for CF, it is a disease that is managed using 
antibiotics, nutrition, physiotherapy and exercise. Exercise capacity, as measured 
by peak oxygen uptake (V̇O2peak), and where possible, maximal oxygen uptake 
(V̇O2max), is reduced in patients with CF and a low V̇O2peak is associated with 
increased risk of hospitalisation, mortality and low quality of life. As a result, 
regular exercise testing is recommended, with cardiopulmonary exercise testing 
(CPET) considered the ‘gold standard’ procedure by leading international clinical 
organisations. The purpose of this thesis was to further our understanding 
surrounding the use of CPET in the assessment and treatment of children and 
adolescents with CF.  
The first component of this thesis sought to identify and evaluate submaximal 
parameters of aerobic function derived from CPET, namely the oxygen uptake 
efficiency slope (OUES) and plateau (OUEP). Findings revealed that allometric 
scaling for body surface area (BSA) was necessary when evaluating OUES, and 
a power function of 1.40 (i.e. OUES/BSA1.40) removed residual effects of body 
size (Chapter 4). Subsequently, results identified that the OUES was not a valid 
surrogate of aerobic fitness in CF, despite a significant correlation (r = 0.47, p = 
0.004) with V̇O2max when expressed relative to body mass, as it was unable to 
discriminate aerobic fitness within a CF group, nor against a control group 
(Chapter 5). As OUES was not a valid surrogate of aerobic fitness, the utility of 
OUEP as an independent marker of aerobic fitness was explored. Whilst the 
Page 4 of 403 
 
OUEP was correlated with V̇O2peak in CF, when expressed as an absolute value 
(r = 0.43, p = 0.010) and when allometrically scaled for body mass (r = 0.52, p = 
0.001), it was unable to discriminate aerobic fitness to the same extent as V̇O2peak. 
However, the OUEP was associated with disease status and severity, being 
significantly (p < 0.001) lower in the CF group, but also significantly and positively 
correlated with lung function (forced expiratory volume in one-second [FEV1]) in 
the CF group (r = 0.43, p = 0.010), a finding that warrants further, longitudinal 
investigation (Chapter 6).  
The second component of this thesis utilised CPET to investigate 
musculoskeletal limitations to the reduced V̇O2max that has previously been 
reported in CF. Parameters of muscle size (thigh cross-sectional area, muscle 
cross-sectional area and thigh muscle volume) were first quantified using 
magnetic resonance imaging, alongside the error associated with estimating 
muscle volume using alternative calculation techniques (Chapter 7). These 
parameters were then allometrically scaled for, which successfully removes 
residual effects of muscle size (i.e. muscle ‘quantity’) from V̇O2max. When this 
scaling is undertaken, V̇O2max is lower in children with CF relative to age- and 
sex-matched controls, indicating that exercise capacity is not size-dependent in 
CF and that intrinsic muscular factors (i.e. muscle ‘quality’) are likely responsible 
for the reduced V̇O2max observed in CF (Chapter 8). 
Finally, the third component identified applications of CPET for both patients with 
CF and staff responsible for care. CPET, using a case-study approach, was 
utilised to describe exercise-related changes in an 11 year old female with CF 
following surgical insertion of a percutaneous endoscopic gastrostomy and 
overnight nutritional supplementation. This evaluation identified a maintenance 
of V̇O2max over one year, in contrast to a fluctuation in FEV1, and increase in body 
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mass index (BMI), therefore highlighting the independent prognostic information 
afforded by use of CPET (Chapter 9). Following this patient-centred application 
of CPET, two meetings were held with NHS staff, to provide a platform for 
exchange of ideas and best practice, but to also survey roles, responsibilities, 
prevalence of CPET and resources needed for effective implementation of 
exercise testing and training (Chapter 10).  
In conclusion, this thesis has further highlighted the utility of CPET in the 
management of CF. Moreover, it has explored the prognostic and diagnostic 
properties of CPET, as well as its implementation for patients and staff alike.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page 6 of 403 
 
ACKNOWLEDGMENTS 
Firstly, I would like to thank my supervisor, Professor Craig Williams. Your 
constant guidance, mentoring and support over the past five years have been 
invaluable, and this thesis would not have been possible otherwise. Not only have 
you guided me through these individual projects, but you have pushed me and 
helped me grow as a researcher, a public speaker, an academic citizen and 
scientist. Your selflessness and faith have let me loose on conferences, talks and 
unwitting delegates to enhance my own career; but you’ve not been afraid to reign 
me in when I’ve needed it. That’s what makes you a great supervisor. Here’s to 
the future.  
 
I also owe particular thanks to my second supervisor, Dr Alan Barker. Your 
patience and faith have been unparalleled; your encyclopaedic knowledge is 
second to none; and your ability to ask the right question, at the right time has 
helped push me as a scientist. You’ve opened my eyes to new ways of thinking 
and teaching, and for that I am eternally grateful. You Jedi master, you. 
 
Furthermore, all of this work would not have been possible without the support 
and enthusiasm of the Cystic Fibrosis Multi-Disciplinary Team at the Royal Devon 
& Exeter Hospital. I thank you all for your friendship, cups of tea and patience to 
put up with my silly questions. Particular thanks must go to Dr Patrick Oades for 
keeping me clinically grounded and my research patient-focused; to Jayne Trott 
for being a constant guide and incredible source of support from day one (and for 
giving me a job!); and James Shelley for the endless hours of help with testing 
and recruitment in clinics, as well as your willingness to help even now you’re 
back ‘oop north’. 
Page 7 of 403 
 
For their help with the experimental chapters, I also thank Lucy Chubbock for her 
help in collating and analysing an incredible amount of oxygen uptake data; Dr 
Jon Fulford for his time, effort, patience and wisdom on all things MRI; and Paul 
Wilson for his assistance in analysing what must have felt like an infinite number 
of muscle images.  
 
To my CHERCALICIOUS family, I owe you big time. From help with testing in the 
early mornings and late nights, to the coffee, beer, pizza, poker, laughs, rants 
and more coffee, it’s a journey we’ve all shared and supported each other on. 
You all rock. The people may change, but the ethos and support has never 
wavered and that’s what makes CHERC a special place to be.  
 
Mum, Dad, Calum, Gwen. You’ve been incredible. Love, encouragement, support, 
money, lifts, lunch and unwavering support over the past eleven years of my 
university education have all been given without a second thought. Family has a 
new definition thanks to you. Emily, I don’t know where to start. You’ve kept me 
sane and moving forward with your incredible support and sacrifice. I can’t thank 
you enough.  
 
And finally, a ‘thank you’ to all the children and parents, whose time, effort, 
determination and sweat, has made this project possible. We keep fighting for a 
life unlimited, and to make this work obsolete. 
 
 
 
 
Page 8 of 403 
 
TABLE OF CONTENTS 
ABSTRACT ........................................................................................................ 3 
ACKNOWLEDGMENTS ..................................................................................... 6 
TABLE OF CONTENTS ..................................................................................... 8 
LIST OF FIGURES ........................................................................................... 16 
LIST OF TABLES ............................................................................................. 28 
LIST OF EQUATIONS ...................................................................................... 30 
LIST OF ABBREVIATIONS .............................................................................. 32 
PhD PUBLICATIONS AND PRESENTATIONS ............................................... 36 
ADDITIONAL PUBLICATIONS AND PRESENTATIONS ................................. 41 
1 INTRODUCTION ....................................................................................... 46 
2 LITERATURE REVIEW ............................................................................. 53 
 Cystic fibrosis ...................................................................................... 53 
2.1.1 Cause of cystic fibrosis ................................................................. 53 
2.1.2 Pathophysiology of cystic fibrosis ................................................. 57 
2.1.3 Demographics of cystic fibrosis .................................................... 61 
2.1.3.1 Prevalence and incidence ...................................................... 61 
2.1.3.2 Age ......................................................................................... 63 
2.1.3.3 Sex ......................................................................................... 66 
2.1.3.4 Life expectancy ...................................................................... 67 
2.1.4 Treatment and management of cystic fibrosis .............................. 70 
2.1.4.1 Pharmacological treatment ..................................................... 71 
2.1.4.2 Nutrition .................................................................................. 72 
2.1.4.3 Physiotherapy ........................................................................ 75 
2.1.4.4 Exercise ................................................................................. 77 
 Exercise in cystic fibrosis .................................................................... 80 
Page 9 of 403 
 
2.2.1 Exercise (dys)function in cystic fibrosis ........................................ 82 
2.2.2 Clinical importance of exercise capacity in cystic fibrosis ............. 86 
2.2.3 Assessment of exercise capacity in cystic fibrosis ........................ 88 
2.2.3.1 Field tests ............................................................................... 89 
2.2.3.2 Cardiopulmonary exercise testing (CPET) ............................. 90 
2.2.3.3 Maximal oxygen uptake (V̇O2max) ........................................... 95 
2.2.3.4 Submaximal measures ........................................................... 97 
2.2.3.5 Relationship of parameters with body size ........................... 104 
 Exercise limitation in children with cystic fibrosis .............................. 106 
2.3.1 Genetic factors............................................................................ 107 
2.3.2 Pulmonary factors ....................................................................... 109 
2.3.3 Cardiac factors............................................................................ 112 
2.3.4 Musculoskeletal factors .............................................................. 113 
 Exercise testing and the cystic fibrosis clinic ..................................... 117 
 Summary ........................................................................................... 121 
 Aims and objectives .......................................................................... 123 
3 GENERAL METHODS ............................................................................ 125 
 Study designs .................................................................................... 125 
3.1.1 Ethics approval ........................................................................... 125 
3.1.2 Funding ....................................................................................... 126 
3.1.3 Participants ................................................................................. 126 
3.1.3.1 Patients with cystic fibrosis................................................... 126 
3.1.3.2 Non-CF controls ................................................................... 128 
3.1.4 Participant information and consent/assent ................................ 129 
3.1.5 Inclusion in multiple studies ........................................................ 130 
 Participant information ....................................................................... 130 
Page 10 of 403 
 
3.2.1 Age and maturation .................................................................... 130 
3.2.1.1 Chronological age ................................................................ 130 
3.2.1.2 Biological age ....................................................................... 131 
3.2.2 Anthropometric measures ........................................................... 132 
3.2.2.1 Stature.................................................................................. 132 
3.2.2.2 Seated stature ...................................................................... 132 
3.2.2.3 Body mass ........................................................................... 133 
3.2.2.4 Body mass index .................................................................. 133 
3.2.2.5 Body surface area ................................................................ 133 
3.2.2.6 Body fat estimation ............................................................... 133 
 Testing procedures............................................................................ 135 
3.3.1 Pulmonary function ..................................................................... 135 
3.3.2 Physical activity .......................................................................... 136 
3.3.3 Cardiopulmonary exercise testing ............................................... 136 
3.3.3.1 Equipment ............................................................................ 137 
3.3.3.2 Protocol ................................................................................ 137 
3.3.3.2.1 Ramp incremental phase ................................................ 138 
3.3.3.2.2 Supramaximal verification phase .................................... 138 
3.3.3.3 Outcome variables ............................................................... 139 
3.3.3.3.1 Maximal oxygen uptake (V̇O2max) .................................... 139 
3.3.3.3.2 Gas exchange threshold ................................................. 143 
3.3.3.3.3 Respiratory compensation point...................................... 146 
3.3.3.3.4 Oxygen uptake efficiency slope ...................................... 146 
3.3.3.3.5 Oxygen uptake efficiency ................................................ 147 
3.3.3.3.6 Rating of perceived exertion and dyspnoea .................... 149 
3.3.3.3.7 Oxygen saturation ........................................................... 149 
Page 11 of 403 
 
3.3.4 Magnetic resonance based variables ......................................... 150 
3.3.5 Scaling of outcome variables ...................................................... 151 
3.3.6 Statistical analyses ..................................................................... 155 
 Practical considerations .................................................................... 156 
3.4.1 Patient safety during exercise ..................................................... 156 
3.4.2 Infection control .......................................................................... 157 
3.4.3 Contraindications to MR scanner environment ........................... 158 
4 SCALING THE OXGEN UPTAKE EFFICIENCY SLOPE FOR BODY SIZE 
IN CYSTIC FIBROSIS .................................................................................... 159 
 Abstract ............................................................................................. 159 
 Introduction ....................................................................................... 160 
 Methods ............................................................................................ 162 
4.3.1 Study participants ....................................................................... 162 
4.3.2 Experimental measures .............................................................. 163 
4.3.3 Experimental protocol ................................................................. 163 
4.3.4 Scaling approaches .................................................................... 164 
4.3.5 Statistical analyses ..................................................................... 166 
 Results .............................................................................................. 166 
 Discussion ......................................................................................... 171 
 Conclusion ........................................................................................ 176 
5 THE OXYGEN UPTAKE EFFICIENCY SLOPE IS NOT A VALID 
SURROGATE OF AEROBIC FITNESS IN CYSTIC FIBROSIS ..................... 177 
 Abstract ............................................................................................. 177 
 Introduction ....................................................................................... 178 
 Materials and methods ...................................................................... 180 
5.3.1 Participants ................................................................................. 180 
Page 12 of 403 
 
5.3.2 Data collection ............................................................................ 181 
5.3.3 Data analysis .............................................................................. 181 
5.3.4 Scaling of data ............................................................................ 182 
5.3.5 Statistical analyses ..................................................................... 182 
 Results .............................................................................................. 183 
5.4.1 Participant characteristics ........................................................... 183 
5.4.2 Correlation between OUES and V̇O2max...................................... 184 
5.4.3 Difference in OUES between CF and CON ................................ 184 
5.4.4 OUES and fitness tertiles ............................................................ 186 
 Discussion ......................................................................................... 189 
6 ANALYSIS OF OXYGEN UPTAKE EFFICIENCY PARAMETERS IN 
YOUNG PEOPLE WITH CYSTIC FIBROSIS ................................................. 194 
 Abstract ............................................................................................. 194 
 Introduction ....................................................................................... 195 
 Methods ............................................................................................ 197 
6.3.1 Participants ................................................................................. 197 
6.3.2 Ethics approval ........................................................................... 198 
6.3.3 Anthropometric variables ............................................................ 198 
6.3.4 Pulmonary function ..................................................................... 198 
6.3.5 Exercise variables ....................................................................... 198 
6.3.6 Statistical analyses ..................................................................... 199 
 Results .............................................................................................. 200 
6.4.1 Differences in OUE between groups ........................................... 200 
6.4.2 Correlation of with OUE with V̇O2peak .......................................... 206 
6.4.3 Differences between aerobic fitness groups ............................... 207 
6.4.4 Relationship with disease severity (FEV1) .................................. 208 
Page 13 of 403 
 
 Discussion ......................................................................................... 210 
 Conclusion ........................................................................................ 214 
7 QUANTIFICATION OF THIGH MUSCLE VOLUME IN CHILDREN USING 
MAGNETIC RESONANCE IMAGING ............................................................ 215 
 Abstract ............................................................................................. 215 
 Introduction ....................................................................................... 216 
 Methods ............................................................................................ 218 
7.3.1 Study population ......................................................................... 218 
7.3.2 Anthropometric measures ........................................................... 219 
7.3.3 Estimation of volume .................................................................. 219 
7.3.4 Statistical analyses ..................................................................... 221 
 Results .............................................................................................. 221 
 Discussion ......................................................................................... 226 
8 SCALING MAXIMUM OXYGEN UPTAKE FOR THIGH MUSCLE VOLUME 
IN CHILDREN WITH CYSTIC FIBROSIS....................................................... 231 
 Abstract ............................................................................................. 231 
 Introduction ....................................................................................... 232 
 Methods ............................................................................................ 234 
8.3.1 Study population ......................................................................... 234 
8.3.2 Anthropometry and pulmonary function ...................................... 235 
8.3.3 Physical activity .......................................................................... 235 
8.3.4 Cardiopulmonary exercise testing ............................................... 235 
8.3.5 Determination of cross-sectional area and muscle volume ......... 236 
8.3.6 Scaling procedures ..................................................................... 237 
8.3.7 Statistical analyses ..................................................................... 237 
 Results .............................................................................................. 238 
Page 14 of 403 
 
 Discussion ......................................................................................... 244 
 Conclusion ........................................................................................ 248 
9 EXERCISE CAPACITY FOLLOWING A PERCUTANEOUS ENDOSCOPIC 
GASTROSTOMY IN A YOUNG FEMALE WITH CYSTIC FIBROSIS: A CASE 
REPORT ........................................................................................................ 249 
 Abstract ............................................................................................. 249 
 Introduction ....................................................................................... 249 
 Patient information ............................................................................ 250 
 Timeline ............................................................................................. 251 
 Diagnostic assessment ..................................................................... 253 
9.5.1 Anthropometric measures ........................................................... 253 
9.5.2 Lung function .............................................................................. 253 
9.5.3 Exercise parameters ................................................................... 253 
 Therapeutic intervention .................................................................... 254 
 Follow-up and outcomes ................................................................... 254 
9.7.1 Anthropometric outcomes ........................................................... 254 
9.7.2 Pulmonary outcomes .................................................................. 254 
9.7.3 Exercise outcomes ..................................................................... 255 
 Discussion ......................................................................................... 258 
 Conclusion ........................................................................................ 260 
10 PROMOTION OF EXERCISE IN THE MANAGEMENT OF CYSTIC 
FIBROSIS – SUMMARY OF NATIONAL MEETINGS .................................... 261 
 Abstract ............................................................................................. 261 
 Introduction ....................................................................................... 262 
 Meetings ............................................................................................ 263 
10.3.1 Meeting 1 – August 2016 ......................................................... 263 
Page 15 of 403 
 
10.3.2 Meeting 2 – February 2017 ..................................................... 264 
 Results .............................................................................................. 268 
10.4.1 Meeting 1 ................................................................................. 268 
10.4.2 Meeting 2 ................................................................................. 270 
 Discussion ......................................................................................... 273 
10.5.1 Roles and responsibilities ........................................................ 273 
10.5.2 Exercise provision ................................................................... 275 
 Conclusion ........................................................................................ 277 
11 GENERAL DISCUSSION .................................................................... 278 
 Submaximal alternatives to V̇O2max ................................................... 278 
 Using CPET to identify musculoskeletal limitations to exercise ......... 282 
 Applying CPET in clinical practice ..................................................... 286 
 Strengths and limitations ................................................................... 289 
 Recommendations for clinical practice .............................................. 292 
 Conclusion ........................................................................................ 294 
12 REFERENCES .................................................................................... 296 
APPENDICES ................................................................................................ 354 
 
 
 
 
 
 
 
 
 
Page 16 of 403 
 
LIST OF FIGURES 
Figure 2.1 Differences in cystic fibrosis trans-membrane conductance regulator 
structure between normal (left), and cystic fibrosis (right), airways. Cl-, chloride; 
Na+, sodium; ASL, airway surface liquid. From Hull (2012, pS3) with permission.
 ......................................................................................................................... 54 
Figure 2.2 Scanning electron micrograph with cilia clearly visible. Layers of 
mucus are also evident on top of the cilia. In cystic fibrosis, the mucus forms a 
continuous layer over the cilia. Reprinted by permission from Springer Customer 
Service Centre GmbH: Springer, Gene Therapy, Gene therapy progress and 
prospects: cystic fibrosis, Griesenbach et al. © (2002, p1345). ........................ 55 
Figure 2.3 Classifications of cystic fibrosis transmembrane conductance regulator 
mutations, with functional defect and examples of mutations. Reprinted from The 
Lancet Respiratory Medicine, Vol. 1(2), Boyle & DeBoeck, A new era in the 
treatment of cystic fibrosis: correction of the underlying CFTR defect, p159, © 
(2012), with permission from Elsevier. ............................................................. 56 
Figure 2.4 Computerised tomography images for two individual adolescents with 
cystic fibrosis (A: 14-year old female; B: 16-year old male). Scans display 
extensive bronchiectasis in the right middle and lingual lobes (A); and widespread 
bronchiectatic changes, but no significant swelling or hardening of tissue (B). 
Reprinted with permission: Saynor et al., (2014), The Effect of Ivacaftor in 
Adolescents With Cystic Fibrosis (G551D Mutation): An Exercise Physiology 
Perspective, Pediatric Physical Therapy, 26(4), p455, doi: 
10.1097/PEP.0000000000000086. .................................................................. 58 
Page 17 of 403 
 
Figure 2.5 Stages of pathologic damage in the airways of patients with cystic 
fibrosis during growth. Reprinted with permission of the American Thoracic 
Society. Copyright © 2018 American Thoracic Society. Ramsey (2007), Use of 
Lung Imaging Studies as Outcome Measures for Development of New Therapies 
in Cystic Fibrosis, Proceedings of the American Thoracic Society, 4, p361. 
Proceedings of the American Thoracic Society is an official journal of the 
American Thoracic Society. .............................................................................. 59 
Figure 2.6 Increase in registered patients with cystic fibrosis in the United 
Kingdom from 2007-2016. Data adapted from Cystic Fibrosis Trust Registry 
(2009, 2013b, 2017b). *Decrease in registered patients due to ‘data cleaning’ 
exercise by Cystic Fibrosis Trust. ..................................................................... 62 
Figure 2.7 Age distribution of patients with cystic fibrosis in the United Kingdom 
in 2016. Data adapted from Cystic Fibrosis Trust Registry (2017b). ................ 64 
Figure 2.8 Change in proportion of patients with cystic fibrosis over the age of 16 
in the United Kingdom from 2007-2016. Data adapted from Cystic Fibrosis Trust 
Registry (2009, 2013b, 2017b). ........................................................................ 65 
Figure 2.9 Relative distribution of patients with cystic fibrosis in the United 
Kingdom in 2016 when separated by sex. Data adapted from Cystic Fibrosis Trust 
Registry (2017b). .............................................................................................. 67 
Figure 2.10 Change in median age of death for patients with cystic fibrosis in the 
United Kingdom, from 2007-2016. Data adapted from Cystic Fibrosis Trust 
Registry (2017b). .............................................................................................. 68 
Figure 2.11 Increases in life expectancy in cystic fibrosis, attributed to introduction 
of novel therapies. AZLI, aztreonam for inhalation solution; CF, cystic fibrosis; 
Page 18 of 403 
 
HTS, high throughput screening; rhDNase, recombinant human 
deoxyribonuclease; TIP, tobramycin inhalation solution. Reproduced with 
permission of the © ERS 2018. European Respiratory Review Mar 2013, 22 (127) 
3-5; doi: 10.1183/09059180.00008112. ............................................................ 70 
Figure 2.12 Schematic diagram of a percutaneous endoscopic gastrostomy, 
presented in a cross-sectional view. From Sohagia and Hertan (2012). Reprinted 
by permission from Springer Customer Service Centre GmbH: Springer, Geriatric 
Gastroenterology by C.S. Pitchumoni & T.S. Dharmarajan (Eds.) © (2012) doi: 
10.1007/978-1-4419-1623-5_13. ...................................................................... 74 
Figure 2.13 Airway clearance techniques used by patients with cystic fibrosis in 
the United Kingdom. PEP, positive expiratory pressure; PWCF, patients with 
cystic fibrosis. Reprinted from Physiotherapy, 101, Hoo et al., Airway clearance 
techniques used by people with cystic fibrosis in the UK, p342., © 2015, with 
permission from Elsevier. ................................................................................. 76 
Figure 2.14 The relative importance assigned by clinicians of both exercise 
testing and exercise training in the management of cystic fibrosis in the United 
Kingdom. Reprinted from Journal of Cystic Fibrosis, 9, Stevens et al., A survey 
of exercise testing and training in UK cystic fibrosis clinics, p304., ©2010, with 
permission from Elsevier. ................................................................................. 81 
Figure 2.15 Schematic showing the integration of the musculoskeletal, 
cardiovascular and pulmonary systems in their contribution towards the oxygen 
consumption pathway and contributing factors to exercise intolerance for each 
system. Reprinted with permission of a) Milani et al., Cardiopulmonary exercise 
testing: how do we differentiate the cause of dyspnoea?, Circulation, 110(4), pe28, 
Page 19 of 403 
 
doi: 10.1161/01.CIR.0000136811.45524.2F, and b) Wasserman, Principles of 
Exercise Testing and Interpretation, 3rd Ed., ©Wolters Kluwer 2004. ............... 82 
Figure 2.16 Survival among adults (A) and children (B) with cystic fibrosis, when 
divided by aerobic fitness (V̇O2peak). A: Reproduced with permission from Nixon 
et al. (1992) New England Journal of Medicine, 327(25), p1786. ©Massachusetts 
Medical Society. B: Reproduced from Thorax, Pianosi et al., 60 (1), p52, ©2005 
with permission from BMJ Publishing Group Ltd. ............................................. 86 
Figure 2.17 Two-stage ramp and supramaximal exercise protocol. A: 3-minute 
warm up at 20 W. B: Incremental ramp exercise at a predetermined rate 
(dependent upon individual data). C: 5-minute active recovery (unloaded 
pedalling). D: 10-minute seated recovery off the cycle ergometer. E: 3-minute 
warm-up at 20 W. F: Supramaximal confirmation bout at 110% of peak power 
output produced during ramp exercise. G: 3-minute recovery (unloaded 
pedalling). Reproduced with permission from Williams et al. (2014), Expert 
Review of Respiratory Medicine, 8(6), p753. doi: 10.1586/17476348.2014.96669.
 ......................................................................................................................... 94 
Figure 2.18 The relationship between V̇O2 and V̇E during incremental exercise 
(left), and when V̇E has been logarithmically transformed (right). The subsequent 
regression equation produces the value for the oxygen uptake efficiency slope (in 
this instance, 1017 mL.min-1.logL-1). Reproduced from Archives of Disease in 
Childhood, Baba et al., 81 (1), p73, ©1999 with permission from BMJ Publishing 
Group Ltd ....................................................................................................... 101 
Figure 2.19 Comparative profiles of a) oxygen uptake efficiency, with the oxygen 
uptake efficiency plateau (42.3) represented by solid black horizontal line, and b) 
Page 20 of 403 
 
the oxygen uptake efficiency slope (2919.9), for a cardiopulmonary exercise test 
in a healthy, 13-year old girl. Reprinted with permission from Bongers et al. 
(2015a). .......................................................................................................... 103 
Figure 2.20 A basic schematic for interpretation of cardiopulmonary exercise test 
results, with likely causes of exercise limitation. AT, anaerobic threshold; CAD, 
coronary artery disease; COPD, chronic obstructive pulmonary disease; ECG, 
electrocardiogram; HR, heart rate; HRR, heart rate reserve; ILD, interstitial lung 
disease; SaO2, arterial blood oxygenation; PET-CO2, end-tidal tension for carbon 
dioxide; PFT, pulmonary function test; V̇E, minute ventilation; V̇O2, volume of 
oxygen consumption; V̇O2max, maximal volume of oxygen consumption; VR, 
ventilatory reserve. Reprinted with permission of the American Thoracic Society. 
Copyright © 2018 American Thoracic Society. ATS/ACCP Statement on 
Cardiopulmonary Exercise Testing (2003), 16, p251. The American Journal of 
Respiratory and Critical Care Medicine is an official journal of the American 
Thoracic Society. ............................................................................................ 107 
Figure 3.1 An example of the V̇O2 response to the ramp incremental and Smax 
exercise bouts, used to determine V̇O2max, for a healthy 16-year old female. 
Dashed vertical lines indicate end of ramp incremental phase and start of Smax 
phase respectively. ......................................................................................... 139 
Figure 3.2 Example V̇O2 responses to increasing work-rate during the ramp 
phase of a cardiopulmonary exercise test, with linear regression plotted to 
establish V̇O2max. A: Linear regression plotted through ‘linear’ portion of the ramp 
incremental phase, excluding the first two minutes, and excluding the last three 
minutes. B: Linear regression is extrapolated to cover final three minutes of test. 
Profile depicts linear response of a 14-year old male with cystic fibrosis. ...... 141 
Page 21 of 403 
 
Figure 3.3 Example V̇O2 responses to increasing work-rate during the ramp 
phase of a cardiopulmonary exercise test. A: Deceleration of V̇O2, producing a 
plateau (17-year old male with cystic fibrosis); B: Linear response (14-year old 
male with cystic fibrosis); C: Acceleration of V̇O2 against power (14-year old male 
with cystic fibrosis). For all cases, the extrapolated regression line is fitted from 
120 seconds, through to volitional exhaustion. ............................................... 142 
Figure 3.4 Example of establishment of gas exchange threshold, using V-slope 
method (above) and ventilatory equivalents for V̇O2 and V̇CO2 (below). Both 
examples display the same cardiopulmonary exercise test data for a 12-year old 
female with cystic fibrosis. .............................................................................. 144 
Figure 3.5 Worked example of establishing the gas exchange threshold using V-
slope method (A), and ventilatory equivalents for V̇O2 and V̇CO2 (B), using 
purpose-built software (LabVIEW; National Instruments, Newbury, UK). Data 
displayed is the same at that in Figure 3.4. .................................................... 145 
Figure 3.6 Establishment of respiratory compensation point using methods of 
Beaver et al. (1986) by examining relationship between V̇E and V̇CO2. ......... 146 
Figure 3.7 An example of the logarithmic transformation of the curvilinear 
ventilatory response to incremental exercise during a cardiopulmonary exercise 
test in a healthy 13-year old male. A: Curvilinear ventilatory response to 
incremental exercise, from the start of the incremental ramp phase to volitional 
exhaustion (i.e. V̇O2peak). B: The same response profile as (A), however 
ventilation has been log-transformed (base 10). The resultant linear regression 
for (B) in the example above produces a value of 2446 for ‘a’ in Equation 3.12. 
Page 22 of 403 
 
This value is the oxygen uptake efficiency slope, which is subsequently carried 
forward for analysis. ....................................................................................... 148 
Figure 3.8 An example of the three parameters of oxygen uptake efficiency 
analysed throughout this thesis, and their position within a cardiopulmonary 
exercise test (from warm-up, to volitional exhaustion) undertaken by a 12-year 
old female with cystic fibrosis. The solid, vertical line at 180 seconds indicates the 
beginning of the ramp incremental phase of the cardiopulmonary exercise test. 
The two dashed, vertical lines entitled ‘GET’ and ‘RCP’ indicate the gas exchange 
threshold and respiratory compensation point, respectively. A: oxygen uptake 
efficiency plateau (OUEP); B: oxygen uptake efficiency at the GET (OUEGET); C: 
oxygen uptake efficiency at the RCP (OUERCP). ............................................ 149 
Figure 3.9 Example magnetic resonance images of the mid-thigh of a 14-year old 
female with cystic fibrosis. A: Cross-sectional area of mid-thigh as seen using 
magnetic resonance imaging software. B: The same image as (A), but with the 
shaded area in red on the left indicates the cross-sectional area used to calculate 
thigh volume (muscle and subcutaneous fat), with the shaded area on the right 
indicating the cross-sectional area used to calculate muscle volume. For both 
volumes, bone is excluded from cross-sectional area and subsequent calculation 
of thigh volume and muscle volume. .............................................................. 151 
Figure 3.10 (overleaf) A: Relationship between body mass (kg) and absolute 
V̇O2peak (L.min-1) in boys (black circles) and girls (white circles). The relationship 
between variables is statistically significant for boys (r = 0.76, p < 0.001) and girls 
(r = 0.80, p < 0.001). B: Relationship between body mass (kg) and ratio-standard 
V̇O2peak (mL.kg.min-1) in boys (black circles) and girls (white circles). The 
relationship between variables is statistically significant for boys (r = -0.49, p < 
Page 23 of 403 
 
0.001) and girls (r = -0.44, p < 0.001). C: Relationship between body mass (kg) 
and allometrically scaled V̇O2peak (mL.kg-0.72.min-1) in boys (black circles) and girls 
(white circles). The relationship between variables is no longer statistically 
significant for boys (r = -0.08, p = 0.429) and girls (r = 0.02, p = 0.815). ........ 155 
Figure 4.1 Relationship between oxygen uptake (V̇O2; mL.min-1) and minute 
ventilation (VE; L.min-1) [1]; and V̇O2 (mL.min-1) and log10VE (L.min-1) [2] during 
incremental exercise in representative 13-year old boys – one with CF [A] and 
one without [B]. Differences in ventilation are clear between participants (i.e. 
linear vs. curvilinear response), however normalisation of ventilation through log 
transformation (thus producing OUES) allows for direct comparison between 
individuals....................................................................................................... 165 
Figure 4.2 Scatter plots with Pearson’s correlation coefficients for CF (●, solid 
line) and CON (○, dashed line) groups for OUES from peak exercise when scaled 
utilising each variable (stature [A], body mass [B] and body surface area [C]) and 
procedure (absolute [1], ratio-standard [2] and allometric [3]). * Significant 
difference (P < 0.05) between the magnitude of the correlation coefficients 
between CF and CON. ................................................................................... 170 
Figure 5.1 Comparison of OUES/BSA1.40 values between children and 
adolescents with CF (black bars) and healthy age- and gender-matched controls 
(white bars) at different exercise thresholds. .................................................. 185 
Figure 5.2 Comparison of V̇O2max, split by V̇O2max tertile (black bars = highest 
tertile, white bars = middle tertile, grey bars = lowest tertile), within the CF and 
healthy control groups. * Significant (p < 0.01) difference from highest tertile. † 
Page 24 of 403 
 
Significant (p < 0.01) difference from middle tertile. § Significant (p < 0.05) 
difference between groups. ............................................................................ 186 
Figure 5.3 Comparison of OUES/BSA1.40 at 100%TTE and OUESGET/BSA1.40 split 
by V̇O2max tertile (black bars = highest tertile, white bars = middle tertile, grey bars 
= lowest tertile), within the CF and healthy control groups. * Significant (p < 0.05) 
difference from highest tertile. † Significant (p < 0.05) difference from middle 
tertiles. ............................................................................................................ 188 
Figure 6.1 Profiles of OUEP, OUEGET and OUERCP in a representative CPET from 
an individual child with CF (female, 12 years, homozygous ΔF508, FEV1 
82.0 %Predicted, V̇O2peak 37 mL.kg-1.min-1, 73 mL.kg-0.86.min-1). Vertical line at 180 s 
indicates end of warm-up, and beginning of ramp phase. Vertical lines also 
indicate point of GET and RCP. Horizontal lines between 200 – 290 s = OUEP 
(31.9 mL.L-1), 240 – 300 seconds = OUEGET (31.0 mL.L-1), 500 – 560 seconds = 
OUERCP (19.7 mL.L-1). .................................................................................... 202 
Figure 6.2 Differences in OUE (V̇O2/V̇E) between two representative children, CF 
(□) and CON (○), throughout a ramp incremental CPET. Vertical line at 180 s 
indicates the end of the warm-up and beginning of ramp phase of the test. Vertical 
lines at 610 s and 640 s indicate exhaustion for CF, and CON participant 
respectively. Solid horizontal lines at 31.9 mL.L-1 (CF) and 43.0 mL.L-1 (CON) 
indicate OUEP (highest 90 s average) for each group, respectively. ............. 203 
Figure 6.3 Individual differences between age- and sex-matched CON and CF 
pairs for CPET derived variables. All plots are calculated as CON minus CF, i.e. 
bars underneath y = 0 on x-axis indicate participant with CF has a greater value 
than CON counterpart. A: Differences in allometrically scaled V̇O2peak between 
Page 25 of 403 
 
pairs. B: Differences in OUEP between pairs, independent of differences in 
V̇O2peak. C: Differences in V̇O2peak (mL.kg-0.86.min-1) between pairs, plotted 
alongside within-pair differences in OUEP (mL.L-1). Black bars represent V̇O2peak, 
and grey bars indicate OUEP. ........................................................................ 205 
Figure 6.4 (overleaf) Comparison of V̇O2peak (A) and OUE parameters (B: OUEP; 
C: OUEGET; D: OUERCP) between CF (black) and CON (white), split by V̇O2peak 
tertile. * = Significant (p < 0.05) difference from highest tertile (within group). § = 
Significant (p < 0.05) difference from middle tertile (within group). † = Significant 
(p < 0.05) difference between groups (within tertile). ..................................... 210 
Figure 7.1 Bland-Altman plots identifying relationships between the differences 
between (y–axis) and mean of (x–axis) estimated and criterion muscle volume 
(MV). Plots display use of different slicing strategies (A = MV2, B = MV3, C = 
MV4, D = MV5) and directions (D-P = black circles, P-D = white circles). Predicted 
MV from CSAM and CSAT are in plots E and F respectively. All plots show: mean 
bias (central dashed horizontal line); 95% limits of agreement limits (±2 standard 
deviations; upper and lower dashed horizontal lines) presented as absolute 
values (cm3) and as a % of MV; correlation between means and differences (solid 
diagonal lines) for each MV estimate. MVn, estimated muscle volume using every 
nth CSA slice; CSAM, muscle only cross-sectional area of mid-thigh; CSAT, whole 
thigh cross-sectional area of mid-thigh ........................................................... 223 
Figure 7.2 The relationship between criterion muscle volume and CSAM (white 
circles) and CSAT (black circles). CSAM, muscle only cross-sectional area of mid-
thigh; CSAT, whole thigh cross-sectional area of mid-thigh; r, Pearson’s 
correlation coefficient; p, significance value; SEE = standard error of the estimate.
 ....................................................................................................................... 224 
Page 26 of 403 
 
Figure 9.1 Changes in BMI as measured by percentile in the three-year period 
preceding the procedure and one-year following. Dashed line at 10.9 years 
indicates diagnosis of CFRD. Dotted lines at 11.8, 12.1, 12.4 and 13.1 years 
indicate T1, T2, T3 and T4 respectively. PEG inserted two-days after T2. ..... 252 
Figure 9.2 Changes in predicted FEV1 (○) (r = -0.64) and absolute VO2max (●) (r 
= 0.40) over the 15-month observation window of this case report. Four vertical 
lines indicate T1-T4. PEG inserted two-days after T2. ................................... 252 
Figure 10.1 Schematic representation of the technician role within a multi-
disciplinary cystic fibrosis team across multiple NHS trusts. *Common duties 
included in the job description of all technicians attending first meeting ......... 269 
Figure 10.2 Responses to question surrounding staff members responsible for 
exercise within the CF MDT (Table 10.1, Q3 and Q4). More than one response 
was permitted if applicable. ............................................................................ 271 
Figure 10.3 Responses to question “How confident do you/your team feel in 
discussing exercise with your patients?” ........................................................ 272 
Figure 11.1 Annual rankings for paediatric (<16 years) patients with cystic fibrosis 
under the care of the Royal Devon & Exeter NHS Foundation Trust Hospital, and 
associated networked clinics (North Devon District Hospital, Barnstaple and 
Torbay District General Hospital, Torquay). Median FEV1 (%Predicted) amongst 
patients ≥ 6 years, with no history of lung transplantation using Global Lung Index 
2012 equations (Quanjer et al., 2012) (solid line). Median body mass index 
percentile among patients 2-15 years (dashed line). Proportion of patients with 
chronic Pseudomonas aeruginosa (dotted line). Number of centres reporting data 
Page 27 of 403 
 
represented by grey bars. Data only available until 2015 as ranking ceased by 
Cystic Fibrosis Trust in favour of funnel plots, which account for centre size. 290 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page 28 of 403 
 
LIST OF TABLES 
Table 2.1 The five most common CFTR genotype mutations in the United 
Kingdom, with patients who carry at least one of each mutation. Numbers are not 
mutually exclusive, and patients may occur twice. Data adapted from Cystic 
Fibrosis Trust (2017b). ..................................................................................... 57 
Table 2.2 Summary of studies examining differences in exercise capacity 
between children and adolescents with cystic fibrosis, and non-cystic fibrosis 
control participants. .......................................................................................... 84 
Table 4.1. Anthropometric, pulmonary and exercise-related differences between 
children with CF and age- and gender-matched controls. .............................. 167 
Table 4.2. Pearson’s correlation coefficients for OUES at peak V̇O2 when scaled 
for body size using differing scaling procedures for whole-group (CF + CON)169 
Table 4.3. Allometric exponents for the OUES measures and body size in young 
patients with CF and healthy age- and gender-matched controls. .................. 172 
Table 5.1. Anthropometric, pulmonary function and exercise-related differences 
between CF and CON groups. ....................................................................... 183 
Table 5.2. Correlations at different thresholds between parameters of oxygen 
uptake and ventilatory efficiency and V̇O2max relative to body mass. .............. 184 
Table 6.1. Anthropometric, pulmonary function and exercise-related differences 
between CF and CON groups. ....................................................................... 204 
Table 6.2. Correlations between OUE parameters and V̇O2peak, and FEV1. ... 206 
Page 29 of 403 
 
Table 7.1. Mean differences between CF and CON groups for anthropometric 
and MRI derived variables. ............................................................................. 218 
Table 7.2 Pearson’s correlation coefficients between differences of each 
estimation method and criterion MV, and body size variables. ....................... 225 
Table 8.1. Anthropometric, pulmonary, exercise and MRI-derived muscle-related 
differences between CF and CON groups. ..................................................... 240 
Table 8.2. Differences between matched pairs for primary anthropometric and 
MRI-derived muscle variables utilised for scaling procedures. ....................... 241 
Table 8.3. Pearson’s correlation coefficients for V̇O2max when scaled for body size 
parameters using differing scaling procedures. .............................................. 242 
Table 8.4. Allometric exponents for V̇O2max and parameters of muscle size in 
young patients with CF and healthy age- and sex-matched controls. ............ 243 
Table 8.5. Mean differences in scaled V̇O2max between children in CF and CON 
groups. ........................................................................................................... 243 
Table 9.1 Changes in anthropometric and lung function measures over the 15-
month observation period. .............................................................................. 256 
Table 9.2. Changes in exercise-related parameters over the 15-month 
observation period. ......................................................................................... 257 
Table 10.1 Questionnaire relating to clinical practice. .................................... 266 
Table 10.2. Questionnaire relating to study day feedback. ............................. 267 
 
 
Page 30 of 403 
 
LIST OF EQUATIONS 
Equation 2.1:  V̇O2 = Q̇ x (Ca – Cv̄) ................................................................ 95 
Equation 2.2:  V̇O2peak (mL.min-1) = 216.3 – 138.7*Sex (0 = female, 1 = male) 
+ 11.5*WRpeak 96 
Equation 2.3:  V̇O2peak (mL.min-1) = (8.262WRpeak) + 177.096 ....................... 96 
Equation 3.1:  -7.999994 + (0.0036124 * (age * height)) ............................ 131 
Equation 3.2:  -7.709133 + (0.0042232 * (age * height)) ............................. 131 
Equation 3.3:  BMI = body mass (kg) / stature (m2) ..................................... 133 
Equation 3.4:  BSA (m2) = mass0.5378 * height0.3964 * 0.024265 .................... 133 
Equation 3.5:  BF% = 1.21 * (triceps + subscapular) – 0.008 (triceps + 
subscapular)2 – 1.7 ......................................................................................... 134 
Equation 3.6:  BF% = 1.21 * (triceps + subscapular) – 0.008 (triceps + 
subscapular)2 – 3.4 ........................................................................................ 134 
Equation 3.7:  BF% = 1.21 * (triceps + subscapular) – 0.008 (triceps + 
subscapular)2 – 5.5 ........................................................................................ 134 
Equation 3.8:  BF% = 1.33 * (triceps + subscapular) – 0.013 (triceps + 
subscapular)2 – 2.5 ........................................................................................ 134 
Equation 3.9:  FFM (kg) = body mass (kg) – (body mass * (%BF / 100)) .... 134 
Equation 3.10:  MVV = FEV1 (L) * 35 ........................................................... 136 
Page 31 of 403 
 
Equation 3.11:  WRpeak (W) = -142.865 + 2.998 * Age (years) – 19.206 * Sex (0 
= male, 1 = female) + 1.328 * Height (cm) + 23.362 * FEV1 (L) ...................... 138 
Equation 3.12:  V̇O2 = a * logV̇E + b ............................................................. 146 
Equation 3.13:  d = M1 – M2 / Spooled ............................................................. 155 
Equation 3.14:  √ [(S12 + S22) / 2] .................................................................. 155 
Equation 4.1: V̇O2 = a (logV̇E) + b .............................................................. 164 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page 32 of 403 
 
LIST OF ABBREVIATIONS 
Δ  Difference 
η2   Partial eta squared (effect size) 
6MWT Six-minute walk test 
31P-MRS 31Phosphorous-magnetic resonance spectroscopy 
90% CI 90% confidence interval 
95% CI 95% confidence interval 
ACT  Airway clearance therapy 
ADP  Adenosine diphosphate 
ANOVA Analysis of variance 
aPHV  Age from peak height velocity 
AT  Anaerobic threshold 
ATP  Adenosine triphosphate 
BIA  Bio-electrical impedance 
BMI  Body mass index 
BMI%  Body mass index percentile 
BRI  Breathing reserve index 
BSA  Body surface area 
Ca  Oxygen concentration of arterial blood 
CF  Cystic fibrosis 
CFRD  Cystic fibrosis related diabetes 
CFTR  Cystic fibrosis trans-membrane conductance regulator 
CON  Control participants 
COPD  Chronic obstructive pulmonary disease 
CPET  Cardiopulmonary exercise testing 
CSA  Cross sectional area 
Page 33 of 403 
 
CSAM  Cross sectional area of muscle 
CSAT  Cross sectional area of thigh 
CV  Coefficient of variation 
Cv̄   Mean oxygen concentration of venous blood 
ECFS  European Cystic Fibrosis Society 
ERS  European Respiratory Society 
ES  Effect size 
FEV1   Forced expiratory volume in one second 
FFM  Fat-free mass 
FVC  Forced vital capacity 
GET  Gas exchange threshold 
HR  Heart rate 
HRmax  Maximal heart rate 
ICC  Intraclass correlation coefficient 
IMT  Inspiratory muscle training 
LAS  Lung allocation score 
LCI  Lung clearance index 
LT  Lactate threshold 
MBI  Magnitude based inference 
mCSA  Muscle cross sectional area 
MDT  Multi-disciplinary team 
MRI  Magnetic resonance imaging 
MST  Modified shuttle test 
MV  Muscle volume 
MVPA  Moderate to vigorous physical activity 
MVT  Thigh muscle volume 
Page 34 of 403 
 
MVV  Maximal voluntary ventilation 
NHS  National Health Service 
NIRS  Near infra-red spectroscopy 
OPEP  Oscillating positive expiratory pressure 
OUE  Oxygen uptake efficiency 
OUEGET Oxygen uptake efficiency at the gas exchange threshold 
OUERCP Oxygen uptake efficiency at the respiratory compensation point 
OUEP  Oxygen uptake efficiency plateau 
OUES  Oxygen uptake efficiency slope 
PA  Physical activity 
PCr  Phosphocreatine 
PEG  Percutaneous endoscopic gastrostomy 
PET-O2 End-tidal tension of oxygen 
PERT  Pancreatic enzyme replacement therapy 
PEP  Positive expiratory pressure 
PHV  Peak height velocity 
Pi  Inorganic phosphate 
Q̇  Cardiac output 
QoL  Quality of Life 
RCP  Respiratory compensation point 
RD&E  Royal Devon & Exeter NHS Foundation Trust Hospital 
REC  Regional Ethics Committee 
RER  Respiratory exchange ratio 
rhDNase Recombinant human deoxyribonuclease 
SEE  Standard error of the estimate  
Smax  Supramaximal (verification bout) 
Page 35 of 403 
 
SpO2   Blood oxygen saturation 
SRT  Steep ramp test 
SV  Stroke volume 
tCSA  Thigh cross sectional area 
TV  Thigh volume 
V̇E   Minute ventilation 
VentEq Ventilatory equivalents 
V̇E/V̇O2 Ventilatory equivalent for oxygen 
V̇CO2  Volume of carbon dioxide production 
V̇O2  Volume of oxygen uptake 
V̇O2max Maximal volume of oxygen uptake 
V̇O2peak Peak volume of oxygen uptake 
VT  Ventilatory threshold 
WRpeak Peak work rate 
 
 
 
 
 
 
 
 
 
 
 
 
Page 36 of 403 
 
PhD PUBLICATIONS AND PRESENTATIONS 
The following publications and presentations are in direct relation to the published 
thesis and studies contained within. All other publications and presentations are 
listed in ‘Additional Publications and Presentations’.  
Journal Articles 
Tomlinson, O. W., Barker, A. R., Oades, P. J., & Williams, C. A. (2016). Exercise 
capacity following a percutaneous endoscopic gastrostomy in a young female 
with cystic fibrosis: A case report. Physiological Reports. 4 (16), e12904. doi: 
10.14814/phy2.12904 
Tomlinson, O. W., Barker, A. R., Oades, P. J., & Williams, C. A. (2017). Scaling 
the oxygen uptake efficiency slope for body size in cystic fibrosis. Medicine 
and Science in Sports and Exercise. 49(10): 1980-1986. doi: 
10.1249/MSS.0000000000001314  
Tomlinson, O. W., Shelley, J., Denford, S., Barker, A. R., Oades, P. J., & 
Williams, C. A. (2018). Promotion of exercise in the management of cystic 
fibrosis – Summary of national meetings. European Journal for Person 
Centred Healthcare. 6(2): 196-203. doi: 10.5750/ejpch.v6i2.1430 
Tomlinson, O. W., Chubbock, L. V., Stevens, D., Saynor, Z. L., Oades, P. J., 
Barker, A. R., & Williams, C. A. (2018). Analysis of oxygen uptake efficiency 
parameters in young people with cystic fibrosis. European Journal of Applied 
Physiology. 118(10): 2055-2063. doi: 10.1007/s00421-018-3926-8.  
Williams, C. A., Tomlinson, O. W., Chubbock, L. V., Stevens, D., Saynor, Z. L., 
Oades, P. J., & Barker, A. R. (2018). The oxygen uptake efficiency slope is 
not a valid surrogate of aerobic fitness in cystic fibrosis. Pediatric 
Pulmonology. 53(1): 36-42. doi: 10.1002/ppul.23896. 
Page 37 of 403 
 
Tomlinson, O. W., Barker, A. R., Fulford, J., Shelley, J., Wilson, P., Oades, P. 
J., & Williams, C. A. (2018). Scaling maximum oxygen uptake for thigh 
muscle volume in children with cystic fibrosis. Pediatric Exercise Science 
(Under Review). 
Tomlinson, O. W., Barker, A. R., Fulford, J., Wilson, P., Oades, P. J., & Williams, 
C. A. (2018). Quantification of thigh muscle volume in children using magnetic 
resonance imaging. European Journal of Sport Science (Under Review). 
 
Published Abstracts 
Tomlinson, O. W., Barker, A. R., Fulford, J., Wilson, P., Shelley, J., Oades, P. 
J., & Williams, C. A. (2017). Scaling maximal oxygen uptake for thigh muscle 
volume in children with cystic fibrosis. Pediatric Exercise Science: 29 (4 Suppl 
1): 6. 
Tomlinson, O. W., Chubbock, L., Stevens, D., Saynor, Z. L., Oades, P. J., Barker, 
A. R., & Williams, C. A. (2017). The oxygen uptake efficiency slope is not a 
valid measure of aerobic capacity in children with cystic fibrosis. Graduate 
Journal of Sport, Exercise & Physical Education Research: 5 (Suppl. 1): S154. 
Williams, C. A., Tomlinson, O. W., Chubbock, L., Stevens, D., Saynor, Z. L., 
Oades, P. J., & Barker, A. R. (2017) The oxygen uptake efficiency slope is 
not a valid measure of aerobic capacity in children with cystic fibrosis. 
Pediatric Exercise Science: 29 (4 Suppl 1): 4. 
Tomlinson, O. W., Barker A. R., Chubbock, L. V., Stevens, D., Saynor, Z. L., 
Oades, P. J., & Williams, C. A. (2018). WS08.1 The utility of oxygen uptake 
efficiency as a marker of aerobic fitness in children with cystic fibrosis. 
Journal of Cystic Fibrosis, 17, S14.  
 
Page 38 of 403 
 
Conference Presentations 
Tomlinson, O. W., Barker, A. R., Oades, P. J., & Williams, C. A. Clinical changes 
in cystic fibrosis after gastric surgery: A case study. University of Exeter Sport 
and Health Science Postgraduate Research Day, 7 January 2016; University 
of Exeter, Exeter, UK.  
Tomlinson, O. W., Chubbock, L., Stevens, D., Saynor, Z. L., Oades, P. J., Barker, 
A. R., & Williams, C. A. The oxygen uptake efficiency slope is not a valid 
measure of aerobic capacity in children with cystic fibrosis. University of 
Exeter Sport and Health Science Postgraduate Research Day, 6 January 
2017; University of Exeter, Exeter, UK.  
Tomlinson, O. W., Chubbock, L., Stevens, D., Saynor, Z. L., Oades, P. J., Barker, 
A. R., & Williams, C. A. The oxygen uptake efficiency slope is not a valid 
measure of aerobic capacity in children with cystic fibrosis. British Association 
of Sport & Exercise Sciences Student Conference, 12-13 April 2017; 
University of St Mark and St John, Plymouth, UK.  
Tomlinson, O. W., Barker, A. R., Fulford, J., Wilson, P. Shelley, J., Oades, P. J., 
& Williams, C. A. Scaling maximal oxygen uptake for thigh muscle volume in 
children with cystic fibrosis. Pediatric Work Physiology Meeting XXX, 3-8 
October 2017; Katerini, Greece. 
Williams, C. A., Tomlinson, O. W., Chubbock, L., Stevens, D., Saynor, Z. L., 
Oades, P. J., & Barker, A. R. The oxygen uptake efficiency slope is not a valid 
measure of aerobic capacity in children with cystic fibrosis. Pediatric Work 
Physiology Meeting XXX, 3-8 October 2017; Katerini, Greece. 
Tomlinson, O. W., Barker, A. R., Fulford, J., Wilson, P. Shelley, J., Oades, P. J., 
& Williams, C. A. Scaling maximal oxygen uptake for thigh muscle volume in 
children with cystic fibrosis. University of Exeter Sport and Health Science 
Page 39 of 403 
 
Postgraduate Research Day, 11 January 2018; University of Exeter, Exeter, 
UK.  
Tomlinson, O. W., Barker, A. R., Chubbock, L., Stevens, D., Saynor, Z. L., 
Oades, P. J., & Williams, C. A. The utility of oxygen uptake efficiency as a 
marker of aerobic fitness in children with cystic fibrosis. 41st European Cystic 
Fibrosis Conference, 6-9 June 2018; Belgrade, Serbia. 
 
Poster Presentations 
Chubbock, L. V., Barker, A. R., Tomlinson, O. W., Saynor, Z. L., Stevens, D., 
Oades, P. J., & Williams, C. A. Oxygen uptake efficiency slope is not a valid 
submaximal measure of aerobic capacity in paediatric cystic fibrosis patients. 
Poster presented at: ‘Fighting for a Life Unlimited’. UK Cystic Fibrosis 
Conference; 2015 September 22 – 23; Manchester, UK.  
Chubbock, L. V., Barker, A. R., Tomlinson, O. W., Saynor, Z. L., Stevens, D., 
Oades, P. J., & Williams, C. A. Oxygen uptake efficiency slope is not a valid 
submaximal measure of aerobic capacity in paediatric cystic fibrosis patients. 
Poster presented at: Exhibition of Clinical Research at the Royal Devon & 
Exeter; 2015 November 5; Exeter, UK 
Tomlinson, O. W., Barker, A. R., Fulford, J., Wilson, P., Shelley, J., Oades, P. 
J., & Williams, C. A. Impact of muscle on exercise capacity in cystic fibrosis 
– quality or quantity? Poster presented at: University of Exeter Postgraduate 
Research Showcase; 2018 May 14 – 18; University of Exeter, Exeter, UK 
 
 
 
 
Page 40 of 403 
 
Invited Presentations 
Tomlinson, O. W. (2014). Cardiopulmonary Exercise Testing. Presented at the 
Royal Devon and Exeter NHS Foundation Trust Hospital Bramble Seminar 
Series, October 28 2014; Exeter, UK.  
Tomlinson, O. W. (2014). Cardiopulmonary Exercise Testing. Presented at the 
South West Cystic Fibrosis Meeting, November 14 2014; Taunton, UK.  
Tomlinson, O. W., Barker, A. R., Williams, C. A., Shelley, J. (2017). 
Cardiopulmonary exercise testing in cystic fibrosis. Presented at UK Cystic 
Fibrosis Conference, September 7 2017; Nottingham, UK.  
Tomlinson, O. W. (2017). The role of cardiopulmonary exercise testing in the 
assessment and treatment of young people with cystic fibrosis. Presented at: 
“CF Through The Looking Glass”. All Wales National Cystic Fibrosis 
Conference, November 10 2017; Cardiff, UK. 
Tomlinson, O. W., & Barker, A. R. (2018). Cardiopulmonary Exercise Testing – 
Making Sense of Data. Presented at ‘Publication to Patient’, Cystic Fibrosis 
and Exercise Network Meeting, February 23 2018; Liverpool John Moores 
University, Liverpool, UK.  
 
 
 
 
 
 
 
 
 
Page 41 of 403 
 
ADDITIONAL PUBLICATIONS AND PRESENTATIONS 
Journal Articles 
Williams, C. A., Saynor, Z. L., Tomlinson, O. W., & Barker, A. R. (2014). Cystic 
fibrosis and physiological responses to exercise. Expert Review of 
Respiratory Medicine, 8 (6), 751 – 762. doi: 10.1586/17476348.2014.966693 
Tomlinson, O. W., Shelley, J., Trott, J., Bowhay, B., Chauhan, R., & Sheldon, C. 
(2018). The feasibility of online video calling to engage patients with cystic 
fibrosis in physical activity. Journal of Telemedicine and Telecare (Under 
Review).  
Williams, C. A., Wedgwood, K. C. A., Mohammadi, H., Prouse, K., Tomlinson, 
O. W., & Tsaneva-Atanasova, K. (2018). Cardiopulmonary responses to 
maximal aerobic exercise in patients with cystic fibrosis. PLoS One (Under 
Review). 
 
Letters and Comments 
Saynor, Z. L., Barker, A. R., Oades, P. J., Tomlinson, O. W., & Williams, C. A. 
(2016). Letter to the Editor: Validity and reliability concerns associated with 
cardiopulmonary exercise testing young people with cystic fibrosis. 
Response to: Statement on Exercise Testing in Cystic Fibrosis (Hebestreit et 
al., 2015 Respiration 90 (4):332-51). Respiration. 91 (1): 61 – 62. doi: 
10.1159/000447642 
Williams, C. A., Saynor, Z. L., Barker, A. R., Oades, P. J., & Tomlinson, O. W. 
(2017). Letter to the Editor: Measurement of V̇O2max in clinical groups is 
feasible and necessary. Journal of Applied Physiology. 123(4): 1017. doi: 
10.1152/japplphysiol.00538.2017 
Page 42 of 403 
 
Williams, C. A., Saynor, Z. L., Tomlinson, O. W., Oades, P. J., & Barker, A. R. 
(2017). Skeletal muscle metabolic abnormalities in cystic fibrosis responses 
of the metabolic system relative to changes in exercise intensity. Comment 
on Crosstalk 32: ‘Skeletal muscle oxidative capacity is/is not altered in 
patients with cystic fibrosis’. Journal of Physiology. 595(5): 1 
 
Published Abstracts 
Tomlinson, O. W., Trott, J., Bowhay, B., Shelley, J., Enderby, B., Chauhan, R. 
& Sheldon, C. (2018). P155 Feasibility of using online video calling to engage 
patients in the management of cystic fibrosis. Journal of Cystic Fibrosis, 17, 
S102-S103. 
Trott, J., Tomlinson, O., Bowhay, B., Williams, C., Withers, N. & Oades, P. 
(2018). P150 Reasons for non-compliance with cardiopulmonary exercise 
testing in cystic fibrosis. Journal of Cystic Fibrosis, 17, S101. 
 
Conference Presentations 
Tomlinson, O. W., Barker, A. R., Oades, P. J., & Williams, C. A. Exercise Testing 
in Children with Lung Disease. CLESCon 2017: Frontiers in Life & 
Environmental Science, 22 June 2017; Living Systems Institute, University of 
Exeter, Exeter, UK. 
 
Poster Presentations 
Tomlinson, O. W., Barker, A. R., Oades, P. J., & Williams, C. A. The feasibility 
of a home-based exercise intervention for the improvement of aerobic 
function in young cystic fibrosis patients. Poster presented at: ‘40 Years of 
Sport and Exercise Science: A History in the Making’. 18th Annual British 
Page 43 of 403 
 
Association of Sport and Exercise Sciences Student Conference; 2015 Mar 
31 – Apr 1; Liverpool John Moores University, Liverpool, UK.  
Tomlinson, O. W., Barker, A. R., Oades, P. J., & Williams, C. A. The feasibility 
of a home-based exercise intervention for the improvement of aerobic 
function in young cystic fibrosis patients. Poster presented at: University of 
Exeter Postgraduate Research Showcase; 2015 April 27 – 29; University of 
Exeter, Exeter, UK.  
Tomlinson, O. W., Barker, A. R., Oades, P. J., & Williams, C. A. The feasibility 
of a home-based exercise intervention for the improvement of aerobic 
function in young cystic fibrosis patients. Poster presented at: Exhibition of 
Clinical Research at the Royal Devon & Exeter; 2015 November 5; Exeter, 
UK.  
Tomlinson, O. W., Barker, A. R., Oades, P. J., & Williams, C. A. Exercise Testing 
in Cystic Fibrosis: Protocols, Patients & Practice. Poster presented at: 
University of Exeter Postgraduate Research Showcase; 2017 May 15 – 17; 
University of Exeter, Exeter, UK. 
Tomlinson, O. W., Barker, A. R., Oades, P. J., & Williams, C. A. Exercise Testing 
in Cystic Fibrosis: Protocols, Patients & Practice. Poster presented at: 
University of Exeter CLESCon: Frontiers in Life & Environmental Science; 
2017 June 22; Living Systems Institute, University of Exeter, Exeter, UK.  
Bland, C. L., Barker, A. R., Tomlinson, O. W., Stevens, D., Saynor, Z., Oades, 
P. J., & Williams, C. A. Sex Differences in Exercise Capacity in Children and 
Adolescents with Cystic Fibrosis. Poster Presented at: UK Cystic Fibrosis 
Conference; 2017 September 6 – 7; Nottingham, UK.  
Bland, C. L., Barker, A. R., Tomlinson, O. W., Stevens, D., Saynor, Z., Oades, 
P. J., & Williams, C. A. Sex Differences in Exercise Capacity in Children and 
Page 44 of 403 
 
Adolescents with Cystic Fibrosis. Poster presented at: ‘Posters in Parliament’, 
British Conference of Undergraduate Research; 2018 February 20; Palace of 
Westminster, London, UK.  
Day, A., Trott, J., Tomlinson, O. W., Oades, P. J., & Withers, N. J. Associations 
between airway clearance techniques and exercise capacity in cystic fibrosis. 
Poster presented at: ‘Facing the Challenges of Today’, 2nd International 
Cystic Fibrosis Conference; 2018 April 26; Manchester, UK. 
Tomlinson, O. W., Barker, A. R., Trott, J., Oades, P. J., & Williams, C. A. 
Developing exercise testing for clinical practice in a UK cystic fibrosis centre. 
Poster presented at: ‘Facing the Challenges of Today’, 2nd International 
Cystic Fibrosis Conference; 2018 April 26; Manchester, UK.  
Tomlinson, O. W., Trott, J., Bowhay, B., Shelley, J., Enderby, B., Chauhan, R., 
& Sheldon, C. Feasibility of using online video calling to engage patients in 
the management of cystic fibrosis. Poster presented at: 41st European Cystic 
Fibrosis Conference; 2018 June 6 – 9; Belgrade, Serbia. 
Trott, J., Tomlinson, O. W., Bowhay, B., Williams, C. A., Withers, N. J., & Oades, 
P. J. Reasons for non-compliance with cardiopulmonary exercise testing in 
cystic fibrosis. Poster presented at: 41st European Cystic Fibrosis Conference; 
2018 June 6 – 9; Belgrade, Serbia.  
 
Invited Presentations 
Tomlinson, O. W. (2015). Exercise – Research in to Practice. Presented at the 
Cystic Fibrosis Nursing Association Meeting (South West & Wales), October 
2 2015; Taunton, UK.  
Page 45 of 403 
 
Tomlinson, O. W. (2016). Impact of diet, exercise and environment on health 
and well-being. Presented at Sidmouth Science Festival, October 9 2016; 
Sidmouth, UK.  
Tomlinson, O. W. (2018). Exercise for Children with Respiratory Disease. 
Presented at Postgraduate MSc, Diploma and Certificate in Advanced 
Paediatric Physiotherapy, March 14 2018; Institute of Child Health (ICH), 
University College London, London, UK. 
Tomlinson, O. W., & Shelley, J. (2018). ‘By failing to prepare, you are preparing 
to fail’ – Exercise prescription and remote monitoring. Presented at 
“Supporting Learning in Lung Transplantation” Association of Chartered 
Physiotherapists in Respiratory Care, June 5 2018; Royal Marsden 
Education Centre, London, UK.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page 46 of 403 
 
1 INTRODUCTION 
Cystic fibrosis (CF) is the most common, life-shortening, genetically inherited 
disease in the Caucasian population. It is caused by a mutation to the cystic 
fibrosis trans-membrane conductance regulator (CFTR) gene, which codes for 
the protein responsible for trans-epithelial chloride transportation (Kerem et al., 
1989). This genetic mutation results in dysfunctional, or absent, chloride 
transporters on the cell membrane and subsequently results in an accumulation 
of a thick, sticky mucus in the lining of the airway and digestive tracts. This 
provides a platform for chronic bacterial infections, inflammation, bronchial 
obstructions, fibrosing of lung tissue and a decline in pulmonary function 
(represented by forced expiratory volume in one second [FEV1]) (Elborn, 2016). 
Consequently, respiratory failure is the leading cause of mortality in CF, 
accounting for 85% of all patient deaths (Flume et al., 2009). Currently, there is 
no cure for CF. Therefore, it is disease that is managed using a combination of 
medication, nutrition, physiotherapy and exercise.  
Currently, CF affects ~11,000 people in the United Kingdom (UK), with ~4,000 of 
these individuals being under the age of 16 (Cystic Fibrosis Trust, 2017b). The 
incidence of CF is currently ~1:2500 (Farrell, 2008), and 1 in 25 people of 
Caucasian ethnicity carry the recessive gene that results in manifestation of CF 
(Massie and Delatycki, 2013). The median age of death for patients with CF is 
currently 31 years, although advances in the understanding and management of 
the disease has increased predicted survival steadily over recent years, and now 
stands at 47 years of age for a new-born with CF (Cystic Fibrosis Trust, 2017b). 
This increase in projected life expectancy represents a fundamental shift in CF, 
having once been treated as a paediatric disease where survival was as low as 
5 years in 1960 (Elborn et al., 1991), to now being treated as an adult disease, 
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with high quality paediatric care presenting a fundamental stage in improving 
longevity trough the adult years.  
Despite promising advances being made recently with regard to a range of 
medications that can improve the functionality of the mutated CFTR protein that 
causes CF (Kuk and Taylor-Cousar, 2015), their widespread administration 
remains low, primarily for financial reasons and limited ability to target all genetic 
mutations (Balfour-Lynn, 2014). For example, Ivacaftor (Kalydeco®) acts as a 
CFTR potentiator by improving chloride transport (Davies et al., 2013), although 
is only suitable for individuals with the G551D mutation, which currently has a 
prevalence of 6% (Cystic Fibrosis Trust, 2017b). Therefore, the predominant 
medication given to patients with CF remain antibiotics to manage recurrent 
infection. However, nutrition, chest physiotherapy and exercise also form a 
cornerstone in the management of CF (Cystic Fibrosis Trust, 2016b, National 
Institute for Health and Care Excellence (NICE), 2017). Exercise training in 
particular, may be linked to numerous benefits, including increased lung function, 
health-related quality of life (QoL), exercise capacity, sputum expectoration and 
reduced breathlessness (Radtke et al., 2017b).  
In addition to the benefits associated with exercise training, exercise capacity 
(represented by peak oxygen uptake [V̇O2peak]) is considered a clinically important 
variable, providing useful prognostic information independently of FEV1. A lower 
V̇O2peak is associated with increased risk of mortality (Nixon et al., 1992, Pianosi 
et al., 2005a) and hospitalisation (Pérez et al., 2014) as well as reduced QoL 
(Hebestreit et al., 2014). Therefore, it is imperative that exercise capacity is 
routinely monitored, with annual testing recommended to take place on at least 
an annual basis (Cystic Fibrosis Trust, 2017a, Hebestreit et al., 2015). 
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Exercise capacity can be measured using a variety of tests, protocols and 
equipment modalities. However cardiopulmonary exercise testing (CPET) is 
recognised as the ‘gold standard’ and is endorsed for use by the European Cystic 
Fibrosis Society (ECFS) and European Respiratory Society (ERS) (Hebestreit et 
al., 2015) and utilises pulmonary gas exchange to directly determine V̇O2peak. 
Furthermore, with the use of an additional supramaximal verification bout, 
maximal oxygen uptake (V̇O2max)1 can be confirmed; a process that is valid and 
reliable in children and adolescents with CF (Saynor et al., 2013a, Saynor et al., 
2013b). However, to obtain V̇O2max requires a maximal effort from patients during 
CPET, which may not be feasible nor possible in some cases. Clinical status, 
motivation, dyspnoea and contraindications during testing may all factor into a 
patient’s ability to perform maximal exercise, and therefore valid submaximal 
measures need to be identified for use in CF (Williams et al., 2014).  
Measures of oxygen uptake efficiency (OUE) may provide submaximal 
alternatives to V̇O2max, although their validity in CF has yet to be robustly 
investigated. One derivative of OUE is the oxygen uptake efficiency slope 
(OUES), which has been investigated in patients (11.8 – 18.7 years) with CF 
(Bongers et al., 2012), although there are several methodological concerns with 
this evaluation such as the scaling procedures used and a failure to standardise 
submaximal parameters to submaximal thresholds (which would account for 
                                            
1  V̇O2peak and V̇O2max are both parameters of oxygen uptake, and are 
representative of the integrated functioning of the cardiovascular, pulmonary and 
muscular systems to transport and utilise oxygen. However, the distinction 
between them is that V̇O2peak represents the highest V̇O2 value obtained during 
an exercise test to exhaustion, whereas V̇O2max is a verified and ‘true’ maximal 
value. The utilisation of supramaximal verification testing, and the invalidity of 
secondary criteria to determine V̇O2max will be discussed and expanded upon in 
Chapter 2. Therefore, throughout this thesis, the terms V̇O2peak and V̇O2max 
appear interchangeably, and do so deliberately, reflecting the protocols of cited 
studies and whether or not a ‘true’ maximum has been determined. For further 
insight into the ‘peak vs. max’ issue, please refer to Poole and Jones (2017). 
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variances in relative exercise intensity across patients). Furthermore, the oxygen 
uptake efficiency plateau (OUEP) has been identified as a significant predictor of 
mortality in patients with heart failure (Sun et al., 2012a), indicating clinical 
importance of this submaximal parameter. Whilst characterisation of parameters 
of OUE has been undertaken in children without CF (Bongers et al., 2015a), its 
profile in children and adolescents with CF remains unknown. Therefore, a re-
analysis of OUES, and exploration of OUEP, in CF are needed.  
Application of CPET in research and clinical practice has consistently identified 
that V̇O2peak is reduced in children and adolescents with CF when expressed in 
absolute terms (Bongers et al., 2012), but also when controlled for body mass 
(Bongers et al., 2012, Bongers et al., 2014b, Keochkerian et al., 2008, Saynor et 
al., 2016b) and fat-free mass (Stevens et al., 2011, Tucker et al., 2018). However, 
the mechanisms by which exercise is impaired in this population are equivocal 
(Hulzebos et al., 2015). Whilst genetic (Radtke et al., 2017a), pulmonary (Pastre 
et al., 2014) and cardiovascular (Rosenthal et al., 2009) limitations to exercise 
have all been proposed, it is the musculoskeletal contributions towards exercise 
intolerance (i.e. reduced V̇O2peak) that provides the most recent evidence, with 
debate surrounding the relative contributions of muscle ‘quality’ vs. muscle 
‘quantity’ (Hulzebos et al., 2017, Rodriguez-Miguelez et al., 2017).  
Recent research has indicated that the CFTR gene is present, yet dysfunctional, 
in skeletal muscle in CF (Divangahi et al., 2009, Lamhonwah et al., 2010), 
indicating that muscle ‘quality’ may be responsible for reduced V̇O2peak. However, 
studies to date have not yet fully accounted for muscle ‘quantity’ when assessing 
V̇O2peak in CF. One previous study controlled for muscle cross-sectional area 
(CSA) as a parameter of muscle size (Moser et al., 2000), finding V̇O2peak (relative 
to CSA) to be significantly reduced in children with CF relative to non-CF controls 
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(CON). However, CSA is only a surrogate for the metabolically active muscle 
volume (MV) engaged in exercise and does not accurately predict MV (Morse et 
al., 2007). Therefore, a replication of the study undertaken by Moser et al. (2000) 
is warranted, utilising appropriately quantified MV (as opposed to CSA), to 
remove the influence of muscle size from V̇O2peak in CF, and to further evidence 
for a ‘qualitative’ contribution to reduced exercise capacity.  
Further to using CPET as a diagnostic and prognostic tool to identify prospective 
clinical risk and causes of exercise intolerance, exercise testing can be utilised to 
evaluate interventions and treatment regimens. Previous research has 
traditionally utilised CPET to evaluate exercise training interventions such as 
those delivered within hospitals (Selvadurai et al., 2002a) and at home 
(Schneiderman-Walker et al., 2000). Moreover, the clinical utility of V̇O2peak as an 
independent prognostic marker has resulted in CPET evaluating antibiotic 
treatment (Alison et al., 1994), CFTR modulator therapy (Saynor et al., 2014a) 
and lung transplantation (Oelberg et al., 1998). Despite the advocacy for use of 
CPET to monitor interventions, no studies to date have utilised exercise testing 
to evaluate nutritional interventions, such as supplemental overnight feeding 
through a percutaneous endoscopic gastrostomy (PEG). Given that ~30% of 
patients with CF receive supplemental feeding (and ~6% via a PEG (Cystic 
Fibrosis Trust, 2017b)), evaluation of this treatment modality is required, and use 
of CPET can provide further clinical evaluation in addition to traditional 
parameters of FEV1 and body mass index (BMI). 
Implementation of CPET into clinical practice is dependent on a number of factors, 
such as personnel, knowledge, expertise, equipment and infrastructure. Only four 
previous surveys have sought to characterise the provision of exercise testing in 
the management of CF (Barker et al., 2004, Kaplan et al., 1991, Radtke et al., 
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2011, Stevens et al., 2010), with all being in agreement that exercise testing is 
an under-utilised tool, particularly CPET. However, these surveys did identify that 
exercise testing was broadly perceived as ‘very important’ (Barker et al., 2004, 
Stevens et al., 2010) and therefore further work is required to identify the current 
status of CPET in the UK, as well as the needs of clinical teams in order to deliver 
effective exercise testing and training.  
As described, the role of CPET in the management of CF is of utmost importance 
in children and adolescents, although several aspects surrounding its application 
warrant further investigation. Therefore, this thesis will: 
 Provide a comprehensive review of the literature to date, with particular 
reference to the role of exercise and exercise testing in the management 
of CF (Chapter 2), as well as an overview of the methodology utilised in 
experimental chapters which contribute towards the thesis (Chapter 3); 
 Provide a comprehensive examination of parameters of OUE and their 
suitability to act as submaximal surrogates of V̇O2max in CF (Chapters 4-
6);  
 Utilise magnetic resonance imaging and CPET to establish relationships 
between MV and V̇O2max, to address the ‘quality’ vs. ‘quantity’ debate in 
muscular limitations to exercise in CF (Chapters 7 and 8);  
 Explore the application and implementation of CPET in the clinical setting, 
by using CPET to evaluate a PEG-based intervention using a case-study 
approach (Chapter 9), as well as providing an update on the current 
provision of exercise in CF centres in the UK (Chapter 10).  
Experimental hypotheses, where applicable, are presented in each chapter 
alongside findings and brief discussions. A summative discussion will be provided 
in Chapter 11, highlighting not only the novelty of each chapter and its 
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contribution to the literature base, but also to wider clinical implications for 
successful utilisation of CPET in the management of CF. Furthermore, limitations 
and prospective research avenues for future studies will be highlighted.  
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2 LITERATURE REVIEW 
This literature review provides an overview of the pathophysiology of CF, its 
demographics and treatment, including the integral role exercise plays in the 
management of the disease. Furthermore, this review provides the basis for why 
assessment of exercise capacity is crucial, how this is undertaken and applied, 
and a summary of current understanding surrounding impaired exercise 
tolerance in individuals with CF. 
 Cystic fibrosis 
Cystic fibrosis is a genetically inherited condition, primarily affecting the 
respiratory and digestive systems. It is the most common genetic life-shortening 
disease amongst the Caucasian population, with median age of survival being 31 
years (Cystic Fibrosis Trust, 2017b). There is currently no cure for CF, and 
therefore it is a disease that is ‘managed’, rather than ‘cured’, using combinations 
of medicine, nutrition, physiotherapy and exercise.  
2.1.1 Cause of cystic fibrosis 
Cystic fibrosis, a Mendelian autosomal recessive disorder, was first identified by 
Dorothy Andersen in 1938, who made the pathological description of CF based 
upon development of cysts and fibrosis in the pancreas (Andersen, 1938). 
However it was not until 1989 that the genetic defect responsible for the disease 
was identified (Kerem et al., 1989). It is expressed as a mutation in the cystic 
fibrosis trans-membrane conductance regulator (CFTR) protein, located on the 
long arm of chromosome 7. The CFTR protein is an adenosine triphosphate 
(ATP)-gated chloride (Cl-) channel that is found predominantly in ionoctyes that 
line the trachea (Montoro et al., 2018, Plasschaert et al., 2018). CFTR is also 
found in other epithelial cell membranes that line the lungs, pancreas, vas 
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deferens and skin, being regulated by cyclic adenosine monophosphate (cAMP) 
(Hull, 2012). When a CFTR mutation occurs, resulting in CF, trans-epithelial Cl- 
transport is reduced, which results in increased trans-epithelial sodium (Na+) 
absorption. This is due to the dependence of epithelial Na+ channels (ENaC) 
upon CFTR, and when CFTR is dysfunctional, ENaC is not appropriately 
regulated (Berdiev et al., 2009). This increased Na+ absorption in turn increases 
water absorption and therefore decreases the hydration status of the mucosal 
lining of the airways and digestive tracts (Figure 2.1).  
 
Figure 2.1 Differences in cystic fibrosis trans-membrane conductance regulator 
structure between normal (left), and cystic fibrosis (right), airways. Cl-, chloride; 
Na+, sodium; ASL, airway surface liquid. From Hull (2012, pS3) with permission. 
 
This mucus is a pus that includes polymerised deoxyribonucleic acid (DNA) from 
degraded neutrophils, rather than mucin which is typically derived from mucus-
producing cells (Henke and Ratjen, 2007), which has important consequences 
for medications used to clear mucus from the airways. This mucus becomes thick 
and viscous, covering the cilia of the airway (Figure 2.2). This also blocks the 
pancreatic ducts and exocrine secretions to the duodenum, which results in 
frequent infection and inflammation of the airways, pancreatic insufficiency, 
malnutrition and stunted growth. 
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Figure 2.2 Scanning electron micrograph with cilia clearly visible. Layers of 
mucus are also evident on top of the cilia. In cystic fibrosis, the mucus forms a 
continuous layer over the cilia. Reprinted by permission from Springer Customer 
Service Centre GmbH: Springer, Gene Therapy, Gene therapy progress and 
prospects: cystic fibrosis, Griesenbach et al. © (2002, p1345). 
 
Several types of mutation occur and consist of duplications, replications, 
deletions and shortenings of the gene, resulting in protein channels that do not 
function at all, function only poorly, are degraded quickly, or have an inadequate 
number (Rowe et al., 2005). These mutations are split into classification, 
dependent upon severity (Figure 2.3). These range from Class I (more severe) 
whereby no functional CFTR proteins are produced, to Class VI (less severe), 
whereby CFTR stability at the cell membrane is merely compromised. To date, 
nearly 2000 CFTR mutations have been reported (De Boeck et al., 2014), 
although not all mutations result in CF, with 159 variants accounting for 96% of 
CF alleles (Sosnay et al., 2013).  
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Figure 2.3 Classifications of cystic fibrosis transmembrane conductance regulator 
mutations, with functional defect and examples of mutations. Reprinted from The Lancet 
Respiratory Medicine, Vol. 1(2), Boyle & DeBoeck, A new era in the treatment of cystic 
fibrosis: correction of the underlying CFTR defect, p159, © (2012), with permission from 
Elsevier. 
 
The most common CFTR mutation that results in CF is the ‘ΔF508’ allele, a three-
nucleotide deletion of phenylalanine at the 508th codon, causing mis-folding of 
the CFTR protein (Bobadilla et al., 2002), and therefore CFTR remains in the 
sarcoplasmic reticulum and is not transported to the cell membrane. In the UK, 
90.9 % of the population possess at least one ‘ΔF508’ allele, with 50.2 % of 
individuals with CF being homozygous for this Class II mutation (Cystic Fibrosis 
Trust, 2017b). The remaining common genotypes in the UK are listed in Table 
2.1.  
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Table 2.1 The five most common CFTR genotype mutations in the United 
Kingdom, with patients who carry at least one of each mutation. Numbers are not 
mutually exclusive, and patients may occur twice. Data adapted from Cystic 
Fibrosis Trust (2017b). 
Mutation Class Number Percentage 
ΔF508 2 8671 90.9 
G551D 3 561 5.9 
R117H 4 489 5.1 
G542X 1 341 3.6 
621+1G->T 1 244 2.6 
 
Presently, new-born screening (Gonska and Ratjen, 2015) is utilised to detect CF 
and has been universally utilised across the UK since 2007. A heel-prick blood-
spot test identifies levels of immunoreactive trypsinogen (Ranieri et al., 1991), 
with the highest 1% of values leading to further clinical investigations to confirm 
diagnosis of CF. Research has shown that individuals with CF that were 
diagnosed using new-born screening show improved nutritional outcomes and 
reduced morbidity, in comparison to patients who were diagnosed based upon 
clinical manifestations (Sims et al., 2005), which include meconium ileus, faltering 
growth and recurrent and chronic pulmonary distress (National Institute for Health 
and Care Excellence (NICE), 2017). Presence of CF is confirmed by a sweat test, 
with a sweat chloride value of >60 mmol.L-1 being considered diagnostic (Smyth, 
2005). In cases where clinical manifestations and sweat chloride indicate CF, 
then genotyping would be undertaken to confirm diagnosis.  
2.1.2 Pathophysiology of cystic fibrosis 
Despite differences in mutation categories, the fundamental manifestation of CF 
in all patients remains the accumulation of mucus in the airway and digestive 
system. When mucus is not sufficiently cleared from the lungs, this results in 
declining pulmonary function due to a progressive fibrosing of lung parenchyma 
and bronchiectasis (Figure 2.4), resulting from consistent airway obstruction, 
infection and inflammation. This obstruction and restriction of the airways and 
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resultant progressive destruction of lung tissue results in respiratory failure, which 
is in turn responsible for 85% of patient deaths (Flume et al., 2009).  
 
 
Figure 2.4 Computerised tomography images for two individual adolescents 
with cystic fibrosis (A: 14-year old female; B: 16-year old male). Scans display 
extensive bronchiectasis in the right middle and lingual lobes (A); and 
widespread bronchiectatic changes, but no significant swelling or hardening of 
tissue (B). Reprinted with permission: Saynor et al., (2014), The Effect of 
Ivacaftor in Adolescents With Cystic Fibrosis (G551D Mutation): An Exercise 
Physiology Perspective, Pediatric Physical Therapy, 26(4), p455, doi: 
10.1097/PEP.0000000000000086. 
 
The timeline of the progressive decline in pulmonary function (Figure 2.5) is 
variable between patients, but a noticeable decline in lung function is observed 
during pubertal years (Liou et al., 2010). Median FEV1 has been shown to drop 
below the targeted 85% of predicted (a threshold indicative of normal lung health 
(Cystic Fibrosis Trust, 2015)) during this period. Whilst CF is a multi-organ 
disease, given that pulmonary dysfunction and failure remains the leading cause 
of death (Flume et al., 2009), maintaining lung function is the primary objective 
for many patients.  
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To categorise disease severity, percentages of predicted lung function (FEV1) are 
commonly used: ≥70%, mild-to-moderate; 40-69%, moderate; <40% severe 
(Cystic Fibrosis Foundation, 2017). Prediction equations are available to quantify 
lung function as a percentage of a predicted value, with recent international 
collaboration resulting in the development of multi-ethnic reference values from 
the Global Lung Initiative, for patients aged between 3-95 years of age, which are 
endorsed by the ERS (Quanjer et al., 2012).  
To further protect the lungs, patients will actively undertake therapies to prevent 
and eradicate accumulation of bacterial infections within the lung. The altered 
mucosal properties observed in the airways of patients make cross-infection 
between patients a serious concern (LiPuma et al., 1990), and subsequently 
stringent guidelines are in place to minimise such risks (Saiman et al., 2014). This 
results in patients being segregated in clinical environments and advised to avoid 
contact with one another (Jain et al., 2014).  
Bacteria such as Staphylococcus aureus are common in childhood and cause 
 
Figure 2.5 Stages of pathologic damage in the airways of patients with cystic 
fibrosis during growth. Reprinted with permission of the American Thoracic 
Society. Copyright © 2018 American Thoracic Society. Ramsey (2007), Use of 
Lung Imaging Studies as Outcome Measures for Development of New 
Therapies in Cystic Fibrosis, Proceedings of the American Thoracic Society, 4, 
p361. Proceedings of the American Thoracic Society is an official journal of the 
American Thoracic Society. 
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epithelial damage. In adults, Pseudomonas aeruginosa becomes the prevalent 
pathogen, with over 80% of patients being colonised (Coutinho et al., 2008), 
which is a significant negative predictor of lung function (Schaedel et al., 2002). 
With increases in life expectancy, exposure to environmental non-tuberculous 
Mycobacteria microorganisms such as Mycobacterium abscessus, bring 
increased burden to patients due to extensive treatment regimens (Hill et al., 
2012) and contraindication to lung transplantation (Taylor and Palmer, 2006). 
Beyond the respiratory manifestations of CF, gastrointestinal issues are also 
common in this group, with poor nutrition, failure to thrive and stunted growth 
being common in CF. These symptoms are due to the pancreatic insufficiency, 
that is caused in part by the pancreatitis (Elborn, 2016) reported by a large 
proportion (43%) of patients (Cystic Fibrosis Trust, 2017b). This is caused by 
blockages of the pancreatic duct by mucus, and therefore gastric enzymes 
required for digestion are prevented from acting on food in sufficient volume to 
appropriately digest food, and blockages of the intestine prevent adequate 
absorption of fat and fat-soluble vitamins. As a result, individuals with CF are 
recommended to increase their daily nutritional intake as part of their disease 
management (Ramsey et al., 1992). This malabsorption can also result in further 
complications such as vitamin deficiencies, osteoporosis, gastro-intestinal reflux 
and liver disease. When combined with increased nutritional intake, occurrence 
of CF related diabetes (CFRD) is likely (Cystic Fibrosis Trust, 2004), with ~7,000 
patients in the UK aged ≥10 years currently receiving treatment for CFRD (Cystic 
Fibrosis Trust, 2017b). These nutritional complications can result in individuals 
with CF being either underweight, or overweight and obese, with an equal 
reporting of extremes of body size in one CF centre in the USA (Hanna and 
Weiner, 2015).  
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Further to the airways and digestive systems, the skin and vas deferens are 
impacted upon by CFTR dysfunction. This results in individuals with CF having 
salty sweat, a manifestation which aids diagnosis, and the majority (97-98%) of 
males being infertile (but not sterile), due to congenital absence of the vas 
deferens (Chen et al., 2012). In addition, in vitro studies have shown CFTR to be 
present in the vascular endothelium (Tousson et al., 1998), cardiac tissue (Davies 
et al., 2004) and skeletal muscle (Lamhonwah et al., 2010). 
2.1.3 Demographics of cystic fibrosis 
The demographics associated with CF are variable based upon nationality, sex 
and age. Therefore, an emphasis within this chapter is placed on the 
demographics of the CF population in the UK.  
2.1.3.1 Prevalence and incidence 
Cystic fibrosis currently affects ~11,000 people in the UK, with ~4,000 of these 
individuals under 16 years of age (Cystic Fibrosis Trust, 2017b). The CF 
population in the UK has increased steadily, as shown in Figure 2.6, and is 
predicted to increase to ~15,000 by 2025, a growth rate of 53.6% (Burgel et al., 
2015), due to improvements in management of the disease.  
This population equates to a prevalence (the proportion of actual cases) rate of 
approximately 1.37 per 10,000, which was the second highest in the European 
Union (EU) in the most recent analysis in 2008 (Farrell, 2008). This is behind the 
Republic of Ireland whose prevalence is the highest at 2.98 per 10,000. The 
prevalence rate of CF in the EU is 0.74 per 10,000, with rates of individual nations 
ranging from as low as 0.10 per 10,000 (Latvia), to above 1.00 per 10,000 (1.03 
in Belgium, 1.37 in the UK, and 2.98 in Ireland) (Farrell, 2008). The prevalence 
of CF in the United States of America (USA) (Farrell, 2008), the only country in 
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the world with a higher total number of patients than the UK, is 0.80 per 10,000. 
In 2016, the CF population of the USA was ~30,000 (Cystic Fibrosis Foundation, 
2017). 
 
The most recent estimated incidence (the probability of occurrence) of CF in the 
UK is 1:2381 (Farrell, 2008), suggesting one in nearly 2,500 births will result in a 
child born with CF. This rate is again second only to the Republic of Ireland, with 
an incidence rate of 1:1353 (Farrell, 2008). This is stark contrast to Japan, 
whereby an incidence of 1:350,000 is reported (Yamashiro et al., 1997), reflecting 
the genetic difference between ethnic groups. Currently, 1 in 25 people of 
Caucasian ethnicity are carriers of the recessive genes responsible for CF 
(Massie and Delatycki, 2013), resulting in a 25% chance of two carriers giving 
 
Figure 2.6 Increase in registered patients with cystic fibrosis in the United 
Kingdom from 2007-2016. Data adapted from Cystic Fibrosis Trust Registry 
(2009, 2013b, 2017b). *Decrease in registered patients due to ‘data cleaning’ 
exercise by Cystic Fibrosis Trust. 
Page 63 of 403 
 
birth to a child with CF.  
2.1.3.2 Age 
Most patients with CF are diagnosed early in life, due in part to the 
aforementioned new-born screening. In 2016, 247 new patients were diagnosed 
with CF, with 180 patients being diagnosed via new-born screening, and the 
median age of diagnoses being two months. Of these new diagnoses, 26 were 
over the age of 16. Of the children (<16 years) in the UK with CF, the majority 
(79%) were diagnosed in the three months following birth, with this increasing to 
93% in children <5 years of age. In contrast, of the adults (≥16 years) within the 
UK, a total of 16% were diagnosed over the age of 16, although the majority (57%) 
were diagnosed <1 year of age, and 78% being diagnosed ≤5 years of age (Cystic 
Fibrosis Trust, 2017b).  
The age of diagnosis is clinically important, and despite the presence of new-born 
screening, patients can still be diagnosed with CF relatively late in life, as 
described above (Cystic Fibrosis Trust, 2017b), either due to a negative new-
born screen (i.e. a negative immunoreactive trypsinogen, or no ‘ΔF508’ mutation), 
or a negative sweat test following a positive new-born screen. A recent 
retrospective review indicates that children who are diagnosed ‘late’ (mean age 
= 1.35 years), relative to those diagnosed immediately following birth (mean age 
= 0.12 years) have higher rates of respiratory illness, hospitalisation, chronic 
colonisation with Pseudomonas aeruginosa and worse lung function (Coffey et 
al., 2017). Furthermore, for adults (≥18 years) who are diagnosed later in life, an 
increased age at diagnosis is a significant predictor of reduced survival, with a 
24% increase in risk of death or transplant with each 5-year increase in age at 
diagnosis (Desai et al., 2018).  
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As noted previously, of the ~11,000 patients in the UK with CF, ~4,000 are under 
the age of 16. This distribution of ages is categorised further in Figure 2.7. The 
age distribution of patients with CF has changed over the past decade, with now 
over 60% of the CF population of the UK being over 16 years of age, as shown 
in Figure 2.8. This distribution reached a significant landmark in 2002 (UKCF 
Database, 2006), when the proportion of adults (i.e. ≥16 years) equalled the 
proportion of children (<16 years), marking an evolution away from being a 
predominantly paediatric condition  
 
 
 
 
 
Figure 2.7 Age distribution of patients with cystic fibrosis in the United Kingdom 
in 2016. Data adapted from Cystic Fibrosis Trust Registry (2017b). 
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This change in age distribution is reflected by a change in the median age of 
patients with CF in the UK, with this now standing at 20 years of age (Cystic 
Fibrosis Trust, 2017b), and has steadily increased over recent years, having been 
as low as 16.1 in 2003 (CF Registry Cystic Fibrosis Trust, 2009). Consequently, 
care teams and medical services have changed from being solely paediatric in 
nature and now include adult services either as independent units, often at 
different hospitals, or as a combined adult/paediatric service under the remit of 
the same hospital. Patients with CF will ‘transition’ from paediatric to adult 
services, with this being recommended to occur between 14-18 years of age 
(Cystic Fibrosis Trust, 2013a), although discussions can begin as young as 11 
years of age, with a view of completing the process by a patients 18th birthday 
 
Figure 2.8 Change in proportion of patients with cystic fibrosis over the age of 
16 in the United Kingdom from 2007-2016. Data adapted from Cystic Fibrosis 
Trust Registry (2009, 2013b, 2017b). 
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(Cystic Fibrosis Trust, 2016b).  
This process moves away from a prescriptive atmosphere in the paediatric 
environment, and places greater autonomy on the patient as opposed to parents 
and/or carers (Nazareth and Walshaw, 2013). This transition period is associated 
with a decline in pulmonary function, although this rate of change is not 
statistically significant (Duguépéroux et al., 2008). There is further conflicting 
evidence on changes in BMI, outpatient attendance and requirement for antibiotic 
treatment (Coyne et al., 2017). Such changes may be attributed to this time being 
a period of ‘flux’, during which patients must acclimate to a new care team 
(Tierney et al., 2013), as well as personal changes in social situations (work, 
study, relocation) (Duguépéroux et al., 2008) and therefore highlights the 
importance of monitoring functional changes through childhood and adolescence.  
2.1.3.3 Sex 
In the UK, ~53% of the CF population are male (Cystic Fibrosis Trust, 2017b), 
with this marginally larger proportion having fluctuated between 52-54% since 
2002 (CF Registry Cystic Fibrosis Trust, 2009, Cystic Fibrosis Trust, 2013b, 
2017b). The relative proportion of males and females is currently equal between 
the ages of 0-3 years, with 8.7% of the population of each respective sex being 
within this age bracket. After this, the proportion of females is higher until 20-23 
years, at which point the relative proportion of males is higher, as seen in Figure 
2.9 (Cystic Fibrosis Trust, 2017b). 
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Females with CF have been reported to have reduced QoL (Arrington-Sanders 
et al., 2006), increased rates of lung function decline (Corey et al., 1997) and 
earlier Pseudomonas aeruginosa acquisition (Demko et al., 1995). Furthermore, 
females have been shown to have a greater mortality risk (hazard ratio = 2.22, 
95% CI 1.79–2.77), even when controlling for lung function, BMI, genotype, 
pancreatic (in)sufficiency and microbiology (Harness-Brumley et al., 2014). 
Whilst precise mechanisms remain unclear, evidence suggests that female 
hormones may alter airway surface liquid (Coakley et al., 2008), cilia beat 
frequency (Jain et al., 2012) and mucoid conversion of Pseudomonas aeruginosa 
(Chotirmall et al., 2012).  
2.1.3.4 Life expectancy 
For patients today with CF, the median age of death is 31 years (Cystic Fibrosis 
Trust, 2017b), and this has steadily increased over the past decade (Figure 2.10). 
 
Figure 2.9 Relative distribution of patients with cystic fibrosis in the United Kingdom in 2016 
when separated by sex. Data adapted from Cystic Fibrosis Trust Registry (2017b). 
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In addition, there were 148 recorded deaths in 2017, totalling 1.5% of the national 
CF population. The age bracket with the highest number of deaths was 28-31 (n 
= 25). Encouragingly, there were fewer deaths in the 0-19 bracket than the 56+ 
group, with 8 and 15 respectively (Cystic Fibrosis Trust, 2017b).  
 
 
For new-born patients however, the median predicted survival age in the UK is 
higher than the current median age of death, and stands at 47 years (Cystic 
Fibrosis Trust, 2017b). Survival rates have increased significantly over the past 
40 years (Dodge et al., 2007, Hurley et al., 2014), and are up from 34.4 years as 
recently as 2009 (Cystic Fibrosis Trust, 2013b), with this figure historically having 
been under 5 years of age in 1960 (Elborn et al., 1991).  
 
Figure 2.10 Change in median age of death for patients with cystic fibrosis in 
the United Kingdom, from 2007-2016. Data adapted from Cystic Fibrosis Trust 
Registry (2017b). 
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With an increase in available data through national registries, a recent study 
conducted by Keogh et al. (2018) suggests that dependent on genotype, age of 
diagnosis and a present decline in annual mortality rates, life expectancy could 
increase up to 65 years for males and 56 years for females. This trend for an 
increase in life expectancy has also been reported for the EU as a whole, as well 
as constituent countries (Quintana-Gallego et al., 2016). Of interest, differing 
survival rates have recently been reported in North America. Canada has been 
reported to a have a median age of survival 10 years higher than the USA (50.9 
vs. 40.6 years), with disparities in healthcare access and delivery having been 
suggested as potential reasons (Stephenson et al., 2017), therefore highlighting 
the importance of understanding and accounting for healthcare delivery methods 
and systems in the management of CF.  
For these observed increases in life expectancy, factors such as early diagnosis, 
nutritional support, effective pulmonary medicines (Lopes-Pacheco, 2016), as 
well as the implementation of multiple, and increasingly personalised treatments, 
have all been acknowledged as contributors (see Figure 2.11 (Elborn, 2013)).  
Traditional clinical factors such as FEV1, BMI, genotype, pancreatic 
(in)sufficiency and pathogen acquisition have all been shown to be predictive of 
survival in CF (Harness-Brumley et al., 2014), as well as exercise derived factors 
such as V̇O2peak (Nixon et al., 1992, Pianosi et al., 2005a) and ventilatory 
equivalents for oxygen (minute ventilation/oxygen uptake; V̇E/V̇O2) (Hulzebos et 
al., 2014), therefore highlighting the importance to monitor exercise alongside 
traditional clinical factors.  
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Figure 2.11 Increases in life expectancy in cystic fibrosis, attributed to 
introduction of novel therapies. AZLI, aztreonam for inhalation solution; CF, 
cystic fibrosis; HTS, high throughput screening; rhDNase, recombinant human 
deoxyribonuclease; TIP, tobramycin inhalation solution. Reproduced with 
permission of the © ERS 2018. European Respiratory Review Mar 2013, 22 
(127) 3-5; doi: 10.1183/09059180.00008112. 
 
2.1.4 Treatment and management of cystic fibrosis 
Currently, there is no cure for CF, and whilst the identification of the genetic cause 
of CF has led to significant advances in the treatment of the disease, with 
resultant increases in life expectancy (Keogh et al., 2018), many new 
pharmacological products are: a) only targeted at a proportion of the CF 
population who possess a certain genotype (Ramsey et al., 2011); b) limited in 
their ability to physically correct for the structural defect (Kuk and Taylor-Cousar, 
2015); or c) too expensive for patients or health services (Balfour-Lynn, 2014).  
Therefore, CF is instead considered a disease that is managed, with a focus on 
alleviating the manifestations of the disease and associated symptoms. In mild-
to-moderate cases of the disease, this is done with a combination of treatments, 
including pharmacological treatments (e.g. antibiotics), nutrition, physiotherapy 
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and exercise (National Institute for Health and Care Excellence (NICE), 2017). In 
severe cases of the disease, lung transplantation is used to increase prognosis 
(Adler et al., 2009). However, this is not routine for all patients, as only 46 adults 
(16 years+) and ≤5 children (<16 years) received a lung transplant in 2016 (Cystic 
Fibrosis Trust, 2017b).  
2.1.4.1 Pharmacological treatment 
Pharmacological treatment in CF consists of a range of products, with its 
respective regimen being dependent on genotype, and current clinical and 
infection status. Given the genetic cause of CF, gene therapy (Koehler et al., 
2001) has presented a promising approach to disease management, however 
diffusion of vectors into the lung has proven more difficult than originally 
anticipated and has yet to demonstrate any clinical benefit (Griesenbach and 
Alton, 2013). Therefore, pharmacological treatment of CF currently includes 
antibiotics, inhaled mucolytics and more recently, CFTR modulators.  
Antibiotics can be administered for prophylaxis, eradication and control of 
bacterial and fungal species that are commonly found in the lung (Cystic Fibrosis 
Trust, 2009). Various regimens are possible, dependent on infection and clinical 
status, with the possibility of them being administered orally (Remmington et al., 
2016), intravenously (Hurley et al., 2015) or inhaled (Ryan et al., 2012a). 
Antibiotics can be delivered either as an in-patient, or within the home 
environment (Balaguer and Gonzalez de Dios, 2012) and either electively, or in 
response to symptoms (Breen and Aswani, 2012). However, optimal regimens 
and modalities remain variable between patients and are dependent on individual 
clinical profiles (Bhatt, 2013). 
Inhaled mucolytics such as mannitol (Hurt and Bilton, 2012), dornase alfa 
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(rhDNase, recombinant human deoxyribonuclease [Pulmozyme®]) (Fuchs et al., 
1994) and hypertonic saline (Enderby and Doull, 2007) work via differing 
mechanisms to reduce in vivo the viscosity of secretions, by either hydrolysing 
bonds within sputum, or increasing airway surface liquid and can augment airway 
clearance and facilitate expectoration (Rubin, 2015).  
Recent developments have sought to correct the basic cellular defect that results 
in CF, by altering the structure and function of the mutated CFTR protein on the 
cell membrane and are termed ‘modulators’. Dependent on a patient’s mutation, 
only certain products will be suitable, and there are currently three modulators 
that are commercially available for use. Ivacaftor (Kalydeco®) is one such 
modulator, designed for patients with gating (Class III) mutations such as ‘G551D’, 
by acting as a potentiator and improving Cl- transport through ion channels. 
Ivacaftor has been shown to improve lung function, QoL and sweat chloride 
(Davies et al., 2013). When ivacaftor is combined with the CFTR correctors 
lumacaftor and tezacaftor (to make Orkambi® and SymdekoTM respectively, and 
increase the volume of CFTR proteins at the cell surface), these resultant 
modulators have been shown to increase lung function and reduce the number 
of pulmonary exacerbations for patients homozygous for the ‘ΔF508’ mutation 
(Taylor-Cousar et al., 2017, Wainwright et al., 2015). However, as previously 
mentioned, limitations of only targeting certain genotypes (Ramsey et al., 2011), 
and price (Balfour-Lynn, 2014) of such modulators does limit their clinical impact.  
2.1.4.2 Nutrition 
Nutritional support in CF incorporates numerous strategies, dependent on an 
individual patients’ maintenance of body mass. Targets for patients (which vary 
by age) are based upon BMI percentiles (BMI%), a screening tool which has been 
validated for use in CF (McDonald, 2008). For example, in patients with CF 
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between 2 and 18 years of age, a BMI% between the 25th and 75th percentiles 
would be considered as having ‘normal’ nutritional status and only require 
preventative nutritional counselling as a management tool (Cystic Fibrosis Trust, 
2016a). However, a reliance on BMI% in children can mask stunted growth and 
therefore it should not be relied upon in isolation as a discrete score. Therefore 
changes in stature and body mass are considered alongside absolute BMI% 
scores in youth (Cystic Fibrosis Trust, 2016a). This is further compounded by 
differing timings and tempos of the onset of pubertal maturation in children, which 
can be delayed and slowed in children with CF (Zhang et al., 2013). 
In CF, nutritional management is predominantly focused upon a) supplementing 
diets with enzymes, vitamins and minerals, and b) increasing caloric intake. The 
primary supplement used is pancreatic enzyme replacement therapy (PERT), a 
mixture of amylase, lipase and protease, collectively known as pancrelipase 
(Creon®), whose use has been shown to be clinically effective in maintaining and 
improving nutritional status (Somaraju and Solis-Moya, 2016). In addition, 
supplementation of fat-soluble vitamins (A, D, E, K, B12), as well as minerals 
such as zinc, may be required if blood-tests reveal deficiencies (Dodge and Turck, 
2006). Alongside these supplements, the recommended energy intake for 
patients varies between 110-200% of that for an age- and sex-matched healthy 
population (Stallings et al., 2008).  
For patients whose body mass falls below the ‘normal’ BMI% boundaries of the 
25th-75th percentiles and have a sustained deviation below the 25th percentile, 
intensive nutritional support, such as a percutaneous endoscopic gastrostomy 
(PEG) may be required. This is a tube that is surgically placed through the 
abdominal wall, inserting directly into the stomach (Figure 2.12) and allows for 
additional calories to be digested overnight. Individual caloric requirements per 
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patient varying dependent on their current body mass status and target body 
mass (Cystic Fibrosis Trust, 2016a). Use of a PEG is clinically effective, 
improving nutritional status (i.e. BMI) and stabilising pulmonary function (FEV1) 
(Woestenenk et al., 2013). Presently, ~6% of patients with CF currently have a 
PEG (Cystic Fibrosis Trust, 2017b).  
 
A proportion of patients with CF are reported to be overweight (15%) and obese 
(8%) (Hanna and Weiner, 2015). Therefore nutritional management will focus on 
advice about healthy eating in order to facilitate loss of fat mass, whilst 
maintaining stature velocity for growing patients (i.e. children and adolescents) 
(Cystic Fibrosis Trust, 2016a). 
Finally, for individuals with a diagnosis of CFRD, regular assessment of blood 
glucose is required, and administration of insulin may be required (Cystic Fibrosis 
Trust, 2004). For patients who achieve good glycaemic control, evidence shows 
an improvement in clinical outcomes for body mass, pulmonary function (FEV1) 
and survival (Moran et al., 2010).  
 
Figure 2.12 Schematic diagram of a percutaneous endoscopic gastrostomy, 
presented in a cross-sectional view. From Sohagia and Hertan (2012). Reprinted by 
permission from Springer Customer Service Centre GmbH: Springer, Geriatric 
Gastroenterology by C.S. Pitchumoni & T.S. Dharmarajan (Eds.) © (2012) doi: 
10.1007/978-1-4419-1623-5_13. 
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2.1.4.3 Physiotherapy 
Physiotherapy for CF management predominantly consists of airway clearance 
therapy (ACT) to remove sputum from airways. Many different techniques are 
available and are broadly split into those that can be performed by a patient 
independently of a physiotherapist; forced expiratory breathing techniques and 
device-dependent techniques; and those that require assistance in the form of 
manual techniques (Main et al., 2015).  
Breathing techniques, such as autogenic drainage and the active cycle of 
breathing, utilise breaths of varying depths and frequencies to facilitate 
movement of sputum from peripheral airways for clearance and are effective in 
producing clinically significant sputum yields (Morgan et al., 2015), although 
neither have been shown to be any more effective than other airway clearance 
techniques (McCormack et al., 2017, McKoy et al., 2016). Positive expiratory 
pressure (PEP) devices provide resistive pressure to the airways during 
exhalation and are of clinical benefit by significantly reducing the number of 
pulmonary exacerbations experienced (McIlwaine et al., 2015). Furthermore, 
oscillating PEP (OPEP) devices (such as the Flutter®, Acapella® and Aerobika®) 
generate intra- and extra-thoracic oscillations alongside PEP to mobilise mucus 
(Morrison and Innes, 2017). A retrospective review shows that ~25% of people 
with CF utilise OPEP devices as a modality of ACT (Figure 2.13) (Hoo et al., 
2015), however their use has not been shown to be any more, or less, effective 
than any other form of chest physiotherapy for CF (Morrison and Innes, 2017). 
Manual techniques, such as postural drainage or percussion, have historically 
been used in the management of CF. However, data indicates that there is no 
clinical benefit over newer ACT devices (Main et al., 2005), and few patients (4%) 
opt for such modalities (Figure 2.13) (Hoo et al., 2015). 
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Airway clearance therapies are combined with mucolytics to further facilitate 
sputum expectoration, and administration of rhDNase prior to ACT improves 
small airway patency in children with CF (van der Giessen et al., 2007). However, 
a lack of conclusive evidence on timing of mucolytics (Dentice and Elkins, 2016) 
has resulted in guidelines personalised to each patient (McIlwaine et al., 2017), 
and directed around by patient preference (Cystic Fibrosis Trust, 2017a). 
In addition to ACT, use of inspiratory muscle training (IMT) has been proposed 
as a modality to improve lung function. Individual studies have shown 
improvements in maximal inspiratory pressure (Sawyer and Clanton, 1993) and 
inspiratory muscle endurance (de Jong et al., 2001), but not traditional pulmonary 
variables of FEV1 or FVC (Houston et al., 2008), nor exercise endurance (Bieli et 
 
Figure 2.13 Airway clearance techniques used by patients with cystic fibrosis 
in the United Kingdom. PEP, positive expiratory pressure; PWCF, patients with 
cystic fibrosis. Reprinted from Physiotherapy, 101, Hoo et al., Airway clearance 
techniques used by people with cystic fibrosis in the UK, p342., © 2015, with 
permission from Elsevier. 
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al., 2017). Given differences in reported outcomes and discrepancies in study 
designs, a systematic review has failed to confirm, nor refute, the efficacy of IMT 
as a treatment option in CF (Houston et al., 2008). 
Compliance with treatments varies between patients and their respective 
modalities of treatment. However, it has been reported that ACT and nebulisers 
have a lower adherence rate than CFTR modulators and antibiotics (Narayanan 
et al., 2017), with availability of time, and lack of enjoyment of ACT, being cited 
as primary reasons behind such non-compliance (Flores et al., 2013). 
Furthermore, the need to ensure airway clearance devices remain clean for 
infection prevention purposes (Manor et al., 2017), can only add to the daily 
treatment burden of patients, which averages over 100 minutes per day, of which 
airway clearance and nebulisers contribute the majority of this time (Sawicki et 
al., 2009). Given the notable burden associated with ACT, a recent ‘Patient 
Setting Partnership’ between patients, carers and clinicians has developed the 
research priority of “Can exercise replace chest physiotherapy for people with 
cystic fibrosis?” (Rowbotham et al., 2018) – thus highlighting the importance of 
utilising exercise in the management of CF. 
2.1.4.4 Exercise  
As previously noted, the role of exercise in the management of CF has been 
highlighted as a patient priority as an alternative form of ACT (Rowbotham et al., 
2018) and currently 16% of patients in the UK use exercise as their primary mode 
of airway clearance (Hoo et al., 2015). In addition to being used for ACT, and 
improving and maintaining pulmonary function (as described below), exercise 
training is also utilised as a conditioning tool prior to, and following, lung 
transplantation in end-stage disease (Cystic Fibrosis Trust, 2017a, Hirche et al., 
2014, Wickerson et al., 2010) 
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Acute bouts of exercise have been shown to aid sputum expectoration, both 
independently of (Dwyer et al., 2011), and in conjunction with (Kriemler et al., 
2016) regular chest physiotherapy. This is potentially due to increased water 
content of mucus (Hebestreit et al., 2001) and resultant increases in airway 
surface hydration following exercise, as well as the oscillations of the trunk 
caused by exercise (Dwyer et al., 2011). In addition, an acute bout of maximal 
exercise significantly improves both FEV1, and lung clearance index (LCI; a 
functional measure of peripheral airway obstruction), increasing within a 10 
minute period following an exercise test to volitional exhaustion (Tucker et al., 
2017). Whilst the mechanisms for increased FEV1 are unclear, it has been 
suggested that the improvements in LCI are due to attenuation of dynamic 
hyperinflation (Tucker et al., 2017), but also improved mucociliary clearance, as 
previously described (Dwyer et al., 2011, Tucker et al., 2017).  
Further to these clinically valuable effects of acute bouts of exercise, exercise 
training has multiple benefits for individuals with CF. Aerobic exercise training 
such as running and cycling has been shown to improve FEV1 following both 
short-term (~3 weeks) (Selvadurai et al., 2002a) and long-term (3 months) 
(Kriemler et al., 2013) interventions, as well as offsetting the rate of annual 
decline in FEV1 over a period of three years, relative to a control group of patients 
(Schneiderman-Walker et al., 2000). In addition to FEV1, V̇O2max has been shown 
to improve following aerobic training for children not only when supervised as an 
in-patient (Selvadurai et al., 2002a), but also when unsupervised as an out-
patient (Hommerding et al., 2015). Furthermore, aerobic training has been shown 
to increase QoL (Selvadurai et al., 2002a), affect positive attitudes towards PA 
(Schneiderman-Walker et al., 2000), increase general self-worth and perceptions 
surrounding physical appearance (Gulmans et al., 1999), reduce breathlessness 
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(O'Neill et al., 1987) and increase sputum expectoration (Salh et al., 1989).  
Increases in FEV1 have been identified one-month and 18-months following 
anaerobic training by Selvadurai et al. (2002a) and Kriemler et al. (2013) 
respectively. In addition to FEV1, anaerobic training significantly improved V̇O2peak 
(Kriemler et al., 2013), physical functioning domains of QoL (Klijn et al., 2004) 
and strength and fat-free mass (FFM, (Selvadurai et al., 2002a)) – factors which 
are likely causatively related. Furthermore, when aerobic and anaerobic training 
are combined, glycaemic control is improved, with reductions in plasma glucose 
following an oral glucose tolerance test, and increases in insulin sensitivity being 
reported (Beaudoin et al., 2017). 
Resistance training has been shown to improve FEV1 (Selvadurai et al., 2002a, 
Shaw et al., 2016), V̇O2peak (Sosa et al., 2012), as well as muscular strength when 
undertaken alongside aerobic training as a supervised inpatient (Sosa et al., 
2012), as an independent mode of training (Selvadurai et al., 2002a), and when 
combined with daily nebuliser treatment (Shaw et al., 2016).  
Responses of V̇O2peak to exercise training in CF have been shown to be 
dependent on baseline fitness levels, independent of lung function, with larger 
increases seen in individuals with a lower baseline fitness (Gruber et al., 2011a), 
a response that is similarly seen in non-CF populations (Skinner et al., 2001). 
Further to baseline fitness, it has been shown that there is no effect of sex in 
responsiveness to training programmes, with males and females showing a    
11.1% and 9.9% increase in V̇O2peak respectively following a six-week mixed 
training programme, consisting of aerobic and resistance exercises (Gruber et al., 
2011b).  
With the breadth of exercise training programmes available, and variances in 
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improvements and maintenance of function, a recent systematic review 
concluded insufficient evidence to promote one modality as superior to another 
(Radtke et al., 2017b). As such, few guidelines have been published, with only a 
single consensus document from the European CF Society being produced 
(Swisher et al., 2015) in addition to generic recommendations from individual 
research groups (Boas, 1997, Williams and Stevens, 2013). Furthermore, the 
authors of the systematic review stated that there is no evidence to suggest that 
exercise should be discouraged (Radtke et al., 2017b). This is further supported 
by a number of exercise training studies that have reported no occurrence of 
adverse events (Kriemler et al., 2013, Santana-Sosa et al., 2014, Sosa et al., 
2012). In addition, a survey of German CF centres and patients identified <1% of 
patients suffered an adverse event during in-patient exercise, but 22% of patients 
reported an asthma attack (or shortness of breath) whilst undertaking out-patient 
exercise (Ruf et al., 2010). Moreover, cases of haemoptysis (3%), hypoglycaemia 
(<1%) and loss of consciousness (<1%) are all low, thus affirming the safety of 
exercise training. 
 Exercise in cystic fibrosis 
Exercise is a fundamental component of CF management and all patients are 
actively encouraged to undertake regular exercise trust (Cystic Fibrosis Trust, 
2017a, National Institute for Health and Care Excellence (NICE), 2017), with 
many different exercise training interventions having been developed to further 
improve exercise capacity (Radtke et al., 2017b). As exercise intolerance (i.e. a 
failure to achieve exercise responses considered normal for age and gender 
(Owens and Gutin, 2000)) is a hallmark of disease progression (Orenstein and 
Higgins, 2005), regular assessment is required for both prognostic and diagnostic 
purposes, as well as prescription of personalised exercise regimens (Williams et 
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al., 2014). Moreover, clinicians in the UK identify exercise training, as well as 
exercise testing (to determine exercise capacity), as an important component of 
a patients’ treatment regimen (Stevens et al., 2010) (Figure 2.14).  
 
It is well established that CF adversely affects the cardiovascular, metabolic and 
muscular systems, in addition to the pulmonary system itself (Ferrazza et al., 
2009). Given the integration of these systems through the oxygen transport and 
consumption pathway (Milani et al., 2004) (Figure 2.15), it is prudent to assess 
these systems simultaneously, both at rest and under metabolic stress. Exercise 
testing offers the simultaneous evaluation of all these systems and can allow 
clinicians and physiologists to determine underlying causes of exercise limitation 
in chronic diseases, such as CF (Palange et al., 2007). 
 
 
Figure 2.14 The relative importance assigned by clinicians of both exercise 
testing and exercise training in the management of cystic fibrosis in the United 
Kingdom. Reprinted from Journal of Cystic Fibrosis, 9, Stevens et al., A survey 
of exercise testing and training in UK cystic fibrosis clinics, p304., ©2010, with 
permission from Elsevier. 
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When considering exercise testing to determine exercise capacity, there are 
multiple procedural factors to consider, including modality, protocols and 
outcome variables. Therefore, exercise capacity has multiple possible definitions, 
dependent on the way it is assessed (field tests vs. laboratory tests) and which 
variables are utilised (e.g. aerobic, aerobic and/or functional parameters). Direct 
measurement of aerobic power through the use of cardiopulmonary exercise 
testing (CPET; a ‘gold standard’ procedure), is now recommended by the ECFS 
and ERS (Hebestreit et al., 2015).  
2.2.1 Exercise (dys)function in cystic fibrosis 
Studies using CPET in CF have consistently shown reduced exercise capacity in 
adults (e.g. Moorcroft et al. (2005), Gruet et al. (2010), Rodriguez-Miguelez et al. 
 
Figure 2.15 Schematic showing the integration of the musculoskeletal, 
cardiovascular and pulmonary systems in their contribution towards the oxygen 
consumption pathway and contributing factors to exercise intolerance for each 
system. Reprinted with permission of a) Milani et al., Cardiopulmonary exercise 
testing: how do we differentiate the cause of dyspnoea?, Circulation, 110(4), 
pe28, doi: 10.1161/01.CIR.0000136811.45524.2F, and b) Wasserman, 
Principles of Exercise Testing and Interpretation, 3rd Ed., ©Wolters Kluwer 
2004. 
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(2016)), for whom progressive disease severity with age will impact upon exercise 
capacity. Exercise capacity has been reported to be higher in children and 
adolescents than adults with CF (40.1 ± 6.3 vs. 32.0 ± 9.5 mL.kg-1.min-1, Causer 
et al. (2018)), given that disease status is typically less severe than their adult 
counterparts, although a longitudinal observation by Pianosi et al. (2005b) has 
shown an annualised decline of 2 mL.kg-1.min-1 per year over a five-year period 
in children and adolescents with CF. 
Exercise capacity in children and adolescents with CF is still markedly reduced 
relative to non-CF peers (Table 2.2). All studies in Table 2.2 have utilised cycle 
ergometery to elicit maximal exercise, and exercise capacity is presented at 
V̇O2peak. However, a further two studies in this table (Saynor et al., 2014b, Saynor 
et al., 2016b) have utilised supramaximal (Smax) verification bouts and therefore 
data for these studies is presented as V̇O2max (the conceptual issue difference 
between V̇O2peak and V̇O2max is elaborated upon further in Chapter 2.2.3.2). Even 
though some studies do not reach statistical significance, the associated effect 
sizes (ES, Cohen (1992)) that indicate reduced V̇O2peak/V̇O2max in CF are shown 
to be ‘moderate’ in size (≥ 0.5), which are likely to be deemed meaningful and 
would become statistically significant with increased sample sizes (e.g. Poore et 
al. (2013), Tucker et al. (2018)). Furthermore, the data in Table 2.2 highlights the 
importance of considering body size when interpreting exercise capacity. For 
example, in Saynor et al. (2016b), there is no statistically significant difference 
between CF and control participants when V̇O2max is expressed in absolute terms 
(i.e. L.min-1), but there is when expressed relative to body mass (mL.kg-1.min-1), 
but not fat-free mass (mL.kgFFM-1.min-1). Similar differences between groups 
dependent upon body size are seen in further studies, where both p values 
(Tucker et al., 2018) and effect sizes (Bongers et al., 2012) change.
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Table 2.2 Summary of studies examining differences in exercise capacity between children and adolescents with cystic fibrosis, and non-cystic fibrosis control 
participants. 
 Group Characteristics Group Exercise Capacity (V̇O2max or V̇O2peak)   
Study CF CON CF CON p Value ES 
Bongers et al. 
(2012) 
n = 22, 13M/9F 
15.7 ± 1.5 y 
n = 22, 13M/9F 
14.2 ± 1.5 y 
2222.1 ± 547.5 mL.min-1 
40.9 ± 7.9 mL.kg-1.min-1 
91.7 ± 18.1 %Predicted (kg-1)a 
2677.4 ± 698.6 mL.min-1 
49.9 ± 7.9 mL.kg-1.min-1 
111.9 ± 18.9 %Predicted (kg-1)a 
<0.05 
<0.001 
<0.01 
0.73 
1. 14 
1.09 
Bongers et al. 
(2014b) 
n = 22, 12M/10F 
14.3 ± 1.3 y 
n = 22, 12M/10F 
14.3 ± 1.4 y 
2126 ± 516 mL.min-1 
42.4 ± 8.7 mL.kg-1.min-1 
2638 ± 685 mL.min-1 
49.1 ± 7.2 mL.kg-1.min-1 
0.01 
<0.01 
0.84 
0.84 
Fielding et al. 
(2015)$ 
n = 16, 6M/10F 
13.1 ± 3.9 y 
n = 15, 6M/9F 
13.6 ± 2.7 y 
1.5 ± 0.7 L.min-1 
70.1 ± 14.3 %Predicted b 
1.8 ± 0.7 L.min-1 
85.4 ± 16.0 %Predicted b 
0.165 
0.009 
0.43 
1.01 
Keochkerian et 
al. (2008) 
n = 9, 7M/2F 
12.6 ± 1.3 y 
n = 9, 7M/2F 
13.3 ± 0.5 y 
34.7 ± 8.4 mL.kg-1.min-1 49.2 ± 4.0 mL.kg-1.min-1 <0.001 2.20 
Moser et al. 
(2000)$$ 
n = 22, 8M/14F 
10.3 ± 3.3 y 
n = 54, 17M/37F 
9.3 ± 0.7 y 
956 ± 380 mL.min-1 1473 ± 397 mL.min-1 <0.001 8.23 
Nixon et al. 
(2001) 
n = 30, 18M/12F 
10.8 ± 2.9 y 
n = 30, 17M/13F 
11.4 ± 2.2 y 
36.5 ± 8.3 mL.kg-1.min-1 41.4 ± 8.9 mL.kg-1.min-1 0.036 0.57 
Poore et al. 
(2013) 
n = 15, 5M/10F 
12.6 ± 3.4 y 
n = 15, 6M/9F 
13.6 ± 2.7 y 
1.44 ± 0.68 L.min-1 
32.8 ± 6.2 mL.kg-1.min-1 
71 ± 14 %Predicted b 
1.81 ± 0.71 L.min-1 
36.6 ± 8.6 mL.kg-1.min-1 
85 ± 16 %Predicted b 
0.156 
0.178 
0.016 
0.53 
0.51 
0.93 
Saynor et al. 
(2014b) 
n = 10, 9M/1F 
12.7 ± 2.8 y 
n = 10, 9M/1F 
12.5 ± 2.8 y 
1.93 ± 0.84 L.min-1 
36.3 ± 7.6 mL.kg-1.min-1 
45.5 ± 9.1 mL.kgFFM-1.min-1 
2.21 ± 0.79 L.min-1 
43.9 ± 5.2 mL.kg-1.min-1 
53.5 ± 6.4 mL.kgFFM-1.min-1 
0.45 
0.01 
0.03 
0.34 
1.11 
0.96 
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Saynor et al. 
(2016b) 
n = 7, 5M/2F 
13.5 ± 2.8 y 
n = 7, 5M/2F 
13.6 ± 2.4 y 
2.08 ± 0.74 L.min-1 
34.30 ± 8.88 mL.kg-1.min-1 
51.87 ± 34.90 mL.kgFFM-1.min-1 
2.51 ± 0.91 L.min-1 
47.75 ± 3.56 mL.kg-1.min-1 
65.52 ± 24.65 mL.kgFFM-1.min-1 
0.34 
<0.01 
0.42 
0.49 
1.79 
0.42 
Stevens et al. 
(2011) 
n = 19, 9M/10F 
13.4 ± 3.1 y 
n = 19, 9M/10F 
13.8 ± 3.5 y 
35 ± 8 mL.kg-1.min-1 
43 ± 9 mL.kgFFM-1.min-1 
44 ± 12 mL.kg-1.min-1 
54 ± 13 mL.kgFFM-1.min-1 
0.01 
0.01 
0.88 
0.98 
Stevens et al. 
(2015) 
n = 19, 9M/10F 
13.4 ± 3.2 y 
n = 19, 9M/10F 
13.8 ± 3.5 y 
79.8 ± 16.9 %Predicted b 101.3 ± 22.5 %Predicted b <0.01 1.08 
Tucker et al. 
(2018) 
n = 14, 6M/8F 
14 ± 3 y 
n = 14, 6M/8F 
14 ± 3 y 
33.0 ± 6.2 mL.kg-1.min-1 
43.7 ± 6.8 mL.kgFFM-1.min-1 
74 ± 12 %Predicted b 
36.4 ± 8.9 mL.kg-1.min-1 
50.4 ± 7.6 mL.kgFFM-1.min-1 
85 ± 16 %Predicted b 
0.252 
0.022 
0.054 
0.44 
0.93 
0.78 
 
CF, cystic fibrosis; CON; control; ES; effect size (Cohen’s d, (Cohen, 1992)), FFM = fat-free mass.  
All valued presented as mean (± standard deviation). Significant (p < 0.05) differences highlighted in bold. 
a. Reference values from Ten Harkel et al. (2011)  
b. No reference provided for calculation of %Predicted.  
$ V̇O2peak data also expressed to mL.kg-1.min-1 (p = 0.136) and mL.kgFFM-1.min-1 (p = 0.014) in figures, but exact values not provided by authors.  
$$ V̇O2peak data also expressed to mL.kg-1.min-1 (p < 0.001) and mL.min-1.cm-2 (p < 0.001) (thigh muscle cross-sectional area) in figures, but exact 
values not provided by authors. 
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2.2.2 Clinical importance of exercise capacity in cystic fibrosis 
Measures of exercise capacity provide useful prognostic information within the 
management of CF, above and beyond traditional lung function parameters. Of 
greatest clinical importance in CF, exercise capacity (V̇O2peak) is predictive of 
mortality in both adults (Nixon et al., 1992) and children (Pianosi et al., 2005a). 
Independent of changes in lung function (FEV1), both longitudinal studies have 
identified significant rates of mortality associated with lower fitness levels. When 
split into tertiles based upon baseline aerobic fitness, both studies identify an 
approximate 70% mortality rate in the groups with lowest fitness (≤58 %Predicted, 
(Nixon et al., 1992); ≤32 mL.kg-1.min-1, (Pianosi et al., 2005a), and higher survival 
rates in the groups with higher fitness; 83% in adults with V̇O2peak ≥82 %Predicted 
(Nixon et al., 1992), and 100% in children with a V̇O2peak >45 mL.kg-1.min-1 
(Pianosi et al., 2005a) (Figure 2.16).  
 
Figure 2.16 Survival among adults (A) and children (B) with cystic fibrosis, when divided 
by aerobic fitness (V̇O2peak). A: Reproduced with permission from Nixon et al. (1992) New 
England Journal of Medicine, 327(25), p1786. ©Massachusetts Medical Society. B: 
Reproduced from Thorax, Pianosi et al., 60 (1), p52, ©2005 with permission from BMJ 
Publishing Group Ltd. 
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Further to V̇O2peak, an elevated breathing reserve index (BRI), which represents 
the ratio between V̇E and maximal voluntary ventilation (MVV), at the lactate 
threshold (LT) is a further predictor of mortality (Tantisira et al., 2002). When the 
BRI at the LT is elevated (≥0.7), a relative hazard risk of 17.5 (p = 0.004) is 
present. To contextualise this result, the hazard risk for FEV1 at the same time 
(when BRI and FEV1 were included in the same multivariate model) was 1.19 (p 
= 0.005). Whilst the magnitude of this result is exceptionally large, it should be 
noted that this study was undertaken solely in patients with CF awaiting lung 
transplantation, and therefore already have severe disease, as shown by 
baseline FEV1 of the cohort who survived the length of the study (n = 30, FEV1 = 
27.3 ± 10.3 %Predicted). 
An increased aerobic fitness is also associated with a reduced risk of 
hospitalisation (Pérez et al., 2014). When considered as independent factors (i.e. 
univariate modelling) contributing towards a risk of admission for an acute 
exacerbation requiring antibiotics, variables of FEV1, FVC, blood oxygen 
saturation (SpO2) and V̇O2peak are all significant predictors. However, when 
considered in a multivariate model, only V̇O2peak significantly predicts 
hospitalisation risk above and beyond age, sex, FEV1, BMI and SpO2.  
In addition to offsetting major ‘endpoints’ of death and hospitalisation, a low 
V̇O2peak is associated with poor glucose tolerance (Foster et al., 2017). Patients 
with CFRD have been identified as having a lower aerobic fitness than patients 
with normal glucose tolerance (33.0 ± 7.7 vs. 41.3 ± 9.4 mL.kg-1.min-1, p = 0.01), 
even though all patients had a preserved FEV1. A lower V̇O2peak is also 
significantly correlated with a higher number of antibiotic treatments over a prior 
three-year period (Vandekerckhove et al., 2017). An increased V̇O2peak is 
additionally associated with higher levels of QoL. Numerous domains of QoL are 
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positively correlated with exercise capacity, including physical functioning (r = 
0.37, p < 0.01), role limitations (r = 0.32, p < 0.05), health perception (r = 0.40, p 
< 0.001) and respiratory symptoms (r = 0.42, p < 0.001) (Hebestreit et al., 2014). 
Exercise capacity (as determined by distance walked in the 6 Minute Walk Test 
[6MWT]) is also used in the calculation of a ‘Lung Allocation Score’ (LAS), to 
prioritise patients awaiting lung transplantation. A walking distance < 150 feet in 
a 6MWT contributes towards a higher LAS, which in turn increases their priority 
for surgery (Egan et al., 2006). An analysis of ~1,400 transplants over a seven 
year period in the USA found that of patients with a higher LAS (≥50), 26.7% had 
a 6MWT score <150 feet, in contrast to 8.5% of patients with a LAS <50 at the 
time of surgery (Braun et al., 2015). The 6MWT score is considered alongside 
traditional factors of FVC, BMI and age, but also factors such as the need for 
supplemental O2 at rest and continuous mechanical ventilation (Braun et al., 
2015), highlighting the importance of exercise testing in screening for functional 
capacity in CF.  
Beyond maximal variables (such V̇O2peak), submaximal parameters derived from 
exercise testing have clinical importance in CF. The gas exchange threshold 
(GET) is related to disease severity (Thin et al., 2002) and the peak ventilatory 
equivalent for oxygen (V̇E/V̇O2) is also predictive of mortality in adolescents with 
CF (Hulzebos et al., 2014).  
2.2.3 Assessment of exercise capacity in cystic fibrosis 
Given the clinical importance of exercise in the assessment and treatment of CF, 
national and international guidelines stipulate that exercise testing should occur 
on at least an annual basis (Cystic Fibrosis Trust, 2017a, Hebestreit et al., 2015, 
National Institute for Health and Care Excellence (NICE), 2017). The use of CPET 
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is identified as the ‘gold standard’ technique, and has recently been advocated 
by the ECFS ‘Exercise Working Group’ as the preferred method of assessing 
exercise tolerance in CF youth, a position which is further endorsed by the ERS 
(Hebestreit et al., 2015). However, the protocol of choice within the position 
statement from Godfrey et al. (1971) has a number of methodological issues 
pertaining to validity and reliability which have been raised by Saynor et al. 
(2016a). However, the concept that CPET should be utilised wherever possible 
is a welcome one, leading the way for the phasing out of previously used field 
tests – a number of which are summarised below.  
2.2.3.1 Field tests 
Prior to the widespread endorsement and advocacy of CPET, exercise capacity 
has previously been assessed using field tests. A survey by Stevens et al. (2010) 
identified that 37% of clinics utilise a modified shuttle test (MST), and 24% a 
6MWT to assess exercise capacity in their patients with CF. The MST, developed 
by Singh et al. (1992) has been shown to be valid (Bradley et al., 1999) and 
reliable (Bradley et al., 2000) in adults with CF, based upon the high correlation 
between MST distance covered and body-mass relative V̇O2peak from a treadmill 
test (r = 0.95, p < 0.01). Furthermore, the MST is apparently valid and 
reproducible in children with CF, again due to a high correlation (r = 0.91) 
between MST distance covered and body-mass relative V̇O2peak (Selvadurai et 
al., 2003). However, a consistent underestimation of V̇O2peak is present (-5.30 ± 
4.63 mL.kg-1.min-1) when compared to a measured V̇O2peak using a treadmill 
protocol. In addition to the MST, the 6MWT is deemed valid and reliable in 
children and adolescents, due to high correlations between walking distance and 
absolute V̇O2peak (r = 0.76, p < 0.001) as well as between two tests when 
performed one-week apart (r = 0.90, p < 0.001) (Gulmans et al., 1996). However, 
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these analyses assessing the MST and 6MWT have largely inferred validity on 
the basis of high correlation coefficients, which fail to account for systematic bias 
between measures. Therefore, the suitability of these field tests as suitable 
alternatives to CPET is called into question.  
Further to the MST and 6MWT, the one-minute sit-to-stand (Gruet et al., 2016) 
and 3-minute step (Narang et al., 2003) tests have been developed. However, 
they have not been found to be suitable replacements for CPET as they fail to 
elicit similar physiological responses (i.e. HRmax, SaO2) as maximal exercise tests, 
and hold no clinical prognostic relevance (unlike CPET).  
The advantage of field testing procedures is that they typically have minimal costs 
associated with them, can be easily implemented with few time, facility, or staffing 
constraints, and provide an opportunity for patients with CF to undertake a 
physical assessment of their exercise tolerance in lieu of CPET. However, results 
hold limited clinical value, protocols are limited in their ability to directly identify 
causes of fatigue and underlying dysfunction (Hebestreit et al., 2015) and there 
is a risk of over-, or under-reporting, performance and function. This in turn can 
have clinical consequences, such as an exaggerated risk of hospitalisation and 
therefore it is clear that ‘gold-standard’ CPET procedures are preferred to 
determine exercise capacity. 
2.2.3.2 Cardiopulmonary exercise testing (CPET) 
Cardiopulmonary exercise testing, in contrast to field tests, makes a direct 
measurement of exhaled gases at the mouth (i.e. O2, CO2) and based upon the 
respective volume of these gases (i.e. V̇O2 and V̇CO2) utilised and generated 
during exercise, researchers and clinicians can identify the energy cost of 
exercise, as well as contributing fuel sources (i.e. carbohydrate, lipids).  
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It has been long established that the oxygen cost of exercise increases with the 
amount of work done (Hill and Lupton, 1923), and that there is a physiological 
upper limit to oxygen consumption (V̇O2max) (Astrand and Saltin, 1961). It is the 
process of eliciting this upper limit to exercise tolerance that forms the basis of 
CPET, with differing modalities (e.g. cycling, running) and protocols (e.g. step, 
ramp) available which increase the amount of work the human body is required 
to undertake.  
Treadmill based protocols utilise increases in speed and incline to increase the 
workload upon the body, with the Bruce protocol (Bruce et al., 1973) being the 
most popular for use (Hebestreit et al., 2015). Whilst the reliability of this protocol 
has been established in a clinical group of children (those with heart murmurs; 
Cumming et al. (1978)), no such data are available for children with CF.  
Primary outcomes of the Bruce protocol (as with all CPET protocols) do include 
V̇O2peak and exercise duration, factors which are in turn associated with traditional 
markers of pulmonary function of FEV1 (Klijn et al., 2003, Pouliou et al., 2001). 
When analysis of pulmonary gas exchange is not available for directly 
determining V̇O2peak, it may be estimated using existing equations (Foster et al., 
1984, Pollock et al., 1982), although the validity of such equations in CF is 
unknown. Furthermore, calculation of WRpeak is possible, although, this requires 
a function of the patient’s body mass, gravitational constant (g; 9.81 m.s-2), final 
incline grade and velocity, as well as time spent on the final stage; a calculation 
that is less accurate than cycle ergometry (Hebestreit et al., 2015). 
Finally, the Bruce protocol has been used to longitudinally monitor exercise 
capacity (Klijn et al., 2003), as well as responses to training (Selvadurai et al., 
2002a) in children with CF. Therefore, this highlights the clinical utility of treadmill 
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testing as a feasible option when undertaking CPET, however there are several 
practical considerations that favour the use of cycle ergometry instead, which are 
elaborated upon below. 
The results of a survey by Ruf et al. (2010) identified no adverse reactions 
associated with exercise testing, although a small number of adverse events were 
recorded by patients with regards to general exercise and activity. These include 
shortness of breath, arthritis and hypoglycaemia, although their relative incidence 
was each <1% per 1,000 patient years. Whilst the survey of Ruf et al. (2010) did 
not identify testing modalities in their survey, it can be argued that a cycle 
ergometer poses fewer risks than a treadmill. Patients who are deconditioned 
have no risk of falling off the cycle ergometer (unlike the risk of falling off a 
treadmill due to a failure to maintain speed); it is easier to terminate exercise 
safely in the case of adverse events; and provides patients with greater control 
of their test, as they can cease exercising immediately if they wish, without the 
need for a treadmill belt to slow, or stop completely. 
The cycle ergometer protocol that is currently endorsed for use by the ECFS is 
the Godfrey protocol (Godfrey et al., 1971), a step incremental test that increases 
work rate based upon a patients stature; either 10 W.min-1 (<120 cm), 15 W.min-
1 (120-150 cm), or 20 W.min-1 (>150 cm). A number of methodological issues 
have been associated with this protocol, notably a lack of validity and reliability 
data in CF (Saynor et al., 2016a). Furthermore, to determine a maximal effort, 
this protocol is reliant upon a plateau in V̇O2 and secondary criteria to verify 
whether a maximal test has been achieved, whereas Smax verification should be 
utilised. In paediatric studies, the secondary criteria include reaching a maximal 
heart rate (HRmax) at or above age-predicted maximum (i.e. 220 – age), a HRmax 
of 95% age-predicted maximum or a HR of 180 beats.min-1; a respiratory 
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exchange ratio (RER) of >1.00, 1.03, 1.05, or 1.10; subjective ratings of perceived 
exertion (RPE) of 9-10 on a 0-10 scale, or ≥17 on a 6-20 scale; and blood lactate 
≥6 mmol.L-1 (Hebestreit et al., 2015, Saynor et al., 2013a). As noted from the list 
of secondary criteria, there are numerous cut-offs to be chosen from, which itself 
poses methodological discrepancies between studies. However, it has also been 
observed that such cut points typically occur at submaximal points of incremental 
exercise in children and adolescents with CF (Saynor et al., 2013a). Furthermore, 
during incremental exercise to exhaustion, only ~1/3 of children without CF will 
exhibit a plateau in V̇O2 (Armstrong et al., 1996, Barker et al., 2011). These 
factors can therefore lead to an under-reporting of V̇O2max, and this subsequently 
explains why the term ‘V̇O2peak’ is utilised instead in the absence of a plateau. 
To circumvent the reliance upon inadequate secondary criteria and truly ascertain 
whether a ‘V̇O2max’ has been reached (as opposed to ‘V̇O2peak’), a two-stage 
exercise test on a cycle ergometer is used. This protocol utilises a combined ramp 
incremental phase and Smax verification bout, as shown in Figure 2.17. The utility 
of Smax verification testing has been widely researched (Barker et al., 2011, Day 
et al., 2003, Rossiter et al., 2006) and reviewed (Schaun, 2017), with a recent 
‘Cores of Reproducibility in Physiology’ (CORP) statement advocating its use in 
CPET as a ‘gold standard’ (Poole and Jones, 2017). 
The work rate increments for the ramp phase are individualised to each patient 
and guided by existing equations to estimate peak power, based upon 
anthropometric and lung function data (Hulzebos et al., 2012), instead of arbitrary 
values for stature as per Godfrey et al. (1971). Following completion of a ramp 
stage to volitional exhaustion, and a brief break off the bike of ~10-15 minutes, 
the patient is asked to cycle again to exhaustion, using a ‘square-wave’ Smax stage 
at 110% of the peak power obtained during the ramp, to verify attainment of 
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V̇O2max. As this secondary bout of exercise is performed in the higher regions of 
the severe intensity domain (Xu and Rhodes, 1999), this stage is typically much 
shorter in duration (~1 – 4 minutes) than the first ramp stage (which is designed 
to typically last 8 – 12 minutes; Buchfuhrer et al. (1983)). If the V̇O2peak obtained 
during the Smax phase is less than a 9% increase, then this indicates that V̇O2max 
has been achieved as there has not been a ‘meaningful’ increase in V̇O2 between 
the bouts. The value of 9% is based upon day to day reliability data obtained in 
children with CF (Saynor et al., 2013b) 
 
 
This protocol has previously been demonstrated to verify V̇O2max in healthy 
children (Barker et al., 2011), and has been validated for use in children with CF 
(Saynor et al., 2013a). Furthermore, reliability data are available with regards to 
the short-term (48 hours) and medium-term (4-6 weeks) reproducibility of V̇O2max 
(Saynor et al., 2013b), and has also been shown to be safe and feasible in adults 
 
Figure 2.17 Two-stage ramp and supramaximal exercise protocol. A: 3-minute warm up 
at 20 W. B: Incremental ramp exercise at a predetermined rate (dependent upon 
individual data). C: 5-minute active recovery (unloaded pedalling). D: 10-minute seated 
recovery off the cycle ergometer. E: 3-minute warm-up at 20 W. F: Supramaximal 
confirmation bout at 110% of peak power output produced during ramp exercise. G: 3-
minute recovery (unloaded pedalling). Reproduced with permission from Williams et al. 
(2014), Expert Review of Respiratory Medicine, 8(6), p753. doi: 
10.1586/17476348.2014.96669. 
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and children with CF (Causer et al., 2018). Therefore, such data indicates the 
combined ramp and Smax protocol is likely more suitable for clinical practice than 
the Godfrey protocol as it shown to identify V̇O2max.  
2.2.3.3 Maximal oxygen uptake (V̇O2max) 
V̇O2max represents the maximal aerobic power of the integrated pulmonary, 
cardiac and musculoskeletal systems (as per Milani et al. (2004), Figure 2.15) to 
utilise oxygen during exercise for movement. The V̇O2 can be calculated with the 
Fick equation: 
Equation 2.1:  V̇O2 = Q̇ x (Ca – Cv̄) 
 
whereby Q̇ is cardiac output, and Ca and Cv̄ are the oxygen concentrations of 
arterial and venous blood respectively. Numerous factors contribute towards the 
respective calculation of cardiac output (e.g. heart rate, stroke volume, ventricular 
capacity, pre-load and after-load) and the arterio-venous oxygen difference (e.g. 
haemoglobin concentration and saturation, capillary density and blood flow, 
alveolar O2 pressure).  
Ideally, aerobic fitness is measured directly using measures of gaseous 
exchange (V̇O2, V̇CO2). However, this may not always be possible in CF, either 
due to restrictions of staff, equipment and/or facilities, or due to risk of cross-
infection. Therefore, when direct measurement of V̇O2 through pulmonary gas 
exchange is not available, estimates can be made based upon sex, stature and 
age (Jones et al., 1985). However, these existing equations do not account for 
exercise performance in terms of completed work, and therefore an equation from 
(Werkman et al., 2014) has been validated for use in children and adolescents 
with CF, which accounts for sex and WRpeak: 
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Equation 2.2:  V̇O2peak (mL.min-1) = 216.3 – 138.7*Sex (0 = female, 1 = 
male) + 11.5*WRpeak 
R2 = 0.909, SEE = 172.57 
 
This equation was developed in a group of 363 children with a wide range of 
disease statuses (FEV1 = 37 – 147 %Predicted), and can prognostically assign 
patients to categories of high, medium, or low fitness (based upon divisions of 
Pianosi et al. (2005a)), although the success rate of prognostic assignment was 
only 50% in patients of high aerobic fitness. Furthermore, this equation has yet 
to be independently validated (although it was internally validated in a group of 
60 children with CF) and therefore the suitability of applying such this formula in 
further groups of people with CF in unknown.  
An alternative to this equation is the use of the steep ramp test (SRT). Originally 
developed for use in patients with chronic heart failure (Meyer et al., 1997), it 
uses work-rate increments between 10-20 W.s-1 (as opposed to 10-20 W.min-1 as 
per traditional CPETs) to elicit fatigue in ~2 minutes and produces peak work rate 
(WRpeak) as its primary outcome. It has since been validated for use in healthy 
children, with development of an equation from which to predict V̇O2peak, using 
WRpeak as a predictor (Bongers et al., 2013): 
Equation 2.3:  V̇O2peak (mL.min-1) = (8.262WRpeak) + 177.096 
R2 = 0.917, SEE = 237.4 
 
The SRT has subsequently been utilised in children with CF, as a Smax verification 
bout (Werkman et al., 2011), and as a predictor of V̇O2peak using the equation 
above from Bongers et al. (2013). When 40 patients with CF (17 boys, 23 girls; 
14.7 ± 1.7 years) undertook both a CPET and SRT, a significant correlation 
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between WRpeak from the SRT and V̇O2peak from a CPET was identified (r = 0.82, 
p < 0.001, Bongers et al. (2015b)). However, use of correlation coefficients does 
not necessarily indicate agreement between values and agreement between 
measured and estimated V̇O2peak was found to over-estimate aerobic power by a 
mean of 0.18 ± 0.31 L.min-1. 
2.2.3.4 Submaximal measures 
Whilst the value of maximal testing is clearly of prognostic relevance in CF, it is 
not always possible to obtain maximal parameters in a clinical population as 
patients may be unwilling, or unable, to exercise to volitional exhaustion. 
Therefore submaximal measures could provide a suitable alternative in the 
assessment of function (Williams et al., 2014), with these broadly split into the 
following ‘thresholds’ and measures of ‘efficiency’.  
The GET is a submaximal threshold during incremental exercise whereby V̇CO2 
increases disproportionately to V̇O2, indicating increase in metabolic acidosis due 
the production and accumulation of lactic acid. This threshold is therefore 
reflective of the anaerobic threshold (AT), lactate threshold (LT) and ventilatory 
threshold (VT) (Beaver et al., 1986). Whilst the AT, LT and VT are separate 
physiological thresholds, they all fundamentally represent the point at which 
exercise enters the ‘heavy’ intensity domain (Xu and Rhodes, 1999). This is 
where a sustained anaerobic contribution towards exercise metabolism is present, 
but a non-exhaustive, V̇O2 steady-state of can be achieved. Individuals 
undertaking exercise in the heavy domain will sense a notable increase in effort 
and breathlessness.  
The GET and LT are significantly correlated in CF, both for patients with mild (r = 
0.86, p < 0.05) and moderate/severe (r = 0.82, p < 0.05) disease (Thin et al., 
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2002). The GET has also been associated with disease severity in CF, with the 
absolute value of the GET decreasing with increasing severity (mild: 1202 ± 562, 
moderate: 995 ± 216, severe: 742 ± 245 mL.min-1) (Thin et al., 2002). However, 
these values are not normalised for body size, nor as a percentage of V̇O2peak, 
therefore limiting their interpretation and comparison with other populations.  
Further evidence in the same study from Thin et al. (2002) suggests that the GET 
is reduced in CF relative to a non-CF CON group (1787 ± 512 mL.min-1), although 
the aforementioned issues with normalisation for body size and exercise intensity 
make this claim difficult to verify. Furthermore, studies which have normalised the 
GET as a percentage of V̇O2peak and V̇O2max, have found no difference between 
groups of children and adolescents with, and without CF, when using the 
validated combined ramp/Smax CPET protocol (Saynor et al., 2014b, Saynor et 
al., 2016b), thus ensuring a ‘true’ V̇O2max has been achieved and utilised, and 
those that have used the Godfrey protocol (Bongers et al., 2014b) and therefore 
reporting GET relative to V̇O2peak. 
The detection rates for the GET are variable: 82% in children (Hebestreit et al., 
2000), 85% in adults with CF (Thin et al., 2002) and 92% in children with CF 
(Saynor et al., 2013b). This detection can vary dependent on the methodology 
used, as multiple approaches are available. Whilst the V-Slope method proposed 
by Beaver et al. (1986) has been used predominantly to date (Hebestreit et al., 
2000, Saynor et al., 2013b, Saynor et al., 2014b, Thin et al., 2002), techniques 
including use of ventilatory equivalents (VentEq) for O2 and CO2, the end-tidal 
tension of oxygen (PET-O2) method and when the RER = 1.0 (Visschers et al., 
2015) have all been used to infer the threshold whereby exercise enters the 
heavy domain. When examined in CF, the intraclass correlation coefficient (ICC; 
of observed V̇O2) for the V-Slope (0.916), VentEq (0.839) and PET-O2 (0.873) 
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methods are higher and produce comparable values for the GET, whereas the 
RER = 1.0 method has a lower ICC (0.747) and produces a significantly different 
values for the GET (as a percentage of V̇O2peak) relative to the other three 
methods (Visschers et al., 2015).  
When the GET is identified in a CPET, the reproducibility can vary between tests 
and the observers (i.e. researchers, clinicians) performing the evaluation. The 
ICC over a short-term period (48 hours) is 0.8, whilst over a medium-term period 
(4-6 weeks), is 0.74 (Saynor et al., 2013b). When multiple observers identify the 
VT, the ICC is high between independent observers (0.94) and also when the 
same data are re-analysed following a period of time (6 weeks; ICC = 0.92, 
Hebestreit et al. (2000)).  
Whilst the evidence for the use of the GET as a submaximal parameter of aerobic 
fitness is robust in terms of its association with disease severity and construct 
validity, normalisation relative to V̇O2peak (for comparisons within and between 
individuals) requires an individual to reach volitional exhaustion itself, thus 
negating its potential as a submaximal replacement for V̇O2peak, as V̇O2peak would 
have been obtained during the process regardless.  
This same argument exists for the use of the respiratory compensation point 
(RCP), a further submaximal threshold between the GET and V̇O2peak, reflective 
of the disproportionate increase in minute ventilation (V̇E), relative to V̇CO2 
(Beaver et al., 1986). As this threshold is normalised to a percentage of V̇O2peak 
and occurs up to ~85% V̇O2peak (Beaver et al., 1986), a peak effort is first required 
and thus rendering such a submaximal value redundant in comparison. 
Furthermore, data surrounding the occurrence and reliability of assessing the 
RCP is unclear as it is rarely reported by studies, with some instead reporting an 
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alternative measure up to the point of the RCP, such as the V̇E/V̇CO2 slope 
(Bongers et al., 2014b). Furthermore, as the RCP is a variable that is 
predominantly driven by ventilation (V̇E), and as breathing patterns during 
incremental exercise are altered relative to non-CF controls and associated with 
disease severity (FEV1) (Keochkerian et al., 2008), it is unclear as to whether 
there is clinical merit in routinely measuring and reporting the RCP in CF.  
Further to use of thresholds, parameters of aerobic efficiency that characterise 
V̇O2 relative to changes in V̇E can account for the impaired pulmonary function 
observed in CF and are relatively unexplored in CF. These include parameters of 
oxygen uptake efficiency (OUE; V̇O2/V̇E), and the oxygen uptake efficiency slope 
(OUES). The OUES has been developed as a submaximal parameter of aerobic 
fitness and is a derivation of the logarithmic relationship between V̇O2 and minute 
ventilation (V̇E), therefore removing the curvilinear component of V̇E observed 
during exercise, allowing for direct comparison with other CPETs through the use 
of the subsequent linear regressions (Baba et al. (1996), Figure 2.18).  
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Figure 2.18 The relationship between V̇O2 and V̇E during incremental exercise (left), 
and when V̇E has been logarithmically transformed (right). The subsequent regression 
equation produces the value for the oxygen uptake efficiency slope (in this instance, 
1017 mL.min-1.logL-1). Reproduced from Archives of Disease in Childhood, Baba et al., 
81 (1), p73, ©1999 with permission from BMJ Publishing Group Ltd 
 
The clinical utility of the OUES has been established in adults with CF, having 
been shown to be a significant predictor (R2 = 0.83, p < 0.01) of absolute V̇O2peak 
(Gruet et al., 2010), however its suitability for use in children, and as an 
independent parameter of aerobic fitness, is unclear. Previous research has 
characterised OUES at differing time points during exercise (50%, 75% and 100% 
of exercise duration; Bongers et al. (2012)) using a group of 22 children and 
adolescents with CF, and 22 non-CF controls. This study identified that absolute 
values for the OUES were lower than CON participants at each time point, 
although not statistically significant (100%, 2598.7 ± 642.9 vs. 2703.9 ± 637.2; 
75%, 2487.1 ± 610.5 vs. 2664.1 ± 695.1; 50% 2201.1 ± 546.1 vs. 2547.2 ± 685.6 
mL.min-1.logL-1). In addition, this study further normalised OUES by scaling 
relative to body surface area (BSA), subsequently finding OUES/BSA at 50% of 
exercise duration to be significantly lower in CF relative to the non-CF controls. 
Moreover, the OUES/BSA values were found to hold medium-to-large 
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correlations with body-mass relative V̇O2peak in the CF (r = 0.41 – 0.54) and CON 
(r = 0.55 – 0.78) groups, with both statistically, and non-statistically, significant 
values for such correlations. Subsequently, the authors of this study concluded 
that the OUES was of limited value in children and adolescents with CF given the 
limited correlations with V̇O2peak and inability to routinely distinguish between 
individuals with, and without, CF. However, there are methodological concerns 
with this study: a) the approach of using time to exhaustion to normalise exercise 
effort fails to account for individual differences in relative exercise intensity as a 
percentage of V̇O2max; and b) the scaling of OUES relative BSA was undertaken 
without an appropriate assessment of whether this scaling procedure effectively 
removed the residual effects of body size. As a result, replication of this study is 
warranted with a robust methodology to clarify the clinical utility of OUES as a 
submaximal parameter of aerobic fitness in children and adolescents with CF.  
Further to the potential use of the OUES, OUE is as another submaximal 
parameter of aerobic efficiency that warrants investigation. In contrast to the 
OUES, the OUE incorporates the curvilinear ventilatory response to exercise 
(Sun et al., 2012b), as seen in Figure 2.19. It has been assessed in chronic 
diseases such as heart failure (Sun et al., 2012a), pulmonary hypertension (Tan 
et al., 2014) and chronic obstructive pulmonary disease (COPD) (Barron et al., 
2016), however, it has yet to be investigated for use in CF. Parameters of OUE 
have been characterised in in a group of 214 Dutch children (without CF), using 
the highest 90-second average (oxygen uptake efficiency plateau [OUEP]), and 
the 60-second OUE average prior to the VT (Bongers et al., 2015a). When 
analysed, no significant differences were found between boys and girls for the 
OUEP (42.6 ± 4.7 vs. 42.3 ± 4.6) and OUE at the VT (42.0 ± 4.6 vs. 41.9 ± 4.7) 
respectively. Furthermore, the OUEP was found to be significantly correlated with 
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V̇O2peak (L.min-1) in this group (r = 0.65, p < 0.001), indicating potential surrogacy 
as a variable of aerobic fitness when V̇O2peak is not available.  
 
OUE has several technical advantages over OUES, having been shown to have 
a lower level of test-retest variability than OUES (Bongers et al., 2015a, Sun et 
al., 2012b), lower variation between participants (Bongers et al., 2015a) and a 
lower correlation with body mass (r = 0.57 vs. r = 0.83; Bongers et al. (2015a), 
indicating that scaling for body size may not be necessary. Furthermore, as 
parameters of OUE do not require a logarithmic transformation (like the OUES), 
this could make OUE an appealing variable of use for clinicians given the minimal 
technical requirements for its calculation.  
Moreover, unlike submaximal thresholds such as GET and RCP which require a 
maximal effort from a CPET (in order to express values relative to V̇O2peak), the 
OUEP only requires the highest V̇O2/V̇E ratio during exercise (which occurs close 
to the GET and VT; Bongers et al. (2015a)). The truly submaximal nature of this 
parameter could characterise aerobic function in patients with CF who are unable, 
 
Figure 2.19 Comparative profiles of a) oxygen uptake efficiency, with the oxygen 
uptake efficiency plateau (42.3) represented by solid black horizontal line, and b) the 
oxygen uptake efficiency slope (2919.9), for a cardiopulmonary exercise test in a 
healthy, 13-year old girl. Reprinted with permission from Bongers et al. (2015a). 
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or unwilling, to perform maximal exercise and therefore warrants investigation as 
a prospective surrogate for V̇O2peak in this disease group.  
2.2.3.5 Relationship of parameters with body size 
Parameters of physiological function (including exercise capacity) are often 
expressed relative to parameters of body size (e.g. body mass) in order to 
facilitate comparisons between individuals of differing sizes, track individual 
changes with growth and maturation (Nevill et al., 1992) and associate with 
disease outcomes (e.g. FEV1, QoL). This process of normalising for body size is 
referred to as ‘scaling’. 
With regards to V̇O2peak, this process of normalisation for body size has been 
widely undertaken in CF, as can be seen in Table 2.2. Studies have normalised 
exercise capacity relative to parameters of body mass (Bongers et al., 2012, 
Bongers et al., 2014b, Saynor et al., 2014b), fat-free mass (Saynor et al., 2014b, 
Saynor et al., 2016b, Stevens et al., 2011, Tucker et al., 2018) as well as muscle 
cross-sectional area (mCSA; Moser et al. (2000)). In addition to V̇O2peak being 
scaled for body size, the OUES has also been expressed relative to BSA 
(Bongers et al., 2012). Moreover, as noted in Chapter 2.2.1, this process of 
normalisation can result in statistically significant differences being found 
between groups (i.e. CF and non-CF controls) for V̇O2peak, where previously there 
where none based upon absolute values (e.g. Saynor et al. (2016b)). This 
therefore highlights the importance of scaling exercise data in CF, particularly 
when large variance in body size are reported within this disease group (Hanna 
and Weiner, 2015). 
However, it has been shown that the use of ratio-standard scaling – the simple 
division of a numerator (i.e. V̇O2peak) by a denominator (i.e. body mass) – does 
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not effectively remove the residual effects of body size from physiological 
parameters (Armstrong and Welsman, 1994) and results in heavier individuals 
being penalised, as this approach can over-control for body size. The fallacy that 
ratio-standard scaling is sufficient is well known (Tanner, 1949), and 
consequently, allometric scaling (Welsman and Armstrong, 2000) has been 
identified as a robust statistical technique that effectively removes the residual 
effects of body size from physiological variables. 
Simply, allometric scaling utilises a power function ratio (Y/Xb), whereby an 
exponent ‘b’ is derived from a regression between logarithmically transformed 
variables (i.e. V̇O2peak and body mass) and this process is elaborated upon further 
in Chapter 3.5. Consequently, this has been successfully utilised in studies 
involving analysis of V̇O2peak in adults and children relative to body mass 
(Welsman et al., 1996), lean mass (Graves et al., 2013), BSA (Rogers et al., 1995) 
and muscle cross-sectional area (Zanconato et al., 1994) and volume (Tolfrey et 
al., 2006). Given the wide variances in body sizes between and within groups of 
children, adults and disease populations, scaling exponents have been reported 
to vary widely, from 0.24 to 1.02, with a recent meta-analysis identifying a pooled 
scaling exponent of 0.70 when scaling V̇O2peak relative to body-mass (Lolli et al., 
2017).  
However, despite the aforementioned variance in body size in CF (Hanna and 
Weiner, 2015), and the evidence in support of allometric scaling, it appears to be 
an underutilised statistical tool when exploring CPET derived parameters (e.g. 
V̇O2peak ,OUES) in this population. Therefore, future studies should consider this 
approach where applicable. Furthermore, whilst the majority of studies have 
scaled for body-mass, additional parameters of body-size such as stature and 
BSA must be considered for scaling if they hold significant correlations with CPET 
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derived parameters as they can be reflective of further physiological differences 
between individuals that can contribute towards differing exercise-related results. 
For example, BSA has been suggested to control for pulmonary volume 
(Hollenberg and Tager, 2000), a parameter of significant interest and clinical 
importance in CF. 
 Exercise limitation in children with cystic fibrosis 
Based upon the results of a CPET, such as V̇O2peak and associated submaximal 
variables, schematics such as the one presented in Figure 2.20 can guide 
clinicians in the interpretation of outcomes and provide an indication as the cause 
of exercise limitation for individual participants and patients, particularly when a 
disease diagnosis may not be known. However, in CF, causes of exercise 
intolerance (including V̇O2peak), as described above in Table 2.2, are widely 
debated. Each organ system (cardiac, pulmonary and musculoskeletal) along the 
oxygen transportation and consumption pathway (i.e. from O2 inhalation in the 
lung, to O2 utilisation in the muscle; (Figure 2.15, Milani et al. (2004)), as well as 
the genetic root of the disease itself, have been proposed as contributors towards 
this exercise intolerance (Hulzebos et al., 2015). As such, a multifactorial 
approach must be considered when discussing exercise intolerance in young CF 
patients (Gruet and Saynor, 2017). The evidence for each of these potential 
contributing factors are briefly reviewed in the following sections. 
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2.3.1 Genetic factors 
Previous research in healthy populations has identified a genetic component of 
exercise trainability (Bouchard et al., 1999) and therefore given the genetic nature 
of CF, it is reasonable to assess genetic components to exercise (in)tolerance in 
this patient group. However, the evidence for a genetic basis to exercise limitation 
is divided, and compounded by the existence of different classifications (as seen 
 
Figure 2.20 A basic schematic for interpretation of cardiopulmonary exercise test 
results, with likely causes of exercise limitation. AT, anaerobic threshold; CAD, 
coronary artery disease; COPD, chronic obstructive pulmonary disease; ECG, 
electrocardiogram; HR, heart rate; HRR, heart rate reserve; ILD, interstitial lung 
disease; SaO2, arterial blood oxygenation; PET-CO2, end-tidal tension for carbon 
dioxide; PFT, pulmonary function test; V̇E, minute ventilation; V̇O2, volume of 
oxygen consumption; V̇O2max, maximal volume of oxygen consumption; VR, 
ventilatory reserve. Reprinted with permission of the American Thoracic Society. 
Copyright © 2018 American Thoracic Society. ATS/ACCP Statement on 
Cardiopulmonary Exercise Testing (2003), 16, p251. The American Journal of 
Respiratory and Critical Care Medicine is an official journal of the American 
Thoracic Society. 
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in Figure 2.3), and the frequency of individual CFTR mutations (De Boeck et al., 
2014).  
The association between genotype and V̇O2peak was first conducted by Kaplan et 
al. (1996), finding a minimal effect size (η2 = 0.08) between two groups of patients, 
based upon presence of the ΔF508 mutation (homozygous ΔF508, n = 10, 
V̇O2peak = 37.0 ± 10.1 mL.kg-1.min-1 vs. heterozygous ΔF508, n = 20, V̇O2peak = 
36.3 ± 12.6 mL.kg-1.min-1). However, only 75% of mutations (including ΔF508) 
were identifiable in this study. A similar stratification approach based upon ΔF508 
was also utilised by McBride et al. (2010), finding no significant differences (p = 
0.99) between three groups of children with CF (homozygous ΔF508, n = 36, 
V̇O2peak = 38.1 ± 8.3 mL.kg-1.min-1 vs. heterozygous ΔF508, n = 19, V̇O2peak = 38.2 
± 8.8 mL.kg-1.min-1 vs. ‘Other/Other’ [i.e. no ΔF508], n = 9, V̇O2peak = 38.1 ± 9.9 
mL.kg-1.min-1).  
A further study by Selvadurai et al. (2002b) only assessed patients who were 
heterozygous for ΔF508 and further separated patients based upon their 
secondary mutation class (as per Figure 2.3). This study identified significant 
differences (p < 0.05) in V̇O2peak between those with a second mutation in Class 
I and II compared to those with a Class III, IV or V mutation (Class I, n = 15, 
V̇O2peak = 29.8 ± 4.2 mL.kg-1.min-1 vs. Class II, n = 38, V̇O2peak = 32.1 ± 4.9 mL.kg-
1.min-1 vs. Class III, n = 17, V̇O2peak = 44.3 ± 6.4 mL.kg-1.min-1 vs. Class IV, n = 17, 
V̇O2peak = 54.0 ± 7.2 ml.kg-1.min-1 vs. Class V, n = 10, V̇O2peak = 54.3 ± 6.8 mL.kg-
1.min-1). However, no control of covariates occurred despite there being a 
significant difference in BMI between groups, thus failing to isolate the sole effect 
of genotype upon exercise capacity.  
The most comprehensive study to date, an international, multicentre study 
analysed CPETs from 726 patients with CF (18.7 ± 8.5 years), from 17 centres 
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across 14 countries (Radtke et al., 2017a). When separated by the milder of the 
two CFTR mutations, patients per group were as follows: Class I/I, n = 32; Class 
≤II/II, n = 550; Class ≤III/III, n = 39; Class ≤IV/IV, n = 63; Class ≤V/V, n = 42. No 
significant differences were found between CFTR classes when V̇O2peak was 
expressed as a percent of predicted using prediction equations of Orenstein 
(1993): Class I/I, 74 ± 17; Class ≤II/II, 79 ± 19; Class ≤III/III, 78 ± 24; Class ≤IV/IV, 
83 ± 18; Class ≤V/V, 74 ± 19 %Predicted. Furthermore, when merged into two 
groups based upon CFTR classification (one group with two CFTR mutations in 
class I-III vs. one group with at least one mutation in class IV or V; n = 621 vs. 
105), no difference was again found in V̇O2peak (79 ± 19 vs. 80 ± 19 %Predicted). 
Finally, univariate prediction models failed to identify an association between 
CFTR functional class and V̇O2peak, whereas age, FEV1 (%Predicted), BMI z-score, 
CFRD and chronic Pseudomonas aeruginosa infection were all associated with 
V̇O2peak. Therefore, the increased sample size (and subsequent power) relative 
to previous studies, as well as robust statistical analyses led the authors to 
conclude there is no role of CFTR genotype upon V̇O2peak in CF. 
2.3.2 Pulmonary factors 
As the primary manifestation of CF is both an obstructive and restrictive 
pulmonary disease, which in turn accounts for the predominant cause of death in 
CF (Flume et al., 2009), a mechanical constraint on the pulmonary contribution 
to exercise is to be expected.  
The structural defects associated with CF (bronchiectasis, bronchial thickening, 
mucus plugging) that cause such chronic obstruction have been shown to be 
associated with a decreased exercise tolerance (Sovtic et al., 2014). This study 
assessed Modified Chrispin-Norman scores – chest radiographs that evaluate 
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over-inflation, and bronchial line, nodular, ring and large shadows in each of the 
four quadrants of the posteroanterior view – in 42 children with CF, aged 8-17 
years. A higher score indicates greater disease severity, and was found be 
significantly and negatively correlated with V̇O2peak (r = -0.41, p < 0.05).  
Furthermore, V̇O2peak has been shown to be more sensitive to structural change 
than pulmonary function. In the absence of significant changes in FEV1, body-
mass relative V̇O2peak decreases when Bhalla scores (a further radiographic score 
of bronchiectasis and peri-bronchial thickening) increase – indicating a worsening 
of structural defects in the lung (Hatziagorou et al., 2016). Furthermore, within 
this study, V̇O2peak was significantly and negatively correlated with the extent of 
bronchiectasis (r = -0.38, p = 0.0495), mucus plugging (r = -0.53, p = 0.004), and 
total Bhalla score (r = -0.48, p = 0.010), whereas FEV1 was not significantly 
correlated with any of the radiographic components that contribute towards the 
Bhalla score. 
Ventilatory parameters that may impair exercise capacity, such as BRI are only 
shown to be significantly compromised (V̇E/MVV > 70%; (American Thoracic 
Society, 2003)) in patients with severe CF (FEV1 < 40 %Predicted), thus showing 
that it is only in severe disease that ventilatory factors are responsible for a 
diminished exercise capacity (Moorcroft et al., 2005). Furthermore, upon the 
onset of exercise, whilst minute ventilation will increase to match metabolic 
demand, the ventilatory pattern with which this increase occurs is variable 
between patients (Keochkerian et al., 2008), therefore making it difficult to identify 
a limiting ventilatory parameter that could potentially be targeted and corrected 
for (e.g. physiotherapy or pharmacological intervention) to improve exercise 
capacity.  
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Finally, both a number of cross-sectional (De Jong et al., 1997, Pianosi et al., 
2005b) and longitudinal (Klijn et al., 2003) studies have identified significant 
positive correlations between FEV1 and V̇O2peak. However, these correlation 
values vary greatly between studies, e.g. r = 0.37 (McBride et al., 2010), r = 0.44 
(Sovtic et al., 2014), r = 0.58 (Perpati et al., 2010), r = 0.60 (Gruber et al., 2011a), 
r = 0.62 (Klijn et al., 2003), r = 0.65 (Kaplan et al., 1996), r = 0.70 (Moorcroft et 
al., 2005). Identifying the true nature of this relationship is further compounded 
by different studies reporting both V̇O2peak and FEV1 in differing formats, with 
absolute, relative and %Predicted values all being utilised in numerous studies, 
therefore making a pooled analysis and evaluation difficult. In addition, values 
such as FEV1 are only indicative of central airflow obstruction within the trachea 
and proximal bronchi and subsequently only account for approximately one-third 
of the reduction in V̇O2peak patients with CF with and FEV1 <50 %Predicted (R2 = 
0.31), and only one-fifth (R2 = 0.18) in patients with an FEV1 ≥50 %Predicted (Pastre 
et al., 2014), thus effectively leaving 82% unexplained variance in V̇O2peak in 
patients with mild-to-moderate disease status.  
Given the shared variance between FEV1 and V̇O2peak, a measure of peripheral 
airway obstruction in the form of the LCI (Chapter 2.1.4.4) has been developed 
and is obtained using a multiple breath washout manoeuvre using an inert gas 
such as N2 or SF6 (Kent et al., 2014), with an increased LCI being associated with 
a worse disease severity. Data examining the association between V̇O2peak and 
LCI are limited, although one study to research this association has identified that 
LCI is a weak, but significant, predictor of V̇O2peak (R2 = 0.19, p < 0.001) in a group 
of 97 Greek children (14.9 ± 4.6 y) with CF of a wide range of disease states 
(FEV1 = 34 – 120 %Predicted) (Avramidou et al., 2018). However, in this study it is 
unclear as to whether this shared variance (R2) between V̇O2peak and LCI is 
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independent of FEV1, and therefore how much this 19% variance explains above 
and beyond traditional pulmonary markers, given that the correlation between 
FEV1 and LCI was moderately negative and significant (r = -0.71, p < 0.001).  
2.3.3 Cardiac factors 
At rest, cardiac output (Q̇) is similar between individuals with CF and non-CF 
controls, but during exercise this is significantly reduced in CF (Rosenthal et al., 
2009). This is primarily caused by a reduced stroke volume (SV) (Marcotte et al., 
1986), and whilst compensated for by an increased HR during exercise (Pianosi 
and Pelech, 1996), it fails to sufficiently increase Q̇ and therefore oxygen delivery 
is reduced during maximal and submaximal exercise (Rosenthal et al., 2009). 
Whilst these studies have estimated Q̇ indirectly using the Fick equation, a 
reduced SV is still to be found when echocardiography is used, with a significant 
level of right ventricular (RV) systolic dysfunction (expressed as amplitude of 
long-axis excursion of the RV free-wall; Florea et al. (2000)), which subsequently 
correlates with disease severity (Ionescu et al., 2001). In addition, post-mortem 
studies have identified RV hypertrophy in 70% of children with CF (Royce, 1951). 
Patients with CF have been shown to have an impaired ability to raise RV ejection 
fraction during exercise (Benson et al., 1984), which results in hypoxaemia 
(Matthay et al., 1980), and subsequently increases the risk of developing 
pulmonary hypertension and further right ventricular dysfunction (Fraser et al., 
1999). It is also feasible that such hypoxemia may be exacerbated by ventilation-
perfusion abnormalities and alveolar hypoventilation (Keochkerian et al., 2008). 
In chronic disease, such as COPD, development of pulmonary hypertension is 
characterised by chronic remodelling of the pulmonary vasculature, and when 
accompanied by dysregulation of the pulmonary vascular response to exercise a 
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substantial intolerance towards exercise is observed (Lewis et al., 2013).  
It has recently been reported that ~51% and ~11% of adults with severe CF (FEV1 
<40 %Predicted) have underlying mild pulmonary hypertension (mean arterial 
pressure [MAP] ≥ 25 mmHg) and severe pulmonary hypertension (MAP ≥ 35 
mmHg, Hayes et al. (2014)). However, despite this prevalence, it is unknown 
whether young people with CF exhibit pulmonary hypertension during exercise 
and whether such pulmonary vascular dysfunction contributes towards impaired 
exercise capacity in young people.  
2.3.4 Musculoskeletal factors 
Muscular strength positively correlates with aerobic fitness (V̇O2peak) in CF (de 
Meer et al., 1999). Given that both muscular strength (Hussey et al., 2002) and 
size are significantly smaller in children with CF when compared to non-CF 
controls (de Meer et al., 1999, Moser et al., 2000), it could be proposed that a 
simple size differential is contributing to the reduced indices of exercise capacity 
(i.e. strength, V̇O2peak) in CF. However, a number of intrinsic factors have also 
been proposed, including mitochondrial (Valdivieso et al., 2012) and vascular 
(Poore et al., 2013, Rodriguez-Miguelez et al., 2016) dysfunction. This has led to 
the development of a muscle ‘quantity’ vs. ‘quality’ debate within the literature 
(Hulzebos et al., 2017, Rodriguez-Miguelez et al., 2017). 
When considering a ‘quantitative’ cause, V̇O2peak remains lower in CF relative to 
a healthy non-CF control group after normalisation for mCSA (V̇O2/CSA; mL.min-
1.cm-2), which is obtained using magnetic resonance imaging (MRI). This 
suggests an intrinsic muscular defect may be present (Moser et al. (2000) as a 
‘quantitative’ defect has been statistically controlled for. However, despite this 
unique insight into a potential muscular defect, mCSA is a poor indicator of total 
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leg muscle volume, as previous research in adults has identified a 27% error rate 
in predicting MV when using a CSA slice at 40% of the length from the distal end 
of the femur. Whilst this error decreases when using a CSA slice from 50% of 
femur length (13% error), and 60% femur length (10% error), such estimations 
still result in systematic under- and over-estimations of MV (Morse et al., 2007). 
Furthermore, it is unclear as to how the use of single CSA slices obtained via MRI 
can be used to predict MV in a paediatric population, given differences in muscle 
volume (Tolfrey et al., 2006) and mass (Barker et al., 2008) between children and 
adults.  
In addition to estimating MV from a single CSA (Morse et al., 2007), it can also 
be estimated by summing multiple CSA slices to infer a total MV. However, 
previous studies have all used differing CSA slice thicknesses, and number of 
total CSA slices to calculate total MV. Studies in heathy populations have used 
as few as seven slices (Walton et al., 1997), with disease groups (COPD) using 
17 slices (Mathur et al., 2008). However, evidence has repeatedly shown that the 
error rate of MV estimation increases as the number of CSA slices decreases 
(Barnouin et al., 2015, Nordez et al., 2009, Tracy et al., 2003) and data pertaining 
to this error rate in paediatrics in lacking. Therefore, an appropriate quantification 
of the error associated with MV estimation in relation to the slicing strategy is 
required in children and adolescents before any analysis can be undertaken to 
precisely define the association between MV and V̇O2peak in CF. 
Previous studies in healthy children have examined the relationship between 
thigh (Welsman et al., 1997), calf (Tolfrey et al., 2006) and total lower leg (Graves 
et al., 2013) MV and aerobic fitness, although no such muscle volume-related 
data exists in a CF cohort. It is appropriate to control V̇O2peak for MV as opposed 
to CSA alone, as it better reflects the amount of metabolically active muscle 
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during exercise and therefore normalising for MV may shed further insight into 
whether aerobic fitness is truly impaired in this patient group once muscle size 
has been accounted for. In addition, previous work has normalised aerobic fitness 
for mCSA using a ratio standard procedure (Moser et al., 2000), whereby 
allometric scaling procedures may be more appropriate (Tolfrey et al., 2006) to 
differentiate between CF and non-CF youth with regards to MV and aerobic 
fitness. Therefore, future studies should control for MV using allometric 
techniques to appropriately remove a ‘quantitative’ defect being responsible for 
reduced V̇O2peak in CF. 
Aside from a ‘quantitative’ element to the musculoskeletal reasons for exercise 
limitation, there are arguments to be made for a ‘qualitative’ component to 
exercise dysfunction in CF. Studies undertaken in vitro have identified that CFTR 
is presented in skeletal muscle, which may cause Ca2+ dysregulation, and in turn 
exercise intolerance (Divangahi et al., 2009, Lamhonwah et al., 2010). 
Furthermore, studies undertaken in vivo have utilised 31Phosphorous-magnetic 
resonance spectroscopy (31P-MRS) to non-invasively monitor muscle 
metabolism at rest and during exercise. Use of 31P-MRS assesses turnover of 
muscle phosphates, finding decreased efficiency in oxidative ATP synthesis (de 
Meer et al., 1995) and delayed post-exercise phosphocreatine (PCr) recovery 
(Wells et al., 2011), thus suggesting impaired muscle aerobic oxidative 
metabolism in patients with CF. However, contrasting work has since yielded no 
significant differences between children with, and without, CF (Werkman et al., 
2015). These discrepancies may be due to limited (and therefore underpowered) 
sample sizes (n = 6, Werkman et al. (2015)) or infection status, as chronic 
Pseudomonas aeruginosa infection has been associated with a decline in 
exercise capacity (van de Weert-van Leeuwen et al., 2012).  
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In addition to 31P-MRS, near-infrared spectroscopy (NIRS) has been utilised as 
an alternative, non-invasive, approach to assessing skeletal muscle oxidative 
metabolism. Use of NIRS is cheaper and more practical, due to their small size 
and portable nature, and has been shown to produce reliable signals to assess 
in vivo oxidative capacity (Ryan et al., 2012b). When this technique has been 
applied in CF, evidence has been found for impaired skeletal muscle metabolism, 
as evidenced by a reduced recovery rate of oxygen consumption of the vastus 
lateralis (Erickson et al., 2015). However, this study isolated muscle contractions 
at rest using externally controlled electrical stimulation and arterial occlusions 
(Erickson et al., 2015), but when children with CF underwent whole body exercise, 
no clear difference in oxygen extraction could be identified between CF and non-
CF children (Saynor et al., 2014b, Saynor et al., 2016b). This unaltered O2 
extraction supports previous research that reduced O2 delivery during exercise is 
primarily responsible for exercise limitation in children with bronchiectasis 
(Rosenthal et al., 2009). When multiple approaches are utilised (31P-MRS and 
NIRS), there is no suggestion of intrinsic metabolic abnormalities in oxygenation 
or oxidative metabolism during exercise in children with CF (Werkman et al., 
2015). However, as patients in this study were of a similar fitness (V̇O2peak) to 
non-CF controls, evidence for impaired metabolic function would be difficult to 
identify if exercise capacity is not in fact impaired in such a small sample. 
Therefore, there is evidence to show an intrinsic defect in skeletal muscle 
metabolism, although there is significant debate surrounding this argument 
(Hulzebos et al., 2017, Rodriguez-Miguelez et al., 2017). However, studies must 
first rule out the possibility of a quantitative defect (i.e. size-dependence) through 
appropriate establishment of MV and allometric scaling, prior to inferences being 
made on qualitative defects.  
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 Exercise testing and the cystic fibrosis clinic 
As described in Chapter 2.1.4.4, markers of exercise function (and in particular 
V̇O2peak) are utilised as outcome variables to assess the efficacy of exercise 
training regimens. However, the use of V̇O2peak should be considered for use as 
an end-point for non-exercise intervention studies given its clinical importance. 
As CF treatment options are rapidly advancing (Armstrong et al., 2014), 
comprehensive and accurate outcomes are needed to evaluate such therapies 
and interventions to determine their efficacy. Furthermore, as V̇O2max has been 
shown to be a reliable measure over the short (48 hours) and medium (4-6 weeks) 
term (Saynor et al., 2013b), this allows for a clinicians and researchers to identify 
whether clinically meaningful changes have occurred, allowing for accurate 
evaluation of non-exercise therapeutic interventions. However, for the use of 
CPET (and therefore V̇O2max) to become standard practice, clinical teams are 
required to adopt CPET and implement it in their own clinics.  
With regards to antibiotic treatment, both shuttle tests (Cox et al., 2006, Cox et 
al., 2011) and CPET (Alison et al., 1994, Cerny et al., 1984, Selvadurai et al., 
2002a) have been used to evaluate functional changes in exercise capacity. 
When using the MST as a marker of exercise performance, performance 
significantly (p < 0.001) increased by a mean distance of 102 m (18%) following 
a hospital admission lasting a mean of 15 days in a group of 28 children and 
adolescents, totalling 40 admissions (Cox et al., 2006). In contrast, no difference 
was found in MST distance following a home-based regimen of antibiotics (Cox 
et al., 2011). Interestingly, FEV1 increased by similar magnitudes in both studies; 
by 15% (p ≤ 0.001; Cox et al. (2006)) and 12% (p < 0.05; Cox et al. (2011)). These 
contrasting findings therefore query the sensitivity and utility of the MST as an 
outcome variable, thus increasing the scope for CPET as the primary exercise 
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test of choice for clinicians. When CPET has been used to assess efficacy of 
antibiotics, an incremental exercise test to exhaustion (without pulmonary gas 
exchange) found increases in WRpeak (relative to body-mass) of 23% (p < 0.001) 
and peak HR by 6% (p < 0.001; Cerny et al. (1984)). When studies have been 
able to utilise pulmonary gas exchange, V̇O2peak increased from 1.11 ± 0.36 to 
1.35 ± 0.46 L.min-1 (22%; p < 0.005) in adults performing exercise on a cycle 
ergometer (Alison et al., 1994). Furthermore, in Selvadurai et al. (2002a), the 
CON group of a three-arm training study also performed CPET, using the Bruce 
protocol on a treadmill, with V̇O2peak declining by 1.22 ± 6.15 mL.kg-1min-1 (4%) 
after a mean 18.6 ± 3.8 days of treatment. Whilst this initial value decreased upon 
discharge, V̇O2peak improved by 2.65 ± 6.02 mL.kg-1.min-1 (8%) above baseline at 
a one month follow up; although both these observations were non-significant (p > 
0.05) relative to baseline values.  
When considering the role of CPET in assessing the efficacy of CFTR modulators, 
the evidence base is sparse given the relative novelty of this therapeutic 
treatment option, and the limited number of patients enrolled on open trials. A 
case report examining the role of Ivacaftor upon two adolescents with the G551D 
mutation found differing directions, and magnitudes, for changes in V̇O2max. One 
patient (14 y old female) improved V̇O2max from 29.4 mL.kg-1min-1 to 31.3 mL.kg-
1min-1 after six weeks of treatment, and further again to 38.3 mL.kg-1min-1 
following a further six weeks. In contrast, a second patient (16 y old male), saw a 
small increase in V̇O2max, from 44.2 mL.kg-1min-1, to 45.7 mL.kg-1min-1 at six weeks, 
before declining to 41.9 mL.kg-1min-1 after a further six weeks (Saynor et al., 
2014a). These findings for V̇O2max contrasted to changes in FEV1, whereby both 
patients increased over the 12-week period, by 4.7% and 11.0% respectively. 
Further to this, a 28-day crossover trial in 20 patients with CF, found no significant 
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differences in the magnitude of improvement in body-mass relative V̇O2peak 
(obtained using cycle ergometry and the Godfrey protocol) relative to the placebo 
group. Both groups displayed a 4-5% increase in V̇O2peak, whereas FEV1 
increased significantly in the Ivacaftor group relative to placebo (+0.4 vs. 
+14.1 %Predicted), highlighting the independence between the two variables 
(Edgeworth et al., 2017). These studies further highlight the utility of CPET to 
evaluate therapeutic outcomes, by providing information that complements 
standard pulmonary measures to enhance the evaluation of therapeutic 
treatment regimens.  
When considering the role of CPET in evaluating surgical procedures, a 
retrospective review of 153 patients who underwent lung transplantation (which 
included 35 with CF), identified a mean increase in V̇O2peak of 21% up to 30 
months post-transplant (Bartels et al., 2011). In contrast, a greater magnitude of 
improvement for FEV1 was observed over the same period, improving by 147%. 
This highlights the discrepancy between pulmonary and exercise related 
outcomes in evaluating such treatments. The relatively small increase in exercise 
capacity is likely related to reduced muscle size (Pinet et al., 2004), and 
subsequent delayed recovery of muscular strength (Walsh et al., 2013). When 
V̇O2peak is assessed in a sole group of 10 patients with end-stage CF (unlike 
Bartels et al. (2011) who pooled data for analyses), exercise capacity is observed 
to increase from 31 ± 3 to 45 ± 4 %Predicted, however clearly remained far below a 
normal result (i.e. 100%, Oelberg et al. (1998)). 
Of interest, there is little data on the effect of nutritional interventions on exercise 
parameters in CF. Given that BMI, alongside V̇O2peak, is a significant predictor of 
mortality in adolescents with CF (Hulzebos et al., 2014), it would seem prudent 
to assess this relationship following nutritional intervention. Furthermore, 6% of 
 
 
Page 120 of 403 
 
people with CF <16 years currently have a PEG in place for supplemental feeding 
(Cystic Fibrosis Trust, 2017b), although the impact of such procedures upon 
V̇O2peak has yet to be reported upon in CF.  
For the successful integration of CPET into the CF clinic, there must be advocacy 
from senior management within organisations, as well as acceptability from staff 
who undertake day-to-day duties within the healthcare system. The recent 
ECFS/ERS statement on exercise testing in CF (Hebestreit et al., 2015) has 
indicated a professional advocacy for the implementation of CPET in clinics 
across Europe. As previously mentioned, a survey by Stevens et al. (2010) of UK 
CF centres showed that clinical teams value exercise testing. However, 18% of 
centres that responded to the survey did not have any equipment available for 
testing (e.g. treadmill, cycle ergometer, pulse oximeter), and only 5% had access 
to a metabolic cart with which to undertake analysis of pulmonary gas exchange. 
It was also reported that physiotherapists perform the majority of exercise testing 
and training. This equipment availability in the UK is in stark contrast to Barker et 
al. (2004), whose survey of 62 German CF centres, identified that 53% of centres 
had access to a metabolic cart. Within the centres surveyed, 18% of tests were 
incremental cycle tests using the Godfrey protocol, and 15% were treadmill tests 
using the Bruce protocol. Further to these surveys, an additional survey of 22 
global centres within the International Pediatric Lung Transplant Collaborative 
found that all centres undertake exercise testing, although only 6/22 centres used 
CPET to evaluate patients as part of transplant assessment and annual 
monitoring (Radtke et al., 2011). Where exercise testing was undertaken, a 
mixture of staff, including physiotherapists, technicians, exercise physiologists 
and specialist nurses were responsible.  
Given that these surveys have highlighted the relatively low rate of CPET 
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implementation and identified the allied health professional responsible for testing 
(i.e. physiotherapists), there is clearly a need to ensure education and training 
surrounding CPET and exercise testing in general is sufficient to support current 
professionals. A recent survey of general practitioners (GPs) in the UK found that 
the majority (80%) are unfamiliar with national physical activity (PA) guidelines, 
and only 43% were confident in discussing PA with patients (Chatterjee et al., 
2017). This therefore further highlights the need for sufficient education and 
training, particularly with regards to CF.  
 Summary 
Exercise capacity (V̇O2peak, V̇O2max) has been shown to be reduced in young 
people with CF (Saynor et al., 2014b) and has several clinical implications, 
notably with regards to an increased risk of hospitalisation (Pérez et al., 2014) 
and mortality (Pianosi et al., 2005a). Given these risks, it is important for patients 
with CF to maintain, or augment, exercise capacity. This is especially pertinent in 
youth, as lung function has been shown to decline in adolescence (Liou et al., 
2010) and the percentage of patients with chronic infections peaks a few years 
later in early adulthood (20-27 years) (Cystic Fibrosis Trust, 2017b). In addition, 
patients with CF will transition from paediatric care to adult care during 
adolescence (Nazareth and Walshaw, 2013), and with adults surviving for longer, 
and in greater numbers (Cystic Fibrosis Trust, 2017b, Dodge et al., 2007), it is 
imperative that this transition process in youth is tailored to individuals (Hewer 
and Tyrrell, 2008) in order to maintain health throughout adolescence and into 
young adulthood (Tuchman and Schwartz, 2013).  
The prognostic value of maximal exercise testing is clear in this population (Nixon 
et al., 1992, Pianosi et al., 2005a), however further work is needed to clarify the 
validity of alternative submaximal measures for patients who are unable and/or 
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unwilling to exercise to a maximal level. Therefore, parameters such as the OUES 
(Baba et al., 1996, Bongers et al., 2012) and OUE (Bongers et al., 2015a) may 
have utility as alternative parameters of aerobic fitness and must be assessed for 
their ability to act as submaximal surrogates for V̇O2peak.  
In establishing factors related to impaired exercise capacity observed in CF, there 
is still no clear consensus as why such limitations occur (Hulzebos et al., 2015), 
particularly with regards to musculoskeletal contributions, where the ‘quality’ vs. 
‘quantity’ debate is contested at present (Hulzebos et al., 2017, Rodriguez-
Miguelez et al., 2017). Therefore, appropriate determination of V̇O2max and 
muscle size, as well as accurate scaling procedures, are required to 
comprehensively evaluate the relationship between muscle size and V̇O2max in 
CF. Resultant findings could subsequently support or contrast the evidence for 
an intrinsic muscular defect contributing towards exercise intolerance.  
Furthermore, despite CPET being advocated as an important outcome measure, 
it is still under-utilised in evaluating interventional strategies, particularly 
strategies aimed at improving body mass and therefore, changes in exercise 
related outcomes associated with insertion of a PEG and supplemental feeding 
need characterising. 
Finally, there is still an apparent dearth of exercise testing taking place in CF 
centres. Therefore, education and training are required for clinical staff (such as 
physiotherapists and technicians) that undertake front line duties to increase 
understanding and confidence when discussing exercise with patients, as well as 
promoting the utilisation of CPET in those centres not currently offering the 
service.  
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 Aims and objectives 
As has been described throughout this review, the role of CPET in the 
management of CF is of utmost importance in children and adolescents. However, 
several aspects surrounding CPET and its application warrant further 
investigation: evaluation of submaximal alternatives to V̇O2max; identifying causes 
for reduced V̇O2max; and furthering the practical applications of CPET for both 
patients with CF and staff alike. Specifically, this thesis will: 
 Determine relationships between parameters of body size (stature, body 
mass and body surface area) with OUES, and identify appropriate scaling 
procedures to adjust for these body size parameters when analysing the 
OUES in CF (Chapter 4); 
 Provide an evaluation of the validity of the OUES as a submaximal 
surrogate for V̇O2max in a group of children and adolescents with CF 
(Chapter 5); 
 Evaluate the utility of OUE as a submaximal surrogate for V̇O2peak in CF, 
with particular reference to OUEP (Chapter 6); 
 Determine the error rate associated with using differing CSA slicing 
strategies (derived from MRI) to quantify MV in children and adolescents 
with and without CF (Chapter 7); 
 Statistically control for MV to evaluate differences in V̇O2max between 
children with and without CF, to determine dependence of exercise 
capacity upon body size (Chapter 8);  
 Using a case-study approach, utilise CPET to evaluate changes in 
exercise capacity following insertion of a PEG and supplemental feeding 
in a young girl with CF (Chapter 9); 
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 Summarise two national meetings held with CF clinical staff across the 
United Kingdom, reporting on the current provision of exercise in CF 
centres (Chapter 10).  
 Provide a summary of key findings, synthesise key themes within this 
thesis, as well as highlighting practical applications of CPET for future 
researchers and clinicians.  
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3 GENERAL METHODS 
This chapter outlines the general, and common methods, utilised in subsequent 
experimental chapters. Further detail, where necessary, is provided in the 
relevant experimental chapters (Chapters 4 to 10).  
 Study designs 
Throughout this thesis, differing study designs are utilised. Chapters 4 to 6 are 
retrospective analyses of existing datasets; Chapters 7 and 8 are observational 
case-control investigations; Chapter 9 is a case study; and Chapter 10 is a cross-
sectional study.  
3.1.1 Ethics approval 
Due to the differing experimental designs utilised, alternative ethics approval 
processes were required, dependent on the nature of the study.  
Chapters 4 to 6 utilise existing data, collated from previous experimental studies 
– all of which were approved by respective ethics committees prior to original 
data collection. Therefore, due to the retrospective, and anonymised, nature of 
the database, additional ethics approval was not required for these chapters. 
For experimental chapters (Chapters 7 and 8), ethics approval was obtained from 
the local NHS Research Ethics Service Committee (14/SW/0061; Appendix A), 
with subsequent approval from Research and Development at the Royal Devon 
and Exeter NHS Foundation Trust Hospital (Appendix B) and the Chair of the 
University of Exeter Sport and Health Science Ethics Committee (Appendix C).  
Ethics approval for the case study in Chapter 9 was obtained due to the prior 
involvement of the patient in an existing study which had obtained approval from 
the local NHS Research Ethics Service Committee (13/SW/0166; Appendix D) 
and Research and Development at the Royal Devon and Exeter NHS Foundation 
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Trust Hospital (Appendix E). In addition, the patient and parent signed journal-
specific assent and consent forms prior to submission for publication, authorising 
release of data (example of consent form in Appendix F).  
Throughout all studies, all personal information pertaining to participant was 
solely restricted to members of the study team. Furthermore, all procedures were 
undertaken, and measures obtained by, researchers with relevant Disclosure and 
Barring Service (DBS) checks to certify their ability with work with young people, 
and Good Clinical Practice (GCP) certificates where necessary. 
3.1.2 Funding 
The primary funding to report is from the Royal Devon & Exeter NHS Foundation 
Trust and the Cystic Fibrosis Trust. Additional funding for Chapters 7 and 8 was 
provided by the Department of Sport & Health Science for facility requirements, 
and salaries for staff were supported via an NIHR grant. Further funding for 
Chapter 10 was provided by the University of Exeter Open Innovation Link Fund. 
All funding to report for studies related to this thesis are stated in the appropriate 
sections of the respective manuscripts published as a result of the research. 
3.1.3 Participants 
Throughout this thesis, data from both children and adolescents with and without 
CF has been utilised retrospectively and generated prospectively. Dependent 
upon the study design, differing inclusion and/or exclusion criteria were applied 
prior to recruitment for studies, which are outlined below.  
3.1.3.1 Patients with cystic fibrosis 
All individuals with CF were recruited from outpatient appointments at the Royal 
Devon & Exeter NHS Foundation Trust Hospital. Patients were approached 
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alongside parent(s)/guardian(s) for inclusion in studies based on clinician’s 
advice and objective, pre-approved criteria: 
 CF diagnosis based on clinical features, supported by an abnormal sweat 
test (sweat chloride > 60 mmol·L-1 > 100 mg sweat), and where possible, 
diagnostic genotyping. 
 Lung function considered stable and within 10 % of their best in the 
preceding 6 months. 
 No increase in symptoms or loss of body mass in the preceding 2 weeks. 
In addition to the above physiological inclusion criteria, additional study-specific 
inclusion criteria were identified, and ethics approved, for Chapters 7 and 8:  
 Child is regularly participating in physical activity  
 Child presents with no contraindications to performing exhaustive exercise 
within an MR scanner 
 Child can understand and cooperate with the study protocol 
Furthermore, for individuals with CF, the following exclusion criteria were 
employed at the screening stage to ensure patient safety and enjoyment during 
studies:  
 Any non-pulmonary conditions that may impair exercise ability, such as 
musculoskeletal disorders (active arthritis, joint or muscle disease) and 
cardiovascular disease (congenital heart disease or cardiomyopathy). 
 Unstable co-morbid asthma (daily pulmonary function variability of >20 %). 
 Child presents with co-morbidities to performing exhaustive exercise 
within an MR scanner. 
 Unable to understand or cooperate with the study protocol due to learning 
difficulties or otherwise. 
 < 10 years of age. 
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 > 18 years of age. 
Furthermore, in addition to the exclusion criteria above used during screening, 
the following exclusion criteria were also utilised at the onset of the study 
described in Chapters 7 and 8: 
 Onset of acute infection. 
 Unable to understand or cooperate with study protocol. 
 Child and/or parent guardian to not wish to participate further.  
 Child presents with co-morbidity which will deem it unsafe for them to 
perform exhaustive exercise within the MR scanner. 
 Child is not happy being within the MR scanner environment. 
3.1.3.2 Non-CF controls 
All non-CF controls were recruited from local schools and sports clubs. After initial 
contact with teachers and coaches, investigators spoke to prospective children. 
Where children identified interest with the project, they were provided with 
participant information sheets and asked to discuss participation with 
parent(s)/guardian(s). Investigators then contacted parent(s)/guardian(s) to 
confirm interest and organise familiarisation visits.  
For experimental processes described in Chapters 7 and 8, the following 
inclusion criteria for CON children were established: 
 Healthy males and females aged 10-18 years who are age- and gender-
matched to patients with CF. 
 No diagnosis of chest disease or asthma. 
 Child is regularly participating in physical activity.  
 Child presents with no contraindications to performing exhaustive exercise 
within an MR scanner. 
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 Child can understand and cooperate with the study protocol. 
Furthermore, the following exclusion criteria were also utilised at the recruitment 
stage: 
 Any pulmonary conditions. 
 Any non-pulmonary conditions that may impair exercise ability, such as 
musculoskeletal disorders (active arthritis, joint or muscle disease) and 
cardiovascular disease (congenital heart disease or cardiomyopathy). 
 Child presents with co-morbidities to performing exhaustive exercise 
within an MR scanner. 
 Unable to understand or cooperate with the study protocol due to learning 
difficulties or otherwise. 
 Not an age- or gender-match for the chest diseased participants. 
 > 18 years of age. 
Furthermore, the following exclusion criteria were applied at the onset of the study: 
 Onset of acute infection. 
 Unable to understand or cooperate with study protocol. 
 Child and/or parent guardian does not wish to participate further. 
 Child presents with co-morbidity which will deem it unsafe for them to 
perform exhaustive exercise within the MR scanner. 
 Child is not happy being within the MR scanner environment. 
3.1.4 Participant information and consent/assent 
All participants (CF and CON) and their parent(s)/guardian(s) were provided with 
ethics approved, written documentation (i.e. participant information sheets), 
detailing the purpose of the study in question, as well as the procedures involved 
and expected time commitments. Once prospective participants and 
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parent(s)/guardian(s) had asked any questions, written informed consent and 
assent was obtained from adults and children respectively. Examples of 
participant information sheets, alongside respective informed consent for 
parent(s)/guardian(s) and assent for children for Chapters 7 and 8 are provided 
in Appendices G to L (CF forms only provided for reference).  
3.1.5 Inclusion in multiple studies 
Participants were involved in multiple studies throughout this thesis for pragmatic 
reasons (i.e. reducing participant burden). Chapters 4 to 6 each describe a 
sample size of n = 72 (36 CF, 36 CON). These are the same 72 individuals used 
throughout each of the three chapters and subsequent analyses. Chapters 7 (n 
= 15, 8 CF, 7 CON) and 8 (n = 14, 7 CF, 7 CON) have utilised the same 
participants. For Chapter 8, one less individual with CF is included in analyses 
due to the requirement to age- and gender-match participants for analyses. The 
individual who is the participant of the case-study in Chapter 9 also contributed 
exercise data to Chapters 4 to 6. For these chapters, only their baseline data (i.e. 
pre-intervention) was included.  
 Participant information 
Numerous anthropometric and exercise related variables were collated 
throughout the course of this thesis. These are described in further detail below.  
3.2.1 Age and maturation 
Age was determined in two different ways – chronological age and biological age.  
3.2.1.1 Chronological age 
Chronological age was calculated, where possible, as a decimal to the nearest 
0.1 year between date of birth and date of testing. Where participants were 
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involved in multiple test visits within a short space of time (as per Chapters 7 and 
8), reported age is age taken at the first visit (i.e. familiarisation).  
3.2.1.2 Biological age 
Given that maturation occurs independently of chronological age in adolescents, 
studies within this thesis also determine biological age. In Chapters 5 and 6, due 
to limitations imposed by the retrospective nature of analyses, age from peak 
height velocity (aPHV) was estimated using published equations (Moore et al., 
2015) that only require the participants age and standing height (measured in cm). 
Maturity offset for boys: 
Equation 3.1:  -7.999994 + (0.0036124 * (age * height)) 
R2 = 0.896, SEE = 0.542 
 
Maturity offset for girls: 
Equation 3.2:  -7.709133 + (0.0042232 * (age * height)) 
R2 = 0.898, SEE = 0.528 
 
In addition, pubertal status was obtained using a validated self-assessment 
(Morris and Udry, 1980) according to the five stages of pubic hair development 
(Marshall and Tanner, 1969, Marshall and Tanner, 1970, Tanner and Whitehouse, 
1976). The scales for boys and girls are presented in Appendices M and N 
respectively. After an explanation of these stages of pubertal development by an 
investigator of the same sex, participants were requested to take the form home 
and circle the stage that best reflect their own development, before returning the 
questionnaire in a sealed envelope on their next visit to the laboratory. These 
envelopes were opened following the participants final visit to the laboratory.  
Both aPHV and pubertal staging were utilised to assess maturity in this thesis, as 
issues do surround the use of aPHV as a marker of pubertal status, particularly 
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in late-maturing individuals (Malina and Koziel, 2014a, Malina and Koziel, 2014b), 
and as equations are not valid in boys >18 years, and girls >16 years. However, 
compliance with pubertal staging is not always guaranteed due to participants 
either forgetting to return questionnaires, having uncertainty regarding answers, 
or being unwilling to respond, hence the use of both methods. 
3.2.2 Anthropometric measures 
The range of anthropometric measures taken are described in detail below. 
3.2.2.1 Stature 
Stature was assessed using a wall-mounted stadiometer. The make and model 
of stadiometer differed between the exercise laboratory (Holtain; Crymych, UK) 
and outpatient clinic in the hospital (Seca; Birmingham, UK). Participants 
removed footwear and placed their heels against the base of the stadiometer, 
with feet together, and stood upright whilst looking forward. With the head in the 
Frankfort plane, stature was taken to the nearest 0.1 cm. 
3.2.2.2 Seated stature 
Seated stature was assessed using a seated stadiometer (Holtain; Crymych, UK). 
Participants sat on the stadiometer, in such a position that no body mass was 
supported by the ground, with participants legs laying over the edge of the 
stadiometer at an approximate 90-degree angle. The participant was instructed 
to sit upright, looking ahead, and the stadiometer was then placed against the 
participants back. With the head in the Frankfort plane, seated stature was taken 
to the nearest 0.1 cm.  
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3.2.2.3 Body mass 
Body mass was taken to the nearest 0.1 kg using an electronic scale (Seca, 
Birmingham, UK). Participants were instructed to remove shoes and heavy 
clothing prior to assessment of mass.  
3.2.2.4 Body mass index 
Body mass index (BMI) was determined using the following equation:  
Equation 3.3:  BMI = body mass (kg) / stature (m2) 
 
BMI was presented as an absolute value, and for Chapter 9, also as a percentile 
using free to download, specialist software (WHO AnthroPlus; World Health 
Organization, Geneva, Switzerland) based upon international growth reference 
data (de Onis et al., 2007)).  
3.2.2.5 Body surface area 
Body surface area (BSA) was calculated using the Haycock equation (Haycock 
et al., 1978): 
Equation 3.4:  BSA (m2) = mass0.5378 * height0.3964 * 0.024265 
 
3.2.2.6 Body fat estimation 
Skinfold measurements were made using skin fold callipers (Harpenden; Baty 
International, Burgess Hill, UK), in line with recommended guidelines (Eston et 
al., 2009). Four sites were assessed - triceps, biceps, subscapular and suprailiac 
– with each measure taken three times, and the median utilised to determine the 
sum of skinfolds (SSkF). Estimates of body fat percentage (BF%) were made 
using published equations (Slaughter et al., 1988) to estimate body fat 
percentage, from which fat-free mass can be calculated.  
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Body fat percentage for pre-pubertal males:  
Equation 3.5:  BF% = 1.21 * (triceps + subscapular) – 0.008 (triceps + 
subscapular)2 – 1.7 
 
Body fat percentage for circum-pubertal males:  
Equation 3.6:  BF% = 1.21 * (triceps + subscapular) – 0.008 (triceps + 
subscapular)2 – 3.4 
 
Body fat percentage for post-pubertal males:  
Equation 3.7:  BF% = 1.21 * (triceps + subscapular) – 0.008 (triceps + 
subscapular)2 – 5.5 
 
Body fat percentage for all females:  
Equation 3.8:  BF% = 1.33 * (triceps + subscapular) – 0.013 (triceps + 
subscapular)2 – 2.5 
 
For the above equations, pubertal stages (Marshall and Tanner, 1969, Marshall 
and Tanner, 1970) were utilised to define pre- (stage 1 and 2), circum- (stage 3), 
and post-pubertal (stage 4 and 5) status, in line with original methodology 
(Slaughter et al., 1988). Where pubertal staging was not available, aPHV in years 
was used to define pre- (aPHV > -2 years), circum- (-2 years > aPHV < +2 years), 
and post-pubertal (+2 years < aPHV) status (Karlberg et al., 2003). 
Once body fat percentage was estimated, fat free mass (FFM; kg) was 
determined using the following equation: 
Equation 3.9:  FFM (kg) = body mass (kg) – (body mass * (%BF / 100)) 
 
This method has been shown to be valid and reliable in children and adolescents 
(Silva et al., 2013), and has subsequently been utilised in studies involving 
children with CF (Saynor et al., 2014b), and without CF (Cockcroft et al., 2015). 
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 Testing procedures 
Further to the age-related and anthropometric measures described above, 
additional testing procedures to obtain measures of pulmonary function, physical 
activity, exercise capacity and muscle volume are described below. 
3.3.1 Pulmonary function 
Pulmonary function was measured throughout according to standardised 
guidelines (British Thoracic Society, 1994, Miller et al., 2005a, Miller et al., 2005b, 
Pellegrino et al., 2005, Wanger et al., 2005), using a hand-held spirometer 
(MicroPlus, Micro Medical Ltd., Rochester, UK). Verbal encouragement was 
given with each manoeuvre, and measures of forced vital capacity (FVC) and 
forced expiratory volume in one second (FEV1) were taken, with the best of three 
manoeuvres recorded. 
The Tiffeneau Index (FEV1/FVC) was subsequently calculated using the highest 
FEV1 and FVC obtained, regardless of if two variables were from the same 
manoeuvre (Miller et al., 2010). 
Volumes were calculated as a percentage of predicted values (based upon age 
and height), using a free-to-download desktop calculator from the Global Lung 
Initiative (GLI) (GLI-2012 Desktop Software for Individual Calculations, v.3.3.1, 
European Respiratory Society, Lausanne, Switzerland) and multi-ethnic 
reference values (Quanjer et al., 2012).  
For Chapters 4 to 6, additional reference values (Quanjer et al., 1993, Zapletal et 
al., 1987) were utilised to calculate FEV1 and FVC as a percent of predicted due 
to the retrospective nature of the database. Recent research suggest that prior 
results based on different equations should be accepted as reliable when 
compared to the GLI equations (Konstan et al., 2017).  
 
 
Page 136 of 403 
 
Finally, maximal voluntary ventilation (MVV) was calculated using the following 
formula: 
Equation 3.10:  MVV = FEV1 (L) * 35 
 
3.3.2 Physical activity 
In Chapter 8, participants wore a triaxial, wrist-mounted, accelerometer 
(GeneaActiv; ActivInsights, Kimbolton, UK) to objectively measure habitual PA. 
This was worn on the participant’s non-dominant wrist for seven consecutive days, 
with data collected at a frequency of 100Hz. An activity diary (Appendix O) was 
utilised to qualitatively describe the activity undertaken by each participant during 
the seven days, broken down into 1-hour slots over the seven days. This was 
also used in conjunction with an ‘on/off’ log (Appendix P) to identify the time the 
accelerometer was worn each day from waking up, to going to bed, as well as 
any non-wear time (e.g. showering, water sports). Data collected by the 
accelerometer was subsequently exported in 60 second epochs, and using 
validated paediatric cut-points (Phillips et al., 2013), the time spent in each PA 
domain (sedentary, light, moderate and vigorous) was determined in both 
absolute number of minutes and as a percentage of wear time. Minimum wear 
time for analyses was set at a reliability coefficient of 0.86, which can be achieved 
with a minimum of 10 hours for two days (Rich et al., 2013).  
3.3.3 Cardiopulmonary exercise testing 
Throughout all chapters, participants have undertaken exercise tests to 
determine V̇O2max. For consistency, the same ergometers and gas analysers 
have been used where possible. If this has not been possible, the same 
make/models have been used to maintain the error within a certain manufacturer.  
 
 
Page 137 of 403 
 
3.3.3.1 Equipment 
For the CPETs used within this thesis, all exercise has been undertaken on 
upright cycle ergometers (Lode Excalibur; Lode, Groningen, the Netherlands). To 
observe outcomes of the CPET, participants wore a rubber oro-nasal facemask 
(Hans Rudolph, Shawnee, KS, USA), connected to a turbine and gas sampling 
line, which in turn were connected to a metabolic cart (Cortex Metalyzer 3B; 
Cortex Biophysik, Leipzig, Germany). This procedure permitted breath-by-breath 
collection of exhaled V̇O2, V̇CO2 and V̇E, which allows for subsequent calculation 
of derivatives such as respiratory exchange ratio (RER). The metabolic cart was 
calibrated for pressure, gas and volume prior to each CPET. Participants also 
wore a Bluetooth heart rate monitor (Polar Electro; Polar, Kempele, Finland) and 
fingertip pulse oximetry (Nellcor N-20; Medtronic, Minneapolis, MN, USA) 
throughout. 
3.3.3.2 Protocol 
A two-stage incremental exercise test to volitional exhaustion was used, utilising 
a ramp phase and Smax verification bout. This has been validated for use in 
children with CF (Saynor et al., 2013a), and healthy controls (Barker et al., 2011). 
Both the ramp and Smax are described in detail below, with a schematic previously 
provided in Figure 2.17. For data utilised in Chapters 4 to 6, several CPETs (n = 
39) were conducted without the use of Smax phase, as it was developed and 
validated following these initial studies from which data was obtained. This 
number of CPETs utilised a single incremental test to volitional exhaustion (i.e. 
no supramaximal verification phase as described below), and therefore some 
V̇O2 values are described as ‘peak’ V̇O2, as opposed to V̇O2max.  
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3.3.3.2.1 Ramp incremental phase 
This protocol starts with a three-minute period of pedalling at a low resistance 
(10-20 W), before an incremental ramp is used to progressively increase the 
resistance against which a participant is cycling. The intensity of this ramp-rate 
differed between children as factors such as age, gender and stature can 
influence peak power. Therefore, an estimate of peak power was made, where 
possible, using the following equation from Hulzebos et al. (2012): 
Equation 3.11:  WRpeak (W) = -142.865 + 2.998 * Age (years) – 19.206 * 
Sex (0 = male, 1 = female) + 1.328 * Height (cm) + 23.362 * 
FEV1 (L) 
       R2 = 0.79, SEE = 21.0 
 
The estimated peak power derived from this equation was divided by 10 as so to 
elicit VO2max in approximately 10 minutes (i.e. within 8-12 minutes as per 
recommendations (Buchfuhrer et al., 1983)), and rounded to the nearest 5 W for 
ease of calculations.  
The child was required to maintain a constant cadence between 60-80 revolutions 
per minute (rpm) throughout the test. The test was terminated when cadence fell 
<10 rpm below the self-selected cadence (i.e. <65 rpm if pedalling at 75 rpm) for 
five consecutive seconds despite strong verbal encouragement. After a five-
minute cool-down at 10-20 W, the participant was given a 10-minute period of 
seated rest prior to the commencement of the Smax phase.  
3.3.3.2.2 Supramaximal verification phase 
After seated rest of at least 10-minutes, the participant returned to the bike, again 
warming up at 10-20 W for three minutes, maintaining the same cadence from 
the first phase. After the three minutes, participants undertook a square-wave 
‘step’ transition to 110% of the peak power achieved in the first bout. Again, the 
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test was terminated when cadence fell <10 rpm below the self-selected cadence 
for five consecutive seconds despite strong verbal encouragement. At exhaustion, 
participants cooled down at 10-20 W for a further three minutes. An example of 
the V̇O2 response from the ramp incremental and Smax phase is given in Figure 
3.1.  
 
 
3.3.3.3 Outcome variables 
Following the CPET, data was exported in a breath-by-breath format before being 
smoothed into 10-second averages for analysis. 
3.3.3.3.1 Maximal oxygen uptake (V̇O2max) 
For all studies utilising V̇O2max as an outcome variable, this was determined using 
methodology previously described for use in adults (Day et al., 2003), and 
 
Figure 3.1 An example of the V̇O2 response to the ramp incremental and Smax 
exercise bouts, used to determine V̇O2max, for a healthy 16-year old female. 
Dashed vertical lines indicate end of ramp incremental phase and start of Smax 
phase respectively. 
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subsequently applied in healthy children (Barker et al., 2011), and children with 
CF (Saynor et al., 2013a). Briefly, a linear regression was plotted over the ‘linear’ 
portion of the ramp-incremental phase, with data from the first two minutes, and 
the three-minutes prior to exhaustion excluded, to exclude the influence of V̇O2 
kinetics, and deviations from linearity (i.e. plateaus) (Figure 3.2a). The V̇O2 from 
this linear portion was then extrapolated over the remainder of the test (Figure 
3.2b), and the residuals from final 60-seconds isolated and examined against the 
extrapolated portion. A negative residual indicated a deceleration in V̇O2 against 
power output and was defined as a plateau when the magnitude of residuals was 
≥5% of projected V̇O2 (Figure 3.3a). Either a positive or negative residual <5% of 
projected V̇O2 indicated a linear response (Figure 3.3b). Finally, a positive 
residual ≥5% indicated an acceleration in V̇O2 against power output (Figure 3.3c) 
(Barker et al., 2011, Saynor et al., 2013a).  
Furthermore, the highest 10-second average V̇O2 value was obtained from the 
Smax verification bout. Where the highest V̇O2 value from the Smax phase 
increased by more than 9% above the peak V̇O2 from the ramp phase – a value 
based upon reliability data (Saynor et al., 2013b) – this was considered a 
‘meaningful’ change between the two peak V̇O2 values and therefore the highest 
V̇O2 value obtained during the CPET was considered a ‘peak V̇O2’ rather than a 
true V̇O2max.  
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Figure 3.2 Example V̇O2 responses to increasing work-rate during the ramp 
phase of a cardiopulmonary exercise test, with linear regression plotted to 
establish V̇O2max. A: Linear regression plotted through ‘linear’ portion of the 
ramp incremental phase, excluding the first two minutes, and excluding the last 
three minutes. B: Linear regression is extrapolated to cover final three minutes 
of test. Profile depicts linear response of a 14-year old male with cystic fibrosis.  
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Figure 3.3 Example V̇O2 responses to increasing work-rate during the ramp 
phase of a cardiopulmonary exercise test. A: Deceleration of V̇O2, producing a 
plateau (17-year old male with cystic fibrosis); B: Linear response (14-year old 
male with cystic fibrosis); C: Acceleration of V̇O2 against power (14-year old 
male with cystic fibrosis). For all cases, the extrapolated regression line is fitted 
from 120 seconds, through to volitional exhaustion. 
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3.3.3.3.2 Gas exchange threshold 
The gas exchange threshold (GET) was identified using the V-slope method, 
described by Beaver et al. (1986). Simply, a plot of V̇CO2 (y-axis) against V̇O2 (x-
axis) is made, with data excluded from the initial 3-minute warm-up phase, and 
between the RCP (described in section 3.3.3.3.3) and volitional exhaustion. 
Subsequently, the first disproportionate increase in V̇CO2 relative to V̇O2 is 
denoted as the GET (Figure 3.4). This is then visually confirmed using the 
ventilatory equivalents of V̇O2 and V̇CO2 (i.e. V̇E/V̇O2, V̇E/V̇CO2), whereby V̇E/V̇O2 
beings to increase, having been stationary or decreasing, whilst no equivalent 
increase in V̇E/V̇CO2 occurs (Figure 3.4). To facilitate determination of GET, 
purpose-built software (LabVIEW; National Instruments, Newbury, UK) was 
utilised (Figure 3.5). The use of the V-Slope methods has been shown to be a 
reliable method of determining GET in children with CF (CV = 11.2% (Saynor et 
al., 2013b)) and healthy control children (CV = 7.5% (Fawkner et al., 2002)). 
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Figure 3.4 Example of establishment of gas exchange threshold, using V-slope 
method (above) and ventilatory equivalents for V̇O2 and V̇CO2 (below). Both 
examples display the same cardiopulmonary exercise test data for a 12-year old 
female with cystic fibrosis. 
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A 
B 
Figure 3.5 Worked example of establishing the gas exchange threshold using V-slope 
method (A), and ventilatory equivalents for V̇O2 and V̇CO2 (B), using purpose-built 
software (LabVIEW; National Instruments, Newbury, UK). Data displayed is the same at 
that in Figure 3.4. 
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3.3.3.3.3 Respiratory compensation point 
In addition to the GET, the RCP was also identified using methods described by 
Beaver et al. (1986). This is identified on a plot of V̇E (y-axis) against V̇CO2 (x-
axis), and the rapid increase observed in V̇E relative to V̇CO2 indicates 
hyperventilation due to increased metabolic acidosis in the tissue and is the RCP 
(Figure 3.6).  
 
Figure 3.6 Establishment of respiratory compensation point using methods of 
Beaver et al. (1986) by examining relationship between V̇E and V̇CO2. 
 
3.3.3.3.4 Oxygen uptake efficiency slope 
In accordance with previous research (Baba et al., 1996), the OUES was 
calculated throughout the linear portion of the CPET (i.e. excluding warm-up and 
cool-down). To derive OUES, V̇O2 is plotted against the common logarithm of V̇E. 
This removes the curvilinear profile of ventilation that can be observed during a 
CPET, and provides a regression coefficient in the following form: 
Equation 3.12:  V̇O2 = a * logV̇E + b 
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In this equation, ‘a’ equals the OUES. This value is then carried forward for 
analysis. An example of the logarithmic transformation of minute ventilation is 
provided in Figure 3.7. 
The OUES was calculated at several points during the incremental phase of the 
CPET, utilising data up to, and including the following thresholds: 100% V̇O2max, 
75% V̇O2max, 50% V̇O2max, 100% time to exhaustion (TTE), 75% TTE, 50% TTE, 
GET and RCP. The OUES value for 100% V̇O2max also describes 100% TTE, 
therefore giving seven OUES variables per participant. OUES was subsequently 
scaled against BSA1.40 (an exponent derived from Chapter 4) for Chapter 5.  
Reliability of the OUES has previously been reported in healthy children and 
adolescents (CV = 33% (Bongers et al., 2015a)) , and those with CF (CV = 12% 
(Saynor et al., 2013b)).  
3.3.3.3.5 Oxygen uptake efficiency 
Three parameters of OUE were collected for Chapter 6. To obtain OUE, each 
V̇O2 (mL.min-1) measure is divided by the corresponding V̇E (L.min-1) throughout 
the linear portion of the CPET. The highest 90-second average of OUE is taken 
to be the oxygen uptake efficiency plateau (OUEP). The average of the 60-
seconds prior to the GET and RCP are taken as the OUEGET and OUERCP 
respectively. Reliability of the OUEP in healthy children has been reported 
previously (CV = 10.9% (Bongers et al., 2015a)). An example of the profiles of 
OUEP, OUEGET and OUERCP in relation to CPET duration for an individual with 
CF is provided in Figure 3.8.  
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Figure 3.7 An example of the logarithmic transformation of the curvilinear 
ventilatory response to incremental exercise during a cardiopulmonary 
exercise test in a healthy 13-year old male. A: Curvilinear ventilatory response 
to incremental exercise, from the start of the incremental ramp phase to 
volitional exhaustion (i.e. V̇O2peak). B: The same response profile as (A), 
however ventilation has been log-transformed (base 10). The resultant linear 
regression for (B) in the example above produces a value of 2446 for ‘a’ in 
Equation 3.12. This value is the oxygen uptake efficiency slope, which is 
subsequently carried forward for analysis. 
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Figure 3.8 An example of the three parameters of oxygen uptake efficiency 
analysed throughout this thesis, and their position within a cardiopulmonary 
exercise test (from warm-up, to volitional exhaustion) undertaken by a 12-year 
old female with cystic fibrosis. The solid, vertical line at 180 seconds indicates 
the beginning of the ramp incremental phase of the cardiopulmonary exercise 
test. The two dashed, vertical lines entitled ‘GET’ and ‘RCP’ indicate the gas 
exchange threshold and respiratory compensation point, respectively. A: 
oxygen uptake efficiency plateau (OUEP); B: oxygen uptake efficiency at the 
GET (OUEGET); C: oxygen uptake efficiency at the RCP (OUERCP). 
 
3.3.3.3.6 Rating of perceived exertion and dyspnoea 
Ratings of perceived exertion (RPE) were obtained at one minute intervals using 
the Pictorial Children’s Effort Rating Table (P-CERT), validated by Yelling et al. 
(2002) (Appendix Q). Ratings of perceived dyspnoea (RPD) were also obtained 
at one minute intervals, using the modified Borg 0-10 scale (Borg, 1982) 
(Appendix R). 
3.3.3.3.7 Oxygen saturation 
Blood oxygen saturation during exercise was estimated via non-invasive via 
fingertip pulse oximetry (SpO2), with nadir SpO2 during the CPET recorded. In 
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addition to a measure of desaturation, SpO2 also provides an objective 
termination point of the CPET, for safety reasons. Initial guidelines from the 
American Thoracic Society (ATS) and American College of Chest Physicians 
(ACCP) suggested a test be terminated at SpO2 < 80% (American Thoracic 
Society, 2003). This cut-off has since been corroborated by disease specific 
guidelines published by the ECFS (Hebestreit et al., 2015).  
3.3.4 Magnetic resonance based variables 
For collection of magnetic resonance (MR) based variables, participants lay 
prone in the MR scanner. Participants’ legs were strapped down to minimise 
movement within the scanner in order to improve clarity of images. CSA, thigh 
volume (TV) and MV were calculated using specialist inbuilt MRI software. Each 
CSA slice was traced around to produce an area for both TV and MV, to isolate 
fat-free mass of the thigh. Each CSA value (in mm2) was multiplied by 5.5 to 
reflect the 5 mm slice thickness and 0.5 mm gap between slices, to produce a 
slice volume in cm3. Each slice volume was then summed, to produce a total 
volume for both TV and MV. An example of the MRI software, with the slices 
around which an area was traced is provided in Figure 3.9. A fuller explanation 
of calculation of MV is provided in Chapter 7.  
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3.3.5 Scaling of outcome variables 
Throughout this thesis, V̇O2max was scaled for body-mass. However, other 
parameters including muscle cross-sectional area and thigh muscle volume, 
derived from MR imaging, were also used in Chapter 8. In addition to scaling for 
V̇O2max, OUES was also scaled against BSA using an exponent of 1.40 (i.e. 
A 
B 
Figure 3.9 Example magnetic resonance images of the mid-thigh of a 14-year 
old female with cystic fibrosis. A: Cross-sectional area of mid-thigh as seen using 
magnetic resonance imaging software. B: The same image as (A), but with the 
shaded area in red on the left indicates the cross-sectional area used to 
calculate thigh volume (muscle and subcutaneous fat), with the shaded area on 
the right indicating the cross-sectional area used to calculate muscle volume. 
For both volumes, bone is excluded from cross-sectional area and subsequent 
calculation of thigh volume and muscle volume.  
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OUES/BSA1.40) in Chapter 5. The process of obtaining this exponent is described 
in greater detail explained in Chapter 4.  
Numerous studies have described the process of scaling V̇O2max for body size in 
children (Armstrong and Welsman, 1994, Tolfrey et al., 2006, Welsman et al., 
1997), and a brief outline of the process is described below.  
To identify if an outcome variable (such as V̇O2max) required scaling for body size, 
an initial correlation coefficient is established between V̇O2max and body-size 
parameters of interest (e.g. mass, FFM). If significant correlation coefficients exist 
between variables, then these variables are related, and scaling is required to 
remove residual effects of body size. For example, in Figure 3.10a, absolute 
V̇O2max is correlated with body-mass in both boys and girls, and therefore scaling 
of V̇O2max is required.  
Ratio standard scaling divides the dependent variable (e.g. V̇O2max) against the 
independent body-size variable (e.g. mass, FFM) in the format Y/X, attempting to 
produce a size-free variable (i.e. V̇O2max/mass). The scaled variable is then 
correlated against the original body-size variable to identify if a relationship with 
body-size still exists (i.e. V̇O2max/mass vs. mass). If a significant correlation 
coefficient remains between the scaled variable and independent body-size 
parameter, then this shows ratio-standard scaling is ineffective in removing 
residual effects of body size. For example, in Figure 3.10b, ratio-standard V̇O2max 
is still correlated with body-mass in both boys and girls (now in a negative 
direction), indicating a residual effect of body size.  
If ratio-standard scaling is not sufficient in removing residual effects of body size, 
allometric scaling is utilised (Welsman and Armstrong, 2000). Briefly, this process 
utilises the natural logarithm of both the dependent and independent variable 
against which it is scaled. The independent variable is inserted into a linear 
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regression model alongside any grouping variable (e.g. disease status, gender). 
The subsequent ‘b’ (β) value that is produced (alongside 95% confidence 
intervals (CIs)) is then carried forward for use as a power function ratio in the 
format Y/Xb. The scaled dependent variable is then correlated against the original 
independent variable to identify if any residual relationship continues to exist. In 
the example provided by Figure 3.10c, a ‘b’ exponent of 0.72 has been derived 
by linear regression and applied to body mass as a scaling factor (i.e. 
V̇O2max/mass0.72), and subsequently produces non-significant correlations, 
indicating that residual effects of body size have been removed.  
Whilst numerous exponents for body-mass have been proposed when scaling 
V̇O2max (0.24 – 1.02; pooled β = 0.70) (Lolli et al., 2017), each study within this 
thesis has derived its own scaling exponents to ensure they remain reflective the 
spectrum of body-sizes reported by participants within these studies and CF in 
general (Hanna and Weiner, 2015).  
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Figure 3.10 (overleaf) A: Relationship between body mass (kg) and absolute 
V̇O2peak (L.min-1) in boys (black circles) and girls (white circles). The relationship 
between variables is statistically significant for boys (r = 0.76, p < 0.001) and 
girls (r = 0.80, p < 0.001). B: Relationship between body mass (kg) and ratio-
standard V̇O2peak (mL.kg.min-1) in boys (black circles) and girls (white circles). 
The relationship between variables is statistically significant for boys (r = -0.49, 
p < 0.001) and girls (r = -0.44, p < 0.001). C: Relationship between body mass 
(kg) and allometrically scaled V̇O2peak (mL.kg-0.72.min-1) in boys (black circles) 
and girls (white circles). The relationship between variables is no longer 
statistically significant for boys (r = -0.08, p = 0.429) and girls (r = 0.02, p = 
0.815). 
 
3.3.6 Statistical analyses 
Throughout this thesis, various statistical techniques have been utilised, 
dependent on the study design and objectives. For all analyses, normality of data 
were assessed using standard ranges for skewness (-1 to +1) and kurtosis (-1 to 
+2). All data were found to be normally distributed throughout.  
All null-hypothesis significance tests were conducted using IBM SPSS (IBM, 
Corp., Armonk NY, USA), using an initial p-value of 0.05 throughout to indicate 
statistical significance, although further post-hoc corrections were undertaken 
where necessary, and therefore adjusting the associated p-value threshold 
required to achieve statistical significance. In addition, effect sizes (ES) for 
between-group comparisons were calculated using the following equation: 
Equation 3.13:  d = M1 – M2 / Spooled 
 
Whereby d = effect size; M1 = mean of group 1; M2 = mean of group 2; Spooled = 
pooled standard deviation for the two groups (S1 and S2 respectively), with this 
being calculated using: 
Equation 3.14:  √ [(S12 + S22) / 2] 
 
Subsequently, thresholds of Cohen (1992) were used to describe the magnitude 
of the effect (small = 0.2, medium = 0.5, large = 0.8). Effects sizes of Cohen (1992) 
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were also utilised to describe the magnitude of correlation coefficients (small = 
0.1, medium = 0.3, large = 0.5).  
Furthermore, in Chapter 8, magnitude-based inferences (MBI) (Hopkins et al., 
2009) were utilised. This process uses 90% confidence intervals (90% CI) and 
the smallest worthwhile ES change of 0.2 (Cohen, 1992), to identify the likelihood 
that an observed effect was substantially positive, trivial, or substantially negative 
and reported using quantitative chances (%) and the following qualitative 
terminology: <0.5%, ‘‘most unlikely’’; 0.5%–5%, ‘‘very unlikely’’; 5%–25%, 
‘‘unlikely’’; 25%–75%, ‘‘possibly’’; 75%–95%, ‘‘likely’’; 95%–99.5%, ‘‘very 
likely’’; >99.5%, ‘‘most likely’’. This statistical methodology has previously been 
utilised previously in assessing clinical differences in exercise capacity between 
children with, and without, CF (Saynor et al., 2014b).  
 Practical considerations 
Undertaking exercise testing in individuals with CF poses unique challenges 
above and beyond working with children without a chronic disease. Whilst 
considerations for patient safety are always a necessity when undertaking CPETs 
in clinical groups, infection control is an additional area of concern within CF 
(Saiman et al., 2014). Additional steps to ensure patient safety are described 
below.  
3.4.1 Patient safety during exercise 
Prior to undertaking exercise, all participants (CF and CON) undertook a medical 
history questionnaire (filled out by parent(s)/guardian(s)) to identify any 
contraindications to exercise (Appendix S). Individuals with CF had been 
recommended for inclusion in studies by their physician, and no patient deemed 
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unsuitable for participation and maximal exercise was recommended, nor 
approached.  
For safety and logistical reasons, all individuals with CF undertook exercise 
testing in a hospital gymnasium. All CON participants undertook tests in the 
paediatric laboratory at the University of Exeter.  
As previously noted, SpO2 was recorded throughout exercise to monitor oxygen 
saturation in individuals with CF. If SpO2 fell below 80%, exercise was terminated, 
in line with current recommendations (American Thoracic Society, 2003, 
Hebestreit et al., 2015). Supplemental O2 was available if patients presented with 
severe hypoxemia, with medical personnel trained in basic life support in adjacent 
wards if needed. Throughout the course of all experimental work, no individuals 
presented with any adverse reactions to exercise.  
Furthermore, patients reported to have cystic fibrosis related diabetes (CFRD) 
were advised to bring sugary snacks/drinks with them for exercise sessions. 
Patients were also advised to monitor blood sugar levels prior to, and following, 
maximal exercise and take corrective responses in the event of adverse readings. 
No adverse glycaemic reactions to exercise were reported across any testing 
session.  
3.4.2 Infection control 
To minimise risk of cross-infection between patients with CF, strict protocols were 
followed as per clinical practice guidelines. This included the following: 
 No two individuals with CF were scheduled for tests at the same time (i.e. 
to avoid face-to-face contact).  
 All rooms and content were cleaned with disinfectant wipes following 
exercise testing and any other meetings/testing periods. Contents 
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included, but was not limited to, exercise bikes, computers, tables and 
chairs.  
 Following cleaning, any room was ventilated for a minimum of a full hour 
and an individual with CF was not permitted into the room for that period. 
 Any shared equipment (e. g. facemasks) underwent a full cleaning 
procedure following use. This included washing with specialised detergent 
(Neutracon; Decon Laboratories, Hove, UK) and sterilising fluid (Milton 
Sterilising Fluid; Milton Pharmaceuticals, Gloucester, UK), before drying in 
a heated cabinet. This cleaning method was approved by the Infection 
Control team at the Royal Devon & Exeter NHS Foundation Trust Hospital.  
 If a patient was positively identified as culturing a non-tuberculosis 
mycobacterium (e.g. Mycobacterium abcessus) during the course of their 
involvement in a study, they were withdrawn to minimise risk to other 
patients. This occurred with one patient in Chapters 7 and 8.  
3.4.3 Contraindications to MR scanner environment 
Prior to participation in the MR scanner in Chapters 7 and 8, participants were 
required to fill out a questionnaire disclosing whether they had any implants, 
devices or objects that may be hazardous in the MR environment (e.g. 
pacemakers, infusion pumps, internal or external metallic objects). No 
participants reported any contraindications to the MR environment. A copy of the 
questionnaire is provided in Appendix T. No participants reported any 
contraindications to being in the scanner environment, and all continued their 
participation in the study without issue.  
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4 SCALING THE OXGEN UPTAKE EFFICIENCY SLOPE FOR BODY SIZE 
IN CYSTIC FIBROSIS 
 Abstract 
Purpose:  
The aim of this study was to describe the relationship between body size and the 
oxygen uptake efficiency slope (OUES) in paediatric patients with cystic fibrosis 
(CF) and healthy controls (CON), in order to identify appropriate scaling 
procedures to adjust the influence of body size upon OUES.  
Methods:  
The OUES was derived using maximal and submaximal points from 
cardiopulmonary exercise testing in 72 children (36 CF and 36 CON). OUES was 
subsequently scaled for stature, body mass (BM) and body surface area (BSA) 
using ratio-standard (Y/X) and allometric (Y/Xb) methods. Pearson’s correlation 
coefficients were utilised to determine the relationship between body size and the 
OUES.  
Results:  
When scaled using the ratio-standard method, OUES had a significant positive 
relationship with stature (r = 0.54, P < 0.001) and BSA (r = 0.25, P = 0.031) and 
significant negative relationship with BM (r = -0.38, P = 0.016) in the CF group. 
Combined allometric exponents (b) for CF and CON were: stature 3.00, BM 0.86, 
BSA 1.40. A significant negative correlation was found between OUES and 
stature in the CF group when scaled allometrically (r = -0.37, P = 0.027). Non-
significant (P > 0.05) correlations for the whole group were found between OUES 
and allometrically scaled BM (CF: r = -0.25, CON: r = 0.15) and BSA (CF r = -
0.27, CON r = 0.13).  
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Conclusions:  
Only allometric scaling of either BM or BSA, and not ratio-standard scaling, 
successfully eliminates the influence of body size upon OUES. Therefore, this 
enables a more direct comparison of the oxygen uptake slope between patients 
with CF and healthy controls.  
 Introduction 
It has been established that a high cardiopulmonary fitness (as represented by 
maximal oxygen uptake [V̇O2max]) is of benefit to young patients with cystic 
fibrosis (CF), being associated with an increased quality of life (Hebestreit et al., 
2014) and reduced risk of hospitalisation (Pérez et al., 2014) and mortality 
(Pianosi et al., 2005a). As such, regular, maximal, exercise testing is 
recommended to provide clinically relevant prognostic information for clinicians 
and patients (Cystic Fibrosis Trust, 2011), with cardiopulmonary exercise testing 
(CPET) endorsed as method of choice by the European Cystic Fibrosis Society 
and European Respiratory Society (Hebestreit et al., 2015). However, measuring 
V̇O2max, by definition, requires a maximal effort and some patients may be unable 
or unwilling to reach a volitional maximum. Therefore, the oxygen uptake 
efficiency slope (OUES) (Baba et al., 1996), a reliable (Saynor et al., 2013b) and 
effort-independent measure of ventilatory efficiency, may be a viable submaximal 
alternative to V̇O2max in this patient group (Gruet et al., 2010).  
Previous research in healthy adults has shown that OUES is strongly related to 
body size variables including stature, body mass (BM) and body surface area 
(BSA) (Buys et al., 2015), and has subsequently been applied to clinical settings 
including cardiac (Van Laethem et al., 2005), neurological (Heine et al., 2014) 
and respiratory (Barron et al., 2016) populations, including a single study of adults 
with CF (Gruet et al., 2010). This strong dependency on body size confounds 
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interpretation of OUES and requires the use of scaling techniques to ensure 
appropriate interpretation within and between groups. However, scaling 
procedures have been performed by most (Barron et al., 2016, Buys et al., 2015, 
Gruet et al., 2010, Van Laethem et al., 2005) but not all (Heine et al., 2014) 
studies to date.  
The strong positive relationship between OUES and body size has further been 
observed in paediatric studies using stature (Marinov et al., 2007), BM (Breithaupt 
et al., 2012) and BSA (Akkerman et al., 2010). Whilst such paediatric studies 
have attempted to control for body size (Akkerman et al., 2010, Bongers et al., 
2012, Bongers et al., 2011, Drinkard et al., 2007), it has been assumed that the 
ratio standard scaling method (OUES/body size [Y/X]) is an effective approach at 
removing the influence of body size. However, there are validity concerns 
associated with the ratio-scaling procedure that have been utilised to date (Nevill 
et al., 1992). This issue may have greater implications in children (Armstrong and 
Welsman, 1994), whose body size is rapidly changing with age, and furthermore 
in children with CF, who are characterised by malnutrition and inadequate growth 
(Culhane et al., 2013).  
Previous research has identified allometric scaling (Y/Xb, where ‘b’ represents a 
power function to which X is raised) as a superior technique to the ratio-standard 
methods for controlling for body size when assessing V̇O2max in both adults 
(Batterham et al., 1999) and children (Graves et al., 2013). However, its 
applicability for scaling OUES in contrast to the currently employed ratio standard 
method remains unknown 
Although the use of OUES in children with CF has been proposed (Bongers et 
al., 2012), there are currently no studies that critically examine the validity of 
scaling methods to adjust for body size. Furthermore, the one previous study to 
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have examined the role of OUES in children with CF (Bongers et al., 2012) scaled 
for BSA using a ratio-standard approach. However, the utility of other body size 
variables that are frequently collected by clinical teams (stature, body mass) were 
not systematically considered.  
Therefore, the aim of this study was twofold: Firstly, to characterise the 
relationship between body size and OUES in children with CF; and secondly, to 
identify the most appropriate procedure (ratio standard or allometric) for scaling 
OUES against different body size variables (stature, BM and BSA) in paediatric 
patients with CF and a matched control (CON) group. It is hypothesised that the 
allometric scaling procedure will remove the residual effects of body size on 
OUES compared to ratio standard procedures.  
 Methods 
4.3.1 Study participants 
Data were extracted from existing databases of valid CPET data, with 45 children 
and adolescents with CF being considered for inclusion in the current analysis. A 
total of 9 participants were excluded due to inadequate data (insufficient, or 
missing data, n = 7; insufficient test length, n = 2), resulting in a final sample of 
36 children and adolescents with CF. Data were then age- and gender-matched 
against existing CON CPETs, resulting in a total sample of 72 participants (36 
CF, 36 CON; mean age 13.3 ± 2.8 years). 
For original data collection, ethics approval was granted by institutional and NHS 
Research Ethics committees. Written informed consent and assent were 
obtained from parents/guardians and children respectively.  
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4.3.2 Experimental measures 
Stature was measured to the nearest 0.1 cm using a wall-mounted stadiometer 
(Holtain Ltd., Crymych, UK) and BM to the nearest 0.1 kg using a digital scale 
(Seca, Birmingham, UK). Body surface area (BSA) was estimated using the 
Haycock equation (Haycock et al., 1978). Pulmonary function was assessed 
using a hand-held spirometer, with values for forced expiratory volume in one 
second (FEV1) and forced vital capacity (FVC) being determined. 
4.3.3 Experimental protocol 
All participants undertook an incremental CPET to volitional exhaustion on an 
electronically braked cycle ergometer (Lode, Groningen, the Netherlands). 
Breath-by-breath gas exchange data were collected using an online Cortex gas 
analysis system (Cranlea, Birmingham, UK) and exported in 10-second averages. 
Within the sample, 33 children (20 CF, 13 CON) undertook an additional 
supramaximal verification bout to determine V̇O2max (Barker et al., 2011, Saynor 
et al., 2013a). However, as not all children undertook the verification bout the 
highest V̇O2 observed is described as peak V̇O2.  
Peak V̇O2 was obtained from the highest 10-second average from either the ramp 
or supramaximal bout (where applicable) and the gas exchange threshold (GET) 
was identified using the V-slope method (Beaver et al., 1986) and confirmed 
through visual inspection of ventilatory equivalents for V̇O2 and V̇CO2. OUES was 
ascertained at three different intensities (100%, 75% and 50% of peak V̇O2), 
using data from the whole test up to, and including, the intensity of interest, in line 
with previous research (Bongers et al., 2012). Simple, linear regressions between 
V̇O2 (mL.min-1) and logV̇E were calculated in the form using GraphPad Prism 
(GraphPad Software, Inc., San Diego, CA, USA):  
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Equation 4.1: V̇O2 = a (logV̇E) + b 
 
Where the constant ‘a’ the slope is defined as the OUES, and ‘b’ the intercept 
with the y-axis (Baba et al., 1996). Regression constants were subsequently 
produced, as per Figure 4.1, to allow comparisons between groups. 
4.3.4 Scaling approaches 
Each body size variable (stature, BM and BSA) was used to scale OUES at peak 
V̇O2, and at the GET, using the ratio-standard (Y/X) and allometric (Y/Xb) scaling 
methods. Allometric scaling of OUES was performed using log-linear regression 
models (Tolfrey et al., 2006) with disease status (CF or CON) and the 
anthropometric variable in question (stature, BM, BSA) entered as predictor 
variables. Age and gender were not entered into the model due to the prior 
matching of patients. The log-linear regression models produced scaling 
exponents (b) and associated 95% confidence intervals (CIs) that were used to 
scale the OUES using a power function ratio (Y/Xb). All regression models 
assumptions (multicollinearity and independence, homoscedasticity, linearity and 
normal distribution of residuals) were checked and satisfied. The log-linear 
regression model was conducted for each group (CF and CON separately) and 
as a combined whole (CF and CON combined) for each OUES parameter (peak 
V̇O2, 75% peak V̇O2, 50% peak V̇O2).  
 
 
 
Page 165 of 403 
 
 
Figure 4.1 Relationship between oxygen uptake (V̇O2; mL.min-1) and minute ventilation (VE; L.min-1) [1]; and V̇O2 (mL.min-1) and log10VE (L.min-
1) [2] during incremental exercise in representative 13-year old boys – one with CF [A] and one without [B]. Differences in ventilation are clear 
between participants (i.e. linear vs. curvilinear response), however normalisation of ventilation through log transformation (thus producing OUES) 
allows for direct comparison between individuals. 
 
 
Page 166 of 403 
 
4.3.5 Statistical analyses 
Statistical analyses were conducted using SPSS v.23 (IBM, Armonk, NY, USA). 
Independent t-tests identified mean differences in the anthropometric and CPET 
outcomes between CF and CON. Pearson’s correlation coefficients were run to 
examine the relationship between each body size variable and the absolute, ratio-
standard scaled and allometrically-scaled OUES to assess size dependence of OUES. 
Fisher’s z-transformations identified group differences between correlations. The 
alpha level was set at 0.05 for all analyses.  
 Results 
All descriptive data are presented as mean and standard deviation. Differences 
between group means with regards to the anthropometric, pulmonary and CPET 
outcomes are presented in Table 4.1. No significant differences (P > 0.05) were 
observed between groups for anthropometric or CPET variables. A significantly (P < 
0.05) lower FEV1 (%Predicted) was observed in the CF group, but no other pulmonary 
variables.  
Each body size variable was significantly (P < 0.001) and positively correlated with 
OUES (Figure 4.2; A1, B1, C1). This finding is consistent across CF, CON, and as a 
combined group (Table 4.2), with the magnitude of the correlation consistently lower 
in CF when compared against CON. However, this was only statistically significant (P 
< 0.05) for absolute OUES when plotted against stature (Figure 4.2; A1).  
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Table 4.1. Anthropometric, pulmonary and exercise-related differences between 
children with CF and age- and gender-matched controls.  
Variable CF CON P Value 
Stature (cm) 155.6 ± 13.6 159.1 ± 15.2 0.32 
Body Mass (kg) 50.2 ± 15.5 51.2 ± 14.5 0.78 
Body Surface Area (m2) 1.46 ± 0.28 1.49 ± 0.28 0.65 
FEV1 (L.min-1)* 2.46 ± 0.97 2.96 ± 0.86 0.07 
FEV1 (%Predicted)* 88.0 ± 19.6 101.9 ± 12.2 0.002 
FVC (L.min-1)* 3.10 ± 1.14 3.44 ± 1.02 0.30 
FVC (%Predicted)* 94.8 ± 15.9 100.2 ± 12.5 0.21 
Peak V̇O2 (L.min-1) 1.74 ± 0.57 2.03 ± 0.88 0.09 
Peak V̇O2 (mL.kg-1.min-1) 38 ± 8 40 ± 11 0.32 
GET (% pV̇O2) 53.3 ± 9.3 55.0 ± 8.0 0.42 
Peak Power Output (W) 146 ± 57 175 ± 72 0.06 
OUES (at 100% peak V̇O2) 1927.58 ± 583.49 2148.77 ± 846.55 0.20 
OUES (at 75% peak V̇O2) 1842.81 ± 541.13 2066.11 ± 892.96 0.20 
OUES (at 50% peak V̇O2) 1604.87 ± 661.75 1815.92 ± 852.51 0.27 
Values are presented as mean ± standard deviation. P value, independent samples t-
test significance level. FEV1, forced expiratory volume in 1 second; FVC, forced vital 
capacity; peak V̇O2, peak oxygen uptake; GET, gas exchange threshold; OUES, 
oxygen efficiency uptake slope. * Unequal groups for pulmonary volumes (CF, n = 36; 
CON, n = 18).  
 
When the ratio-standard scaling (Y/X) method was used, significant and positive 
correlations were present between the scaled maximal OUES and both stature and 
BSA for the combined group (Table 4.2) and CON group (Figure 4.2; A2, C2), but not 
the CF group. Whilst OUES scaled for BM did not retain a significant relationship with 
BM itself at the combined level (Table 4.2), it approached significance (P = 0.073). 
When split into sub-groups, a significant negative relationship was observed between 
scaled OUES and BM in CF (Figure 4.2; B2). 
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The output from the log-linear regression models is displayed in Table 4.3. Smaller ‘b’ 
exponents were observed for the CF group, when compared to CON, for each 
anthropometric factor. The exponents for the combined group were as follows: at 50% 
peak V̇O2 (stature = 3.60, BM = 1.06, BSA = 1.72); at 75% peak V̇O2 (stature = 2.93, 
BM = 0.80, BSA = 1.31), and at 100% peak V̇O2 (stature = 2.59, BM = 0.77, BSA = 
1.24). A greater difference was evident between the scaling exponents (Δb) of CF and 
CON groups for stature (1.39) relative to those for body mass (0.16) and BSA (0.36). 
When the exponents were averaged across groups and OUES parameters, the scaling 
factors were stature = 3.00, BM = 0.86, and BSA = 1.40.  
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Table 4.2. Pearson’s correlation coefficients for OUES at peak V̇O2 when scaled for body size using differing scaling procedures 
for whole-group (CF + CON) 
 CF CON Combined 
Absolute 
Stature vs. OUES 
 
r = 0.545, P < 0.001 
 
r = 0.800, P < 0.001 
 
r = 0.703, P < 0.001 
Mass vs. OUES r = 0.536, P < 0.001 r = 0.747, P < 0.001 r = 0.640, P < 0.001 
BSA vs. OUES r = 0.578, P < 0.001 r = 0.783, P < 0.001 r = 0.685, P < 0.001 
Ratio Standard 
Stature vs. OUES/Stature 
 
r = 0.296, P = 0.079 
 
r = 0.704, P < 0.001 
 
r = 0.543, P < 0.001 
Mass vs. OUES/Mass r = -0.379, P = 0.016 r = -0.042, P = 0.806 r = -0.212, P = 0.073 
BSA vs. OUES/BSA r = 0.021, P = 0.905 r = 0.447, P = 0.006 r = 0.254, P = 0.031 
Allometric 
Stature vs. OUES/Stature3.00 
 
r = -0.369, P = 0.027 
 
r = 0.111, P = 0.520 
 
r = -0.139, P = 0.245 
Mass vs. OUES/Mass0.86 r = -0.253, P = 0.136 r = 0.150, P = 0.383 r = -0.041, P = 0.730 
BSA vs. OUES/BSA1.40 r = -0.272, P = 0.108 r = 0.129, P = 0.453 r = -0.062, P = 0.606 
Bold text indicates a significant (P < 0.05) correlation. Bivariate plots are shown in Figure 4.2.  
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Figure 4.2 Scatter plots with Pearson’s correlation coefficients for CF (●, solid line) and CON (○, dashed line) groups for OUES from peak 
exercise when scaled utilising each variable (stature [A], body mass [B] and body surface area [C]) and procedure (absolute [1], ratio-standard 
[2] and allometric [3]). * Significant difference (P < 0.05) between the magnitude of the correlation coefficients between CF and CON. 
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When OUES was scaled allometrically (Y/Xb) using the averaged exponents from 
Table 4.3, no significant correlations were present against BM or BSA at either the 
group (Figure 4.2; B3, C3) or combined (Table 4.2) level. However, a significant (P < 
0.05) negative relationship was evident within the CF group between allometrically-
scaled OUES and stature (Figure 4.2; A3). Furthermore, allometric scaling of OUES 
at submaximal intensities (50% peak V̇O2 and 75% peak V̇O2), using the exponents 
identified in Table 4.3 for BM and BSA produced non-significant correlations (P > 0.05; 
data not reported). 
 Discussion 
The aims of this study were to initially describe the relationship between OUES and 
body size in children with CF and to identify appropriate procedures for scaling OUES 
against different body size variables. The main results have shown both significant 
relationships between OUES and body size; and that ratio-standard scaling is 
ineffective in controlling for body size, whereas allometric scaling does remove 
residual influences.  
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Table 4.3. Allometric exponents for the OUES measures and body size in young patients with CF and healthy age- and gender-
matched controls. 
 
 
 
 
 
 
 
 
 
 
 
b: scaling exponent; 95% CI: 95% confidence interval for b. Averaged exponents are highlighted in bold. Δb indicated difference in 
exponents between CF and CON groups.  
  CF CON  COMBINED 
OUES measure Body size variable b 95% CI b 95% CI Δb b 95% CI 
50% peak V̇O2 Stature (cm) 2.77 1.19 - 4.36 4.17 3.23 - 5.10 1.40 3.60 2.72 - 4.47 
 Body Mass (kg) 1.06 0.62 - 1.51 1.06 0.61 - 1.51 0.00 1.06 0.75 - 1.37 
 BSA (m2) 1.63 0.94 - 2.33 1.78 1.14 - 2.42 0.15 1.72 1.26 - 2.17 
75% peak V̇O2 Stature (cm) 2.17 1.26 - 3.08 3.56 2.74 - 4.37 1.39 2.93 2.31 - 3.55 
 Body Mass (kg) 0.68 0.42 - 0.95 0.91 0.55 - 1.27 0.23 0.80 0.58 - 1.02 
 BSA (m2) 1.09 0.68 - 1.49 1.52 1.00 - 2.04 0.43 1.31 0.98 - 1.64 
Peak V̇O2 Stature (cm) 1.88 0.87 - 2.89 3.17 2.41 - 3.92 1.29 2.59 1.96 - 3.21 
 Body Mass (kg) 0.66 0.39 - 0.94 0.88 0.57 - 1.18 0.22 0.77 0.57 - 0.98 
 BSA (m2) 1.03 0.60 - 1.47 1.44 1.00 - 1.88 0.41 1.24 0.94 - 1.55 
AVERAGE Stature (cm) 2.23 1.54 - 2.91 3.62 3.11 – 4.12 1.39 3.00 2.58 - 3.43 
 Body Mass (kg) 0.78 0.58 - 0.97 0.94 0.72 - 1.15 0.16 0.86 0.72 – 1.01 
 BSA (m2) 1.21 0.91 - 1.51 1.57 1.26 - 1.88 0.36 1.40 1.18 - 1.62 
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The relationships between body size and OUES for the present study are shown 
in Table 4.2 and Figure 4.2. These analyses identified large correlations for the 
CON group, with the magnitude closely resembling previous OUES research in 
healthy 7-18 year olds (Marinov et al., 2007). No previous study has detailed the 
magnitude of the relationship between OUES and body size in children with CF. 
The magnitude of the correlation in the CF group is lower than the CON group 
and reached statistical significance for the relationship between OUES and 
stature (Table 4.2, Figure 4.2). This could be due to the shorter stature typically 
observed in children with CF (Cystic Fibrosis Trust, 2016c) – a consequence of 
the chronic malnutrition associated with the disease (Culhane et al., 2013). 
However, the reported non-significant difference in body size, including stature, 
and OUES at peak exercise between CF and CON groups is similar to previous 
studies, despite decreased mean OUES values at peak exercise for both CF and 
CON groups in relation to previous research – a difference potentially accounted 
for by differences in aerobic fitness (Bongers et al., 2012). This suggests 
additional body size independent factors affect the OUES in CF and therefore 
may account for the smaller correlation coefficients observed in the present study.  
When ratio-standard scaling is utilised to adjust OUES, significant correlations 
exist against all the body size variables (Table 4.2, Figure 4.2; A2, B2, C2), with 
the magnitude, and significance, of coefficients being different for each body size 
variable and group. These significant positive coefficients result in biasing against 
individuals with a smaller stature or BSA. Whilst the combined correlation 
coefficient for BM is non-significant, it remains significant and negative within the 
CF group, thus biasing against heavier individuals, and removing its potential to 
be uniformly utilised across both groups. Furthermore, evidence against the use 
of the ratio-standard method to scale OUES is provided by the b values obtained 
 
 
Page 174 of 403 
 
in the log-linear regression. For the ratio-standard method to be effective, the b 
values would be required to equal, or at least be very close to, 1 (Tanner, 1949). 
As is shown in Table 4.3, the obtained values do not equal 1, nor do the 95% CI, 
which represent the uncertainty of the point estimate, span 1 consistently across 
both groups. Therefore, the ratio-standard procedure does not uniformly control 
for size in children with, and without CF, for each body size variable.  
Previous research has advocated scaling of OUES in children using a ratio-
standard approach, controlling for fat-free mass (FFM) or BSA (Akkerman et al., 
2010). However, the authors did not verify the assumption that this technique 
appropriately removes the influence of body size. As a result, subsequent studies 
have cited this study as reason for scaling OUES in such a manner when making 
comparisons between groups in paediatric populations with chronic disease 
(Bongers et al., 2012, Bongers et al., 2011, Tsai et al., 2016). However, the 
results of the current study have shown the ratio standard approach to be invalid 
and is likely to result in incorrect conclusions in previous OUES research due to 
the inaccurate expression of data (Bongers et al., 2012).  
Upon utilising allometric scaling, non-significant relationships (P > 0.05) were 
found between the corrected OUES from peak exercise and both BM and BSA 
for CF and CON groups, as well as the combined group values. However, the 
magnitude of coefficient is between -0.25 and -0.30 for BM and BSA in the CF 
group, indicating that this method does not fully control for size, but remains an 
improvement on the ratio-standard method. Unlike BM and BSA, stature retained 
a significant relationship with allometrically corrected OUES within the CF group 
(P < 0.05; Figure 4.2; A3). A non-significant mean difference between CF and 
CON for stature was found, therefore suggesting it is not stature itself, but the 
interaction of the two (stature and OUES) that is different between groups. This 
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difference in the relationship between stature and OUES is further evidenced by 
‘b’ values between groups (Table 4.3), with the Δb between CF and CON of 1.39 
being over three times greater than that of BSA (Δb = 0.36). Therefore, our data 
suggest stature is an unsuitable variable for scaling OUES, regardless of which 
scaling procedure is used. In contrast, the more homogenous ‘b’ values between 
CF and CON groups for both BM and BSA (Table 4.3) indicate these body size 
variables should be used for future allometric scaling of OUES, as the exponents 
can be uniformly applied to both groups. The same results were found for OUES 
at submaximal intensities (50% peak V̇O2 and 75% peak V̇O2), with allometric 
scaling proving to be the optimal methodology for removing residual effects of 
body size. This is a notable finding, as it highlights the importance of scaling, 
even for submaximal parameters of exercise, given that many patients may be 
unable, or unwilling, to perform maximal exercise. 
The results shown above indicate that either BM or BSA is an appropriate body 
size variable against which to scale OUES, provided an allometric approach is 
used. However, previous research is equivocal on which body size variable to 
use, with both BM (Baba et al., 1996, Breithaupt et al., 2012, Marinov et al., 2007, 
Rogowski et al., 2012) and BSA (Bongers et al., 2012, Bongers et al., 2011, 
Breithaupt et al., 2012, Tsai et al., 2016) being frequently used. BSA has been 
suggested for use, due to its ability to normalise for pulmonary volume 
(Hollenberg and Tager, 2000). However due to progressive declining of lung 
function observed in individuals with CF (Harun et al., 2016), it is unclear whether 
BSA appropriately normalises for pulmonary volume, a point further supported by 
the significant differences in lung function between groups in the current study. 
In addition, whilst BM remains a suitable anthropometric scaling variable, ideally, 
FFM should be used as it better reflects the metabolic cost of exercise (Akkerman 
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et al., 2010). However, this measure is not routinely collected by CF clinics, and 
body composition data, as estimated from skinfold and bioelectrical impedance 
methods, have poor accuracy at the individual level (Alicandro et al., 2015). As 
such, there is no evidence to suggest superiority of either BM or BSA for use in 
scaling OUES. Therefore, the suitability of each anthropometric variable needs 
to be investigated further to ensure future standardisation of research.  
Clinicians involved in the management of CF perceive CPET as a useful tool 
(Stevens et al., 2010), with regular exercise testing recommended for individuals 
with CF (Hebestreit et al., 2015). Given the clinical importance of exercise testing, 
it is therefore essential that appropriate measures and methodologies are being 
utilised to analyse outcomes. In order to streamline analyses for clinical teams, 
the ‘b’ exponent values for BM and BSA provided here may be utilised, provided 
patient characteristics are in line with current study. However, the purpose of this 
study was not to create a universal scaling exponent for OUES, as it is likely that 
scaling exponents may change between patient cohorts, and therefore future 
studies should utilise these described methodologies to derive their own 
exponents to ensure a size-free expression of OUES.  
 Conclusion 
This study has identified that ratio-standard scaling of the OUES is an invalid 
scaling method when using stature, BSA or BM as a significant relationship still 
exists with body size. In contrast, allometric scaling of BM and BSA was better 
able to control for body size in young people with CF and age and sex matched 
controls and should be used in future research investigating the clinical utility of 
OUES in this patient group. Therefore, this study recommends that allometrically 
scaled BM or BSA should be promoted for use in future research and/or clinics 
where OUES is sought as an outcome measure from a CPET.  
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5 THE OXYGEN UPTAKE EFFICIENCY SLOPE IS NOT A VALID 
SURROGATE OF AEROBIC FITNESS IN CYSTIC FIBROSIS 
 Abstract 
Background:  
Maximal cardiopulmonary exercise testing is recommended on an annual basis 
for children with cystic fibrosis (CF), due to a clinically useful prognostic 
information provided by maximal oxygen uptake (V̇O2max). However, not all 
patients are able, or willing, to reach V̇O2max, and therefore submaximal 
alternatives are required. This study explored the validity of the oxygen uptake 
efficiency slope (OUES) as a submaximal measure of V̇O2max in children and 
adolescents with CF.  
Methods:  
Data were collated from 72 cardiopulmonary exercise tests (36 CF, 36 controls), 
with OUES determined relative to maximal and submaximal parameters of 
exercise intensity, time and individual metabolic thresholds. Pearson’s correlation 
coefficients, independent t-tests and factorial ANOVAs were used to determine 
validity.  
Results: Significant (p < 0.05) correlations with V̇O2max were observed for most 
expressions of OUES, but were consistently weaker in CF (r = 0.30 – 0.47) when 
compared to CON (r = 0.58 – 0.89). Mean differences for all OUES parameters 
between groups were not significant (p > 0.05). When split by V̇O2max tertiles, 
minimal significant differences were found between, and within, groups for OUES, 
indicating poor discrimination of V̇O2max. 
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Conclusions:  
The OUES is not a valid (sub)maximal measure of V̇O2max in children and 
adolescents with mild-to-moderate CF. Clinicians should continue to use maximal 
markers (i.e. V̇O2max) of exercise capacity.  
 Introduction  
Previous research indicates the benefit of high levels of cardiorespiratory fitness, 
as characterised by maximal oxygen uptake (V̇O2max), for young people with 
cystic fibrosis (CF). A high V̇O2max is associated with an improved quality of life 
(Hebestreit et al., 2014), reduced risk of hospitalisation for pulmonary 
exacerbations (Pérez et al., 2014) and reduced mortality risk (Pianosi et al., 
2005a). Consequently, individuals with CF are advised to increase their exercise 
and habitual physical activity levels, with regular maximal cardiopulmonary 
exercise testing (CPET) also recommended and endorsed by the European CF 
Society (Hebestreit et al., 2015) and European Respiratory Society, to monitor 
changes in their aerobic fitness status.  
However, assessing V̇O2max requires patients to provide a maximal physical effort 
and is thus considered an ‘effort dependent’ test. Motivation, discomfort, 
excessive dyspnoea, chronic fatigue and naivety towards protocols may make 
patients with CF more unwilling or unable to reach volitional exhaustion and their 
V̇O2max. Therefore, physiological markers of aerobic fitness that can be attained 
during submaximal regions of a CPET can be particularly useful (Williams et al., 
2014).  
One such marker is the oxygen uptake efficiency slope (OUES), a submaximal, 
effort-independent parameter describing the relationship between V̇O2 and the 
common logarithm of minute ventilation (V̇E) (Baba et al., 1996). Given the 
curvilinear relationship between ventilation and oxygen uptake during 
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incremental exercise, it is difficult to model and therefore normalisation of 
ventilation (i.e. logV̇E) allows for direct comparison between tests (and groups). 
A higher value for the OUES indicates a greater ventilatory efficiency. The OUES 
has been shown to significantly and positively correlate with V̇O2max in healthy 
children (Marinov et al., 2007) and children with heart disease (Baba et al., 1996), 
indicating its potential as a submaximal surrogate of aerobic fitness in paediatric 
groups.  
Despite OUES appearing to be a valid determinant of exercise tolerance in adults 
with CF (Gruet et al., 2010), evidence for its use in children and adolescents with 
CF requires further verification. Only one study has previously sought to validate 
the OUES as an effort-independent marker of V̇O2max in a paediatric population 
with mild-to-moderate CF (Bongers et al., 2012). This study calculated OUES at 
100%, 75% and 50% of the test duration and concluded it invalid, due to the 
observed moderate positive correlations between the OUES and V̇O2max (r = 0.41 
– 0.54). Furthermore, despite decreased V̇O2max in children with CF, the OUES 
was unable to differentiate fitness status between children with, and without CF; 
leading authors to conclude the invalidity of OUES in this patient group. However, 
there are multiple methodological weaknesses to this study. Firstly, utilising 
CPET time to exhaustion (TTE) as a measure of intensity may be flawed, as it 
does not account for variances in individual metabolic thresholds. As the 
presence of reduced maximal capacity (Saynor et al., 2014b) and an altered 
oxygen cost of exercise (Moser et al., 2000) have been demonstrated in 
individuals with CF, it is conceivable that patients in this previous study (Bongers 
et al., 2012) may be exercising at differing relative exercise intensities (i.e. as a 
percentage of V̇O2max), and even within differing intensity domains, despite being 
matched for exercise duration. Secondly, there was a lack of appropriate 
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normalisation for the influence of body size, with authors utilising ratio-standard 
scaling, whereas previous research has shown this to be insufficient at removing 
residual effects of body size from OUES (Tomlinson et al., 2017).  
Given aforementioned issues associated with previous research (Bongers et al., 
2012), OUES should instead be assessed at individually determined parameters 
of relative exercise intensity (%V̇O2max) and domain thresholds, such as the gas 
exchange threshold (GET) and respiratory compensation point (RCP) (Beaver et 
al., 1986), alongside utilising allometric scaling protocols to ensure a size-free 
analysis of OUES (Tomlinson et al., 2017). 
Therefore, the purpose of this study was to examine correlates of allometrically-
scaled OUES with V̇O2max, and to systematically investigate differences in the 
OUES between children with CF and healthy controls (CON) at appropriately 
matched parameters of relative exercise intensity (%V̇O2max), TTE and individual 
metabolic boundaries (GET and RCP). In addition, the study will examine whether 
the OUES can differentiate between patients of differing aerobic fitness statuses 
vs. healthy matched controls and, therefore, its suitability as a submaximal 
surrogate for V̇O2max.  
 Materials and methods 
5.3.1 Participants 
Data from 45 children and adolescents with CF were considered for inclusion in 
the current retrospective analysis. Nine children were excluded due to inadequate 
data (insufficient, or missing data, n = 7; insufficient test length, n = 2). Remaining 
data were subsequently age- and gender-matched from existing exercise 
databases of healthy children, resulting in a final sample of n = 72 (36 CF, 36 
CON; 21 males per group; mean age 13.3 ± 2.8 years). All CON children were 
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screened for contraindications to exercise prior to CPET participation, including 
pulmonary disorders and unstable co-morbid asthma.  
As the study was a retrospective analysis of existing data, additional ethics 
approval was not required. Ethics approval for data collected was originally 
approved by South West NHS Research Ethics and local institutional ethics 
committees, whereby fully informed written consent and assent were obtained 
from parents/guardians and paediatric participants, respectively.  
5.3.2 Data collection 
All participants undertook a CPET to volitional exhaustion on an electronically 
braked cycle ergometer, to determine V̇O2max and submaximal measures of 
cardiorespiratory fitness. If required by patients with CF, bronchodilators were 
administered prior to CPET. Pulmonary function was assessed using a hand-held 
spirometer, with maximal values of forced expiratory volume in one-second (FEV1) 
and forced vital capacity (FVC) compared to normative values (Quanjer et al., 
2012, Quanjer et al., 1993, Zapletal et al., 1987). Pubertal status of children was 
determined as age from peak height velocity (aPHV), using published equations 
(Moore et al., 2015).  
5.3.3 Data analysis 
Pulmonary gas exchange and ventilation data were collected breath-by-breath, 
and subsequently averaged to 10 second time intervals. Previously described 
techniques were utilised to ascertain V̇O2max (Barker et al., 2011), GET and RCP 
(Beaver et al., 1986). To ascertain OUES values, linear regressions were 
obtained between V̇O2 and the logarithmic transformation of V̇E (logV̇E), using 
data up to the following boundaries: 100%, 75% and 50% of TTE (100TTE, 75TTE, 
50TTE), 100%, 75% and 50% of V̇O2max (100V̇O2max, 75V̇O2max, 50V̇O2max), GET and 
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RCP. The time point of 100%V̇O2max also describes 100%TTE – providing eight 
OUES parameters per participant.  
5.3.4 Scaling of data 
All OUES values were allometrically scaled to BSA (Haycock et al., 1978), in line 
with recent recommendations (Tomlinson et al., 2017). An allometric model was 
applied to remove residual effects of body size, with OUES scaled to BSA1.40. 
V̇O2max was not scaled using allometric procedures as ratio-standard scaling 
sufficiently removed residual effects of body size.  
5.3.5 Statistical analyses 
Descriptive data are reported as mean (± standard deviation (SD)) unless 
otherwise stated. Pearson’s correlation coefficients were calculated between 
V̇O2max and each of the eight normalised OUES values, to identify if the two 
variables are significantly related. Independent samples t-tests were also 
performed to identify differences between CF and CON for all variables, and 
identify the impact of disease status upon OUES. Finally, factorial ANOVAs were 
conducted to identify the interaction between V̇O2max status, split by tertile 
(Pianosi et al., 2005a), and disease status upon V̇O2max and OUES/BSA1.40. 
Where main or interaction effects were found, pairwise comparisons using 
Bonferroni corrections were applied to identify where relationships existed. 
Statistical significance was set at an alpha of 0.05 and Cohen’s thresholds are 
used to report effect sizes (ES) and illustrate the magnitudes of the mean 
difference (Cohen, 1992). 
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 Results 
5.4.1 Participant characteristics 
Participant characteristics and mean differences between groups are presented 
in Table 5.1. Significant differences were observed between CF and CON for 
pulmonary function and the absolute V̇O2 at the GET.  
Table 5.1. Anthropometric, pulmonary function and exercise-related differences 
between CF and CON groups.  
Variable CF CON p value Effect Size 
Stature (cm) 155.6 (13.5) 159.1 (15.2) 0.32 0.24 
Body mass (kg) 50.2 (15.5) 51.2 (14.5) 0.78 0.07 
BMI (kg.m-2) 20.28 (3.67) 19.91 (4.18) 0.70 0.09 
BSA (m2) 1.46 (0.28) 1.49 (0.28) 0.65 0.11 
aPHV 0.27 (2.70) 0.65 (2.44) 0.89 0.15 
FEV1 (L)* 2.46 (0.97) 2.96 (0.86) 0.07 0.53 
FEV1 (%Predicted)* 88.0 (19.6) 101.9 (12.2) 0.002 0.79 
FVC (L)* 3.10 (1.14) 3.44 (1.02) 0.30 0.31 
FVC (%Predicted)* 94.8 (15.9) 100.2 (12.5) 0.21 0.36 
V̇O2max (L.min-1) 1.74 (0.57) 2.03 (0.88) 0.093 0.39 
V̇O2max (mL.kg-1.min-1) 38 (8) 40 (11) 0.32 0.23 
GET (L.min-1) 0.91 (0.28) 1.12 (0.54) 0.035 0.49 
GET (% V̇O2max) 53.4 (9.3) 55.0 (8.0) 0.42 0.18 
HRmax (beats.min-1) 182 (8) 185 (14) 0.30 0.26 
V̇Emax (L.min-1) 74.66 (35.62) 69.18 (33.45) 0.50 0.16 
RERmax 1.27 (0.23) 1.21 (0.13) 0.22 0.32 
Measures are presented as mean (± SD). Significant mean diffeences are 
denoted by a bolded p vlaue. * Unequal groups for pulmonary volumes (CF, n 
= 36; CON, n = 18). BMI: body mass index; BSA, body surface area; aPHV, age 
from peak height velocity; FEV1, forced expiratory volume in one second; FVC, 
forced vital capacity; V̇O2max, maximal oxygen uptake; GET, gas exchange 
threshold; HR, heart rate; V̇E, minute ventilation; RER, respiratory exchange 
ratio.  
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5.4.2 Correlation between OUES and V̇O2max 
All OUES/BSA1.40 variables significantly correlated with body mass relative 
V̇O2max, apart from 50%TTE within the CF group (Table 5.2). 
 
Table 5.2. Correlations at different thresholds between parameters of oxygen 
uptake and ventilatory efficiency and V̇O2max relative to body mass.  
Oxygen Uptake Parameter CF CON 
OUES/BSA1.40 @ 50% V̇O2max  0.36 (0.040) 0.75 (< 0.001) 
OUES/BSA1.40 @ 50%TTE 0.30 (0.071) 0.76 (< 0.001) 
OUES/BSA1.40 @ 75%V̇O2max 0.33 (0.049) 0.85 (< 0.001) 
OUES/BSA1.40 @ 75%TTE 0.38 (0.023) 0.87 (< 0.001) 
OUES/BSA1.40 @ 100%V̇O2max & TTE 0.47 (0.004)  0.89 (< 0.001) 
OUES/BSA1.40 @ GET 0.35 (0.042) 0.58 (< 0.001) 
OUES/BSA1.40 @ RCP 0.45 (0.007) 0.88 (< 0.001) 
Values are presented as correlation coefficients (r) with p values in parentheses.  
 
5.4.3 Difference in OUES between CF and CON 
Mean values for BSA corrected OUES values were lower, but not significantly, in 
CF compared to CON at each threshold (50V̇O2max: 923 ± 273 vs. 992 ± 290; 
75V̇O2max: 1088 ± 224 vs. 1153 ± 293; 50TTE: 1019 ± 219 vs. 1091 ± 273; 75TTE: 
1101 ± 225 vs. 1182 ± 284; 100V̇O2max and 100TTE: 1141 ± 257 vs. 1206 ± 267; 
GET: 958 ± 296 vs. 996 ± 361; RCP: 1148 ± 251 vs. 1189 ± 297; p > 0.05 for all 
comparisons (range = 0.18 – 0.63); units for all parameters: mL.min-1.logL.-1.m-2.8). 
Figure 5.1 represents the data for OUES relative to BSA, according to categories 
of duration, intensity and the metabolic thresholds. 
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Figure 5.1 Comparison of OUES/BSA1.40 values between children and adolescents with CF (black bars) and healthy age- and gender-matched 
controls (white bars) at different exercise thresholds. 
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5.4.4 OUES and fitness tertiles 
When the data were split by tertiles according to V̇O2max (Figure 5.2), a significant 
difference was observed between tertiles within both CF (46 ± 5 vs. 38 ± 2 vs. 30 
± 5 mL.kg-1.min-1, respectively) and CON (52 ± 6 vs. 39 ± 3 vs. 29 ± 6 mL.kg-1.min-
1, respectively) groups with regards to aerobic fitness (p < 0.001 for all pairwise 
comparisons, ES = 2.07 – 3.84). However, there was only a significant difference 
in V̇O2max between CF and CON in the highest aerobic fitness tertile (p < 0.001, 
ES = 1.19).  
 
Figure 5.2 Comparison of V̇O2max, split by V̇O2max tertile (black bars = highest tertile, 
white bars = middle tertile, grey bars = lowest tertile), within the CF and healthy 
control groups. * Significant (p < 0.01) difference from highest tertile. † Significant 
(p < 0.01) difference from middle tertile. § Significant (p < 0.05) difference between 
groups. 
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When split by V̇O2max tertiles, there was no significant difference in OUES/BSA1.40 
at 100%TTE (p > 0.05). In CF, at 100%TTE, OUES/BSA1.40 was significantly higher 
in the highest (1271 ± 241) relative to the lowest (1020 ± 281) fitness tertile (p = 
0.016, ES = 0.96). The middle tertile (1131 ± 198) was not significantly different 
between either the highest (p = 0.34, ES = 0.63) or lowest tertile (p = 0.62, ES = 
0.46). By comparison, in the CON group significant differences were found 
between the highest (1441 ± 211) and lowest (957 ± 206; p < 0.001, ES = 2.32), 
between the middle (1219 ± 108) and the lowest (p = 0.011, ES = 1.59) and 
middle and highest (p = 0.041, ES = 1.32; Figure 5.3) tertiles. 
There was no significant difference in OUESGET/BSA1.40 between the groups (p > 
0.05). When OUESGET/BSA1.40 was split by aerobic fitness tertiles, a significant 
difference was only found within the CON group between the highest (1221 ± 336) 
and lowest tertiles (798 ± 273, p = 0.005, ES = 1.38). The middle tertile (952 ± 
356) was not significantly different to either the highest (p = 0.114, ES = 0.78) or 
lowest tertile (p = 0.712, ES = 0.49). In the CF group, no significant differences 
were found between any tertiles (highest: 1017 ± 273; middle: 1006 ± 324; lowest: 
854 ± 290, all p > 0.61, ES = 0.04 – 0.58). No significant differences between 
groups were observed for each tertile (all p > 0.11, ES = 0.16 – 0.64; Figure 5.3). 
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Figure 5.3 Comparison of OUES/BSA1.40 at 100%TTE and OUESGET/BSA1.40 split by 
V̇O2max tertile (black bars = highest tertile, white bars = middle tertile, grey bars = lowest 
tertile), within the CF and healthy control groups. * Significant (p < 0.05) difference from 
highest tertile. † Significant (p < 0.05) difference from middle tertiles. 
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 Discussion 
The primary purpose of this study was to investigate the validity of the OUES as 
a submaximal alternative to V̇O2max in young people with CF – utilising a larger 
CF cohort than previous research (Bongers et al., 2012, Bongers et al., 2014b). 
Specifically, we comprehensively compared differences in the OUES, when 
appropriately normalised for BSA (Tomlinson et al., 2017), between children and 
adolescents with mild-to-moderate CF and their healthy peers, at parameters of 
time and relative exercise intensity. Although OUES was associated with V̇O2max 
in both CF and CON groups, coefficients were consistently smaller in CF. Despite 
differences in these correlations, statistically significant differences in OUES 
could not be found between groups, regardless of whether it was standardised to 
percentage of V̇O2max, test duration or submaximal metabolic thresholds. 
Furthermore, OUES could not discriminate fitness status within, and between, 
groups. Taken collectively, these observations suggest OUES does not provide 
a valid surrogate of V̇O2max in children and adolescents with CF, supporting 
previous findings (Bongers et al., 2012). 
In this present study, significant correlations were observed between body-mass 
relative V̇O2max and the majority of BSA corrected OUES thresholds, except at 
50%TTE in the CF group. The locations of significance are identical to the only 
previous OUES study in children with a similar severity of CF during incremental 
cycling exercise, with magnitudes of correlations in the CF and CON groups 
corroborating previous work (Bongers et al., 2012) as CON shows larger effect 
sizes (r = 0.58 – 0.89) in comparison to the medium effect sizes (r = 0.30 – 0.47) 
of the CF cohort. As the correlation coefficients in the CF groups suggest a 
shared variance (R2) of between 9 and 22% (unlike 34 – 79% in CON), these 
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results suggest that despite their association, OUES may not be a viable 
surrogate for V̇O2max. 
Despite positive correlations with V̇O2max, no mean differences in OUES were 
observed between CF and CON at each parameter (of intensity, time and 
metabolic thresholds) – a finding contrasting previous adult and paediatric studies 
assessing OUES in independent groups (Akkerman et al., 2010, Baba et al., 1996, 
Drinkard et al., 2007, Gruet et al., 2010, Marinov et al., 2007). However, it could 
be argued that since a significantly lower V̇O2max was not observed in CF versus 
CON in the present study, in contrast to previous findings (Bongers et al., 2014b, 
Saynor et al., 2014b), a recruitment bias may be present. The lack of differences 
between groups may be due to deconditioning of control participants (as opposed 
to increased fitness in CF), with V̇O2max being 10 mL.kg-1.min-1 lower in the current 
study, when compared to previous research (Bongers et al., 2012). Consequently, 
it would also be expected that no differences in OUES would be observed. 
However, factorial ANOVAs sought to identify the sensitivity of the OUES 
measurement in discriminating between children of differing fitness. As the OUES 
supposedly represents V̇O2max when maximal exercise efforts cannot be reached 
(Baba et al., 1996), it is assumed that the OUES should follow a similar profiling 
pattern to V̇O2max and differentiate between patients of differing clinical and 
aerobic fitness states.  
When data were categorised into fitness based upon aerobic fitness tertiles, a 
division shown to predict mortality in CF (Pianosi et al., 2005a), a significant 
difference in V̇O2max was clearly evident both within and between the groups, but 
the former was only seen at the highest fitness level. This observation identifies 
that differences in aerobic fitness (V̇O2max) can be isolated within children with CF. 
However, when represented as aerobic fitness tertiles, differences in the OUES 
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and OUESGET (Figure 5.3) were not clearly defined, with a difference only evident 
between high-fit and low-fit children and adolescents with CF for OUES at 
100%TTE. In contrast, better discriminatory sensitivity was evident in the CON 
group, showing differences in OUES between all tertiles for aerobic fitness. Thus, 
even though some discriminatory power may be evident between children and 
adolescents with CF for high and low aerobic fitness, this was only found for 
OUES at 100%TTE. This suggests that to isolate individuals of differing fitness 
status, a measurement of OUES would need to be taken at maximal exercise, as 
opposed to a submaximal parameter which can be identified in real-time during 
a CPET, such as the GET (characterised by a disproportionate increase in V̇CO2 
relative to V̇O2). However, if participants would be required to reach volitional 
maximum to produce a maximal OUES value, clinicians would benefit from 
utilising V̇O2max as opposed to OUES from peak exercise.  
Since the purpose of the OUES is to provide a measure that is useful in lower 
functioning patients, i.e. those unable/unwilling to reach volitional exhaustion, 
differentiation between these patients is a key requisite of this CPET parameter, 
especially at submaximal thresholds. Unfortunately, this study demonstrates that 
the OUES does not provide such sensitivity in children and adolescents with CF. 
Therefore, despite the OUES showing potential as a clinical outcome in other 
paediatric cohorts (Baba et al., 1996, Drinkard et al., 2007), its use as a surrogate 
of V̇O2max in children and adolescents with CF is doubtful.  
Previous studies have assessed the validity of the OUES in clinical populations, 
such as congestive heart failure (Hollenberg and Tager, 2000) and congenital 
heart disease (Bongers et al., 2011), finding it, to an extent, to be a suitable, 
effort-independent, parameter of aerobic fitness. Moreover, two previous studies 
have assessed the applicability of the OUES in individuals with CF. One, 
 
 
Page 192 of 403 
 
conducted in 31 adults and 34 healthy controls, concluded that OUES at 80% of 
test duration is a valid predictor of maximal aerobic fitness, due to high correlation 
(r = 0.91) with V̇O2peak – and therefore may be a clinically useful submaximal 
exercise parameter (Gruet et al., 2010). In addition, Bongers et al. (2012) sought 
to validate the OUES at 50%, 75% and 100% of test duration in 22 children and 
adolescents with CF and 22 healthy controls. In contrast to earlier findings in 
adults, it was concluded to be an invalid measure, due to limited distinguishing 
properties and moderate correlations with V̇O2max. However, previous studies 
have analysed OUES at submaximal parameters of time, without attempts to 
standardise and individualise exercise intensity, meaning participants may be 
exercising in differing metabolic domains, despite matching for exercise duration. 
Hence, the current study accounted for these factors, by analysing OUES at 
submaximal parameters of intensity, time and individual metabolic thresholds. 
Furthermore, the groups in the existing paediatric study (Bongers et al., 2012) 
were poorly matched, with a significant difference in age evident between children 
with CF and healthy counterparts. As previous work has identified age- and sex-
related differences in the OUES (Marinov et al., 2007), this may have 
inadvertently affected results. In addition, inappropriate ratio-standard scaling 
methods were utilised, whereas previous research has shown that allometric 
procedures are required to remove residual effects of body size from OUES 
(Tomlinson et al., 2017). In order to solely isolate the effects of disease status, 
the current study deliberately age- and gender-matched participants, utilising 
allometric scaling to ensure all influencing factors were controlled for.  
Given that the OUES is physiologically dependent on metabolic CO2 production 
(V̇CO2) and the ratio of pulmonary dead space to tidal volume (VD/VT) (Baba et 
al., 1996), it is prudent to examine which factors are altered in CF which may 
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account for its weaker relationship with V̇O2max compared to their healthy 
counterparts. Whilst a reduced V̇O2max has been reported in children with CF 
(Bongers et al., 2014b, Saynor et al., 2014b), no differences exist between CF 
and CON for the percentage of V̇O2max at which GET (an indication of the onset 
of metabolic acidosis (Beaver et al., 1986)) occurs (Bongers et al., 2012, Bongers 
et al., 2014b, Saynor et al., 2014b, Saynor et al., 2016b), suggesting metabolic 
development of CO2 is not impaired in CF, and it may be the VD/VT ratio 
responsible for reduced OUES – a suggestion proposed, and supported by, 
previous research (Bongers et al., 2012). Given the progressive decline in lung 
function with age in CF, due to bronchiectasis and airway obstruction (Elborn, 
2016), such pulmonary impairments may contribute towards elevated dead space 
ventilation in CF (Thin et al., 2004), thus impacting upon OUES. As this decline 
in lung function is observed with age (Harun et al., 2016), this may account for 
the discrepancy observed between the current research and previous OUES 
analyses in adults with CF (Gruet et al., 2010). Furthermore, given that the 
majority of patients in this study had mild-to-moderate CF (FEV1 > 70 %Predicted in 
31/36 patients), it is unclear if the OUES will display a differing profile in patients 
with severe CF (FEV1 < 40 %Predicted).  
In conclusion, the OUES is not a valid submaximal surrogate of aerobic fitness in 
children and adolescents with CF. This research subsequently provides clinical 
teams with the clear evidence that only maximal markers of prognostic value (i.e. 
V̇O2max) should continue to be measured in patients with CF. Furthermore, 
continued research is required to identify submaximal variables that may hold 
clinical utility in this patient population when unable or unwilling to exercise to 
volitional exhaustion.  
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6 ANALYSIS OF OXYGEN UPTAKE EFFICIENCY PARAMETERS IN 
YOUNG PEOPLE WITH CYSTIC FIBROSIS 
 Abstract 
Purpose:  
This study characterised oxygen uptake efficiency (OUE) in children with mild-to-
moderate cystic fibrosis (CF). Specifically, it investigated 1) the utility of OUE 
parameters as potential submaximal surrogates of peak oxygen uptake (V̇O2peak), 
and 2) the relationship between OUE and disease severity.  
Methods:  
Cardiopulmonary exercise test (CPET) data were collated from 72 children (36 
CF, 36 age- and sex-matched controls [CON]), with OUE assessed as its highest 
90-s average (plateau; OUEP), the gas exchange threshold (OUEGET) and 
respiratory compensation point (OUERCP). Pearson’s correlation coefficients, 
independent t-tests and factorial ANOVAs assessed differences between groups 
and the use of OUE measures as surrogates for V̇O2peak.  
Results:  
A significant (p < 0.05) reduction in allometrically scaled V̇O2peak and all OUE 
parameters was found in CF. Significant (p < 0.05) correlations between 
measurements of OUE and allometrically scaled V̇O2peak, were observed in CF (r 
= 0.49 – 0.52) and CON (r = 0.46 – 0.52). Furthermore, measures of OUE were 
significantly (p < 0.05) correlated with pulmonary function (FEV1%Predicted) in CF (r 
= 0.38 – 0.46), but not CON (r = -0.20 – 0.14). OUEP was able to differentiate 
between different aerobic fitness tertiles in CON but not CF.  
Conclusions:  
OUE parameters were reduced in CF, but were not a suitable surrogate for 
V̇O2peak. Clinical teams should, where possible, continue to utilise maximal CPET 
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parameters to measure aerobic fitness in children and adolescents with CF. 
Future research should assess the prognostic utility of OUEP as it does appear 
sensitive to disease status and severity.  
 Introduction 
It is well established that a high level of aerobic fitness, typically characterised by 
peak oxygen uptake (V̇O2peak), is of benefit for young people with cystic fibrosis 
(CF). A higher V̇O2peak is associated with an improved quality of life (Hebestreit 
et al., 2014), reduced risk of hospitalisation for pulmonary exacerbations (Pérez 
et al., 2014) and reduced mortality risk (Nixon et al., 1992, Pianosi et al., 2005a). 
As a result, regular cardiopulmonary exercise testing (CPET) is recommended by 
the European CF Society and endorsed by the European Respiratory Society 
(Hebestreit et al., 2015), to monitor changes in aerobic fitness and guide 
decisions concerning clinical status and therapeutic interventions. 
CPET is considered the gold standard method to assess aerobic fitness, with 
assessment of V̇O2peak requiring the individual to provide a maximal physical 
effort. Factors such as excessive dyspnoea and/or a lack of motivation may cause 
individuals with CF to be unwilling or unable to reach volitional exhaustion and 
thus   V̇O2peak. It has, therefore, been proposed that submaximal markers of 
aerobic fitness should be investigated as viable alternatives that can provide 
clinically useful information in such circumstances (Williams et al., 2014).  
Previous research has shown the oxygen uptake efficiency slope (OUES) (Baba 
et al., 1996) to be a potentially useful submaximal parameter of aerobic fitness 
due to its high correlation with V̇O2peak in clinical populations, including adults with 
CF (Gruet et al., 2010). However, there are several issues that preclude the use 
of OUES as an alternative marker of aerobic fitness in CF. Firstly, OUES is 
dependent on body size and requires allometric scaling to normalise data 
 
 
Page 196 of 403 
 
(Tomlinson et al., 2017) – a process that may be time consuming in clinical 
practice. Secondly, the OUES has a high level of variability (as measured by 
coefficients of variation [CV]), both between participants, and in terms of test-
retest reproducibility in healthy adults (Sun et al., 2012b) and children (Bongers 
et al., 2015a). Finally, the OUES is unable to discriminate aerobic fitness within 
children and adolescents with mild-to-moderate CF (Williams et al., 2018).  
The utility of other submaximal CPET parameters in children with CF, such as 
oxygen uptake efficiency (OUE) – the ratio between oxygen uptake (V̇O2) and 
ventilation (V̇E) (V̇O2/V̇E (Sun et al., 2012b)), therefore warrants consideration. 
Unlike the OUES, which utilises a log-transformation of V̇E (Baba et al., 1996) to 
linearise the non-linear ventilatory profile often observed during incremental 
exercise, the OUE parameter accommodates this curvilinear relationship 
between V̇E and V̇O2 (Bongers et al., 2015a). Furthermore, OUE has been shown 
to have less variability (CV) than OUES within groups of adults (39.5% vs. 14.6%) 
(Sun et al., 2012b) and children (32.9% vs. 10.9%) (Bongers et al., 2015a) and 
is not dependent on body size (Sun et al., 2012b). This independence of body 
size therefore removes potential bias due to growth and the subsequent need to 
scale data, which may be of further benefit in a clinical setting. 
Practically, OUE can be measured at any point during an incremental exercise 
test. However the highest 90 second (s) plateau (oxygen uptake efficiency 
plateau; OUEP), which typically occurs prior to, or at, the ventilatory threshold 
(VT) (Bongers et al., 2015a) or gas exchange threshold (GET) (Sun et al., 2012b), 
has been shown to be a predictor of mortality in heart failure (Sun et al., 2012a). 
Despite demonstrated clinical utility in cardiac populations, its role in chronic 
respiratory disease remains unknown. Furthermore, given that the ratio of V̇E to 
V̇O2 (ventilatory equivalent for oxygen) at peak exercise has been shown to be a 
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more significant predictor of mortality in children and adolescents with CF than 
body-mass relative V̇O2peak (Hulzebos et al., 2014), it is clear that the relationship 
between V̇E and V̇O2 is of clinical significance, and warrants further investigation, 
particularly when it is not feasible nor possible to assess V̇O2peak, e.g., due to 
pathophysiological or motivational reasons. Therefore, the OUE (and in particular 
the OUEP) has the potential to be considered submaximal measures of aerobic 
fitness that could be used to quantify pathophysiological and/or therapeutically-
induced changes. However, evidence for this utilisation of OUE is required, with 
recent research calling for further investigation into the prognostic properties of 
other OUE parameters in children and adolescents with chronic health conditions, 
such as CF (Bongers et al., 2015a).  
Therefore, the aim of this study was to explore the utility of OUE parameters, in 
children and adolescents with mild-to-moderate CF, as potential submaximal 
surrogates for V̇O2peak. This is conducted firstly by characterising the OUE 
responses during CPET in children and adolescents with mild-to-moderate CF, 
compared with age- and sex-matched controls. Secondly, by assessing the utility 
of OUE as an objective, submaximal surrogate for V̇O2peak in this population. 
Thirdly, identifying the relationship between OUE parameters and disease status 
and severity in individuals with CF. 
 Methods 
6.3.1 Participants 
Data from 72 children and adolescents (36 with mild-to-moderate CF and 36 age- 
and sex-matched CON; 21 males per group; mean age 13.3 ± 2.8 years) were 
included in this study. Participant characteristics are presented in Table 6.1. 
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6.3.2 Ethics approval 
This study was a retrospective analysis of existing data, and therefore did not 
require additional ethics approval. Ethics approval for original data collected was 
approved by the South West NHS Research Ethics Committee and the University 
of Exeter Sport and Health Sciences Ethics Committee. Fully informed written 
consent and assent were obtained from parents/guardians and paediatric 
participants, respectively.  
6.3.3 Anthropometric variables 
Stature was measured to the nearest 0.1 cm using a stadiometer (Holtain Ltd., 
Crymych, UK) and body mass to the nearest 0.1 kg using digital scales (Seca, 
Birmingham, UK). Body mass index (BMI) was subsequently calculated, and 
body surface area (BSA) was estimated using the Haycock equation (Haycock et 
al., 1978).  
6.3.4 Pulmonary function 
Pulmonary function was assessed using flow-volume loop spirometry, with the 
maximal values from three acceptable manoeuvres for forced expiratory volume 
in 1 s (FEV1) and forced vital capacity (FVC) expressed relative to normative 
reference values from the Global Lung Function Initiative (Quanjer et al., 2012). 
Maximal voluntary ventilation (MVV) was calculated by multiplying FEV1 (L) by 
35 (Wasserman et al., 2005).  
6.3.5 Exercise variables 
All participants undertook a CPET to volitional exhaustion on an electronically 
braked cycle ergometer (Lode, the Netherlands) to determine maximal and 
submaximal measures of aerobic fitness. Breath-by-breath changes in pulmonary 
gas exchange and ventilation were measured, and subsequently averaged to 10 
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s time intervals. Of the 72 participants within the study, 33 children (20 CF, 13 
CON) undertook a previously described supramaximal verification bout to 
determine a ‘true’ V̇O2max (Barker et al., 2011, Saynor et al., 2013a). However, as 
not all participants underwent this verification testing, the highest V̇O2 obtained 
during the course of testing procedures is referred to as ‘V̇O2peak’. Following 
determination of V̇O2peak, the GET and respiratory compensation point (RCP) 
were independently verified by two researchers using methods described by 
Beaver et al. (1986) – the disproportionate increases in V̇CO2 relative to V̇O2 (i.e. 
V-slope method for GET) and V̇E relative to V̇CO2 for RCP. This process is 
reliable in children with CF (CV = 11.2%, Saynor et al. (2013b)), and those without 
CF (CV = 7.5%, Fawkner et al. (2002)). V̇O2peak was compared to normative 
reference values, chosen due their similar participant characteristics and 
methodology, whilst also accounting for age and sex (Bongers et al., 2014a), and 
split into aerobic fitness tertiles (a division shown to predict mortality in CF 
(Pianosi et al., 2005a)) for each group. Reliability of all gaseous exchange 
variables for children and adolescents with CF (Saynor et al., 2013b), and without 
CF (Bongers et al., 2015a, Welsman et al., 2005), have previously been reported.  
OUE values were calculated in line with previous work (Sun et al., 2012b), and 
were obtained by averaging V̇O2/V̇E in the 60 s prior to the GET (OUEGET) and 
RCP (OUERCP). The OUEP was taken as the highest 90 s V̇O2/V̇E average. 
Warm-up and cool-down data during exercise were omitted from data analysis in 
order to isolate the incremental profile of the CPET. OUEP was also compared 
to normative values (Bongers et al., 2015a, Bongers et al., 2014a).  
6.3.6 Statistical analyses 
Statistical analyses were performed using IBM SPSS Statistics v23 (IBM Corp., 
Armonk NY, USA). Allometric scaling was utilised to remove the influence of body 
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mass from V̇O2peak in both CF and CON groups (Welsman et al., 1996). Scaling 
of OUE variables was not required as there were no significant relationships with 
body size, thereby indicating size-independence, as previously reported in adults 
(Sun et al., 2012b). 
Pearson’s correlation coefficients determined relationships between all OUE 
parameters and V̇O2peak, as well as, the traditional clinical marker of disease 
severity, FEV1 (expressed as a percentage of predicted). Independent samples t-
tests established mean differences in anthropometric, pulmonary function and 
CPET parameters between groups. Factorial analyses of variance (ANOVAs) 
were used to establish interaction effects between disease status and aerobic 
fitness tertiles (as described in ‘Exercise Variables’) upon V̇O2peak and OUE 
parameters. For ANOVAs, the tertiles for V̇O2peak to which participants were 
categorised (i.e., high, middle, low) remained the same throughout all ANOVAs, 
regardless of OUE value. Where significant effects occurred, planned pairwise 
comparisons with a Sidak correction factor were applied, chosen for its correction 
of multiple comparisons (reducing Type 1 error), whilst simultaneously being less 
conservative than Bonferroni corrections (thus reducing Type 2 error) (Abdi, 
2007). Statistical significance was set at an alpha level of 0.05, and effect sizes 
(ES) for mean comparisons were described using Cohen’s thresholds (small = 
0.2, medium = 0.5, large = 0.8) (Cohen, 1992).  
 Results 
6.4.1 Differences in OUE between groups 
All OUE outcomes were detected in 68/72 participants (94%). Both OUEGET and 
OUERCP were identified in 35/36 (97%) of children and adolescents in the CF 
group. In the CON group, OUEGET was detected in all participants (36/36, 100%), 
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and OUERCP was detected in 34/36 (94%) of participants. The profile of OUEP, 
OUEGET and OUERCP during a CPET for a representative individual with CF are 
shown in Figure 6.1. A representative comparison of OUEP for one participant 
with CF against CON is shown in Figure 6.2. 
Differences between groups were observed for pulmonary function, absolute 
GET, OUEGET, OUERCP and OUEP, with CON being significantly higher than CF. 
No significant difference was observed between CF and CON groups for V̇O2peak, 
when expressed as an absolute value. However, the CON group was revealed to 
have a significantly (p < 0.05) greater V̇O2peak when allometric scaling had 
removed residual effects of body size (Table 6.1). Individual differences between 
age- and sex-matched pairs for V̇O2peak and OUEP are displayed in Figure 6.3.  
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Figure 6.1 Profiles of OUEP, OUEGET and OUERCP in a representative CPET 
from an individual child with CF (female, 12 years, homozygous ΔF508, FEV1 
82.0 %Predicted, V̇O2peak 37 mL.kg-1.min-1, 73 mL.kg-0.86.min-1). Vertical line at 180 
s indicates end of warm-up, and beginning of ramp phase. Vertical lines also 
indicate point of GET and RCP. Horizontal lines between 200 – 290 s = OUEP 
(31.9 mL.L-1), 240 – 300 seconds = OUEGET (31.0 mL.L-1), 500 – 560 seconds 
= OUERCP (19.7 mL.L-1). 
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Figure 6.2 Differences in OUE (V̇O2/V̇E) between two representative children, 
CF (□) and CON (○), throughout a ramp incremental CPET. Vertical line at 180 
s indicates the end of the warm-up and beginning of ramp phase of the test. 
Vertical lines at 610 s and 640 s indicate exhaustion for CF, and CON 
participant respectively. Solid horizontal lines at 31.9 mL.L-1 (CF) and 43.0 
mL.L-1 (CON) indicate OUEP (highest 90 s average) for each group, 
respectively. 
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Table 6.1. Anthropometric, pulmonary function and exercise-related differences 
between CF and CON groups.  
Variable CF CON p-value ES 
Age (years) 13.4 (2.7) 13.2 (2.9) 0.77 0.08 
Stature (cm) 155.6 (13.5) 159.1 (15.2) 0.32 0.24 
Body mass (kg) 50.2 (15.5) 51.2 (14.5) 0.78 0.07 
BMI (kg.m-2) 20.28 (3.67) 19.91 (4.18) 0.70 0.09 
BSA (m2) 1.46 (0.28) 1.49 (0.28) 0.65 0.11 
FEV1 (L)* 2.46 (0.97) 2.96 (0.86) 0.07 0.55 
FEV1 (%Predicted)* 85.0 (20.0) 97.5 (10.6) 0.004 0.71 
FVC (L)* 3.10 (1.14) 3.44 (1.02) 0.30 0.31 
FVC (%Predicted)* 92.7 (16.6) 98.6 (11.0) 0.18 0.39 
MVV (L.min-1)* 86.2 (34.0) 103.6 (30.0) 0.07 0.53 
V̇O2peak (L.min-1) 1.74 (0.57) 2.03 (0.88) 0.09 0.39 
V̇O2peak (mL.kg-1.min-1) 38 (8) 40 (11) 0.32 0.23 
V̇O2peak (mL.kg-0.86.min-1) 75 (15) 85 (24) 0.031 0.52 
Relative V̇O2peak (%Predicted) 83.3 (16.8) 87.8 (20.8) 0.32 0.24 
GET (L.min-1) 0.91 (0.28) 1.12 (0.54) 0.035 0.49 
GET (% V̇O2peak) 53.4 (9.3) 55.0 (8.0) 0.42 0.18 
HRmax (beats.min-1) 182 (8) 185 (14) 0.30 0.26 
V̇Emax (L.min-1) 74.66 (35.62) 69.18 (33.45) 0.50 0.16 
V̇Emax (% MVV)* 88.3 (30.4) 60.9 (23.3) 0.001 0.97 
OUEP (mL.L-1) 35.58 (5.40) 45.09 (5.78) <0.001 1.70 
OUEGET (mL.L-1) 34.08 (5.40) 43.24 (5.08) <0.001 1.75 
OUERCP (mL.L-1) 29.49 (4.95) 35.15 (4.52) <0.001 1.19 
OUEP (%Predicted) 83.2 (13.9) 105.7 (13.0) <0.001 1.68 
Measures are presented as mean (± SD). Significant mean differences are 
denoted by a bold p-value. * Unequal groups for pulmonary variables: CF = 36, 
CON = 18. BMI, body mass index; BSA, body surface area; FEV1, forced 
expiratory volume in 1 s; FVC, forced vital capacity; MVV, maximal voluntary 
ventilation; V̇O2, volume of oxygen uptake; GET, gas exchange threshold; HR, 
heart rate; V̇E, minute ventilation; RER, respiratory exchange ratio; OUEP, 
oxygen uptake efficiency plateau; OUEGET, oxygen uptake efficiency at the gas 
exchange threshold; OUERCP, oxygen uptake efficiency at the respiratory 
compensation point; ES, effect size. 
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Figure 6.3 Individual differences between age- and sex-matched CON and CF pairs 
for CPET derived variables. All plots are calculated as CON minus CF, i.e. bars 
underneath y = 0 on x-axis indicate participant with CF has a greater value than CON 
counterpart. A: Differences in allometrically scaled V̇O2peak between pairs. B: 
Differences in OUEP between pairs, independent of differences in V̇O2peak. C: 
Differences in V̇O2peak (mL.kg-0.86.min-1) between pairs, plotted alongside within-pair 
differences in OUEP (mL.L-1). Black bars represent V̇O2peak, and grey bars indicate 
OUEP. 
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6.4.2 Correlation of with OUE with V̇O2peak 
OUEP and OUEGET were significantly and positively correlated with absolute 
V̇O2peak in the CF and CON groups, however OUERCP was not correlated with 
absolute V̇O2peak in either CF or CON groups. OUEP and OUEGET, but not 
OUERCP, were correlated with allometrically scaled V̇O2peak in both CF and CON 
(Table 6.2).  
 
Table 6.2. Correlations between OUE parameters and V̇O2peak, and FEV1.  
 CF CON Combined 
Absolute V̇O2peak (L
.min-1) 
OUEGET 0.36 (0.036) 0.40 (0.017) 0.41 (<0.001) 
OUERCP 0.12 (0.50) 0.29 (0.09) 0.28 (0.022) 
OUEP 0.43 (0.010) 0.42 (0.010) 0.44 (<0.001) 
OUEP (%Predicted) 0.22 (0.20) 0.12 (0.51) 0.24 (0.040) 
Allometrically Scaled V̇O2peak (mL
.kg-0.86.min-1) 
OUEGET 0.49 (0.003) 0.46 (0.005) 0.51 (<0.001) 
OUERCP 0.31 (0.08) 0.24 (0.17) 0.35 (0.003) 
OUEP 0.52 (0.001) 0.52 (0.002) 0.54 (<0.001) 
OUEP (%Predicted) 0.49 (0.003) 0.38 (0.021) 0.47 (<0.001) 
FEV1 (%Predicted)* 
OUEGET 0.38 (0.026) -0.06 (0.83) 0.44 (0.001) 
OUERCP 0.07 (0.68) 0.14 (0.61) 0.24 (0.08) 
OUEP 0.43 (0.010) -0.20 (0.43) 0.43 (0.001) 
OUEP (%Predicted) 0.46 (0.005) -0.19 (0.45) 0.44 (0.001) 
Values are presented as correlation coefficients (r) with p-values in parentheses. 
Bold text indicates a significant (p < 0.05) coefficient. V̇O2, oxygen uptake; FEV1, 
forced expiratory volume in 1 s. * Unequal samples for pulmonary variables: CF 
= 36, CON = 18. 
 
 
 
 
 
Page 207 of 403 
 
6.4.3 Differences between aerobic fitness groups 
When the data were split by tertiles according to allometrically scaled V̇O2peak, a 
significant difference in aerobic fitness was observed between tertiles within both 
CF (high: 91 ± 8 vs. mid: 75 ± 5 vs. low: 58 ± 8 mL.kg-0.86.min-1) and CON (110 ± 
16 vs. 86 ± 7 vs. 62 ± 13 mL.kg-0.86.min-1) groups (p < 0.05 for all pairwise 
comparisons, ES = 1.91 – 4.13). However, when comparisons were made 
between groups, a significant difference in allometrically scaled V̇O2peak between 
CF and CON was only evident in the high (p < 0.001, ES = 1.47) and middle (p = 
0.50, ES = 1.85) aerobic fitness tertiles, not for the lowest (p = 0.39, ES = 0.38).  
When assessing OUEP by fitness tertile and disease group, significant main 
effects were seen for group (p < 0.001) and fitness tertile (p < 0.001), but no 
significant fitness tertile by group interactions were evident (p = 0.20; Figure 6.4). 
Pairwise comparisons identified mean differences between CF and CON for 
OUEP at each level of fitness respectively (high; 38.32 ± 4.21 vs. 50.26 ± 5.22, p 
< 0.001, ES = 2.52, middle; 36.22 ± 4.57 vs. 43.19 ± 5.06, p = 0.001, ES = 1.45, 
low; 32.19 ± 5.73 vs. 41.81 ± 2.93, p < 0.001, ES = 2.11).  
Mean differences for OUEP were found between the highest and lowest between 
aerobic fitness tertiles within CF (p = 0.006, ES = 1.22), but not between high and 
middle (p = 0.62, ES = 0.48) nor middle and low (p = 0.11, ES = 0.78). Further 
pairwise comparisons revealed differences within the CON group, as the tertile 
with the highest aerobic fitness had a significantly higher OUEP than the middle 
(p = 0.001, ES = 1.38) and lowest (p < 0.001, ES = 2.00) tertiles. No significant 
difference was evident between the middle and lowest tertiles with regards to 
OUEP for CON (p = 0.85, ES = 0.33; Figure 6.4).  
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When ANOVAs were repeated for OUEGET and OUERCP, significant main effects 
for group were found (p < 0.001) for both parameters. Further significance (p < 
0.05) between groups was identified when split by fitness tertile. A main effect for 
fitness tertile was present for OUEGET (p < 0.001), but not OUERCP (p = 0.08). 
Main interaction effects between group and aerobic fitness were not present for 
either OUEGET (p = 0.34) or OUERCP (p = 0.88; Figure 6.4). However, for OUEGET, 
pairwise comparisons revealed significant differences within CF between high 
and low fitness tertiles (p = 0.021, ES = 1.01). For CON, differences were found 
between high and low (p = 0.002, ES = 1.48), and high and middle fitness tertiles 
(p = 0.026, ES = 1.15). For OUERCP, no differences between tertiles within groups 
(p = 0.37 – 1.00, ES = 0.01 – 0.86). In addition, pairwise comparisons revealed 
significant differences (p < 0.05) between groups at each tertile for both OUEGET 
and OUERCP (Figure 6.4).  
6.4.4 Relationship with disease severity (FEV1) 
OUEP and OUEGET were significantly correlated with FEV1 within the CF group, 
but OUERCP was not. None of the OUE parameters were significantly correlated 
with FEV1 within CON (Table 6.2). Allometrically scaled V̇O2peak was significantly 
correlated with FEV1 (%Predicted) in CF (r = 0.46, p = 0.004), but not CON (r = -0.20, 
p = 0.43).  
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Figure 6.4 (overleaf) Comparison of V̇O2peak (A) and OUE parameters (B: 
OUEP; C: OUEGET; D: OUERCP) between CF (black) and CON (white), split by 
V̇O2peak tertile. * = Significant (p < 0.05) difference from highest tertile (within 
group). § = Significant (p < 0.05) difference from middle tertile (within group). † 
= Significant (p < 0.05) difference between groups (within tertile). 
 
 Discussion 
In this study, whilst all OUE parameters were significantly reduced in children and 
adolescents with CF in the current study, results show that OUE does not provide 
a viable surrogate for V̇O2peak in this group. However, the novel finding of this 
study is that OUE appears to hold clinical utility as an independent marker of 
aerobic fitness, since it can differentiate between CF and CON, and holds a 
significant relationship with disease severity (as shown by FEV1) in the CF group. 
An example is shown in Figure 6.3, whereby allometrically scaled V̇O2peak was 
greater in individuals with CF in 16/36 (44 %) age- and sex-matched pairs, but 
OUEP was only greater in individuals with CF in 5/36 (14 %) matched pairs (and 
V̇O2peak and OUEP were only greater in CF in 4/36 (11%) of cases), thus 
indicating reduced OUE in CF, regardless of fitness status. This is further 
corroborated by the significant relationship between OUE (OUEP, OUEGET) and 
FEV1 (%Predicted) within the CF cohort, showing that OUE is associated with 
traditional clinical markers of disease severity. 
For individuals with CF, a reduced aerobic fitness is a hallmark of disease 
progression (Orenstein and Higgins, 2005) and assessment of V̇O2peak is 
therefore recommended on at least an annual basis (Hebestreit et al., 2015). 
However, as maximal testing may not always be possible in this patient group 
(due to pathophysiological and/or motivation related factors), viable submaximal 
measures are needed to assess aerobic fitness. Whilst submaximal physiological 
thresholds such as the GET are related to disease severity (Thin et al., 2002), 
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detection rates are variable in CF (12/13; 92% (Saynor et al., 2013b)), and non-
CF (45/55; 82% (Hebestreit et al., 2000) groups and are typically dependent on 
knowledge of V̇O2peak in order to be expressed as a percentage of maximal 
capacity. In the present study, all OUE values were identified in the majority (94%) 
of participants, with OUEP identified in 100% of participants. The identification of 
OUEP is related to the averaging of 90-s of data and is not dependent on prior 
detection of the GET or RCP (to produce OUEGET and OUERCP). The OUEP 
occurs at a submaximal point near the VT (Bongers et al., 2015a) and/or GET 
(Sun et al., 2012b), a threshold that reportedly occurs at 50-60% of V̇O2peak in 
children and adolescents with CF (Bongers et al., 2014b, Saynor et al., 2014b, 
Saynor et al., 2016b). Therefore, the exercise intensity required to generate a 
value for OUEP should be feasible for most children to achieve despite being 
unable or unwilling to exercise to exhaustion, such as those with advanced 
pulmonary disease, or more prone to increased levels of dyspnoea and 
desaturation upon exertion. The simplicity of the OUEP measure highlights how 
feasible a measure it may be to implement in busy clinical environments, suiting 
patients, researchers and clinicians alike. 
In the current study, OUE variables were significantly correlated with V̇O2peak in 
the CON and CF groups, indicating the two variables have a medium (as defined 
by Cohen (1992)) relationship (R2 = 27% between OUEP and allometrically 
scaled V̇O2peak in both CF and CON). Given previous research (Williams et al., 
2018) has identified differences in V̇O2peak within, and between, CF and CON 
groups when split by aerobic fitness tertile, a division shown to predict for 
mortality (Pianosi et al., 2005a), it would therefore be anticipated that parameters 
of OUE would follow a similar pattern in discriminating between individuals’ of 
differing aerobic fitness statuses. Differences are seen within the CON group for 
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OUEP, with the highest fitness tertile having significantly greater OUEP relative 
to children in the middle and lowest fitness tertiles. Thus, showing OUEP can 
discriminate between individuals on different fitness status. However, the same 
discriminatory ability is not seen for the CF group as it is only the group with the 
lowest aerobic fitness that is different to the group with the highest fitness (Figure 
6.4). Therefore, despite a relationship with V̇O2peak, the inability to discriminate 
between the fitness groups shows that the OUEP cannot act as a surrogate for 
V̇O2peak. 
Of the limited research to have characterised the OUEP in youth, a large cross-
sectional study of 214 healthy Dutch children identified similar mean values for 
OUEP (boys, 42.6 ± 4.7; girls, 42.3 ± 4.6 mL.L-1) and OUE at the VT (boys, 42.0 
± 4.6; girls, 41.9 ± 4.7 mL.L-1) to those of the CON group in the current study 
(Bongers et al., 2015a). They also identified a stronger relationship (r = 0.65, p < 
0.01) between the OUEP and absolute V̇O2peak than the CON group in the current 
study, potentially due to the higher V̇Emax observed in both boys and girls (80 ± 
25; 71 ± 21 L.min-1 respectively) relative to the current CON group (69.2 ± 33.5 
L.min-1), which may therefore bias the relationship between V̇O2 and V̇O2/V̇E 
(OUE). However, as the current study builds upon this previous work and is the 
first to comprehensively examine OUE at multiple metabolic thresholds in children 
and adolescents with CF, only limited comparisons can be made, as no previous 
research has provided values against which to compare our novel data. 
Furthermore, the only application of OUE in clinical groups has been in adults 
with heart failure (Sun et al., 2012a), pulmonary hypertension (Tan et al., 2014), 
chronic obstructive pulomary disease (Barron et al., 2016) and pulmonary 
embolism (Guo et al., 2016). However, minimal comparisons and inferences can 
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be made against children with CF and these adult-onset, and predominantly 
vascular conditions.  
As the current study has shown that OUEP (nor any OUE parameter) is not able 
to act as a surrogate measure of aerobic fitness, alternative submaximal factors 
must be considered. Ventilatory drive (V̇E/V̇CO2) has received recent attention in 
predictive models of mortality (Hulzebos et al., 2014), and may be a viable 
candidate, given its low variability compared to V̇E/V̇O2 (Sun et al., 2002) and 
superior prognostic value relative to OUES in patients with heart failure (Arena et 
al., 2007). As such, further research should continue to explore the potential utility 
of this variable in individuals with CF, either as an alternative for V̇O2peak, or an 
independent prognostic variable. However, it is unclear whether any parameter 
of OUE may be of use in individuals with a more severe form of CF, or have 
longitudinal relevance in mild-to-moderate CF, and therefore further research is 
warranted.  
A number of limitations associated with the present study are worthy of comment. 
Primarily, this study is focused in children and adolescents with mild-to-moderate 
CF (FEV1 > 40 %Predicted). However, defining severity on FEV1 alone does not 
account for the nutritional measures, number of exacerbations, inflammatory 
markers and infection statuses that also contribute towards a patient profile and 
definition of severity. Consequently, these results may not be applicable to those 
with lower lung function, a cohort for whom FEV1 has a greater influence upon 
V̇O2peak (Pastre et al., 2014). Furthermore, the CON group in the current study 
display a reduced level of aerobic fitness relative to previous studies investigating 
OUE (Bongers et al., 2015a), which may explain the number of individuals with 
CF having a higher V̇O2peak within age- and gender-matched pairs (Figure 6.3). 
In addition, the lack of all participants undertaking supramaximal verification 
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bouts (Barker et al., 2011) within CPETs could potentially influence detection of 
a ‘true’ V̇O2max (hence our use of V̇O2peak). This is likely to have minimal effect, as 
previous work has shown that the ramp only test elicits a ‘true’ V̇O2max in ~90% 
of healthy children (Barker et al., 2011) and ~80% of children with CF (Saynor et 
al., 2013a). Finally, when these methodological issues are considered in 
conjunction with our sample size, true effects may be obscured regarding the 
ability for OUEP to discriminate aerobic fitness. For example, the difference 
between middle- and low-fitness tertiles in CF revealed a p-value of 0.11, yet an 
ES of 0.78, thus indicating an effect is likely present but cannot be statistically 
confirmed. We have utilised the Sidak correction factor in this study as opposed 
to the more conservative Bonferroni in an attempt to alleviate the potential for 
Type 2 errors, yet statistical significance was not found in some comparisons and 
a statistical error might still have occurred. Larger clinical sample sizes would be 
advantageous but are not always feasible in young people who are sick. 
 Conclusion 
The current study is the first to comprehensively characterise parameters of OUE 
in children and adolescents with mild-to-moderate CF, and assess the utility of 
such parameters as submaximal surrogates for V̇O2peak. Despite promising 
findings in other clinical populations, and a significant relationship between OUE 
and allometrically scaled V̇O2peak in the present study, the inability to differentiate 
between aerobic fitness statuses indicates that OUE is unable to provide a viable 
surrogate for V̇O2peak in this population. Further research is therefore warranted 
to identify suitable submaximal variables to characterise aerobic fitness status in 
children and adolescents with CF when determination of V̇O2peak is not possible. 
Moreover, the prognostic utility of OUE in CF when V̇O2peak cannot be determined 
also warrants investigation.  
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7 QUANTIFICATION OF THIGH MUSCLE VOLUME IN CHILDREN USING 
MAGNETIC RESONANCE IMAGING 
 Abstract 
Quantifying muscle volume (MV) using magnetic resonance imaging (MRI) 
requires a time-consuming process of summating multiple cross-sectional area 
(CSA) slices. Estimation of MV using a reduced number of CSA slices introduces 
error that is known in adults but not in children, where body size can differ greatly 
due to growth and maturation. This study sought to identify error in estimating leg 
MV in children when using fewer CSA slices. Fifteen children (11 males, 14.8 ± 
2.1 years) underwent MRI scans of the right thigh using a 1.5 T scanner. A 
criterion MV was determined by tracing around and summing all CSAs, with MV 
subsequently estimated using every second, third, fourth and fifth CSA slice. 
Bland-Altman plots displayed mean error and limits of agreement (LoA) between 
methods for calculating MV. CSA measures at 50% thigh length were also used 
to predict MV. Pearson’s correlation coefficients determined relationships 
between error and measures of body size/composition. Criterion MV was 
positively correlated with estimated MVs (r = 1.0, p < 0.001 for all). LoA increased 
as CSA slice count decreased, to a maximum of ±2.0%. CSA at mid-thigh 
predicted MV (R2 = 0.94, 0.53; SEE = 199, 570 cm3). All body size/composition 
measures were correlated (r = -0.78 – 0.86, p < 0.05) with the error between 
criterion and estimated MV. It was concluded that MV can be accurately 
estimated using fewer CSA slices. However, the associated error must be 
considered when calculating MV in studies involving children and adolescents, 
as body size biases estimates. 
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 Introduction 
Accurate quantification and interpretation of muscle size is important in 
physiological studies, such as those measuring hypertrophy following training 
(Tracy et al., 1999), muscle atrophy following immobilisation (Wall et al., 2014) or 
aging (Ogawa et al., 2012), and examining the consequences of chronic disease 
(Godi et al., 2016).  
To quantify muscle volume (MV), magnetic resonance imaging (MRI) is 
considered the preferred technique due to use of non-ionising radiation, while 
producing high resolution images (Narici et al., 1992), and consists of the 
measurement and summation of multiple sequential cross-sectional areas (CSA) 
(Barnouin et al., 2015, Tracy et al., 2003). As this is time consuming, studies have 
sought to identify the measurement error associated with increasing the distance 
between measured CSAs with the objective of reducing the number of CSAs 
required and the time taken for analysis (Barnouin et al., 2015, Tracy et al., 2003, 
Walton et al., 1997). However, as the number of CSA slices decreases, the 
associated error with estimated MV increases. For example, Tracy et al. (2003) 
reports the limits of agreement (LoA) increasing from ±0.7% to ±6.4% of total MV 
when 11 mm and 91 mm gaps between slices are used.  
A further consideration is the direction in which CSA slices are sequentially 
summed to estimate MV. Previous studies have estimated MV from the knee, 
working towards the hip (i.e. distal to proximal [D-P]) (Nordez et al., 2009, Tracy 
et al., 2003), a process that may under-estimate thigh volume. However, no study 
has systematically evaluated whether the direction of measurement (i.e. D-P, or 
a proximal-to-distal [P-D] direction) has a bearing on final MV estimates.  
To our knowledge, studies examining the errors associated with determining MV 
have only been undertaken in adults. Therefore, the measurement strategies 
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applied may not be suitable for groups involving children and adolescents. 
Compared to adults, children have a different body geometry (Feber and 
Krásničanová, 2012) and the process of maturation (timing and tempo of maturity 
stages) leads to children of equal chronological age, but different body size 
(Mirwald et al., 2002) and MV (Pitcher et al., 2012). These factors are likely to 
influence the error when determining MV using MRI, and warrant further 
investigation.  
The recognition of measurement errors are vital in clinical populations. For 
example, Duchenne muscular dystrophy, where progressive MV decline can 
arise and has previously been quantified using MRI (Godi et al., 2016). Similarly, 
nutritional complications in cystic fibrosis (CF) lead to considerable variations in 
body-size (Culhane et al., 2013), and recent debate has queried whether a 
qualitative or quantitative muscular defect is predominantly responsible for 
impaired oxidative metabolism (Hulzebos et al., 2017, Rodriguez-Miguelez et al., 
2017). Within CF, some studies have utilised only muscle CSA from a single slice 
(e.g. at 50% of limb length) to reflect muscle size, most likely due to wanting to 
minimise time and cost. However, whilst single site CSA is a poor surrogate for 
total MV in healthy adults (Morse et al., 2007), this has yet to be examined in 
clinical and non-clinical groups of children and adolescents. 
The primary aim of this study was to identify the error associated with estimating 
MV from MRI using a differing number of CSA slices in two groups of children 
and adolescents; healthy controls (CON), and a group with CF. Secondary aims 
included: a) identifying the difference in estimated MV when employing a P-D or 
D-P approach to analysing CSA slices; b) identify the relationship between body 
size and the error in quantifying MV; and c) identify the utility of mid-thigh CSA to 
predict MV.  
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 Methods 
7.3.1 Study population 
Fifteen children (8 CF [2 female, 6 male], 7 healthy controls [CON; 2 female, 5 
male], 14.8 ± 2.1 years) volunteered for the study, with descriptive characteristics 
presented in Table 7.1. Children with CF were age- and sex-matched against 
non-CF controls. Children were recruited from a hospital CF clinic, local schools 
and sports clubs. Ethical approval was obtained from NHS Regional Ethics 
Committee (14/SW/0061), and children and parents/guardians provided written 
informed assent and consent respectively.  
 
Table 7.1. Mean differences between CF and CON groups for anthropometric 
and MRI derived variables.  
Variable Combined  
(n = 15) 
CF  
(n = 8) 
CON  
(n = 7) 
p Value ES 
Age (years) 14.8 (2.1) 15.10 (2.14) 14.43 (2.21) 0.57 0.31 
Stature (m) 1.62 (0.11) 1.63 (0.11) 1.62 (0.11) 0.84 0.09 
Sitting stature (m) 0.85 (0.56) 0.85 (0.06) 0.84 (0.06) 0.63 0.33 
Leg length (m) 0.78 (0.52) 0.77 (0.05) 0.78 (0.06) 0.89 0.18 
Body mass (kg) 57.2 (15.5) 61.7 (18.0) 52.1 (11.0) 0.25 0.63 
Body fat (%) 17.8 (6.1) 18.6 (6.3) 16.7 (6.1) 0.61 0.31 
FFM (kg) 46.5 (11.5) 49.3 (12.5) 43.3 (10.1) 0.33 0.52 
Fat mass (kg) 10.8 (6.5) 12.4 (8.1) 8.8 (3.7) 0.30 0.56 
Criterion MV (cm3) 2778 (801) 2823 (763) 2726 (901) 0.83 0.12 
CSAM (cm2) 59.67 (15.57) 62.75 (13.99) 56.15 (17.61) 0.43 0.42 
CSAT (cm2) 93.17 (24.16) 98.86 (25.64) 86.66 (22.41) 0.35 0.50 
CSAM (% of CSAT) 64.7 (10.1) 64.6 (11.4) 64.7 (9.5) 0.98 0.01 
Data are presented as mean ± standard deviation. FFM, fat-free mass; MV, 
muscle volume; CSAM, muscle cross-sectional of area at mid-thigh; CSAT, cross-
sectional area of muscle and subcutaneous fat at mid-thigh; ES, effect size.  
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7.3.2 Anthropometric measures  
Stature, seated stature and leg length (i.e. stature – seated stature) were 
obtained using wall-mounted and seated stadiometers (Holtain, Crymych, Wales) 
to the nearest 0.1 cm. Body mass (BM) was measured to the nearest 0.1 kg (Seca, 
Birmingham, UK). Skinfold callipers and published equations (Slaughter et al., 
1988) were used to estimate body fat percentage, which was used to determine 
fat mass and fat-free mass (FFM).  
7.3.3 Estimation of volume 
MV of the right thigh was determined using a 1.5 T superconducting whole-body 
scanner (Gyroscan Intera, Philips, the Netherlands), utilising a T1 weighted 
image sequence to obtain a series of transverse slices covering the whole upper 
leg with optimal fat/muscle signal contrast. Participants lay in the prone position 
within the scanner, with the hips and upper legs extended and secured to avoid 
unnecessary movement, but not to cause compression of muscle tissue.  
Slices were acquired with 5 mm thickness and 0.5 mm slice gap, similar to 
previous research (Barnouin et al., 2015, Nordez et al., 2009). CSA was 
determined using Philips software, by manually tracing around the muscle within 
each slice. The CSA value for each individual slice, apart from the first and last 
was multiplied by 5.5 mm (5 mm slice thickness + 0.5 mm slice gap) to produce 
individual slice volumes. The slices at the distal and proximal ends were 
multiplied by 5.25 mm to reflect the absence of the 0.25 mm contribution from the 
adjacent slice gap. All individual volumes were then summed over all slices to 
calculate a criterion measure of MV. This method has been used previously (Lund 
et al., 2002, Walton et al., 1997) and is favourable in comparison to the truncated 
cone formula (Ross et al., 1996), which and has been shown to produce a higher 
level of error (Barnouin et al., 2015, Nordez et al., 2009). 
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In accordance with previous research (Tracy et al., 2003), estimated MV was 
calculated by increasing the interval between CSA slices using every second 
(MV2), third (MV3), fourth (MV4) and fifth (MV5) slice. For MV2 – MV5, each slice 
CSA, apart from for the first and last slice, was multiplied by 11, 16.5, 22 or 27.5 
mm respectively, prior to summing over all slices to calculate MV. When the 
number of CSA slices covering the upper leg did not exactly fit the slice sampling 
frequency, a reduced number of slices were examined (Tracey et al. 2003). For 
example, where 30 CSA slices covered the leg, with the MV5 strategy, slices 1, 
6, 11, 16, 21 and 26 were examined. Under such circumstances a new criterion 
measure was established to ensure the distance covered on the thigh remained 
equal between measures. In this example, CSA slices 1-26 were used to create 
a criterion measure specific to this individual and slicing strategy. This procedure 
was completed for both the D-P and P-D directions, and therefore for the 
described example, in the P-D direction slices 30, 25, 20, 15, 10 and 5 would be 
used to estimate MV5, and would be compared against further criterion measure 
calculated using each slice from 30-5.  
In addition, the CSA of the slice obtained that lay nearest to 50% of the length of 
the measured femur (i.e. midpoint between femoral head and medial epicondyle) 
was assessed to determine the predictive ability of a single slice in estimating MV. 
The CSA of the whole thigh (muscle and subcutaneous fat; CSAT) and muscle-
only CSA (CSAM) were recorded. Bone was excluded from all CSA slices. 
CSA analyses were undertaken by two investigators, with a within-observer 
coefficient of variation (CV) < 1.5% and a between-investigator CV of 1.2%. The 
number of CSA slices required to cover the whole thigh ranged from 40 to 56, 
dependent on thigh length.  
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7.3.4 Statistical analyses 
Pearson’s correlation coefficients and paired samples t-tests were conducted to 
identify relationships and mean differences, respectively, between the criterion 
MV, and each of the MV estimates (i.e. MV2 to MV5). Bland-Altman plots (Bland 
and Altman, 1986) were produced to identify the mean bias between measures 
of MV (MV and MV2, MV3, MV4, MV5 for both D-P and P-D directions), and 
associated 95% LoA. Furthermore, Bland-Altman analyses were conducted 
between predicted MV from both CSAT and CSAM. The MV predicted from CSAT 
and CSAM was obtained using simple bi-linear regression. For each Bland-Altman 
plot, Pearson’s correlations between means (x-axis) and differences (y-axis) 
were conducted to identify whether the size and direction of the error is 
associated with estimated MV itself.  
To identify if the over- or under-estimation of MV is associated with 
anthropometric variables, the absolute difference between each MV estimate and 
the criterion MV was calculated and correlated against chronological and 
biological age, as well as body size parameters (stature, leg length, body mass, 
FFM, fat mass) using Pearson’s correlation coefficients. All statistical analyses 
were performed using SPSS v.23 (IBM Corp., Armonk, NY, USA), with statistical 
significance taken at an alpha value of 0.05. Effect sizes (ES) were described for 
mean comparisons (small = 0.2, medium = 0.5, large = 0.8) and correlation 
coefficients (small = 0.1, medium = 0.3, large = 0.5) (Cohen, 1992).  
 Results 
No differences were observed between children with, and without, CF for any 
anthropometric, MV or CSA variables (p > 0.05, Table 7.1). Therefore, all 
variables are pooled (i.e. n = 15) for subsequent analyses.  
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Mean values (with associated LoA) for the difference from each respective 
criterion MV for all estimation methods and directions are displayed in Figure 7.1. 
The mean criterion MV was significantly greater than each estimated volume 
using the D-P slicing direction, and significantly lower than each estimated 
volume for the P-D direction (all p < 0.001, ES = 0.03 – 0.12). All estimated MV 
variables were significantly, and positively correlated with their respective 
criterion MV (all r = 1.0, all p < 0.001). Furthermore, the mean bias and LoA 
associated with each estimation method increased as the interval between slices 
increases (see Figure 7.1 using Bland-Altman plots). When using the D-P 
direction, a significant and positive correlation was evident between the mean 
difference between criterion and estimated MV, and the respective means for 
MV3 (r = 0.77, p = 0.001), MV4 (r = 0.78, p = 0.001) and MV5 (r = 0.82, p < 0.001), 
but not MV2 (r = 0.29, p = 0.30). For P-D, significant and negative correlations 
are observed between the means and differences of criterion and estimated MV 
for all slicing strategies (MV2, r = -0.69, p = 0.004; MV3, r = -0.83, p < 0.001; MV4, 
r = 0.83, p < 0.001; MV5, r = -0.70, p = 0.004).  
Both CSAM and CSAT were significant predictors of MV (Figure 7.2). When each 
predictive equation was used to estimate MV, mean bias was equal to zero for 
both CSA parameters, with LoA for CSAM (384 cm3, 13.8%) being smaller than 
CSAT (1099 cm3, 39.6%; Figure 7.1). The correlations between the mean and 
difference of the criterion and estimated MV for CSAM (r = 0.12, p = 0.66) and 
CSAT (r = 0.43, p = 0.13) were positive, but not statistically significant. 
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Figure 7.1 Bland-Altman plots identifying relationships between the differences between (y–axis) and mean 
of (x–axis) estimated and criterion muscle volume (MV). Plots display use of different slicing strategies (A = 
MV2, B = MV3, C = MV4, D = MV5) and directions (D-P = black circles, P-D = white circles). Predicted MV 
from CSAM and CSAT are in plots E and F respectively. All plots show: mean bias (central dashed horizontal 
line); 95% limits of agreement limits (±2 standard deviations; upper and lower dashed horizontal lines) 
presented as absolute values (cm3) and as a % of MV; correlation between means and differences (solid 
diagonal lines) for each MV estimate. MVn, estimated muscle volume using every nth CSA slice; CSAM, 
muscle only cross-sectional area of mid-thigh; CSAT, whole thigh cross-sectional area of mid-thigh 
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Figure 7.2 The relationship between criterion muscle volume and CSAM (white 
circles) and CSAT (black circles). CSAM, muscle only cross-sectional area of 
mid-thigh; CSAT, whole thigh cross-sectional area of mid-thigh; r, Pearson’s 
correlation coefficient; p, significance value; SEE = standard error of the 
estimate. 
 
Significant correlations were found between age and body size values, and both 
the absolute and percentage difference between criterion and estimated MV 
(Table 7.2) for both the D-P (r = 0.13 – 0.86, r = -0.04 – -0.51) and P-D (r = -0.20 
– -0.78, r = -0.29 – 0.75) directions. Differences from criterion MV estimated using 
CSAM were associated with leg length, and estimates using CSAT were 
associated with stature, leg length, body fat percentage, FFM and fat mass. The 
only slicing strategy to not hold any significant correlations (in either absolute or 
percentage terms) was MV2 in the D-P direction. Leg length significantly 
correlated with the greatest number of slicing estimate differences.  
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Table 7.2 Pearson’s correlation coefficients between differences of each estimation method and criterion MV, and body size variables. 
 
MVn, estimated muscle volume using every nth CSA slice; CSAM, muscle only cross-sectional area of mid-thigh; CSAT, whole thigh cross-
sectional area of mid-thigh; FFM, fat-free mass. Significant results (p < 0.05) are highlighted in bold. Subscript ‘a’ and ‘%’ indicate whether 
error is expressed as an absolute value or percentage. 
 Age (years) Stature (m) Leg Length (m) Body Mass (kg) Body Fat (%) FFM (kg) Fat Mass (kg) 
Distal to Proximal 
MV2a r = 0.33, p = 0.23 r = 0.19, p = 0.50 r = 0.14, p = 0.62 r = 0.13, p = 0.66 r = 0.16, p = 0.57 r = 0.13, p = 0.64 r = 0.62, p = 0.83 
MV2% r = -0.25, p = 0.37 r = -0.46, p = 0.08 r = -0.47, p = 0.08 r = -0.39, p = 0.15 r = 0.22, p = 0.43 r = -0.48, p = 0.07 r = -0.07, p = 0.80 
MV3a r = 0.73, p = 0.002 r = 0.64, p = 0.011 r = 0.55, p = 0.035 r = 0.65, p = 0.009 r = 0.03, p = 0.92 r = 0.70, p = 0.004 r = 0.31, p = 0.26 
MV3% r = -0.08, p = 0.78 r = -0.37, p = 0.18 r = -0.36, p = 0.18 r = -0.15, p = 0.60 r = 0.17, p = 0.55 r = -0.28, p = 0.31 r = -0.14, p = 0.62 
MV4a r = 0.86, p < 0.001 r = 0.70, p = 0.004 r = 0.56, p = 0.031 r = 0.71, p = 0.003 r = 0.31, p = 0.26 r = 0.70, p = 0.004 r = 0.47, p = 0.08 
MV4% r = -0.04, p = 0.90 r = -0.40, p = 0.14 r = -0.43, p = 0.11 r = -0.15, p = 0.59 r = 0.56, p = 0.029 r = -0.39, p = 0.15 r = -0.32, p = 0.24 
MV5a r = 0.80, p < 0.001 r = 0.78, p = 0.001 r = 0.61, p = 0.016 r = 0.83, p < 0.001 r = 0.32, p = 0.25 r = 0.82, p < 0.001 r = 0.53, p = 0.045 
MV5% r = -0.09, p = 0.76 r = -0.40, p = 0.14 r = -0.51, p = 0.005 r = -0.07, p = 0.81  r = 0.56, p = 0.031 r = -0.30, p = 0.27 r = -0.37, p = 0.18 
Proximal to Distal 
MV2a r = -0.64, p = 0.011 r = -0.67, p = 0.006 r = -0.49, p = 0.067 r = -0.74, p = 0.001 r = -0.43, p = 0.11 r = -0.69, p = 0.004 r = -0.55, p = 0.045 
MV2% r = 0.32, p = 0.24 r = 0.46, p = 0.08 r = 0.57, p = 0.027 r = 0.18, p = 0.52 r = -0.55, p = 0.036 r = 0.41, p = 0.13 r = -0.29, p = 0.30 
MV3a r = -0.70, p = 0.003 r = -0.76, p = 0.001 r = -0.72, p = 0.002 r = -0.65, p = 0.009 r = 0.07, p = 0.80 r = -0.76, p = 0.001 r = -0.20, p = 0.48 
MV3% r = 0.27, p = 0.33 r = 0.42, p = 0.11 r = 0.33, p = 0.23 r = 0.31, p = 0.27 r = -0.09, p = 0.75 r = 0.40, p = 0.14 r = 0.03, p = 0.93 
MV4a r = -0.78, p = 0.001 r = -0.76, p = 0.001 r = -0.57, p = 0.026 r = -0.74, p = 0.002 r = -0.24, p = 0.39 r = -0.76, p = 0.001 r = -0.41, p = 0.13 
MV4% r = 0.47, p = 0.08 r = 0.68, p = 0.005 r = 0.75, p = 0.001 r = 0.44, p = 0.10 r = -0.34, p = 0.22 r = 0.63, p = 0.012 r = -0.06, p = 0.84 
MV5a r = -0.69, p = 0.005 r = -0.71, p = 0.003 r = -0.63, p = 0.012 r = -0.65, p = 0.009 r = -0.30, p = 0.28 r = -0.64, p = 0.011 r = -0.42, p = 0.12 
MV5% r = 0.42, p = 0.09 r = 0.65, p = 0.009 r = 0.61, p = 0.016 r = 0.47, p = 0.08 r = -0.35, p = 0.21 r = 0.66, p = 0.007 r = -0.06, p = 0.040 
Mid-point Cross Sectional Areas 
CSAMa r = 0.21, p = 0.45 r = 0.27, p = 0.33 r = 0.73, p = 0.002 r = -0.05, p = 0.85 r = -0.16, p = 0.57 r = 0.03, p = 0.92 r = 0.23, p = 0.42 
CSAM% r = 0.28, p = 0.32 r = 0.40, p = 0.14 r = 0.55, p = 0.035 r = 0.09, p = 0.74 r = -0.09, p = 0.74 r = 0.17, p = 0.55 r = -0.07, p = 0.78 
CSATa r = 0.25, p = 0.37 r = 0.56, p = 0.034 r = 0.50, p = 0.06 r = 0.10, p = 0.73 r = -0.71, p = 0.003 r = 0.44, p = 0.10 r = 0.76, p = 0.001 
CSAT% r = 0.32, p = 0.24 r = 0.67, p = 0.007 r = 0.79, p = 0.001 r = 0.23, p = 0.40 r = -0.57, p = 0.026 r = 0.53, p = 0.041 r = -0.39, p = 0.16 
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 Discussion 
This study confirms, in children and adolescents, that as the interval between 
slices increases (and therefore the number of CSA slices decreases), the mean 
bias and 95% LoA associated with the error also increases. In addition, it has 
been shown that the direction of slicing affects the magnitude of the mean bias 
and associated LoA, although for both P-D and D-P directions, as MV increases, 
as does the error associated with their respective over- and under-estimation. 
Furthermore, our results have established the error associated with using a single 
CSA slice to predict MV, and the relationships between measures of body size 
and differences between criterion MV and estimated MV. These findings are 
novel for children and adolescents, adding to previous work conducted in adults 
(Barnouin et al., 2015, Tracy et al., 2003), and therefore have implications for the 
accurate determination of MV in individuals that present different morphology to 
adults, including children with chronic disease.  
In the current study, as the number of slices decreased (i.e. from MV2 to MV5), 
the error associated with estimating MV increased – in agreement with research 
in adults (Barnouin et al., 2015, Nordez et al., 2009, Tracy et al., 2003, Walton et 
al., 1997). Within this finding, the greatest bias was evident at MV5 (27.5 mm gap; 
LoA = ±2.0% of MV), a finding that is similar to Tracy et al. (2003), who utilised a 
slice gap of 31 mm (Tracy et al., 2003), and resulted in a LoA of ±1.7% of MV. 
Previous studies in adults, however, have only sought to identify the MV of the 
quadriceps femoris (QF) group, whereas the present study used the MV of the 
whole thigh. Studies investigating structure and functional relationships should 
consider utilising whole-thigh MV (as the current study has done), as research 
has identified equal recruitment of both quadriceps and hamstrings during cycling 
exercise (Richardson et al., 1998).  
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Whilst the error established in this study could be considered small, the 
acceptability of such error is dependent on the research question being 
addressed. In cross-sectional studies assessing differences in MV between 
groups with disease (Mathur et al., 2008), or age differences in healthy 
participants (Maden-Wilkinson et al., 2014, Tolfrey et al., 2006), such error would 
be consistently applied across both groups and therefore such estimation 
methods could be acceptably utilised. However, interventional studies 
investigating temporal changes in MV (i.e. atrophy, hypertrophy) may be required 
to detect changes that may fall inside the margins of error established in the 
current study. For example, a bed-rest study in adults from Belavy et al. (2009), 
identified reductions in MV in individual thigh muscles ranging from 9 cm3 (7.3%; 
biceps femoris) to 34 cm3 (12.3%; semimembranosus) following 56 days of 
immobilisation; such changes in MV may not be detected when a larger inter-
slice distance is used. Therefore, the acceptable slice interval will be dependent 
on the level of precision needed in any outcome variables.  
A new outcome in this study is that the measurement error is dependent upon 
the direction of measurement (i.e. D-P vs. P-D), which has not previously been 
assessed in children and adolescents. In previous work (Nordez et al., 2009, 
Tracy et al., 2003), measures from the knee towards the hip (D-P), have under-
estimated MV. The findings of the current study identified a reduced LoA 
observed in the P-D direction compared to D-P. This difference was greatest 
between estimates using MV5, where a LoA of 15 cm3 (0.6%) was reported. 
Whilst the mean bias and LoA do show a difference for the slicing directions, 
given the magnitude of previously described MV changes following interventions 
(Belavy et al., 2009), the direction of measurement is unlikely to have a clinically 
meaningful impact upon final MV estimates. However, as shown in Figure 7.1, 
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the significant correlation between the means and differences of each criterion 
and estimated MV measure using the P-D direction suggests that use of this 
direction may be biased. The only MV measure that did not identify a significant 
correlation is MV2 using the D-P direction, indicating this option may be the most 
suitable MV estimate in the current study.  
A further noteworthy finding within this study is the association between body size 
and the absolute and percentage differences between criterion and estimated MV 
(Table 7.2). These findings suggest that a child’s age and body size can impact 
the final MV estimates, and have implications when heterogeneous groups of 
children are being assessed (e.g. those with variances in age, stature and mass). 
Results show that when the error is presented as a percentage of criterion MV 
(to minimise further bias by muscle size), the error associated with estimates 
using MV2 and MV3 in the D-P direction do not provide significant correlations 
with body size and may therefore be suitable for future use as they are not biased 
by the range of different body sizes within children and adolescents. Of note, leg 
length held medium correlations (r > 0.3) with all MV errors when expressed as a 
percentage, further confirming our concerns regarding biasing of estimates due 
to body size. This association was shown to be significant when greater inter-
slice distances are used (i.e. MV5), and therefore this may result in an upper-limit 
to the value of the inter-slice distance used when estimating MV. This is of further 
concern when studies utilise a fixed number of CSA slices to calculate MV 
(Mathur et al., 2008, Nordez et al., 2009) as this can result in a varying inter-slice 
distance for each participant dependent on the size of the limb being investigated. 
This is of concern in studies involving children and adolescents, where body size 
is heterogeneous, as evidenced by the use of between 40 and 56 CSA slices per 
participant to calculate the criterion MV in the current study. Therefore, when the 
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relationship between error and body size, and the possible evidence for an upper 
limit between slices is considered, use of a fixed number of slices may not provide 
a uniform amount of bias across participants in studies calculating MV. Therefore, 
this approach cannot be recommended for use without an appropriate 
comparison of the respective methodologies (i.e. fixed inter-slice distance vs. 
fixed number of slices). 
The number of studies using MRI to undertake MV calculations in disease groups 
is limited, with Duchenne muscular dystrophy (Godi et al., 2016), chronic 
obstructive pulmonary disorder (Mathur et al., 2008) and CF (Moser et al., 2000) 
utilising this methodology. In individuals with CF, we are aware of only one 
previous study that has utilised MRI to identify muscle size, which used mid-thigh 
CSA to infer reduced exercise capacity (Moser et al., 2000). However, the use of 
a single CSA slice has been shown to be a poor predictor (R2 = 0.79, SEE = 27%) 
of MV in adults (Morse et al., 2007). The current study agreed with Morse et al. 
(2007) in identifying a significant relationship between CSA and MV (Figure 7.2). 
Whilst the shared variance between these variables (R2 = 0.53, 0.94) would 
initially indicate a predictive ability, a large SEE was also identified, with nearly 
40% error being reported as the LoA for MV predicted from CSAT and over 13% 
for CSAM. These errors are over twenty-times, and seven-times, the size of the 
largest LoA for MV5 reported in the present study, respectively. Therefore, whilst 
the use of a single CSA slice is a time-efficient method in comparison to 
summation of multiple CSA slices, the magnitude of error observed suggests 
estimation from a single CSA slice is not a valid method for determining MV and 
should be discouraged. 
In summary, when calculating MV in children and adolescents using CSA slices 
obtained from MRI scans, this study has identified: a) an increased error when 
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the intervals between slices is increased: b) an influence of the direction in which 
MV is estimated: c) the poor predictive ability of a single CSA slice to estimate 
MV, and d) when a slice interval of MV3 and above is used, the resultant 
differences are related to body size. These findings lead to a practical 
recommendation that use of MV2 in the D-P direction may be suitable for 
quantification of MV in children as: a) it halves the time required for analysis whilst, 
b) the resultant error does not hold a relationship with body size parameters, nor 
is systematically biased by the mean of the criterion and estimated MV itself. 
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8 SCALING MAXIMUM OXYGEN UPTAKE FOR THIGH MUSCLE VOLUME 
IN CHILDREN WITH CYSTIC FIBROSIS 
 Abstract  
Purpose:  
Maximal oxygen uptake (V̇O2max) is reduced in children with cystic fibrosis (CF) 
with intrinsic metabolic deficiencies (muscle ‘quality’) and skeletal muscle size 
(muscle ‘quantity’) proposed as potential causes. This study utilises allometric 
scaling to remove residual effects of muscle size from V̇O2max to address this 
‘quality’ vs. ‘quantity’ debate. 
Methods:  
Fourteen children (7 CF vs. 7 age- and sex-matched controls) participated in this 
study. V̇O2max was allometrically scaled for muscle cross-sectional area (mCSA) 
and thigh muscle volume (MVT), derived from magnetic resonance imaging. 
Effect sizes (ES) and magnitude-based inferences identified differences between 
groups and associations between V̇O2max, mCSA and MVT. 
Results:  
Differences between groups for mCSA and MVT were ‘unclear’ and absolute 
V̇O2max was ‘possibly lower’ in CF. mCSA and MVT had ‘likely’ positive 
relationships with absolute V̇O2max. These became ‘unclear’ when allometrically 
scaled for mCSA and MVT. Allometrically scaled V̇O2max was ‘likely’ lower in CF 
when controlled for mCSA (ES = 1.82) and MVT (ES = 0.91).  
Conclusions:  
Allometric scaling of mCSA and MVT removes residual effects of muscle size from 
V̇O2max. A lower V̇O2max is found in children with CF after scaling for mCSA and 
MVT, suggesting reduced muscle ‘quality’ in CF, likely reflecting intrinsic 
metabolic defects.  
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 Introduction 
A high aerobic fitness (as represented by peak oxygen uptake [V̇O2peak]) in people 
with cystic fibrosis (CF) is associated with increased quality of life (Hebestreit et 
al., 2014) and reduced risk of hospitalisation (Pérez et al., 2014) and mortality 
(Pianosi et al., 2005a). It has further been shown that V̇O2peak is reduced in 
children with CF compared to healthy peers (Bongers et al., 2014b, Saynor et al., 
2014b), although the mechanisms have yet to be resolved (Hulzebos et al., 2015). 
Recent debate has surrounded the contributions of skeletal muscle metabolism 
towards reduced V̇O2peak (Hulzebos et al., 2017, Rodriguez-Miguelez et al., 2017), 
and whether muscle size or its intrinsic function (muscle ‘quantity’ or ‘quality’ 
respectively) is predominantly responsible.  
Previous research has shown that muscular force positively correlates with 
V̇O2peak (de Meer et al., 1999) and that muscle size is significantly smaller in 
children with CF (de Meer et al., 1999, Moser et al., 2000). Consequently, it could 
be proposed that a muscle-size deficit contributes towards the reduced V̇O2peak 
in CF. This observation may be explained by the nutritional compromise that 
occurs in individuals with CF (Culhane et al., 2013), alongside delayed and 
attenuated pubertal growth (Zhang et al., 2013) and catabolism during pulmonary 
exacerbations (Bhatt, 2013). Previous studies have expressed V̇O2peak relative to 
both body mass (BM) and fat-free mass (FFM) (Saynor et al., 2014b, Stevens et 
al., 2011, Tucker et al., 2018), in order to account for differences in body size. 
However, expressing V̇O2peak relative to BM and FFM may not be appropriate, as 
they: a) only provide surrogates for the metabolically active muscle during 
exercise, and b) the ratio between FFM and leg muscle volume (MV) is not stable 
during periods of growth, with MV increasing per unit of FFM as FFM itself 
increases (Tolfrey et al., 2006). Therefore, FFM may be an inferior surrogate of 
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MV during growth and therefore accounting for leg MV when assessing V̇O2peak 
in CF may be more appropriate than BM and/or FFM as a parameter of body size.  
Presently, only one study has accounted for muscle size when examining V̇O2peak 
in CF, scaling for muscle cross-sectional area (CSA), in an attempt to create a 
size-free expression of aerobic fitness (V̇O2/CSA; mL.min-1.cm-2). This study 
subsequently identified a reduced V̇O2peak in children with CF relative to healthy 
control (CON) participants when muscle CSA was controlled for, with the authors 
proposing an intrinsic muscular defect may be present (Moser et al., 2000). 
However, participants in this previous study were not age- nor sex-matched, with 
analyses based on uneven samples (CF = 22, CON = 54). Furthermore, muscle 
CSA may be a poor indicator of total leg MV, as previous research has reported 
a standard error of the estimate of up to 27% when CSA is used to estimate MV 
(Morse et al., 2007). 
Previous studies in healthy children have established positive correlations 
between thigh (Welsman et al., 1997), calf (Tolfrey et al., 2006) and total lower 
leg (Graves et al., 2013) MV, and V̇O2peak, as opposed to using CSA alone. 
However, no MV-related data exists in children with CF. Quantifying MV data in 
CF could therefore establish relationships with V̇O2peak and provide novel insight 
into the ‘quantity’ vs. ‘quality’ debate as to why V̇O2peak is impaired compared to 
healthy peers. In addition, previous work has normalised V̇O2peak relative to 
muscle CSA using a ratio standard procedure (Moser et al., 2000), whereas 
allometric scaling procedures may be more appropriate (Tolfrey et al., 2006). Use 
of allometric scaling has been shown to be effective in removing the residual 
effects of body size from alternative parameters of aerobic power (the oxygen 
uptake efficiency slope) when comparing children and adolescents with CF to a 
control group (Tomlinson et al., 2017). 
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Therefore, the purpose of this study was to: a) establish the relationship between 
thigh MV (MVT) and CSA, measured using magnetic resonance imaging (MRI), 
and V̇O2peak in children with CF and age- and sex-matched controls, and b) extend 
the research of Moser et al. (2000) by using allometric scaling procedures to 
explore whether V̇O2peak is impaired in CF patients compared to CON after 
normalising for parameters of volume (thigh volume [TV], MVT) and CSA (thigh 
CSA [tCSA], muscle CSA [mCSA]). Findings could provide further insight into the 
muscle ‘quantity’ vs. ‘quality’ debate; once muscle size is allometrically controlled 
for, should V̇O2peak remain lower in CF, this would support an intrinsic muscular 
defect in this disease group.  
 Methods 
8.3.1 Study population 
Ten children with mild-to-moderate CF (i.e. forced expiratory volume in 1 second 
[FEV1] >40 %Predicted) were recruited from outpatient clinics at a local CF centre 
and 15 healthy children were recruited from local sports clubs and schools to act 
as an age- and sex-matched CON group. Ethics approval was provided an NHS 
Research Ethics Committee (14/SW/0061), and written informed consent and 
assent were obtained from both parents/guardians and participating children prior 
to any procedures being undertaken. 
Inclusion criteria for patients with CF included a positive diagnosis of CF based 
upon clinical features, supported by an abnormal sweat test and where possible, 
diagnostic genotyping; a stable lung function (i.e. within 10 % of their best in the 
preceding 6 months); and no increase in symptoms or loss of body mass in the 
preceding 2 weeks. Furthermore, no contraindications towards exhaustive 
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exercise, nor presence inside an MR scanner (e.g. metallic implants) were 
required for the CF and CON groups alike.  
8.3.2 Anthropometry and pulmonary function 
Stature was measured to the nearest 0.1 cm (Holtain stadiometer, Crymych, 
Wales) and BM to the nearest 0.1 kg (Seca, Birmingham, UK). Body fat 
percentage was estimated using skinfold callipers and validated equations for 
use in healthy children (Slaughter et al., 1988), with fat-mass (FM) and FFM 
subsequently calculated. Pubertal status was determined by self-assessment of 
the five stages of pubic hair development (Morris and Udry, 1980).  
Pulmonary function was obtained using a hand‐held spirometer (MicroPlus, Micro 
Medical Ltd, Rochester, UK), with values of forced expiratory volume in 1 second 
(FEV1), forced vital capacity (FVC), FEV1/FVC ratio being recorded. The best of 
three attempts was taken as the maximal value, with results expressed relative 
to normative values (Quanjer et al., 2012).  
8.3.3 Physical activity 
Physical activity (PA) was objectively assessed using accelerometers 
(GENEActiv; ActivInsights, Kimbolton, UK) worn on the non-dominant wrist for 
one week. PA was analysed in 60-second epochs, using cut-points validated for 
use in healthy children and adolescents (Phillips et al., 2013). Data from at least 
two days with 10 hours each (Rich et al., 2013) was included for analyses. 
Number of minutes, and percentage of wear time, for sedentary and moderate-
to-vigorous PA (MVPA) were reported.  
8.3.4 Cardiopulmonary exercise testing 
All participants undertook a combined ramp incremental and supramaximal 
cardiopulmonary exercise test (CPET) to volitional exhaustion on an 
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electronically braked cycle ergometer (Lode, Groningen, the Netherlands). 
Breath-by-breath gas exchange data were collected using an online Cortex gas 
analysis system (Cranlea, Birmingham, UK) and exported in 10-second averages, 
with V̇O2max taken as the highest 10-second average, and the gas exchange 
threshold (GET) obtained by previously validated methods (Beaver et al., 1986). 
This CPET employed an initial ramp phase with a supramaximal verification bout, 
to establish a ‘true’ V̇O2max. This protocol has been validated for use in children 
with (Saynor et al., 2013a) and without (Barker et al., 2011) CF. V̇O2max (L.min-1) 
was expressed to a percent of predicted using age and sex reference data 
(Bongers et al., 2014a).  
8.3.5 Determination of cross-sectional area and muscle volume 
Parameters of TV, MVT, tCSA and mCSA were determined using a 1.5 T 
superconducting whole-body MR scanner (Gyroscan Intera, Philips, the 
Netherlands). A T1 weighted image sequence was used to optimise fat/muscle 
signal contrast to obtain a stack of axial images from below the knee to above 
the hip. Participants were positioned in a prone position within the scanner, with 
the hips and upper legs secured to the bed with straps to avoid unnecessary 
movement. Parameters of TV and MVT were calculated from MRI scans, using 
the sum of each anatomical CSA multiplied by 5.5 mm (5 mm slice thickness + 
0.5 mm slice gap). The slices at the distal and proximal ends were multiplied by 
5.25 mm to reflect the absence of the 0.25 mm contribution from the adjacent 
slice gap. Starting from the medial epicondyle and terminating at the head of the 
femur, TV (muscle and adipose) and MVT (muscle only, no adipose) were 
determined by manually tracing around each CSA compartment using inbuilt 
Philips software. Parameters of tCSA and mCSA were established at mid-thigh 
(i.e. 50% of thigh length between medial epicondyle and femoral head) (Moser et 
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al., 2000). Bone was excluded from all analyses. Analyses were undertaken by 
two investigators with an intra-investigator coefficient of variation (CV) < 1.5%. 
Between-investigator CV was 1.2%. For consistency of analyses, the largest 
tCSA and mCSA (whether from right or left legs), and total TV and MVT (i.e. right 
plus left leg) were utilised to control for prospective leg dominance.  
8.3.6 Scaling procedures 
Where absolute V̇O2max was significantly correlated with parameters of muscle 
size, these were carried forward for allometric scaling to remove residual effects 
of body size. Allometric scaling utilised log-linear regressions (Tolfrey et al., 2006, 
Tomlinson et al., 2017), with disease status (i.e. CF, CON) and body size 
variables entered as predictors to obtain a subsequent scaling exponent (b), with 
its associated 95 % confidence intervals (CIs), to use as a power function to which 
body size variables were raised (i.e. Y/Xb). All regression assumptions 
(multicollinearity of independent variables and independence, homoscedasticity, 
linearity and normal distribution of residuals) were checked and satisfied. Age 
and sex were not entered into the models due to the prior matching of groups.  
8.3.7 Statistical analyses 
Data are reported as mean (± standard deviation) unless stated otherwise. 
Independent samples t-test (SPSS v.24; IBM, Armonk, NY, USA) derived p 
values were used for subsequent inferential analyses of mean differences. 
Facilitated by published spreadsheets (Hopkins, 2007), 90% CIs and effect sizes 
(ES) were utilised to derive magnitude-based inferences (MBI) on the observed 
effect statistic (Hopkins et al., 2009) and identify any influence of CF upon 
anthropometric, pulmonary, exercise, MRI-derived muscular variables and PA; 
as well as scaled differences in V̇O2max.  
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Using 90% CI and the smallest worthwhile ES change of 0.2 for mean differences 
(Cohen, 1992), the likelihood that the observed effect was substantially greater 
(e.g. higher V̇O2max), trivial, or substantially lower (e.g. lower V̇O2max) was 
reported using the following mechanistic inferences: <0.5%, ‘‘most unlikely’’; 
0.5%–5%, ‘‘very unlikely’’; 5%–25%, ‘‘unlikely’’; 25%–75%, ‘‘possibly’’; 75%–
95%, ‘‘likely’’; 95%–99.5%, ‘‘very likely’’; >99.5%, ‘‘most likely’’. This statistical 
methodology has been utilised previously in assessing clinical differences in 
exercise capacity in children with CF (Saynor et al., 2014b).  
Furthermore, following prior research (Tomlinson et al., 2017), Pearson’s 
correlation coefficients were run to assess relationships between body-size, 
V̇O2max and subsequent allometrically-scaled V̇O2max. Cohen thresholds (Cohen, 
1992) for small (0.1), moderate (0.3), large (0.5), and very large (0.7) 
relationships describe magnitudes of correlations. The smallest worthwhile ES of 
0.1 (Cohen, 1992) was used to determine magnitude based inferences for 
correlation coefficients. 
 Results 
Of the 10 children with CF recruited, n = 8 undertook all required procedures for 
this study. Two patients withdrew from this study, one due to increasing 
pulmonary instability, and one due to a positive culture of non-tuberculosis 
mycobacteria. Of the 15 CON children recruited, 12 completed all measurements. 
Two did not undertake CPET, and one did not undertake MRI scans to determine 
MV. When age- and sex-matching are considered, a total of seven suitable pairs 
were identified, resulting in a final n = 14 (7 CF, 7 CON) carried forward for 
analyses. Genotypes of patients with CF included in the current study include: 
ΔF508/ΔF508 (n = 3), ΔF508/Unknown (n = 1), ΔF508/E585X (n = 1), 
ΔF508/711+1G->T (n = 1) and 18G->T/1-8G->C (n = 1).  
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Mean differences between CF and CON for anthropometric, pulmonary, exercise, 
MRI-derived muscle and PA variables are listed in Table 8.1. Mechanistic 
inferences show that the CF group ‘likely’ had a higher GET (%V̇O2max), and a 
‘very likely’ higher FEV1/FVC ratio relative to CON, but also a ‘possibly’ lower 
V̇O2max (L.min-1) and GET (L.min-1), as well as a ‘very likely’ lower HRmax and time 
spent in MVPA (mins). Further to differences in group means, individual 
differences between each respective CF-CON pair is presented in Table 8.2.  
All body size variables had a ‘likely’ positive relationship with V̇O2max at the 
combined group level (Table 8.3). When categorised by groups, relationships 
between V̇O2max and MRI-derived muscular variables varied from ‘unclear’ (tCSA, 
TV) to ‘most likely’ positive (mCSA, MVT).  
For the allometric scaling procedures, only tCSA, mCSA and MVT were significant 
predictors of V̇O2max. The derived exponents for each of these MRI-derived 
variables are displayed in Table 8.4. Application of these power functions (tCSA, 
β = 0.76; mCSA, β = 1.02; MVT, β = 0.78) to scale V̇O2max resulted in ‘unclear’ 
size-residual correlations (Table 8.3).  
When mean differences in scaled V̇O2max (Table 8.5) are assessed, V̇O2max in CF 
was ‘likely’ lower than the CON group when MVT was controlled for (ES = -0.91), 
and ‘most likely’ lower when mCSA was controlled for (ES = -1.82). Use of tCSA 
resulted in an ‘unclear’ difference between groups, although a medium effect size 
was present (ES = -0.77).  
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Table 8.1. Anthropometric, pulmonary, exercise and MRI-derived muscle-related differences between CF and CON groups.  
 
Measures are presented as mean ± SD. 90% CI, 90% confidence interval. CF, cystic fibrosis; CON, control; FM, fat mass; FFM, fat free mass; 
FEV1, forced expiratory volume in one second; FVC, forced vital capacity; V̇O2max, maximal oxygen uptake; GET, gas exchange threshold; HR, 
heart rate; tCSA, thigh cross-sectional area; mCSA, muscle cross-sectional area; TV, thigh volume; MVT, muscle volume of the thigh; MVPA, 
moderate to vigorous physical activity. *Sedentary time and MVPA are measured as a percentage of daily wear-time.  
 
Variable CF (n = 7) CON (n = 7) Mean difference, 90% CI Inference in CF Effect size 
Age (years) 14.8 ± 2.1 14.6 ± 2.4 0.2 ± 1.7 Unclear 0.09 
Stature (cm) 161.9 ± 10.1 160.1 ± 8.3 1.8 ± 27.8 Unclear 0.19 
Body mass (kg) 56.7 ± 12.1 51.0 ± 9.0 5.7 ± 10.2 Unclear 0.54 
Body Fat (%) 17.0 ± 4.7 17.7 ± 5.5 -0.7 ± 5.0 Unclear -0.14 
FM (kg) 9.7 ± 3.8 8.7 ± 3.8 1.0 ± 3.6 Unclear 0.26 
FFM (kg) 47.0 ± 10.2 42.3 ± 7.9 4.7 ± 8.7 Unclear 0.52 
FEV1 (L) 3.32 ± 0.88 2.98 ± 0.67 0.64 ± 0.74 Unclear 0.43 
FEV1 (%Predicted) 104.7 ± 11.3 98.1 ± 21.8 6.6 ± 16.5 Unclear 0.38 
FVC (L) 3.80 ± 0.98 3.74 ± 0.69 0.06 ± 0.83 Unclear 0.07 
FVC (%Predicted) 103.9 ± 9.5 101.7 ± 11.4 2.2 ± 10.3 Unclear 0.21 
FEV1/FVC (%) 87.61 ± 4.05 79.52 ± 7.93 8.1 ± 5.9 Very likely higher 1.28 
V̇O2max (L.min-1) 2.28 ± 0.76 2.57 ± 0.69 -0.29 ± 0.69 Possibly lower -0.40 
V̇O2max (%Predicted) 87.2 ± 22.8 101.6 ± 12.5 -14.4  ± 17.5 Unclear -0.78 
GET (L.min-1) 1.18 ± 0.45 1.20 ± 0.32 -0.02 ± 0.46 Possibly lower -0.05 
GET (%V̇O2max) 54.4 ± 9.1 48.5 ± 4.8 5.9 ± 6.8 Likely higher 0.81 
HRmax (beats.min-1) 182 ± 7 196 ± 9 -14 ± 13 Very likely lower -1.74 
tCSA (cm2) 92.1 ± 18.2 87.1 ± 22.0 5.0 ± 19.3 Unclear 0.25 
mCSA (cm2) 61.3 ± 14.2 57.0 ± 17.1 4.3 ± 15.0 Unclear 0.27 
TV (cm3) 8921 ± 2410 9139 ± 2554 -218 ± 2365 Unclear -0.09 
MVT (cm3) 5426 ± 1532 5450 ± 1828 -25 ± 1606 Unclear -0.01 
MV (%TV) 61.5 ± 12.0 59.7 ± 10.3 1.8 ± 10.7 Unclear 0.16 
Sedentary time (mins) 396 ± 107 444 ± 62 48 ± 83 Unclear -0.55 
Sedentary time (%)* 54.2 ± 10.1 56.4 ± 5.4 2.2 ± 7.7 Unclear -0.27 
MVPA (mins) 93 ± 33 128 ± 41 35 ± 35 Very likely lower -0.94 
MVPA (%)* 14.0 ± 6.7 16.4 ± 5.7 2.4 ± 5.9 Unclear -0.39 
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Table 8.2. Differences between matched pairs for primary anthropometric and 
MRI-derived muscle variables utilised for scaling procedures. 
 Pair/Sex 1/M 2/M 3/M 4/M 5/F 6/F 7/M 
CF Age (years) 12.1 13.2 13.5 14 16.6 16.9 17.5 
Pubertal Stage* - 3 - 4 4 5 5 
Body mass (kg) 35.5 51.5 51.8 64 55.2 69.6 69.2 
V̇O2max (L.min-1) 1.24 2.21 2.23 3.29 1.82 1.9 3.27 
Total MVT (cm3) 2663 4843 6394 6190 5014 5352 7525 
CON Age (years) 11.9 12.4 12.9 13.9 15.6 17 17.4 
Pubertal Stage* 2 4 - 3 4 4 - 
Body mass (kg) 39.4 46.7 41.1 50.7 59.3 57.2 62.3 
V̇O2max (L.min-1) 2.22 2.02 2.34 2.41 2.06 2.98 4.04 
Total MVT (cm3) 3384 4033 4546 5036 5413 7138 8601 
Difference (Δ) Age (years) 0.2 0.8 0.6 0.1 1.0 -0.1 0.1 
Pubertal Stage* - 1 - 1 0 1 - 
Body mass (kg) -3.9 4.8 10.7 13.3 -4.1 12.4 6.9 
V̇O2max (L.min-1) -0.98 0.19 -0.11 0.88 -0.24 -1.08 -0.77 
Total MVT (cm3) -721 810 1848 1154 -399 -1786 -1076 
Difference (%) Age (years) 1.7 6.5 4.7 0.7 6.4 -0.6 0.6 
 Body mass (kg) -9.9 10.3 26.0 26.2 -6.9 21.7 11.1 
 V̇O2max (L.min-1) -44.1 9.4 -4.7 36.5 -11.7 -36.2 -19.1 
 Total MVT (cm3) -21.3 20.1 40.7 22.9 -7.4 -25.0 -12.5 
Measures are presented as individual values with matched pairs, ordered from 
youngest (pair 1) to oldest (pair 7). CF, cystic fibrosis; CON, control; M, male; F, 
female; V̇O2max, maximal oxygen uptake; MVT, muscle volume of the thigh; Δ, 
absolute difference (CF – CON); % difference indicates CF relative to CON. 
*Pubertal stage information only available for 4 age- and sex-matched pairs due 
to participants declining to return self-assessment forms.  
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Table 8.3. Pearson’s correlation coefficients for V̇O2max when scaled for body size parameters using differing scaling procedures.  
 CF CON Combined 
Absolute    
BM vs. V̇O2max r = 0.69 ± 0.45, Likely positive r = 0.61 ± 0.51, Likely positive r = 0.56 ± 0.34, Very likely positive 
FFM vs. V̇O2max r = 0.84 ± 0.29, Very likely positive r = 0.79 ± 0.36, Very likely positive r = 0.69 ± 0.27, Very likely positive 
tCSA vs. V̇O2max r = 0.52 ± 0.56, Unclear r = 0.60 ± 0.52, Unclear r = 0.51 ± 0.36, Likely positive 
mCSA vs. V̇O2max r = 0.94 ± 0.13, Most likely positive r = 0.92 ± 0.17, Most likely positive r = 0.86 ± 0.15, Most likely positive 
TV vs. V̇O2max r = 0.41 ± 0.61, Unclear r = 0.50 ± 0.58, Unclear r = 0.45 ± 0.38, Likely positive 
MVT vs. V̇O2max r = 0.85 ± 0.28, Very likely positive r = 0.90 ± 0.20, Most likely positive r = 0.86 ± 0.15, Most likely positive 
Allometric    
tCSA vs. V̇O2max/tCSA0.76 r = 0.18 ± 0.66, Unclear r = -0.15 ± 0.67, Unclear r = -0.05 ± 0.46, Unclear 
mCSA vs. V̇O2max/mCSA1.02 r = 0.62 ± 0.51, Unclear r = -0.44 ± 0.60, Unclear r = -0.12 ± 0.45, Unclear 
MVT vs. V̇O2max/MVT0.78 r = 0.32 ± 0.64, Unclear r = -0.23 ± 0.66, Unclear r = 0.03 ± 0.46, Unclear 
Correlations are presented as coefficients ± 90% confidence interval, with mechanistic inference. CF, cystic fibrosis; CON, control; BM, 
body mass; FFM, fat-free mass; tCSA, thigh cross-sectional area at 50% thigh length; mCSA, muscle cross-sectional area at 50% thigh 
length; TV, thigh volume; MVT, muscle volume of the thigh; V̇O2max, maximal oxygen uptake. 
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Table 8.4. Allometric exponents for V̇O2max and parameters of muscle size in young patients with CF and healthy age- and sex-matched 
controls. 
 
 
 
 
b, scaling exponent; 95% CI, 95% confidence interval for b; R2, shared variance between V̇O2max and body size parameter; SEE, standard 
error of the estimate. tCSA, thigh cross-sectional area at 50% thigh length; mCSA, muscle cross-sectional area at 50% thigh length; MVT, 
muscle volume of the thigh.  
 
 
 
 
Table 8.5. Mean differences in scaled V̇O2max between children in CF and CON groups.  
V̇O2max/Body Size CF CON Mean difference, 90% CI Inference (in CF) Effect 
Size 
V̇O2max (L
.min-1) 2.28 ± 0.76 2.57 ± 0.69 -0.29 ± 0.69 Unclear -0.40 
/tCSA0.76 (mL.min-1.cm-1.52) 73.04 ± 19.59 87.48 ± 17.80 -14.44 ± 21.80 Unclear -0.77 
/mCSA1.02 (mL.min-1.cm-2.04) 33.85 ± 4.18 42.48 ± 5.25 -8.62 ± 5.52 Most likely lower -1.82 
/MVT0.78 (mL.min-1.cm-2.34) 2.68 ± 0.64 3.09 ± 0.42 -0.40 ± 0.51 Likely lower -0.91 
Measures are presented as mean ± SD. 90% CI, 90% confidence interval. CF, cystic fibrosis; CON, control; tCSA, thigh cross-sectional 
area at 50% thigh length; mCSA, muscle cross-sectional area at 50% thigh length; MVT, muscle volume of the thigh; V̇O2max, maximal 
oxygen uptake. Absolute V̇O2max values provided for reference. 
 
Body size variable b 95% CI R2 SEE 
tCSA 0.76 0.08 – 1.44 0.40 0.25 
mCSA 1.02 0.71 – 1.33 0.84 0.13 
MVT 0.78 0.48 – 1.09 0.76 0.16 
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 Discussion 
The main results of this study have shown that absolute V̇O2max has positive 
relationships with MRI-derived variables of tCSA, mCSA, TV and MVT. 
Furthermore, allometric scaling successfully removed the residual effects of 
muscle size (mCSA, MVT) from V̇O2max. Use of this scaling method subsequently 
reveals that V̇O2max is ‘likely’ lower in CF. Thus, after accounting for muscle 
‘quantity’, these data support the case for muscle ‘quality’ being responsible for 
reduced V̇O2max in CF.  
Large correlation coefficients have been reported before in healthy children 
between absolute V̇O2peak and BM (Welsman and Armstrong, 2000), FFM (Tolfrey 
et al., 2006), CSA (Moser et al., 2000) and MV (Welsman et al., 1997). For 
children with CF, a similar correlation between mCSA and V̇O2max (r = 0.89) has 
been previously reported (Moser et al., 2000), indicating a strong positive 
relationship between the two variables. However, no study has previously 
detailed the relationship between MVT and V̇O2max in this disease group. The 
correlation coefficients for the combined (r = 0.86) and CF (r = 0.85) groups in 
the current study are similar to previous research in healthy children (r = 0.80-
0.81), whereas the magnitude of the correlation between V̇O2max and MVT is 
higher in the current CON group (r = 0.90) than the study from Welsman et al. 
(1997). This small difference in the magnitude of coefficients between studies 
may be accounted for by differences in the size and heterogeneity of samples, or 
the increased mean ages and V̇O2max in the present study. Due to the larger 
coefficients established (and therefore shared variance) between V̇O2max, and 
mCSA and MVT (relative to BM and FFM), these results suggest that these MRI-
derived parameters of muscle size are superior variables against which to scale 
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V̇O2max, likely because they better reflect the musculature activated during 
exercise. 
This study has identified that allometric scaling is effective in removing the 
residual effects of body size from V̇O2max. As shown in Table 8.3, when allometric 
procedures were utilised (using coefficients from Table 8.4), residual effects of 
tCSA, mCSA and MVT appear to be removed from V̇O2max. The resultant 
correlations between scaled V̇O2max and parameters of muscle size at the group 
level were ‘unclear’, and an increased sample size would be required to change 
this to ‘trivial’. Therefore, a dependence on muscle-size cannot be fully excluded, 
although the reported ES are ‘small’ (r = -0.12 – 0.03) suggesting that allometric 
scaling successfully partitioned the residual effects of body size from V̇O2max in 
this study.  
The point estimate for the MVT scaling coefficient (β = 0.78) in the current study 
is larger than a previous finding in healthy children (β = 0.62) (Tolfrey et al., 2006), 
with this difference potentially due to the inclusion of the CF group, but also use 
of a treadmill protocol and scaling for calf volume (as opposed to a cycling 
protocol and use of thigh volume as per the present study). The previous study 
by Tolfrey et al. (2006) had a similar sample size (n = 15) to the present study (n 
= 14), and the current study presents a consistently greater magnitude of 
difference in both the mean values for BM (+17%) and V̇O2max (+15%). Whilst no 
reference data are available for MVT coefficients in individuals with CF, the 
exponent derived for mCSA (β = 1.02) is strikingly similar to that established for 
the CF group of Moser et al. (β = 1.03 ± 0.12), but not their CON group (β = 0.80 
± 0.16) (Moser et al., 2000), suggesting differing relationships between mCSA 
and V̇O2peak between CF and CON in previous work. Unfortunately, no combined 
exponent from Moser et al. (2000) was presented with which to draw comparisons 
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to the current study. Moreover, within the previous study of Moser et al. (2000), 
the authors utilised ratio-standard scaling, despite the derivation of different 
scaling exponents for each group as mentioned previously. Furthermore, no 
analyses were undertaken to identify if ratio-standard scaling sufficiently removed 
residual effects of muscle size. 
When allometric scaling was undertaken, V̇O2max was reduced in CF, with large 
effect sizes between groups for V̇O2max found for both mCSA (1.82) and MVT 
(0.91) and a medium effect size for tCSA (0.77). These indicate that V̇O2max in 
children with CF is ‘likely’ lower when scaled for MVT and ‘most likely’ lower when 
scaled for mCSA. These finding are in agreement with previous research that 
identifies a reduced V̇O2peak in children with CF, particularly when BM (Bongers 
et al., 2014b, Saynor et al., 2014b) and FFM (Saynor et al., 2014b, Stevens et al., 
2011, Tucker et al., 2018) are accounted for. However, as previously mentioned, 
BM and FFM are poor surrogates for the metabolically active muscle and 
therefore quantification of muscle size has been advocated in previous studies 
(Graves et al., 2013, Tolfrey et al., 2006), with statistical control of mCSA and 
MVT undertaken in this study. The conclusions of the current study are akin to 
those of Moser et al. (2000), despite the aforementioned concerns related to the 
scaling methods used, and use of mCSA as opposed to MVT. 
Collectively, the findings of the current study and previous work by Moser et al. 
(2000) indicate a ‘qualitative’ defect in skeletal muscle function in CF. Studies 
conducted in vitro have identified the protein responsible for manifestation of CF 
(CFTR) is normally expressed in the sarcoplasmic reticulum (Divangahi et al., 
2009), lower resting ATP and Ca2+ dysregulation in CF muscle (Lamhonwah et 
al., 2010) and mitochondrial dysfunction (Valdivieso et al., 2012). Furthermore, in 
vivo studies in patients with mild-to-moderate CF have also identified vascular 
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dysfunction, which is significantly associated with V̇O2peak (Poore et al., 2013, 
Rodriguez-Miguelez et al., 2016), as well as prolonged phosphocreatine recovery 
following exercise, as identified using magnetic resonance spectroscopy, 
inferring impaired aerobic oxidative metabolism (Wells et al., 2011). Whilst the 
current study was not designed to identify which of these factors is responsible 
for the reduced V̇O2max in CF, it is likely that a combination of these factors is 
responsible.  
A strength to the current study is the age- and sex-matching of participants, which 
strives to ensure that disease status remains the discerning characteristic 
between groups. Furthermore, the children and adolescents with CF in the 
current study were relatively healthy. They had preserved pulmonary function 
(FEV1 = 104.7 ± 11.3 %Predicted) and were physically active, with both groups 
presenting a mean MVPA above the recommended daily guidelines of 60 minutes 
per day (Janssen, 2007). This therefore indicates that despite increased FEV1 
and PA, factors associated with increased V̇O2peak in this group (Hebestreit et al., 
2006), exercise capacity was still reduced in the CF group relative to age- and 
sex-matched peers.  
It is acknowledged that this study has a limited sample size – an unfortunate 
consequence of research in clinical populations and deliberate age- and sex-
matching, which has resulted in a limited number of pairs. As a result, inferences 
were made using MBI, based upon ES (Batterham and Hopkins, 2006). The 
simultaneous presentation of both MBI and ES provides several perspectives on 
the data, and complement one another in lieu of traditional p values, derived from 
null hypothesis significance testing. However, further research is warranted to 
corroborate these findings in a larger sample of children with CF.  
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Finally, in accord with previous research (Tomlinson et al., 2017), the body size 
exponents derived in the current study are not intended for immediate use by 
clinicians or researchers, as patient groups will inevitably vary in their clinical 
status, but highlight the requirement for allometric scaling when analysing 
variables (such as V̇O2max) may be influenced by body size. As exponents can 
vary greatly between studies (Lolli et al., 2017), future studies will be required to 
derive their own scaling exponents for use with the presented statistical 
methodology.  
 Conclusion 
In addition to identifying that allometric scaling successfully removed residual 
effects of muscle size from V̇O2max, this study has identified that once muscle 
‘quantity’ is controlled for, a difference in V̇O2max is still evident between 
individuals with and without CF. This therefore suggests that an intrinsic muscular 
defect is likely responsible for reduced exercise capacity in children with CF, with 
evidence for a skeletal muscle defect (i.e. muscle ‘quality’) being strengthened 
by the current study. 
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9 EXERCISE CAPACITY FOLLOWING A PERCUTANEOUS ENDOSCOPIC 
GASTROSTOMY IN A YOUNG FEMALE WITH CYSTIC FIBROSIS: A 
CASE REPORT 
 Abstract 
Cystic fibrosis (CF) is a genetic condition affecting the respiratory and 
gastrointestinal systems, with patients experiencing problems maintaining weight, 
especially during rapid growth periods such as puberty. The aim of this case 
report was to monitor the effect of gastrostomy insertion and implementation of 
overnight supplemental feeding upon clinical outcomes, including body mass 
index (BMI), lung function (FEV1) and exercise related variables (maximal oxygen 
uptake [VO2max] and ventilatory efficiency [VE/VO2]) in an 11-year-old female with 
CF. Combined incremental and supra-maximal exercise testing to exhaustion 
was performed at four time-points: three-months prior to the procedure (T1), 2-
days prior to (T2), four-months (T3), and one-year following the procedure (T4). 
Improvements following gastrostomy insertion were observed at the one year 
follow up with regards to BMI (+ 20%); whilst absolute VO2max remained stable 
and lung function fluctuated throughout the period of observation. Declines in 
function with regards to body weight relative VO2max (- 16.3%) and oxygen uptake 
efficiency (+ 7.5%) were observed during this period. This case report is the first 
to consider exercise-related clinical outcomes in assessing the effect of 
implementing gastrostomy feeding in CF. The varied direction and magnitude of 
the associations between variables shows that further investigations are required. 
 Introduction 
Cystic fibrosis (CF) is a genetically inherited, life-shortening disease 
characterised by respiratory and digestive problems which manifests in a 
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decreased exercise capacity (Saynor et al., 2014b) and malnutrition 
(Panagopoulou et al., 2014). Increased mortality risk is reported when patients 
exhibit decreased lung function and poor nutritional status (Liou et al., 2001). 
However, exercise related predictors of mortality, including maximal oxygen 
uptake (VO2max) (Pianosi et al., 2005a) and peak ventilatory equivalent ratio for 
oxygen (a measure of ventilatory efficiency; VE/VO2) (Hulzebos et al., 2014) are 
also reported in this patient group.  
Patients with CF are encouraged to increase their exercise levels (Swisher et al., 
2015) and daily caloric intake (Stallings et al., 2008) to improve clinical outcomes, 
in line with clinical practice guidelines (Cystic Fibrosis Trust, 2011). However, 
nutritional targets are not always met despite a high level of calorie intake relative 
to non-CF controls (Woestenenk et al., 2014). When patients fail to gain weight 
as predicted and conservative dietary interventions fail, invasive support through 
the insertion of a percutaneous endoscopic gastrostomy (PEG) may be required. 
This procedure has been shown to improve nutritional status (Williams et al., 
1999) and stabilise lung function (Bradley et al., 2012).  
Exercise testing is a valuable tool for evaluating interventions and profiling the 
clinical status of patients with CF (Cystic Fibrosis Trust, 2011), but has yet to be 
utilised to assess the effectiveness of this procedure. Therefore, this case report 
is the first to describe exercise-related changes alongside nutritional status and 
lung function following a PEG implant, and supplemental feeding, in a paediatric 
patient with CF, over a 15-month period. 
 Patient information 
The subject of this case report, an 11-year-old female, presented at birth with 
meconium ileus requiring surgery and was subsequently confirmed to have CF 
(sweat chloride > 60 mmol.L-1 and homozygous for the ΔF508 mutation). 
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Her clinical course through childhood was complicated by Pseudomonal and 
Staphylococcal chest infections as well as relapsing Allergic Broncho-Pulmonary 
Aspergillosis, treated with recurrent courses of antibiotics, inhaled mucoactives 
(DNase and hypertonic saline), corticosteroids, antifungals and chest 
physiotherapy (autogenic drainage and oscillating PEP). She developed 
impaired glucose tolerance at age 9, then CF-related diabetes requiring insulin 
treatment at 10 years of age (as shown in Figure 9.1).  
During the 15-month period reported in the current paper, the patient was 
unstable (as shown by FEV1 in Figure 9.2) and underwent 22 days of intravenous 
antibiotic treatment. 
 Timeline 
Changes in clinically important measures of exercise performance over a 15-
month period were assessed for this report, with anthropometric and lung function 
data provided for the three years prior to the procedure and one year following. 
Exercise testing was conducted at scheduled clinical appointments, 
corresponding with four time points: three-months pre-procedure (T1); two-days 
pre-procedure (T2); four-months post-procedure (T3) and one-year post-
procedure (T4).  
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Figure 9.1 Changes in BMI as measured by percentile in the three-year period 
preceding the procedure and one-year following. Dashed line at 10.9 years 
indicates diagnosis of CFRD. Dotted lines at 11.8, 12.1, 12.4 and 13.1 years 
indicate T1, T2, T3 and T4 respectively. PEG inserted two-days after T2. 
 
 
 
 
Figure 9.2 Changes in predicted FEV1 (○) (r = -0.64) and absolute VO2max (●) 
(r = 0.40) over the 15-month observation window of this case report. Four 
vertical lines indicate T1-T4. PEG inserted two-days after T2. 
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A fall in body mass index (BMI) from the 64th to 5th percentile in 10 months (Figure 
9.1) prompted the need to investigate weight-gain methods, after conservative 
dietary changes (visiting the patient’s school, meetings with parents and 
introduction of twice daily Enshake® drinks) failed. Her growth failed to respond 
to these non-invasive nutritional supplements, leading to consideration of 
overnight supplemental feeding via a PEG. 
 Diagnostic assessment  
9.5.1 Anthropometric measures 
Stature was measured to 0.1 cm (Holtain wall-mounted stadiometer; Crymych, 
Wales) and body weight to 0.1 kg (Seca electronic column scale; Birmingham, 
England), with BMI compared to normative percentiles (de Onis et al., 2007).  
9.5.2 Lung function 
Lung function was assessed using a hand-held spirometer (MicroPlus, Micro 
Medical Ltd; Rochester, UK), with maximal (best of three) values of forced 
expiratory volume in one-second (FEV1), forced vital capacity (FVC) and 
FEV1/FVC ratio being recorded and compared to normative values (Quanjer et 
al., 2012).  
9.5.3 Exercise parameters 
The patient exercised on an electronically-braked cycle ergometer (Lode 
Excalibur Sport, Lode; Groningen; The Netherlands), completing a validated 
(Saynor et al., 2013a) combined ramp-incremental and supra-maximal test to 
exhaustion to determine VO2max and gas exchange threshold (GET) (Saynor et 
al., 2014b). Measures of VO2max were normalised to a percentage of predicted 
maximum (Bongers et al., 2014a). The same work-rate (15 W.min-1), warm-up 
and recovery timings were used across all tests. Pulmonary gas exchange was 
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assessed with a calibrated metabolic cart (Cortex Metalyzer 3B, Cortex Medical; 
Leipzig, Germany). Blood oxygen saturation (SpO2) was measured throughout 
the test (Nellcor N-20, Medtronic; Minneapolis, USA) and subjective ratings of 
perceived effort (RPE) and dyspnoea (RPD) on a 1-10 scale were assessed.  
 Therapeutic intervention 
A PEG tube was inserted under general anaesthetic into the stomach, as 
described previously (Russell et al., 1984). Overnight supplemental feeding with 
500 mL of Fresubin® HP Energy (630 kJ/150 kcal) was subsequently introduced. 
Composition of the feed (per 100 mL) was: 7.5 g protein (20% total energy); 17 g 
carbohydrate (45%); 5.8 g fat (35%). This volume avoided interference with 
morning appetite and minimised vomiting risk with physiotherapy. 
 Follow-up and outcomes 
9.7.1 Anthropometric outcomes 
Anthropometric and pulmonary outcomes are shown in Table 9.1. From T1 to T2, 
increases in stature (+ 1.7 cm), but a fall in body weight (0.6 kg), resulted in a 
decrease in BMI by 0.63 kg.m-2 (- 8.6 percentile points). Following the PEG 
procedure (T3), increases in stature (+ 1.5 cm) and body weight (+ 3.5 kg), 
resulted in a gain of 11.7 BMI percentile points (+ 1.26 kg.m-2). At the one-year 
(T4) follow up, stature had increased by 3.2 cm relative to T2, as had body weight 
(+ 9.2 kg) and BMI (+ 3.02 kg.m-2), resulting in an increase to the 38th percentile 
for BMI.  
9.7.2 Pulmonary outcomes 
Changes in lung function (Figure 9.2) showed large variation across the 15-month 
observation period, although an overall trend for a decline in function was evident 
(r = – 0.64). There was an increase in FEV1 from T1 (69.9%) in the lead up to the 
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procedure (T2; 77.1%), before declining at the subsequent observations, T3 
(71.5%) and T4 (59.9%). 
9.7.3 Exercise outcomes 
Exercise related measures are listed in Table 9.2. Time to exhaustion increased 
by 49% across all trials (T1 to T4), with an 18% increase observed at the one-
year follow up (T2 to T4). Absolute VO2max fluctuated over the 15-month period, 
decreasing from T1 (1.15 L.min-1) to T2 (1.09 L.min-1), before increasing at T3 
(1.18 L.min-1) at T4 (1.15 L.min-1). When VO2 was expressed relative to body 
mass a decrease was observed over the one-year follow up period (-16.3% from 
T2 to T4), a change associated with the observed weight gain. When normalised 
for body weight VO2max decreased as a percentage of predicted from 79.3% (T2) 
to 66.0% (T4).  
Changes were observed in relation to VE/VO2, with a large increase seen 
between T1 (34.83) and T2 (51.17). Further, but smaller, increases were then 
observed at T3 (53.14, +3.8%) and T4 (55.00, +7.5%), relative to T2. VE/VCO2 
decreased over the one year follow up (T2 = 44.62, T4 = 42.53; -4.7%), although 
the magnitude of change was not as large as that of VE/VO2. Ventilation (VE), 
increased from T2 (55.78 L.min-1) to T4 (63.80 L.min-1; + 14.4%).  
  
 
 
Page 256 of 403 
 
Table 9.1 Changes in anthropometric and lung function measures over the 15-month observation period.  
Variable T1 
(3M-Pre) 
T2  
(2D-Pre) 
T3  
(4M-Post) 
% Change from 
T2-T3 
T4  
(1Y-Post) 
% Change from 
T2-T4 
Date 11.06.2014 19.09.2014 19.01.2015  21.09.2015  
Age (years) 11.83 12.10 12.44 2.8 13.11 8.4 
Stature (cm) 146.6 148.3 149.8 1.0 153.0 3.2 
Stature (Percentile) 29.7 30.2 28.6 -5.3 29.0 -4.0 
Weight (kg) 33.9 33.3 36.8 10.5 42.5 27.6 
BMI (kg.m-2) 15.77 15.14 16.40 8.3 18.16 20.0 
BMI (Percentile) 14.9 6.3 18.0 185.7 38.1 504.8 
FVC (L) 1.67 2.06 2.17 5.3 2.23 8.3 
FVC (%Predicted) 64.3 76.5 78.3 2.4 75.2 -1.7 
FEV1 (L) 1.61 1.84 1.76 -4.4 1.58 -14.1 
FEV1 (%Predicted) 69.9 77.1 71.5 -7.3 59.9 -22.3 
FEV1/FVC (%) 96.41 89.32 81.11 -9.2 70.85 -20.7 
Time points: 3M-Pre (3 months prior to the procedure); 2D-Pre (2 days prior to the procedure); 4M-Post (4 months following the procedure); 
1Y-Post (1 year following the procedure).  
BMI (body mass index); FVC (forced vital capacity); FEV1 (forced expiratory volume in one second). 
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Table 9.2. Changes in exercise-related parameters over the 15-month observation period.  
Variable T1 
(3M-Pre) 
T2  
(2D-Pre) 
T3  
(4M-Post) 
% Change from 
T2-T3 
T4  
(1Y-Post) 
% Change from 
T2-T4 
Peak Power (W) 84 98 101 3.1 115 17.4 
Exercise Duration (min) 4m 43s 5m 58s 6m 17s 5 7m 3s 18 
VO2max (L.min-1) 1.15 1.09 1.18 8.3 1.16 6.4 
VO2max (mL.kg-1.min-1) 34 33 32 -1.2 27 -16.3 
VO2max (L.min-1; %Predicted)  63.8 59.0 62.0 5.1 57.6 -2.4 
VO2max (mL.kg-1.min-1; %Predicted)  82.4 79.3 78.1 -1.5 66.0 -16.8 
VCO2 (L.min-1) 1.16 1.25 1.43 14.4 1.50 20.0 
RER 1.01 1.15 1.21 5.2 1.29 12.2 
VE (L.min-1) 40.06 55.78 62.70 12.4 63.80 14.4 
VE/VO2 34.83 51.17 53.14 3.8 55.00 7.5 
VE/VCO2 34.53 44.62 43.85 -1.7 42.53 -4.7 
HRmax (beats.min-1) * 196 - 175  -  
GET (L.min-1) 0.77 0.71 0.73 2.8 0.65 -8.5 
GET (% VO2max) 67 65 62 -4.6 56 -13.9 
SpO2 96 98 94 -4.1 96 -2.0 
RPE 5 6 6 0 4 -33.3 
RPD 4 3 4 33.3 4 33.3 
* HRmax only available for two tests due to equipment malfunction.  
VO2max: maximal oxygen uptake; VCO2: maximal carbon dioxide production; RER: respiratory exchange ratio (VCO2/VO2); VE: minute ventilation; 
VE/VO2: peak ventilatory equivalent ratio for oxygen; VE/VCO2: ventilatory equivalent for carbon dioxide; HRmax: maximal heart rate; GET: gas 
exchange threshold; SpO2: arterial oxygen saturation; RPE: rating of perceived effort; RPD: rating of perceived dyspnoea
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 Discussion 
This case report shows the inclusion of exercise-related factors amongst short 
term fluctuations in clinical measures, following the insertion of a gastrostomy 
and implementation of overnight feeding in a young CF patient.  
For this patient to have been considered a ‘normal’ BMI (i.e. 50th percentile), she 
was required to weight 39.75 kg at T2. At T4, this requirement was 44.25 kg. The 
difference in required and achieved weight at T4 (1.75 kg) relative to T2 (6.45 kg) 
has justified the requirement of the PEG and supplemental feeding. Such gains 
are in accordance with prior gastrostomy feeding studies, which have shown 
similar increases in body weight (Levy et al., 1985) and BMI (Truby et al., 2009).  
Whilst lung function has not been shown to increase following a gastrostomy, 
studies have shown stabilising of function (Bradley et al., 2012, Williams et al., 
1999). However, these studies only present lung function data at distant time 
points following such interventions (e.g. one year) and do not provide serial 
measurements, which may bias assessment of intervention efficacy, dependent 
on the patients function at the time of clinical review. This case reports all clinical 
visits (averaging every 41 days; range 7 – 62 days) over the 15 months follow-up 
period and show large fluctuation and a trend for decline in lung function.  
As see in Figure 9.2, absolute VO2max remained stable over the 15 months, 
despite the fluctuating FEV1, highlighting the independence between the two 
outcomes. As exercise related factors can be predictors of mortality (Pianosi et 
al., 2005a) and indicators of disease severity (Thin et al., 2002) when they are 
very low, it is therefore important to incorporate such factors in assessing 
progression of disease alongside FEV1 and BMI. 
Changes in absolute VO2max were minimal and fall within the typical error 
associated with the CPET over the medium term (4-6 weeks; (Saynor et al., 
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2013b)) and as such, a minimal change in predicted absolute VO2max at the one-
year follow up (+0.07 L.min-1; 59.0 to 57.6 %; Table 9.2) was observed. However, 
as VO2max is highly dependent on body size, changes are routinely expressed 
relative to body weight, thus resulting in a decrease in body weight relative VO2max, 
from T2 to T4 (-6 mL.kg-1.min-1; 79.3 % to 66.0 %Predicted; Table 9.2). This change 
is greater than previously observed annualised declines (Pianosi et al., 2005b) 
and the decline in predicted relative VO2max has a greater magnitude of change 
than the predicted absolute VO2max value. This decline is of particular relevance 
given its clinical implication (i.e. risk of mortality (Pianosi et al., 2005a) and 
hospitalisation (Pérez et al., 2014)). Whilst it would normally suggest a 
deconditioning effect, it could be proposed that the rapid increase in weight (+9.2 
kg from T2-T4, resulting in an increase of 31.8 BMI percentile points) is driving 
this change and deconditioning is not in fact occurring. However, to appropriately 
determine and interpret such changes, an accurate assessment of body 
composition (e.g. skinfolds) is required. However, clinical constraints prevented 
such measures in the current report.  
Increases in VE without a corresponding increase in VO2max (Table 9.2) indicates 
a reduction in the efficiency of gaseous exchange. However, given the increase 
in VCO2 alongside the increase in VE and the stability of VE/VCO2, it can be 
suggested that an increase in CO2 release may be driving the change in 
ventilation. This is supported by the rise in RER from T1 to T4, suggesting an 
increased ‘non-metabolic’ increase in CO2 at maximal exercise perhaps due to 
increased anaerobic metabolism, carbohydrate metabolism and/or CO2 storage 
during exercise. The increase in peak power (exercise performance) indicates an 
increase in muscle power, but as no increase in absolute VO2max was observed, 
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this suggests oxidative capacity of the muscle was not enhanced and a greater 
contribution likely originated from anaerobic metabolism. 
 Conclusion 
This case report has provided novel data combining clinical and exercise 
measures in a young patient with CF following the implementation of gastrostomy 
feeding. Of the key measures described, BMI increased whilst relative VO2max 
showed a decline due to body weight changes, amid a fluctuating FEV1. 
Furthermore, absolute VO2max remained stable against a decreased function of 
VE/VO2. The direct impact of the feeding protocol upon exercise capacity cannot 
be directly obtained due to the patients’ clinical instability and lack of a control 
patient. This case report does highlight the utility of exercise and body 
composition testing in assessing the outcome profile of individual patients 
following interventions, warranting its further use in the assessment and 
treatment of CF. 
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10 PROMOTION OF EXERCISE IN THE MANAGEMENT OF CYSTIC 
FIBROSIS – SUMMARY OF NATIONAL MEETINGS 
 Abstract 
Rationale, aims and objectives: 
Physical activity (PA) and exercise are important in maintaining and improving 
health and wellbeing in people with cystic fibrosis (CF), and measures of exercise 
capacity are useful outcomes in monitoring disease progression. The roles and 
responsibilities of CF multi-disciplinary team (MDT) members in supporting PA 
and exercise have yet to be fully defined. This communication reports on national 
meetings of CF MDT staff whose interest is to improve and standardise exercise 
provision and testing as part of routine CF care. We also introduce the role of the 
physiotherapy technician in supporting PA interventions.  
Meetings: 
The two meetings covered a range of presentations, discussions and workshops, 
focusing on the role of exercise and PA in CF management. Forty people from 
15 NHS Hospital Trusts and 3 universities were asked to provide feedback via a 
questionnaire.  
Results: 
The common roles and responsibilities of clinical staff involved in exercise testing 
and prescription are described, with a wide range of duties identified. In addition, 
physiotherapists were reported as the main MDT member responsible for 
exercise provision. The majority of teams reported discussing exercise at every 
clinical visit (57%) and felt confident in discussing exercise with patients (67%).  
Conclusions: 
Whilst this report highlights the current provision of exercise in CF MDTs, it also 
gives insight into the resources MDTs may require in order to enhance the profile 
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of exercise within CF services, including enhanced training, guidelines and 
standardised clinical roles. 
 Introduction 
It is well established that physical activity (PA) (Hebestreit et al., 2014) and 
exercise (Bradley and Moran, 2008) are of benefit to individuals with cystic 
fibrosis (CF). However, exercise testing and training are currently underutilised in 
CF clinics due to limited resources such as time, personnel, facilities and 
equipment (Stevens et al., 2010), despite patients identifying the role of exercise 
as a top priority in the management of their condition (Rowbotham et al., 2018). 
This potential lack of external support can contribute to adherence issues 
experienced by patients with CF (Prasad and Cerny, 2002).  
Whilst all members of the CF Multi-Disciplinary Team (MDT) have a role in 
promoting PA, a survey of CF clinics in the United Kingdom (UK) has shown that 
physiotherapists are the main MDT member responsible for exercise advice, 
testing and prescription (Stevens et al., 2010). There are a number of 
recommendations for the physiotherapy management of CF, which pertain to 
exercise testing and prescription. It is recommended that patients should have 
access to prescribed exercise programmes and should receive education and 
verbal and written support with exercise, as well as having the opportunity to 
exercise daily during hospital admissions (Cystic Fibrosis Trust, 2017a). In 
addition to this, patients should undergo an annual exercise test, with a 
cardiopulmonary exercise test (CPET) currently considered the gold standard 
(Hebestreit et al., 2015), with further PA assessment using motion sensors and 
questionnaires being recommended (Cystic Fibrosis Trust, 2017a).  
Meeting such recommendations is only one component of the physiotherapy 
management of CF which also includes; CF clinic provision, musculo-skeletal 
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review, incontinence assessment, nasal airway treatments, airway clearance 
treatments and inhalation therapies. Furthermore, it is acknowledged that the 
assessment of PA and exercise capacity, using motion sensors and CPET 
respectively, can be technical and require specific expertise (Cystic Fibrosis Trust, 
2017a). In supporting the role of physiotherapists, psychologists will help 
motivate patients, and dieticians support the nutritional requirements of physical 
activity and optimal body composition, therefore highlighting the potential for an 
exercise professional to support duties relating to the provision of exercise. 
The purpose, and use, of exercise professionals within general clinical practice 
has been discussed previously (Franklin et al., 2009). However, unlike other 
clinical staff members (Brown et al., 2013, Cottrell and Burrows, 2009) the role of 
such exercise-based clinical staff within the CF MDT has yet to be fully defined. 
Such definition will best be achieved by the sharing of good practice and the 
standardisation of roles and procedures.  
Therefore, to further understand and enhance the role of exercise provision within 
the CF MDT, this document reports on two meetings held in August 2016 and 
February 2017, of health care professionals with an interest in the importance of 
exercise in CF care in the UK. This document aims to report on the outcomes of 
these meetings, specifically; current exercise provision within the CF MDT, 
identifying staff members responsible for exercise promotion in the CF MDT (and 
their respective roles and responsibilities), reporting the requirements in terms of 
exercise provision of all staff involved in exercise provision within the CF MDT.  
 Meetings 
10.3.1 Meeting 1 – August 2016 
Seven delegates from five National Health Service (NHS) CF Centres and one 
university from across the UK attended a free one-day meeting at the Royal 
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Devon and Exeter NHS Foundation Trust Hospital, with the purpose of 
exchanging best-practice ideas and establishing a continuing network of non-
physiotherapist professionals involved in utilising and promoting exercise and PA, 
in CF management.  
Given the small number of non-physiotherapist staff involved in exercise 
provision in the UK, attendees were invited to this meeting based upon word of 
mouth and personal communications. Themes and topics discussed included; the 
development of a uniform job description for those in a similar, but non-affiliated 
position, the potential to seek affiliation to a recognised body (to set standards 
and govern practice), the development of a continuing network and the exchange 
of clinical practices, including virtual clinics (use of Skype), CPET and the use of 
technology in engaging patients in exercise. Furthermore, it was verbally agreed 
to advertise the network broadly and invite additional attendees to a further 
meeting. 
10.3.2 Meeting 2 – February 2017 
Following the initial meeting, it was agreed to host a second and to invite further 
members of the CF MDT to discuss exercise provision. Forty delegates from 15 
NHS CF Centres (regional centres and networked clinics) and three universities, 
from across the UK, attended a free one-day event at the Children’s Health and 
Exercise Research Centre, University of Exeter. This meeting was open to all 
health care professionals (30/40 attendees) and researchers (10/40 attendees) 
with an interest in CF and exercise and was again advertised through word of 
mouth and personal contacts as well as details being circulated via the 
Association of Chartered Physiotherapists in Cystic Fibrosis group.  
The content of this meeting was discussed among attendees of the previous 
meeting and consisted of sessions deemed important/useful by members of the 
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network, including; presentations on the clinical benefits associated with exercise, 
exercise testing and infection control. There were also interactive workshops on 
exercise testing, physical activity monitoring, behavioural change and patient 
engagement. There was also an open discussion on the roles of staff in exercise 
promotion and testing. Throughout, collaboration and sharing of best practice 
was encouraged to allow individuals to identify where their own clinical practice 
and resources differed from that of others.  
As part of the feedback process, attendees completed two questionnaires. The 
first questionnaire (Table 10.1) related to current clinical practices within their own 
MDT. Where multiple representatives were in attendance from the same CF 
centre, attendees were asked to complete one survey per centre to avoid 
duplication. In addition, all clinical attendees were asked to complete a further 
questionnaire (Table 10.2) with a non-clinical focus, relating to the running of the 
meeting itself.  
Questions (from Table 10.1) pertained to staff members responsible for exercise 
testing and prescription, as well as what resources would assist with exercise 
provision. Questions were presented on a 5-point Likert scale (with five as the 
maximum score), categorical responses produced quantitative feedback and 
open answers allowed for qualitative feedback. Questions from a prior survey 
(Stevens et al., 2010) were used to provide an overview of current provision 
amongst CF centres represented at the meeting. Descriptive statistics, and 
thematic summaries of the free text qualitative responses are presented. 
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Table 10.1 Questionnaire relating to clinical practice. 
 
Cystic Fibrosis and Exercise Questionnaire 
1. Is your centre paediatric/adult/combined? 
 ADULT PAEDIATRIC COMBINED 
2.  Who is primarily responsible for exercise provision in your MDT? 
Circle more than one if necessary. 
 CLINICIAN/DOCTOR NURSE PHYSIOLOGIST 
 PHYSIOTHERAPIST EXERCISE 
TECHNICIAN 
MULTIPLE STAFF 
 OTHER (PLEASE SPECIFY) 
3.  What exercise testing (if any) is currently undertaken? And by whom? 
 WALKING TEST (6 
MIN) 
WALKING TEST (12 
MIN) 
SHUTTLE TEST 
(INCREMENTAL) 
 STEP TEST TREADMILL TEST 
(MAX) 
CYCLE ERGOMETRY 
(MAX) 
 NONE OTHER (PLEASE SPECIFY) PERFORMED BY: 
4. Who is primarily responsible for exercise training/prescription in your 
MDT? 
 CLINICIAN/DOCTOR NURSE PHYSIOLOGIST 
 PHYSIOTHERAPIST EXERCISE 
TECHNICIAN 
MULTIPLE STAFF 
 OTHER (PLEASE SPECIFY) 
5.  How often do you currently discuss exercise prescription at clinics? 
 EVERY VISIT REGULARLY (1 IN 2 
VISITS) 
RARELY (MORE THAN 
1 IN 2) 
 ANNUAL REVIEW ONLY WHEN PATIENT 
REQUESTS 
NEVER 
6.  What exercise advice is given? (e.g. discussions, written 
programmes, booklets etc.) 
  
  
7.  How confident do you/your team feel in discussing exercise with your 
patients? 
 NOT CONFIDENT AT ALL  VERY CONFIDENT 
 1 2 3 4 5 
8. Do you feel you would benefit from additional exercise 
resources/training in exercise provision? 
 YES NO 
9.  If yes, what would you like/find useful? (e.g. guidelines, video 
resources, apps, meetings, training, qualifications etc.) 
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Table 10.2. Questionnaire relating to study day feedback. 
 
Study Day Feedback 
1. How useful was today at enhancing exercise knowledge for CF? 
 NOT USEFUL AT ALL  VERY USEFUL 
 1 2 3 4 5 
2. How useful was the advance information (agenda, transport, 
communication etc.)? 
 NOT USEFUL AT ALL  VERY USEFUL 
 1 2 3 4 5 
3.  Will this help inform future practice in your own clinic? 
 YES NO 
4.  If Yes – How? If No – Why not? 
  
  
5. What did you find useful today? 
  
  
6.  What could be improved? 
  
  
7.  Which afternoon session did you attend? 
 CARDIOPULMONARY 
EXERCISE TESTING 
PHYSICAL ACTIVITY BEHAVIOUR 
CHANGE 
8. How useful was this? 
 NOT USEFUL AT ALL  VERY USEFUL 
 1 2 3 4 5 
9. What was useful? 
  
  
10.  What could be improved? 
  
  
11.  Would you attend a future meeting? 
 YES NO 
12. If Yes – How frequently? If No – Why not? 
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 Results 
10.4.1 Meeting 1 
The attendees of this first meeting held different job titles, and subsequently had 
different responsibilities within their own MDTs, despite having an overall duty to 
cater for the exercise and PA needs of patients. The titles of attendees were as 
follows: Therapy Practitioner in CF, Respiratory Technician, Physiotherapy 
Technical Instructor, Physiotherapy Technician, Therapy Assistant and Exercise 
Practitioner. Attending staff members were from centres that were collectively 
responsible for 614 paediatric, and 1200 adult patients, representing 14% of the 
paediatric and 21% of the adult CF populations of the UK respectively (Cystic 
Fibrosis Trust, 2016c).  
The common, and differing, roles and responsibilities of these staff members in 
terms of exercise provision are provided in Figure 10.1. Further discussion led to 
consensus among attendees that an established network of such professionals, 
with appropriate schemes for accreditation, training and affiliation was required. 
Several organisations, such as the Health and Care Professions Council, 
Chartered Society of Physiotherapists, the Registration Council for Clinical 
Physiologists and the British Association of Sport and Exercise Scientists were 
suggested to provide a basis for such demands.  
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Figure 10.1 Schematic representation of the technician role within a multi-disciplinary cystic fibrosis team across multiple NHS trusts. 
*Common duties included in the job description of all technicians attending first meeting 
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10.4.2 Meeting 2  
Attending clinical staff were from five adult centres (33%), seven paediatric centres 
(47%), and three combined centres (20%), collectively responsible for 1336 paediatric 
and 2153 adult patients, representing 31% of the paediatric and 38% of the adult CF 
population of the UK respectively (Cystic Fibrosis Trust, 2016c). Attendees 
represented major and networked centres from across England, Scotland and Wales 
were represented, with a variety of clinical roles attending, including: Physiotherapist, 
Physiotherapy Assistant, Physiotherapy Technician, Therapy Technician, 
Physiotherapy Technical Instructor, Research Physiotherapist, Exercise Practitioner, 
Therapy Support Practitioner, Respiratory Clinical Physiologist and Consultant 
Paediatrician.  
Questionnaires (from Table 10.1) were returned from attendees from all 15 CF centres. 
Furthermore, 23/30 clinical attendees completed the questionnaire presented in Table 
10.2. Ninety one percent of respondents rated the day as useful (4/5 or 5/5). 
Furthermore, all respondents stated that the meeting would inform future practice in 
their own clinics, as well as stating that they would attend a similar day in the future. 
The majority of centres stated that physiotherapists were responsible for exercise 
testing (79%) and prescription of exercise training (75%; Figure 10.2). Fifty seven 
percent of MDTs discuss exercise prescription at every clinical visit; with another 29% 
discussing it regularly (at least alternate visits) and 14% rarely discuss it (less than 
alternate visits).  
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Figure 10.2 Responses to question surrounding staff members responsible for 
exercise within the CF MDT (Table 10.1, Q3 and Q4). More than one response was 
permitted if applicable. 
 
When asked to describe what exercise advice is given to their patients, delegates 
reported that advice included; general discussions about exercise (n = 7), general 
education (2), information about the benefits of exercise (2), information about how to 
exercise (types of exercise, frequency and intensity) (2), information about guidelines 
(2) and information about available applications (apps) or technology (4). Two 
delegates mentioned encouragement and motivation, and eight delegates provided 
patients with written or verbal exercise programs. 
Clinics performed a range of exercise tests at annual review, including gold-standard 
CPET (Hebestreit et al., 2015), with 4 centres (27%) using cycle ergometery and 2 
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centres (13%) using a treadmill. Additionally, 73% of centres performed an incremental 
shuttle test, 53% performed the 6 minute walk test (6MWT), and 40% performed a 
step test. Tests are performed by various members of staff, including physiotherapists, 
physiotherapy technicians (exercise technicians) and physiologists which are external 
to the CF MDT (i.e. respiratory clinical physiologists).  
When rating confidence in discussing exercise (“How confident do you/your team feel 
in discussing exercise with your patients?”), 67% of respondents felt confident in 
discussing exercise (rating 4 or 5 out of 5; Figure 10.3). Of respondents, 100% 
answered ‘yes’ to the question “Do you feel you would benefit from additional exercise 
resources/training in exercise provision?”.  
 
 
 
Figure 10.3 Responses to question “How confident do you/your team feel in 
discussing exercise with your patients?” 
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To elaborate on the previous question, delegates were then asked to discuss what 
resources would be useful with regards to exercise prescription. Six delegates noted 
that training courses and practical sessions would be beneficial. Videos, resources 
and applications were also mentioned (5). Delegates stated that the following would 
be useful; more meetings and other opportunities for collaborations (3), CF specific 
exercise guidelines (3), training on the interpretation of CPET results (1), information 
on how to engage patients (1), and four delegates highlighted the need for 
accreditation, qualifications, or standardisation of technicians roles. 
 Discussion 
The purpose of this report was to discuss the roles and responsibilities of exercise 
professionals within the CF MDT; and provide quantitative and qualitative feedback 
from meetings of interested personnel regarding the provision of exercise within the 
CF MDT.  
10.5.1 Roles and responsibilities 
A number of NHS CF Centres in the UK now employ additional health care 
professionals to complement MDTs, relieve the workload of physiotherapists, and 
assist with exercise provision. The roles of these professionals vary in title (personal 
trainers, physiotherapy technicians, and physiology technicians amongst others) and 
responsibility, with specific duties differing depending on individual skills, the patient 
cohort, funding, capital infrastructure or equipment available. The first meeting of such 
professionals not only provided impetus for establishment of a network, but also 
provided the first categorical description of the different roles within the CF MDT that 
are responsible for exercise delivery, detailing key responsibilities, with results 
displayed in Figure 10.1. The only common duty amongst attending staff was the 
provision of in-patient and ward-based exercise. In contrast, there were a number of 
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tasks that were not mutually undertaken by all – involvement in clinics, research, 
physical activity monitoring, exercise testing, out-patient exercise and physiotherapy 
duties. This represents a wide array of skills that can require specialised education 
and training.  
Given the advent of international guidance on exercise prescription (Swisher et al., 
2015), refinement and implementation of defined roles within the CF MDT require 
further work. The physiotherapy technician/physiologist/exercise technician is 
potentially an important additional team member who could enable this. However, 
given the lack of uniformity in job descriptions, necessary qualifications, accreditation, 
roles, responsibilities and expectations, further discussions are warranted at both the 
local and national level. The practicalities of standardised service development and 
provision could be recognised by organisational impetus from national or international 
bodies (e.g. European Cystic Fibrosis Society), or by peer liaison and support – which 
was subsequently enabled by the secondary meeting of interested health care 
professionals.  
Delegates at this second meeting found the day useful, citing that they would attend 
again. As exercise is considered a key requirement of CF management (Cystic 
Fibrosis Trust, 2017a), it is prudent that clinical staff are given access to courses and 
educational resources to enhance knowledge, and improve clinical care as well as 
contributing to their own continued professional development. 
It is noted that physiotherapists are currently the key staff members responsible for 
exercise testing and prescription, which is consistent with previous findings (Stevens 
et al., 2010). However, whilst physiotherapists have traditionally held this role, it is 
worthy to note that additional health care professionals (exercise technicians and 
physiologists) appear to have an increasingly important role within the MDT.  
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Unlike Australia (Smart et al., 2016) and Canada (Warburton et al., 2013), two 
countries with similar prevalence of CF to the UK (Cystic Fibrosis Australia, 2016, 
Cystic Fibrosis Canada, 2016), there are no formal guidelines in the UK regarding 
ancillary exercise staff in the NHS. As the role is not a protected title (like 
physiotherapists), there are no formal qualification criteria, or professional affiliations 
required to attain such a position. Whilst advances have been made in CF Trust 
Standards of Care (Cystic Fibrosis Trust, 2017a) with definitions of Therapy 
Practitioners, recommendations stop short of detailing fully-qualified exercise 
professionals. Furthermore, as National CF Service Specifications (Specialised 
Respiratory Clinical Reference Group, Specialised Respiratory Clinical Reference 
Group) do not mention these roles, it is subsequently desirable for there to be a clear 
‘top-down’ (i.e. NHS) definition of roles and responsibilities of CF MDT members in 
relation to their support of PA and exercise provision, and for this to include exercise 
technicians. The roles and responsibilities exemplified in Figure 10.1 make clear the 
independent nature of the role of the exercise technician (i.e. not being 
physiotherapists), and their unique skill set they can provide to the CF MDT.  
In addition, there would be a requirement for further support from physicians, hospital 
management teams and policy makers to actively value, recruit and efficiently utilise 
such exercise technicians. However, this will only be feasible if CF centres continue 
to value the role of exercise testing and training and have adequate resources 
available to them.  
10.5.2 Exercise provision  
The results from meeting two provided updated evidence on the role exercise testing 
plays in the CF clinic. Whilst there is an increase in the utilisation of CPET since a 
previous survey (Stevens et al., 2010), this again may be biased by the nature of the 
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attending centres. However, it is encouraging to note that all centres were adhering to 
recommendations (Cystic Fibrosis Trust, 2017a) and performing some form of 
exercise test annually. Furthermore, results of this meeting also revealed the 
frequency with which exercise prescription is discussed with patients. Of the attending 
centres, 86% stated that they discuss exercise prescription with patients at least every 
one in two visits, if not every visit. This is an encouraging statistic, but may be biased 
by the fact that attending delegates may have already had an increased interest in 
exercise and are therefore more likely to discuss this with patients – especially if their 
role was that of an ‘exercise technician’ (or similar non-physiotherapist allied health 
professional). Details of what is discussed ranged from a generic “exercise is 
recommended”, to an increased level of detail that may involve use of individualised 
programmes, applications, websites, diaries and even further referrals. This variety in 
responses provides scope for further development of standardised checklists, or a pro-
forma, to guide practice and patient progress. Such a tool could be utilised by an 
exercise technician to prescribe individualised CF care, and would align with recent 
calls for ‘personalised’ medicine, but fundamentally remain affordable (Balfour-Lynn, 
2014). However, the process required for such development and standardisation 
requires further investigation and collaboration.  
Furthermore, it is worthy to highlight the confidence with which MDT members have in 
discussing exercise with patients. Of the respondents, 67% reported feeling confident 
in discussing exercise with patients, which is a positive finding. Contrastingly a 
considerable number of respondents (33%) were either neutral, or not fully confident 
in discussing exercise with patients – a statistic that may in turn contribute towards the 
fact that exercise is not always discussed with patients, as previously discussed. This 
results in a number of individuals that are not confident in discussing exercise, with 
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this number potentially being higher for individuals/MDTs that did not attend and may 
not place as a high a priority on exercise. Consequently, this is reflected in the fact 
that 100% of respondents felt they would benefit from additional, specific, training, 
resources, and accreditation. This is a similar response to a previous survey in 
German CF centres (Barker et al., 2004).  
These results provide a unique insight into the current provision of exercise within CF 
MDTs in the UK. However, they represent an opportunistic, cross-sectional view of a 
limited number of NHS Trusts, and may be biased by answering questions following 
the study day as opposed to prior to it, and the nature of attendees themselves – 
already being interested in the role of exercise management of CF. A further challenge 
will be to engage clinicians and CF MDTs that do not place an emphasis on exercise 
provision; whether by choice, or necessity (i.e. funding, infrastructure). 
However, the views and requests of CF MDT staff clearly suggest that more work is 
required to increase resources and knowledge, to ensure an increased level of 
confidence and ability in prescribing and discussing exercise with patients. 
Furthermore, it identifies the need to define and standardise roles, including new, and 
complementary ones.  
 Conclusion 
The meetings discussed here have highlighted the roles and responsibilities that allied 
health professionals have in using exercise to manage CF in UK MDTs. Furthermore, 
the role exercise plays in managing CF appears to be growing, successfully heeding 
the advice national and international recommendations.  
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11 GENERAL DISCUSSION 
This thesis focused on the role of CPET within the management of CF, with an 
emphasis on evaluating submaximal parameters as surrogates for V̇O2max; quantifying 
the relationship between MV and V̇O2max; and applying CPET in clinical practice for 
both patients and staff alike. The experimental chapters outlined within this thesis have 
made a distinct contribution towards the existing literature and are summarised within 
the broad themes outlined below. Furthermore, implications for clinical practice, 
strengths and limitations of the work, and topics for future investigation are also 
discussed.  
 Submaximal alternatives to V̇O2max 
Whilst V̇O2max has been established as a parameter of interest in patients with CF, 
given its clinical associations with mortality (Pianosi et al., 2005a) and hospitalisation 
(Pérez et al., 2014), there is a requirement for valid, submaximal parameters of aerobic 
fitness for patients unable or unwilling to perform exhaustive exercise to obtain V̇O2max 
(Williams et al., 2014). A recent service evaluation identified that 14% of patients within 
a single, combined (adult and paediatric) CF centre, were unable to complete an 
annual CPET for clinical reasons, including clinical instability (requiring antibiotics), 
musculoskeletal problems, obesity, pregnancy/maternity and being pre/post lung 
transplantation (Trott et al., 2018), and therefore these submaximal parameters could 
be of use in this subset of patients.  
This thesis sought to assess whether parameters of OUE, particularly the OUES and 
OUEP, could be utilised as submaximal, alternative, measures of aerobic power (as 
opposed to V̇O2max). The advantage of using the OUES is that it removes the 
curvilinear ventilatory response observed during incremental exercise, allowing for a 
direct comparison between individuals over the course of an entire test, or identify 
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changes within an individual over time. Furthermore, its submaximal nature ensures 
the OUES is an effort independent test as it does not require the patient to work to 
volitional maximum, as the ventilatory efficiency can be measured up to any point 
during an incremental test, such as the metabolic boundaries of the GET or RCP. As 
a result, the OUES has been widely characterised in clinical populations, having 
originally been developed as an objective and independent measure of aerobic fitness 
for use in patients with cardiac disease (Baba et al., 1996), before being further applied 
in heart failure (Van Laethem et al., 2005), multiple sclerosis (Heine et al., 2014), 
COPD (Barron et al., 2016) and adults with CF (Gruet et al., 2010). The only previous 
study to evaluate OUES in children with CF concluded that it was OUES was an invalid 
measure of cardiopulmonary exercise capacity (Bongers et al., 2012). However, there 
were a number of aforementioned methodological issues with the study of Bongers et 
al. (2012), pertaining to scaling of OUES, and use of time to exhaustion (as opposed 
to metabolically matched thresholds) to characterise OUES. These limitations were 
addressed in the current thesis.  
Results from Chapter 4 indicated that: a) OUES was significantly correlated with 
stature, body mass and BSA; b) ratio-standard scaling was ineffective in removing 
residual effects of body-size, and that allometric scaling was successful; and c) 
allometric scaling for body mass and/or BSA best controlled for body size when OUES 
was utilised as a parameter of interest in CF. When OUES was assessed (in Chapter 
5) using appropriately scaled variables (i.e. OUES/BSA1.40) and at metabolic 
boundaries of the GET and RCP, it was not different between: a) CF and CON groups 
at each metabolic threshold and duration marker; b) between groups when split into 
tertiles of V̇O2max; nor c) within groups when split into tertiles of V̇O2max. Therefore, it 
was concluded that the OUES cannot be used as a submaximal surrogate of V̇O2max 
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in children and adolescents with CF. However, because this study was only undertaken 
in children and adolescents with mild-to-moderate CF and it is unclear as to whether 
the same results would be observed in patients with severe disease. Given the 
relationship between V̇O2peak and FEV1 has been shown to be greater when FEV1 ≤ 
50 %Predicted (R2 = 31%), as opposed to when FEV1 > 50 %Predicted (R2 = 18% Pastre et 
al. (2014)), it is feasible the relationship between alternative forms of aerobic power 
(such as OUES) may be influenced by disease severity.  
The requirement to perform a logarithmic transformation of V̇E in order to obtain a 
value for OUES requires additional analysis time from clinical staff, which can 
therefore reduce the appeal for using the OUES. In contrast, the simplicity of 
calculating the OUEP by using a direct ratio between V̇E and V̇O2 enhances the appeal 
of this measure for clinical teams. However, there are no reference data in disease 
groups for this parameter in contrast to the OUES, having only been described in 
healthy children (Bongers et al., 2015a). Therefore, this thesis explored whether 
parameters of OUE could be used as a submaximal surrogate for V̇O2peak (Chapter 6). 
All parameters of OUE were significantly (p < 0.001) reduced in CF, indicating a 
sensitivity to disease status that did not occur with parameters of OUES. Furthermore, 
even though V̇O2peak was marginally different between groups within this thesis, OUEP 
was consistently lower in the CF group, with only 11% of matched pairs having both a 
greater V̇O2peak and OUEP within the individual with CF, showing that regardless of 
fitness status, OUEP is reduced in CF, thus suggesting a sensitivity to aerobic fitness 
independent of V̇O2peak that warrants further investigation. In addition, absolute V̇O2peak 
was also significantly and positively correlated with OUEP (r = 0.43, p = 0.010). 
However, when split by tertiles of aerobic fitness, the ability to discriminate aerobic 
fitness within groups was limited and therefore it was concluded that parameters of 
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OUE were not valid submaximal surrogates for V̇O2peak. However, as per Chapter 5, 
these findings are only applicable to children and adolescents with mild-to-moderate 
CF, and it is unknown as to whether the same result would be found in patients with 
severe CF. 
As CF is characterised by pulmonary dysfunction and a progressive decline in lung 
function, it is feasible that the variation in lung function within the CF group may impact 
upon parameters of ventilation during exercise. Previous research has shown that 
children with lower lung function (50-60 %Predicted) augment increases in V̇E by 
increasing breathing frequency, with minimal increases in tidal volume (Keochkerian 
et al., 2008). This indicates a mechanical restriction to exercise performance and can 
in turn suggest the presence of dynamic hyperinflation. Whilst a rapid and shallow 
breathing pattern has a lower energetic cost relative to deep breathing (Younes and 
Burks, 1985), the associated alveolar ventilation is less efficient, due to the increased 
dead space ventilation that occurs during exercise (Thin et al., 2004). Therefore, as 
the OUES is a direct function of V̇E, the disease status of individuals with CF and 
compromised airways (including increased ventilatory dead space) may unduly bias 
the V̇E observed during exercise as less physiological space is available for gaseous 
exchange within the lung. This, therefore, may account for the conclusion that OUES, 
a useful parameter in cardiac conditions, is not valid in CF. In support of this 
explanation, the study undertaken by Bongers et al. (2012), identified that the mean 
ratio of residual volume relative to total lung capacity was elevated in CF (153 ± 
43 %Predicted; range = 93 – 276 %Predicted). However, dead space ventilation was not 
measured in the studies that compromise this thesis, and so these possible 
pathophysiological explanations cannot be completely confirmed within the context of 
the present results.  
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In addition to issues surrounding disease severity that may account for the invalidity 
of OUES as an alternative for aerobic power, it is also possible that the relatively poor 
level of repeatability (relative to OUEP) may further account for the observed invalidity. 
The CV, as determined by Bongers et al. (2015a), for OUES has been shown to be 
32.9%, whereas it is 10.9% for OUEP. Even when controlled for BSA (using ratio-
standard scaling), the CV of the OUES reduces, but remains higher than OUEP, at 
18.3%. It is unclear whether using allometric scaling has further reduced the CV of the 
OUES in the current thesis, however it is feasible that the reduced CV for OUEP – 
whose magnitude is in line with other parameters of aerobic power (Saynor et al., 
2013b) – may account for its greater potential as a submaximal surrogate for aerobic 
power relative to the OUES.  
Whilst this thesis has concluded that OUES is not valid as submaximal surrogates for 
V̇O2peak in CF, the association between FEV1 and OUEP in Chapter 6 indicates this 
parameter is sensitive to disease status and severity. Therefore, future research is 
warranted to identify any clinical utility of OUEP beyond acting as a surrogate for 
V̇O2peak, for example longitudinal changes and any independence from simultaneous 
changes in FEV1 with disease progression. Additionally, alternative submaximal 
parameters such as ventilatory drive warrant further investigation in this population 
given its association with mortality (Hulzebos et al., 2014), low variability (Sun et al., 
2002) and superior prognostic value relative to OUES in a cardiac population (Arena 
et al., 2007).  
 Using CPET to identify musculoskeletal limitations to exercise 
The findings of these initial chapters clearly identified that V̇O2max remains the primary 
variable of interest from CPET with which to measure maximal exercise capacity. This 
is due to the validity and reliability of obtaining this parameter (Saynor et al., 2013a, 
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Saynor et al., 2013b) and lack of suitable submaximal alternatives (Tomlinson et al., 
2018, Williams et al., 2018) – although there appears to be some detail that could be 
added by use of OUE given its association with disease status and severity. Therefore, 
attention must also be given to CPET and V̇O2max as a diagnostic too, in order to 
identify limitations to exercise capacity and enhance and improve patient care and 
outcomes.  
CPET is acknowledged for its use as a differential tool for evaluating undiagnosed 
exercise intolerance (American Thoracic Society, 2003) and can aid in the 
identification of cardiac, pulmonary and musculoskeletal limitations to exercise in 
individuals with chronic disease. Identifying these symptom limitations therefore allow 
for appropriate, personalised, exercise prescription to counter the dysfunction in the 
identified system. Whilst this has clear applications for individuals, use of CPET on a 
wider, population level allows for broader causes of general exercise intolerance.  
As noted in Chapter 2.3, there are several factors associated with exercise limitation 
in CF (Hulzebos et al., 2015). As CF is predominantly a pulmonary disease, the 
influence of lung function cannot be discounted. However, as previously discussed, 
the shared variance (R2) between FEV1 and V̇O2peak in patients with mild-to-moderate 
CF (FEV1 ≥ 50 %Predicted) is 18% (in a positive direction), and therefore leaves a further 
~80% of this variance unaccounted for (Pastre et al., 2014). Therefore, this thesis has 
utilised group level data of V̇O2max and MV to ascertain the musculoskeletal 
contributions towards reduced V̇O2max in CF in an attempt to address the ‘quality’ vs. 
‘quantity’ debate within the literature (Hulzebos et al., 2017, Rodriguez-Miguelez et al., 
2017). The strengths and novelty of the methods employed within this thesis surround 
the use of accurately determined V̇O2max and MV, identified using gold-standard CPET 
(with supramaximal verification bouts) and MRI. 
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To calculate MV, this thesis expanded upon previous work in adults that identified 
large SEE when using mCSA to estimate MV (27%; Morse et al., 2007), by identifying 
a lower SEE of 14% in children (Chapter 7). However, to use mCSA as a parameter 
to estimate MV necessitates acquisition of such measures via MRI which is a costly 
and lengthy process. In contrast, tCSA can be obtained easily by clinical teams 
through surface anthropometry, although this thesis identified an even greater error 
associated with using TV (~40%) and therefore, summation of multiple mCSA slices 
is required to accurately quantify MV. The error associated with quantifying MV in 
Chapter 7 was broadly in line with previous studies in adults (Barnouin et al., 2015, 
Nordez et al., 2009, Tracy et al., 2003) and this was the first time such error was 
quantified in children and adolescents, as well as those with CF. Use of this volume 
data is more reflective of metabolically active muscle during exercise and therefore, 
when V̇O2max is allometrically scaled using these parameters of MV, the resultant 
reduced V̇O2max can be attributed to a ‘qualitative’ defect with greater confidence than 
the study of Moser et al. (2000) whose use of ratio-standard scaling (and mCSA) may 
not have accurately reflected, and controlled for, effects of muscle size (Chapter 8). 
The results from the present thesis support aforementioned in vitro studies showing 
lower resting ATP and Ca2+ dysregulation (Lamhonwah et al., 2010) and mitochondrial 
dysfunction (Valdivieso et al., 2012) in CF muscle, as well as in vivo studies showing 
vascular dysfunction (Poore et al., 2013, Rodriguez-Miguelez et al., 2016). However, 
not all studies have shown a difference between CF and non-CF controls with regards 
to a ‘qualitative’ defect in CF muscle. A study conducted by Werkman et al. (2015) 
utilised 31P-MRS to non-invasively assess changes in muscle metabolism during 
incremental exercise in a group of adolescents with CF and age-matched CON. This 
study reported no difference between groups in end-exercise PCr or inorganic 
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phosphate (Pi) following incremental exercise, nor a difference in the time constants 
of PCr recovery. Furthermore, the patients with CF in the Werkman et al. (2015) study 
were similar to those in the current thesis, with preserved pulmonary function (FEV1: 
92.8 ± 14.6 %Predicted) and matched PA, albeit with a reduced amount spent in higher 
intensities relative to CON, using a self-assessed subjective questionnaire validated 
for use in CF (Wells et al., 2008b). However, whilst this study does appear to conflict 
with the present thesis by providing in vivo data during exercise on metabolic markers, 
it could be proposed that the patients with CF, as well as CON, failed to reach a 
maximal V̇O2 and were therefore exercising at a lower relative intensity. No 
supramaximal verification was undertaken to confirm V̇O2peak, and the HRmax reached 
in both groups (CF, 162 ± 12; CON, 164 ± 9 beats.min-1) was lower than the secondary 
criteria typically used to confirm a maximal effort (Hebestreit et al., 2015); although it 
is acknowledged that secondary criteria cannot be wholly relied upon for such 
verification (Saynor et al., 2013a). Therefore, given this lower relative exercise 
intensity within Werkman et al. (2015), it may be proposed that exercise dysfunction 
observed in CF is intensity-dependent, and that muscle ‘quality’ may only be defective 
in heavier domains. This is supported by slowed oxygen uptake kinetics in adolescents 
with mild-to-moderate CF during very-heavy intensity (60%Δ), but not moderate 
intensity (90% GET), exercise (Saynor et al., 2016b). Furthermore, patients with CF 
have been reported to have slower PCr recovery following 90-seconds of high intensity 
exercise relative to CON participants, but no differences in PCr recover following a 
five-minute moderate intensity bout (Wells et al., 2011). These studies therefore 
provide evidence that qualitative defects in skeletal muscle become evident at higher 
metabolic rates in CF.  
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Whilst the present thesis has not confirmed these findings, the diagnostic use of CPET 
has furthered the evidence for such a ‘qualitative’ defect in CF. To further investigate 
the cause of exercise intolerance in CF, multi-modal assessments are required (Gruet 
and Saynor, 2017) and therefore, inclusion of modern techniques such as 
aforementioned MRI and 31P-MRS, as well as blood-oxygen level dependent imaging, 
NIRS, echocardiography and LCI can be used in conjunction with one another to 
provide greater detail on univariate and multivariate causes of exercise intolerance 
and move this area of investigation forward.  
 Applying CPET in clinical practice 
This thesis has successfully shown that CPET can be used in clinical practice to 
monitor individual patient treatment, but that its implementation as a standard 
prognostic and diagnostic test is still not universally applied across the NHS. CPET 
has been previously utilised to assess outcomes associated with antibiotic therapy 
(Alison et al., 1994, Selvadurai et al., 2002a), CFTR modulator therapy (Edgeworth et 
al., 2017, Saynor et al., 2014a) and lung transplantation (Oelberg et al., 1998), and 
this thesis provides the first reported application of CPET in evaluating the efficacy of 
insertion of a PEG and a supplemental feeding regimen (Chapter 9). The results 
clearly indicate a gain in body mass, although it is unclear as whether this is driven by 
gains in muscle mass, fat mass, or a more likely combination of both.  
Assessing body composition in CF is complicated by the variances in body size seen 
within the patient population (Hanna and Weiner, 2015). Studies have found conflicting 
results with regards to the validity of different methods. Studies suggest skin-fold 
equations of Slaughter et al. (1988) may be suitable, although there are wide 95% 
limits of agreement for percentage body-fat (-0.7 ± 6.9 %) and lean body mass (0.4 ± 
3.2 kg) when compared against dual energy x-ray absorptiometry (DEXA) (Wells et 
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al., 2008a). Furthermore, use of bio-electrical impedance (BIA) has been shown to 
have poor agreement with DEXA (Ziai et al., 2014) and skin-fold equations (Alicandro 
et al., 2015), with a mean bias of 10% and up to 19% respectively, and therefore body 
composition is not routinely undertaken within the CF clinic, nor is it recommended 
because of the lack of validated techniques and low-cost equipment.(Cystic Fibrosis 
Trust, 2016a). Therefore, in the absence of these techniques, a stable V̇O2max can be 
used to infer no change in aerobic contributions to exercise, and the increased WRpeak 
– alongside changes in V̇E, V̇E/V̇CO2 and RER – indicate an increased anaerobic 
contribution to exercise and are likely due to increased muscle mass as a result of the 
supplemental feeding. This case has shown that CPET can be utilised to infer 
mechanisms of change following interventions. 
For similar applications of CPET to be undertaken in clinical practice, staff within the 
NHS must be adequately resourced and trained to implement exercise testing. This 
thesis has identified that CPET is undertaken in CF centres, in agreement with 
Stevens et al. (2010), although the self-selective nature of centres attending the 
training days in Chapter 10 means that this finding is not necessarily representative of 
the wider NHS. Therefore, a wider survey is required, preferably with an international 
response in light of international recommendations (Hebestreit et al., 2015) to gauge 
prevalence of CPET across CF centres.  
The findings of Chapter 10 further identified that additional resources and training are 
required to improve knowledge and understanding. Whilst the ‘Exercise is Medicine’® 
initiative has been present for a number of years (Lobelo et al., 2014), it would appear 
education pertaining to exercise and PA is lacking, with over 50% of medical schools 
in the USA not providing courses on PA (Cardinal et al., 2015). This is reflective of 
GP’s understanding of PA in the UK, whereby 55% report not having any training with 
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regards to encouraging PA, and 80% being unfamiliar with current guidelines 
(Chatterjee et al., 2017). Of medical students currently undergoing training in the UK, 
a survey has shown that 74% believe they have received sufficient teaching about the 
benefits of PA, although only 52% stat they feel adequately trained to provide PA 
advice (Dunlop and Murray, 2013). To combat this dearth of knowledge, the ‘Exercise 
Works!’ initiative has developed in order to develop training resources surrounding PA 
and exercise for medical schools in the UK (Gates, 2015, Gates, 2016), although it is 
unclear how much detail this programme will provide on the topics of exercise testing 
and exercise prescription. In physiotherapy, curricula have a greater provision of 
exercise testing and prescription, with 100% of courses in Ireland providing some form 
of exercise prescription content (O'Donoghue et al., 2011), although 66% of 
practitioners are unhappy with their knowledge and require further training 
(O'Donoghue et al., 2012). Unfortunately, data is not available for UK physiotherapy 
curricula, and therefore future research is required. However, a survey of UK 
physiotherapists reveals that 77% routinely discuss PA with patients and 68% routinely 
deliver brief interventions (Lowe et al., 2017), further indicating that front-line staff can, 
and do, discuss PA with patients. However, such discussions are largely focused on 
short-term restoration of function (Lowe et al., 2018) and barriers such as time 
restraints and a focus on discharge (Walkeden and Walker, 2015) can limit the 
effectiveness of discussions and interventions. Therefore, whilst physiotherapists 
have historically been responsible for exercise testing (Stevens et al., 2010), the role 
of exercise therapists, therapy practitioners and therapy assistants, as per Chapter 10, 
have an increasingly valuable role to play in exercise for provision for CF and training 
and continuing professional development is needed for this specialist sub-group of 
NHS staff. In addition, the NHS has developed a national ‘Scientist Training 
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Programme’ to train individuals as clinical scientists, with respiratory and sleep science 
being a sub-speciality that seeks to employ use of CPET as a diagnostic and 
prognostic tool (National School of Healthcare Science, 2018).  
 Strengths and limitations 
The methodological strengths associated with the studies are related to statistical 
control for body size, and use of ‘gold-standard’ CPET. As with any studies involving 
paediatric participants, a wide range in body size can bias results, which is further 
compounded by the range of body sizes observed in CF (Hanna and Weiner, 2015). 
Therefore, use of allometric scaling within this thesis has allowed for removal of 
residual effects of body size from parameters of aerobic function (OUES, Chapter 4; 
V̇O2max, Chapter 8) and removes potential sources of bias in the results. Furthermore, 
in contrast to international recommendations that advocate use of the Godfrey (1971) 
protocol (Hebestreit et al., 2015), this thesis has utilised, where possible, a valid and 
reliable ramp-Smax protocol to verify V̇O2max had been achieved (Saynor et al., 2013a, 
Saynor et al., 2013b). This verification of V̇O2max ensures that a ‘true’ maximal value 
is obtained and there is no risk of a submaximal V̇O2peak being carried forward for 
analysis. Furthermore, this thesis has used MRI as a gold-standard technique that to 
ensure accurate measures of MV have been obtained and carried forward for analysis, 
as opposed to a reliance on CSA, which has previously been shown to have a high 
level of error (Morse et al., 2007) and may not appropriately reflect the metabolically 
active muscle during exercise. 
Of the limitations associated with this thesis, the first to be addressed is that the 
majority of participants presented with mild-to-moderate disease only (FEV1 ≥ 
40 %Predicted). This therefore means that findings may not necessarily be applied to 
those with severe CF (FEV1 < 40 %Predicted) as the shared variance between exercise 
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capacity and FEV1 is increased when FEV1 <50 %Predicted in CF, relative to those with 
an FEV1 >50 %Predicted (Pastre et al., 2014). Furthermore, these participants were 
recruited from a single CF centre, with a history of a high median FEV1, high median 
BMI and low rates of chronic Pseudomonas aeruginosa colonisation (Figure 11.1). 
Whilst this ensures that patients recruited for the current thesis all received similar 
care and advice, it also partially limits the external validity of findings to the wider UK 
CF community.  
 
 
Figure 11.1 Annual rankings for paediatric (<16 years) patients with cystic fibrosis 
under the care of the Royal Devon & Exeter NHS Foundation Trust Hospital, and 
associated networked clinics (North Devon District Hospital, Barnstaple and Torbay 
District General Hospital, Torquay). Median FEV1 (%Predicted) amongst patients ≥ 6 
years, with no history of lung transplantation using Global Lung Index 2012 
equations (Quanjer et al., 2012) (solid line). Median body mass index percentile 
among patients 2-15 years (dashed line). Proportion of patients with chronic 
Pseudomonas aeruginosa (dotted line). Number of centres reporting data 
represented by grey bars. Data only available until 2015 as ranking ceased by Cystic 
Fibrosis Trust in favour of funnel plots, which account for centre size. 
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The second limitation to be addressed is the validity associated with measures of 
somatic maturation used within this thesis. Due to the retrospective nature of analyses 
in Chapters 4-6, pubertal stage data based upon secondary sex characteristics 
(Marshall and Tanner, 1969, Marshall and Tanner, 1970) were not available and 
therefore aPHV has been presented as a measure of somatic maturation in lieu where 
applicable. However, the association between secondary sexual characteristics and 
aPHV differs between sexes, with the majority of girls (69.1%) having reached PHV 
by the time they are pubertal stage 3, whereas the majority of boys (58.9%) reach PHV 
by pubertal stage 4 (Granados et al., 2015). The variability in timing of PHV suggest 
that it is part of a dynamic process and that reliance upon a single measure of 
maturation may not be appropriate, especially when researching mixed groups of 
children (i.e. boys and girls). Furthermore, use of aPHV as a continuous variable may 
be invalid (Malina and Koziel, 2014a, Malina and Koziel, 2014b), and therefore it may 
only provide categorical information about the cohort of children being studied (i.e. 
pre-, or post-aPHV). Finally, common equations to establish aPHV (e.g. Mirwald et al. 
(2002), Moore et al. (2015)) have been developed and validated in groups of healthy 
children and therefore their validity in children with CF remains unknown, especially 
given that pubertal maturation can be delayed and slowed in children with CF (Zhang 
et al., 2013). 
The final limitation to be acknowledged is the amalgamation of data for male and 
female aerobic power (Chapters 4, 5, 6 and 8). Whilst V̇O2peak has been shown to 
greater in boys than girls (e.g. Armstrong et al. (1991)), the same difference has yet 
to be shown in children and adolescents with mild-to-moderate CF. A training study in 
adults with CF by Gruber et al. (2011b) identified a greater V̇O2peak in men compared 
to women (32.1 ± 8.9 vs. 29.5 ± 7.9 mL.kg-1.min-1, p < 0.001), although this difference 
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is only partially explained by clinical factors as males had significantly higher BMI, yet 
females had significantly FEV1 (%Predicted). It is unclear whether the same difference 
would be observed in children and adolescents, especially as a number of clinical 
factors may bias the analyses (e.g. FEV1, BMI, pancreatic (in)sufficiency) and the need 
to be statistically controlled for. Whilst an optimal approach to analyses within the 
current thesis would involve separating male and female data, the sample sizes (e.g. 
male = 21, female = 15; Chapters 4-6) per group would reduce statistical power and 
require a greater number of comparisons between groups to identify mean differences; 
a process whereby statistical corrections can falsely inflate Type 2 error. In lieu of 
further separating CF and CON groups by sex, the studies within the thesis have 
sought to deliberately age- and sex-match children and adolescents with CF against 
health controls to prospectively remove these confounding effects. Future research is 
warranted to examine the difference between boys and girls with CF whilst correcting 
for aforementioned clinical factors.  
 Recommendations for clinical practice 
The novel findings from this thesis have several implications for clinical practice. 
Because of the findings of Chapters 4-6, V̇O2max remains the primary clinical parameter 
that clinical team should strive to identify in patients with CF; although future research 
is warranted with regards to OUE, given its sensitivity to disease status and severity. 
Use of V̇O2max does therefore require a maximal CPET to be conducted, in line with 
international recommendation (Hebestreit et al., 2015). Whilst there is debate on the 
exact protocol to be utilised to elicit such a maximal response (Saynor et al., 2016a), 
it is still acknowledged that V̇O2peak (and where possible, V̇O2max) is the primary 
outcome. How V̇O2peak should be presented however, is still variable between studies, 
as it has been presented in absolute terms, and using ratio-standard scaling relative 
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to body mass and fat-free mass. Furthermore, standardisation of predicted values is 
required, to ensure uniform reporting across centres and research studies, as studies 
to date have utilised differing equations, whilst some studies have failed to reference 
which equations have been used (e.g. Table 2.2). Although numerous prediction 
equations are available (Paap and Takken, 2014), a comprehensive evaluation and 
validation has yet to occur in CF. Until such standardisation is set, research studies 
and clinicians should utilise reference values that are most appropriate for the study 
and/or patient group at hand. The present thesis utilised reference values of Bongers 
et al. (2014a) for this very reason, as equations had been developed in both young 
boys and girls, using cycle ergometry to elicit V̇O2peak. 
The results of Chapters 7 and 8, identifying a probable ‘qualitative’ defect in skeletal 
muscle function has implications for exercise training in CF (Gruet et al., 2017), and 
places an emphasis upon aerobic training and intensity-specific exercise regimens (i.e. 
to a set percentage of V̇O2max). This prescription of exercise intensity (using V̇O2max) 
has only been undertaken by a small number of training studies to date (e.g. Beaudoin 
et al. (2017), Kriemler et al. (2013)). Otherwise, training studies have utilised 
percentages of HRmax (e.g. Elbasan et al. (2012), Orenstein et al. (2004), Schmidt et 
al. (2011)), or percentage of WRpeak (Gulmans et al., 1999), although these 
approaches do not ensure that training is occurring at the same metabolic intensity for 
all patients. These discrepancies in study design may provide an explanation as to 
why exercise training programmes have failed to find an optimal modality or intensity 
for patients with CF, particularly with reference to aerobic training (Radtke et al., 
2017b).  
However, resistance training to increase muscle volume must not be fully discounted. 
Whilst muscular hypertrophy may not directly increase V̇O2max, muscle size remains a 
 
 
Page 294 of 403 
 
clinically important parameter. Increased muscle size is associated with favourable 
post-operative outcomes following lung transplantation such as length of time on 
mechanical ventilation and time in intensive care (Weig et al., 2016), as well as 
recovery of exercise capacity (Walsh et al., 2013). 
The application of patient-centred CPET and its implementation in CF clinics indicates 
that this is a useful tool to take forward and implement at annual reviews for patients, 
to monitor longitudinal changes in function and evaluate responses to therapeutic 
treatments such as pharmacological, nutritional, or surgical procedures. Importantly, 
the outcomes associated with CPET (such as V̇O2max) can be used independently of 
traditional factors, such as BMI and FEV1, to provide a holistic analysis of a patient’s 
condition and disease trajectory.  
 Conclusion 
This thesis has provided a number of experimental chapters, encompassing 
prognostic, diagnostic and practical applications of CPET in the management of CF. 
Specifically, it has: a) provided novel insight into submaximal markers obtained from 
CPET; b) furthered evidence for a defective ‘qualitative’ musculoskeletal contribution 
towards exercise (in)tolerance; and c) provided a novel patient-centred application of 
CPET, as well as updated information regarding the role of CPET in the UK CF clinic 
and the staffing requirements for implementation of this testing modality.  
Exercise testing is essential for successful monitoring of disease status and 
progression in CF (Cystic Fibrosis Trust, 2017a, Hebestreit et al., 2015), and the 
endorsement of CPET as the method of choice by the ECFS and ERS is a welcome 
one (Hebestreit et al., 2015). However, further research is still warranted on the utility 
of submaximal measures obtained from CPET, and their clinical associations and 
significance. As the CF population grows and ages (Keogh et al., 2018), the demand 
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for exercise testing, and CPET, is also set to increase. This will be particularly pertinent 
amongst patients of greater disease severity, who are typically excluded from small-
scale observational studies, but stand to benefit from clinical decisions made from 
CPET results. These could include listing for transplantation, change of medication to 
include CFTR modulators, or even re-classification of their disease status and 
treatment if V̇O2max is shown to be independent of FEV1 in some individuals. 
Furthermore, to facilitate the incorporation of CPET into the UK CF clinic, reference 
data must be developed to ensure accurate interpretation in patients of all disease 
status and severity. In addition, multimodal assessments of aerobic function are 
required (Gruet and Saynor, 2017), to truly identify causes of exercise intolerance in 
CF and provide therapeutic treatment options for future patients.  
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Appendix C 
 
 
 
Owen Tomlinson 
Post Graduate Research student 
 
 
14th December 2016 
 
Dear Owen 
 
Re: Direct investigation of skeletal muscle metabolic, pH and blood oxygenation exercise 
response of young cystic fibrosis and non-cystic fibrosis bronchiectatic patients 
 
The SHS REC is satisfied with the approval you received from the South West - Exeter 
Research Ethics Committee on the 14th October 2016. In addition, the relevant paperwork 
has been reviewed by David Childs, a member of the SHS ethics committee and the health 
and safety advisor to the committee. He is satisfied that all procedures meet the required 
standards. 
 
Kind regards 
 
 
 
Melvyn Hillsdon 
Chair, SHS research ethics committee 
m.hillsdon@exeter.ac.uk 
01392 7222868 
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Appendix F 
 
Patient Consent Form 
To record a patient’s consent to publication of information about them or their relative in 
Physiological Reports.  
 
NAME OF PATIENT: ____________________________________________________  
 
TITLE OF CASE REPORT: _________________________________________________ 
___________________________________________________________________  
 
CORRESPONDING AUTHOR: ______________________________________________  
 
CORRESPONDING AUTHOR’S ADDRESS: __________________________________________ 
__________________________________________________________________________  
 
MANUSCRIPT NUMBER, IF KNOWN: __________________________________________  
____________________________________________________________________  
 
I, [...................................................................................................NAME OF PATIENT / PARENT / GUARDIAN / 
RELATIVE***], give my permission to [........................................................................................NAME OF HEALTH 
PROFESSIONAL] to use information (including photographs) about 
[...................................................................................NAME AND RELATIONSHIP***] in Physiological Reports 
published by John Wiley & Sons, Ltd. (“Wiley”) such permission to extend to publication of the 
information by Wiley and its licensees in all media and languages throughout the world.  
 
***In cases where the patient has died or is incapable of giving consent, consent may be given by the 
next of kin. If the patient is under the age of 16, consent should be given by a parent or guardian.  
 
I have seen and read the material to be submitted to the journal.  
 
I understand that:  
(1) My name will not be published and Physiological Reports will endeavour to ensure I remain 
anonymous, other than in relation to identifiable photographs for which I have given consent. 
However I also understand that it is possible somebody may recognise me from the case report.  
(2) I understand that Physiological Reports is an open access publication, and content is made available 
under the terms of the Creative Commons, primarily the Creative Commons Attribution Non-
Commercial License which permits use, distribution and reproduction in any medium, provided that 
the content is properly cited and is not used for commercial purposes. This means that my 
information can be read and used by anyone around the world for free.  
(3) I can change my decision to give consent to publish information about me at any time before final 
approval for publication by Wiley, but once the case report has been approved for publication in its 
final form it will not be possible to change my decision to give consent.  
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***SIGNATURE OF PATIENT / PARENT / GUARDIAN / NEXT OF KIN:  
 
 
_______________________________________________________________________________________________________  
 
***IF PARENT / GUARDIAN / NEXT OF KIN, STATE RELATIONSHIP TO PATIENT:  
 
 
_______________________________________________________________________________________________________  
 
ADDRESS:  
 
_______________________________________________________________________________________________________  
 
_______________________________________________________________________________________________________  
 
DATE: ___________________________________  
 
 
 
SIGNATURE OF HEALTH PROFESSIONAL:  
 
 
_______________________________________________________________________________________________________  
 
ADDRESS:  
 
_______________________________________________________________________________________________________  
 
_______________________________________________________________________________________________________  
 
DATE: ____________________________________  
 
Note to corresponding author: The original signed consent form should be retained by the 
corresponding author. You do not need to upload the consent documentation when submitting your 
manuscript. However, we may request copies of the documentation at any time.  
 
Note to health professional: In addition to the consent form, please ensure that any other necessary 
permissions are cleared for use of the information, including any permissions required for use of 
information contained in medical records. 
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Appendix G 
 
 
 
 
Exercise Study for Young People with Chest Disease  
 
        Study Number: 14/SW/0061     
                     Version 3 
          Date 18-08-2014 
Patient’s Letter (10-15 years of age) 
 
Dear Patient, 
We would like to ask you to take part in a study at the University of Exeter. Please read this 
sheet very carefully before you decide to take part or not. 
What is the study about? 
 The study will help us find out how your leg muscles respond during exercise to help us 
understand why you may become more tired during exercise than somebody who does 
not have a chest disease.  
 
 
What will happen? 
 
 You will visit the university in Exeter 3 times to carry out some leg exercise  
 During the exercise tests you will be within a scanner (you may have seen one of these 
before if you have ever has an MRI scan) 
 You will not feel anything when in the scanner, but it may be a bit noisy.  
 You will be given clear instructions about everything 
 The first visit will be to make sure you understand what we need you to do and that you 
are happy with exercising in the scanner 
 The people who will be testing you will be different to your usual direct care team at the 
hospital, but they are trained in exercise testing like this and regularly exercise test 
young people.  
 
Are the exercise tests safe? 
 
 The exercise tests are very safe.  
 Your doctor will also look at your health records before you exercise to check that it is 
safe for you to take part.  
 The research team will be watching you during all exercise tests just in case there are 
any problems. 
 Although the exercise is safe, it is exhausting and this means that it is likely that you 
will have tired heavy legs after exercising. This feeling may continue for 1-2 days.  
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What else will happen on each visit? 
 
Visit 1: 
 
 On your first visit to our exercise centre we will measure how tall you are and how 
much you weigh.  
 We will then measure the amount of fat on your arm, back and hip. We do this by very 
gently pinching the skin and using an instrument to measure the fold of skin. This does 
not hurt but may tickle.  
 You will then be shown the equipment we will use  
 Finally, you will practice lying inside a pretend scanner so that you can get used to this 
and then you will practice the exercise test a number of times 
 You will need to be at the exercise centre for about 2 hours for this 1st visit.  
 
 
Visits 2 and 3: 
 
 The next 2 times that you come to the exercise centre you will be doing the same 
exercise test you have practiced in a real scanner.  
 This scanner is not different however it may make some noise – you do not need to 
worry about this 
 Before you have to do any exercise you will be asked to rest  
 During the exercise test you will be doing leg exercise when we tell you and will be 
encouraged to keep going for as long as possible until your legs are so tired that you 
must stop 
 We will talk you through all of the details of what we will be asking you to do.  
 We will then give you a drink and you can rest before going home. 
 
After you have finished taking part in the study 
 
 We also need to know how developed your body is. To do this we will ask you to go 
look at yourself at home and answer a question about how far your body has 
developed. The question is an easy choice out of 5. We would also like you to wear a 
device like a watch for 1 week after you have finished your testing, to see how much 
exercise/play you usually do and how hard this is. You and your parent/guardian will 
also keep a record of what type of activities you are doing and when you take off the 
watch.   
 
What else will you have to do if you do decide to take part? 
 
1. For 2 – 3 days before each visit you must not do any really hard exercise (if possible).  
2. You can eat and drink as normal but do not drink or eat foods which contain caffeine 
such as tea, coffee, Coca-Cola for 3 hours before coming to see us. Speak to your 
parent or carer if you aren’t sure what caffeine is.  
3. You will also be asked if you would like to have your photograph taken during testing, 
for us to use when talking about the findings from this study in the future. This is 
completely up to you and you don’t have to say yes. If you do agree that you would like 
your photograph taken, your face will be covered so that nobody can see it. 
Do you have to take part? 
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 It is up to you if you take part.  
 If you take part you can drop out at any time and don’t have to give us a reason.  
 It is important that you understand that you will need to attend all 3 visits which will 
require some of your time.  
 
What should you do if you want to take part or have any questions? 
 
1. If you would like to take part you must have your parent/carer’s permission by getting 
them to complete their consent form.  
2. You must also complete a form which tells us you would like to take part and return it to 
a member of the research team.  
3. If you have any questions please get your parent or carer to get in touch with a 
member of the research team who are on the bottom of this page. 
 
 
Thank you for reading this letter. 
 
Details to Contact the Research Team: 
Primary contact: Mr Owen Tomlinson 
(Children’s Health & Exercise Research Centre, University of Exeter) 
Tel (work): (01392) 264721 
E-mail: o.w.tomlinson@exeter.ac.uk 
 
Miss Zoe Louise Saynor  
(Children’s Health & Exercise Research Centre, University of Exeter) 
Tel (work): (01392) 724759 
E-mail: z.l.saynor@exeter.ac.uk 
 
Dr. Jon Fulford 
(Exeter Medical School MRI Unit, University of Exeter) 
Email: j.fulford@exeter.ac.uk 
 
Dr. Alan Barker  
(Children’s Health & Exercise Research Centre, University of Exeter) 
Tel: (01392) 722766 
E-mail: a.r.barker@exeter.ac.uk 
 
Dr. Patrick J. Oades  
(Consultant Paediatrician, Royal Devon and Exeter Healthcare NHS Trust) 
Tel: (01392) 402665 
E-mail: patrick.oades@nhs.net 
 
Professor Craig. A. Williams  
(Children’s Health & Exercise Research Centre, University of Exeter) 
Tel: (01392) 724809 
E-mail: c.a.williams@exeter.ac.uk 
 
Miss Jamille Paschoal-Vicente 
(Children’s Health & Exercise Research Centre, University of Exeter) 
E-mail: jp446@exeter.ac.uk 
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Appendix H 
 
 
 
 
 
PATIENT (16-18 y) INFORMATION SHEET 
FOR 
 
THE EFFECTS OF CHRONIC CHEST DISEASE ON THE LEG MUSCLE RESPONSE 
DURING EXERCISE 
Version number: 4 
Date: 18/08/14 
 
1. Study Title 
 
Direct investigation of skeletal muscle metabolic, pH and blood oxygenation exercise response of 
young cystic fibrosis and non-cystic fibrosis patients.  
 
 
2. Invitation paragraph  
 
You are being invited to take part in a research study. Before you decide whether or not to be involved, 
it is important for you to understand why the research is being done and what it will involve. Please 
take time to read the following information carefully and discuss it with friends, relatives and your 
clinician/GP if you wish. Ask us if there is anything that is not clear or if you would like more 
information. Take time to decide whether or not you wish to take part. 
 
 
Thank you for reading this information sheet. 
 
3. What is the purpose of the study?  
 
It is recommended that children and teenagers with cystic fibrosis (CF) take part in sports and games 
to stay fit and healthy. Exercise not only helps improve fitness and enhances their quality of life 
through socialising with peers and friends, but it may also help them to cope better with aspects of 
their disease. We know that people with chronic chest diseases often have lower aerobic fitness than 
those who are healthy. However, we still need to find out more information about what causes this.  
 
This study will look at whether there are any differences between how your leg muscles respond 
during exercise compared with young people who don’t have chest disease. We are interested in 
whether there are differences in how much blood and oxygen is delivered to the muscles which need 
it and any differences in the size and response of your muscle itself to exercise tasks.   
 
Although the main aim of this study is to gather the above information, it will also provide you with 
useful information about how well you tolerate exercise. Additionally, we know that participating in 
CHILDREN’S HEALTH AND EXERCISE 
RESEARCH CENTRE 
 
Sport and Health Sciences 
St. Luke’s Campus 
Heavitree Road 
Exeter 
EX1 2LU 
 
Tel: +44 (0) 1392 264721 
Email: o.w.tomlinson@exeter.ac.uk 
Web: www.sshs.ex.ac.uk 
 
EX1 2LU 
 
Tel: +44 (0) 1392 264889 
Email: zls202@ex.ac.uk 
Web: www.sshs.ex.ac.uk 
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regular exercise is beneficial to your health and, as such, this research project will also serve as 3 
sessions of supervised leg exercise. 
4. Why have I been chosen? 
 
We are interested in young people with CF and non-CF bronchiectasis, aged between 10-18 years 
old, who have stable disease and regularly take part in physical activity.  
 
 
5. Do I have to take part? 
 
Taking part is entirely voluntary and it is up to you to decide whether or not you want to take part. If 
you do want to be involved, you will be given this information sheet to keep, and be asked to sign a 
consent form giving your permission (your parent/guardian will do the same). Even if you say yes, 
you will be free to withdraw from the study at any time and there is no need to give a reason. Any 
decision to withdraw at any time or a decision not to take part in the first place will not affect the 
standard clinical care you receive. 
 
 
6. What will happen to me if I do want to take part? 
 
The study will involve 4 trips to the St. Luke’s campus (University of Exeter), separated by at least 
48 h and ideally completed over a maximum 2 week period (to minimise the chance of any significant 
change in your health and/or fitness). All testing will take place at times which are suitable for you 
and your parent(s)/guardian(s) and this can be at weekends or after school if preferred. Visit 1 will 
take place in an exercise laboratory within Sport and Health Sciences, where you will be familiarised 
with a replica scanner (like an MRI scanner). Visits 2 and 3 will take place within the Exeter Medical 
School MRI Unit.  
 
 
Visit 1 – Baseline assessments and familiarisation session  
 
You and your parent(s)/guardian(s) will be given the opportunity to discuss any queries you may 
have, give your informed consent and be familiarised with the equipment and testing procedures that 
we will use during the next 3 testing visits.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. A child performing exercise testing inside the MR scanner. 
 
Participant 
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Baseline assessments: We will first obtain some information about your body composition. Your 
height, sitting height, and weight will be measured. We will then measure a number of ‘skin folds’ at 
the front and back of your arm, just below your shoulder blade and at the front of your hip. This is 
done by very gently pinching the skin and measuring the width of the fold of skin between the thumb 
and index finger. We will then measure your lung function at rest, this will involve you taking a big 
breath and breathing into a plastic tube – I am sure you have probably done this a number of times in 
clinic.  
 
Familiarisation session: We will then get you used to exercising within an MR scanner environment. 
We will use a pretend scanner for this. You will perform the identical tasks that you will be asked to 
do when you come back to the next real testing sessions. The exercise test involves you carrying out 
single-legged (right leg) exercise whilst lying on your front inside the scanner. Your right foot will 
be fastened to a Velcro strap, which is connected to a basket using a rope and pulley system (see 
figure 1). This system means that there will be some resistance when you move your leg up and down.  
 
Your first task will be to practice exercising at different intensities whilst keeping up with instructions 
you will be given. You will then complete at least 3 practice tests to exhaustion. We will separate 
these with rest periods. The test will then be changed slightly to one with more rest periods, which 
will be a modified test used during visits 3 and 4. These protocols will be exactly the same as what 
we will ask you to perform in the real scanner. How many practice tests you will need to do will 
depend on how long it takes you to be comfortable with what we need you to do. This will typically 
be at least 3 practice tests.  
 
You and your parent(s)/guardian(s) can ask any questions to the research staff at any time during the 
session.  
 
This session (visit 1) will usually last ~2 hours.  
 
Visits 2-4 – Exercise testing within the MR scanner 
 
During visits 2-4 you will carry out the same exercise test that you learnt during the familiarisation 
session, however we will be collecting various different measurements during these sessions using 
the scanner. However, this will not mean anything different to you and you will either be laying down 
resting or carrying out the same exercise test. Visits 2 and 3 will each usually last ~1 hour.  
Visit 2:  
Overview: At the start of visit 2, we will measure the size of your thigh muscles. Whilst we are 
measuring these things, you will simply need to relax and lie still within the scanner. As the scanner 
is a little noisy, you can wear headphones if you like. The exercise test itself will simply require you 
to move your leg (attached to the pulley system) up and down in time with the instructions for 24 
seconds and, following enough rest, you will then complete and incremental exercise test until you 
are too tired to continue. You will then perform the 24 second test again immediately. The amount of 
oxygen present in your blood (oxygen sats.) will also be monitored throughout all exercise via the 
fingertip and a box on your leg will be measuring oxygen in the blood in the leg muscles. The research 
team will always be keeping an eye on you to make sure that you are ok.  
 
Visits 3 and 4:  
Overview: At the start of visits 3 and 4, we will measure the size of your thigh at rest. This should 
not take as long as the previous visit. During these 2 visits you will not need to complete the 24 second 
exercise test with rest, you will just come in and complete an intermittent test until you are exhausted. 
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These visits will be shorter than visit 2. Again, the amount of oxygen present in your child’s blood 
(oxygen sats.) will also be monitored throughout all exercise via the fingertip and on the thigh. 
 
 
Post-testing 
Maturation: As well as your age, we also need to know how mature your body is (growth and 
development). To do this we will need you to self-assess something called your pubertal stage, by 
simply selecting from 5 options on a picture chart which shows different pictures of pubic hair through 
the stages of maturation. You will do this at home after your last visit with us and your parent/guardian 
will be asked to return the paperwork to us in a sealed envelope.  
 
Physical activity: We are also interested in getting an idea of how active you usually are. To measure 
this you will wear a small device (like a watch) on your wrist for 7 days, whilst also completing a 
simple diary about what physical activities you have been doing between waking up and going to 
bed. Your parent/guardian will also complete an on-off log in consultation with you to keep a record 
of when you are wearing the monitor.   
 
 
7. What else will I have to do? 
 
If you do choose to take part and you have permission from your parent(s)/guardian(s), we would 
need you to attend all 3 visits. We ask that you are rested when you arrive, more specifically that you 
have not performed any exhaustive exercise in the 2-3 days before you come (other than involvement 
in this study). Any specific questions regarding any exercise training or sport you may be doing prior 
to testing sessions can be discussed with the research team on an individual basis.  
 
Each time you come to the laboratory we also ask that you have had enough to eat and drink and that 
you wear the same or similar clothes for each exercise test (i.e., sports kit, usually shorts, t-shirt and 
trainers). We also ask that you don’t consume any caffeine 3 hours prior to each visit (ask your parents 
about this if you are not sure what contains caffeine). However, it is important that you do eat a light 
meal or snack before each visit (i.e. sandwich, cereal etc.). 
 
We will ask you and your parent(s)/guardian(s) if we can take photographs during your visits. The 
purpose of these photographs is to possibly be used within University of Exeter publicity materials, 
in Owen Tomlinson’s and Zoe Saynor’s PhD theses and in conference or teaching presentations, such 
as posters and PowerPoint presentation. This is completely voluntary and will in no way affect any 
subsequent involvement in the study if you and/or your parent(s)/guardian(s) do not want these to be 
taken. Permission to take any photographs will be obtained in writing before involvement in the study 
and if you say no then no photographs will be taken. Your face will not be identifiable from any 
photographs used in future presentation materials. 
 
 
8. What are the possible risks of me taking part? 
 
The exercise testing is very safe. An assessment of your health will be made before you start any 
exercise tests to see if it is safe for them to take part. During the exercise tests you will be carefully 
monitored and observed by members of the research team to make sure that you are safe. Due to the 
fact that the leg exercise in this study is exhaustive, you will experience tired heavy legs following 
exercise and this may continue for the next 24-48 hours. This study will also require a certain time 
commitment from you and your parent guardian, as you will need to attend 3 testing visits. 
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Measures will be taken to minimise the possible risk of cross-infection. Segregation of patients will 
be observed in testing places. In addition, both equipment and the testing environment will be 
thoroughly cleaned using appropriate bacteriocidal wipes and solutions between patients and at least 
2 hours will separate testing sessions during which time period the laboratory will be ventilated. N.B. 
It will be rare that 2 patients are tested within the same 12 hour period.  
 
9. What are the potential benefits of me taking part?  
 
This research is intended to help us understand why children with chronic chest disease may find 
exercise more difficult than healthy children and to help us inform interventions to improve fitness. 
Hopefully, you will also find involvement to be a positive and enjoyable experience. Sessions will 
also act as supervised leg exercise sessions for you, using hi-tech equipment. You will be given the 
results of your exercise tests and talked through them by a member of the research team. This will 
hopefully prove an interesting and constructive exercise, particularly if you are interested and/or 
involved in sport or exercise. 
 
 
10. What happens if I do not want to continue in the study? 
 
You are free to withdraw from the study at any point without giving a reason. Dropping out of the 
study will not affect your clinical care in any way or your relationship with the paediatric staff.  
 
If you do decide not to continue with the study then you will not be required to complete any 
additional exercise tests, or attend any additional visits to the centre that are associated with the 
research. Results from any tests that you have previously completed will still be available to you and 
your parent(s)/guardian(s). 
 
 
11. What if something goes wrong? 
 
If taking part in this study harms you, compensation arrangements are under the directive of the 
University of Exeter.  Your rights are the same as any person undergoing research, i.e. if you are 
harmed due to someone’s negligence, then you may have grounds for legal action, but you may have 
to pay for it.  If you or your parent(s)/guardian(s) wish to complain, or have any concerns about any 
aspect of the way you have been approached or treated during the course of this study, the normal 
University complaints procedures will be available to you. In any such case, complaints should be 
directed to Professor Craig Williams, Director of Research for Sport and Health Sciences, University 
of Exeter [+44 (0) 1392 724890; c.a.williams@exeter.ac.uk].  
 
 
12. Will my involvement in this study be kept confidential? 
 
We have a responsibility to inform you of how we will collect, store and use any of the information 
gathered about you during this study. The primary concern is that any information that we collect 
about you will be confidential. All information, such as your name, date of birth, contact details, 
details of health and test results will be transferred to a paper study file, which will be kept in a secure 
room in a locked filing cabinet. Members of the research team will be outside your direct standard 
care team and will have access to their data. However, your information will be kept anonymous by 
assigning you a unique study code and participant number. Only your date of birth will be used to 
identify the results. The results from the exercise tests are collected on paper and stored in a locked 
filing cabinet. The exercise results are then transferred from paper and stored on a computer. The 
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only personal information stored on computer will be your date of birth and participant number. Their 
exercise results will be password protected, as will the computer used to store the information. All 
the paper and computer files will be stored for 15 years, after this period paper files will be destroyed 
and computer files erased. Only the researchers directly involved in the study will have access to your 
medical records and exercise results. 
 
13. What will happen to the results of the study? 
 
Once the study is completed, which is targeted to be September 2014, the results will be analysed and 
interpreted and your parent(s)/guardian(s) will subsequently be sent a summary of our research 
findings. It is the intention to submit the results of the research to relevant journals for publication, 
and to inform our colleagues of the findings at scientific meetings. In publishing and talking about 
the study you will not be identifiable. Some of the data will also be used to form Miss Paschoal-
Vicente’s MSc degree dissertation.  
 
You and your parent(s)/guardian(s) will be given the opportunity to comment on the research protocol 
and testing procedure. This information will be collated and may inform future studies. Your 
parent(s)/guardian(s) will also receive the results and conclusions from the research and are free to 
request information regarding your individual data.  
 
14. Who is organising and funding the research? 
 
The study is a collaboration between the Paediatric Unit of the Royal Devon and Exeter (RD&E) 
NHS Foundation Trust Hospital, Children’s Health and Exercise Research Centre and Medical School 
(Dr. Jon Fulford) at the University of Exeter. The study is sponsored by the RD&E NHS Foundation 
Trust and has been supported financially by internal funding from the University of Exeter. A 
monetary contribution will be provided to go some way towards covering your travel expenses and/or 
parking costs, bus or rail fares when attending testing sessions.  
 
15. Who has reviewed the study? 
 
The scientific content of the study has been reviewed by the Peninsula Research and Development 
Support Unit. All research within the National Health Service (NHS) is looked at by an independent 
group of people, called a Research Ethics Committee (REC). RECs safeguard the rights, safety, 
dignity and well-being of people participating in research in the NHS. They review applications for 
research and give an opinion about the proposed participant involvement and whether the research is 
ethical. The present study has been reviewed and given favourable opinion by the NRES Committee 
South West – Exeter.  
 
16. What should I do if I would like to take part? 
 
If you would like to take part in the study you must give your permission by completing the consent 
form and your parent/guardian must also complete their form. Your parent/guardian should then 
return the two forms to a member of the research team.  
 
 
17. What if I have a question? 
 
If you or your parent(s)/guardian(s) have any questions please do not hesitate to get in touch with a 
member of the research team using the details provided on page 7 and at the top of page 1. 
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18. Contact for further information 
 
If you need further information please contact the research time using the details presented on page 
7 and at the top of page 1.  
 
For more information regarding participation in research you can access the public information pack 
published by INVOLVE (a non-profit organization promoting public involvement in the NHS, public 
health and social care research). Visit their website www.involve.org.uk/ or obtain a paper copy by 
writing to: Involve, Royal London House, 22-25 Finsbury Square, London, EC2A 1DX.  
 
More specialised information regarding participation in clinical research is published by the UK 
Clinical Research Collaboration (UKCRC). For further information visit www.ukcrc.org or request a 
printed copy from: UKCRC, 20 Park Crescent, London, W1B 1AL.  
 
The Research Team 
Primary contact: Mr Owen Tomlinson 
(Children’s Health & Exercise Research Centre, University of Exeter) 
Tel (work): +44 (0)1392 264721 
E-mail: o.w.tomlinson@exeter.ac.uk  
 
Miss Zoe L. Saynor (Children’s Health & Exercise Research Centre, University of Exeter) 
Tel (work): +44 (0)1392 724759 
E-mail: z.l.saynor@exeter.ac.uk  
 
Dr. Jon Fulford (Exeter Medical School MRI Unit, University of Exeter) 
E-mail: j.fulford@exeter.ac.uk 
 
Dr. Alan Barker (Children’s Health & Exercise Research Centre, University of Exeter) 
Tel (work): +44 (0)1392 722766 
E-mail: a.r.barker@exeter.ac.uk  
 
Dr. Patrick Oades (Consultant Paediatrician, Royal Devon and Exeter Healthcare NHS Trust) 
Tel (work): +44 (0)1392 402665 
E-mail: patrick.oades@nhs.net 
 
Prof. Craig Williams (Children’s Health & Exercise Research Centre, University of Exeter) 
Tel (work): +44 (0)1392 724809 
E-mail: c.a.williams@exeter.ac.uk 
 
Miss Jamille Paschoal-Vicente 
(Children’s Health & Exercise Research Centre, University of Exeter) 
E-mail: jp446@exeter.ac.uk 
 
N.B. Contact outside of office hours should be made to Mr Owen Tomlinson.  
 
 
Thank you for considering taking part in this study. Please read this information carefully, before 
you sign the consent form. Please take this leaflet home for reference. 
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Appendix I 
 
 
 
 
 
PARENT(S)/GUARDIAN(S) INFORMATION SHEET 
FOR 
 
THE EFFECTS OF CHRONIC CHEST DISEASE ON THE LEG MUSCLE RESPONSE 
DURING EXERCISE 
Version number: 3 
Date: 18/08/14 
 
1. Study Title 
 
The effects of chronic chest disease on the leg muscle response during exercise.  
 
 
2. Invitation paragraph  
 
You are being invited to take part in a research study. Before you decide whether or not to be involved, 
it is important for you to understand why the research is being done and what it will involve. Please 
take time to read the following information carefully and discuss it with friends, relatives and your 
clinician/GP if you wish. Ask us if there is anything that is not clear or if you would like more 
information. Take time to decide whether or not you wish to take part. 
 
Thank you for reading this information sheet. 
 
3. What is the purpose of the study?  
 
It is recommended that children and teenagers with cystic fibrosis (CF) take part in sports and games 
to stay fit and healthy. Exercise not only helps improve fitness and enhances their quality of life 
through socialising with peers and friends, but it may also help them to cope better with aspects of 
their disease. We know that people with chronic chest diseases often have lower aerobic fitness than 
those who are healthy. However, we still need to find out more information about what causes this.  
 
This study will look at whether there are any differences between how your child’s leg muscles 
respond during exercise compared with young people who don’t have chest disease. We are interested 
in whether there are differences in how much blood and oxygen is delivered to the muscles which 
need it and any differences in the size and response of your child’s muscle itself to exercise tasks.   
 
Although the main aim of this study is to gather the above information, it will also provide your child 
with useful information about how well they tolerate exercise. Additionally, we know that 
participating in regular exercise is beneficial to their health and, as such, this research project will 
also serve as 3 sessions of supervised leg exercise. 
 
4. Why has my child been chosen? 
 
CHILDREN’S HEALTH AND EXERCISE 
RESEARCH CENTRE 
 
Sport and Health Sciences 
St. Luke’s Campus 
Heavitree Road 
Exeter 
EX1 2LU 
 
Tel: +44 (0) 1392 264721 
Email: o.w.tomlinson@exeter.ac.uk 
Web: www.sshs.ex.ac.uk 
 
EX1 2LU 
 
Tel: +44 (0) 1392 264889 
Email: zls202@ex.ac.uk 
Web: www.sshs.ex.ac.uk 
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We are interested in young people with CF and non-CF bronchiectasis, aged between 10-18 years 
old, who have stable disease and regularly take part in physical activity.  
 
5. Does my child have to take part? 
 
Taking part is entirely voluntary and it is up to you and your child to decide whether or not you want 
to take part. If you do want to be involved, you will be given this information sheet to keep, and be 
asked to sign a consent form giving your permission (your child will do the same). Even if you say 
yes, you will be free to withdraw your child from the study at any time and there is no need to give a 
reason. Any decision to withdraw at any time or a decision not to take part in the first place will not 
affect the standard clinical care your child receives in any way. 
 
6. What will happen to my child if they do want to take part? 
 
The study will involve 4 trips to the St. Luke’s campus (University of Exeter), separated by at least 
48 h and ideally completed over a maximum 2 week period (to minimise the chance of any significant 
change in your child’s health and/or fitness). All testing will take place at times which are suitable 
for you and your child and this can be at weekends or after school if preferred. Visit 1 will take place 
in an exercise laboratory within Sport and Health Sciences, where you will be familiarised with a 
replica scanner (like an MRI scanner). Visits 2 and 3 will take place within the Exeter Medical School 
MRI Unit.  
 
 
Visit 1 – Baseline assessments and familiarisation session  
 
You and your child will be given the opportunity to discuss any queries you may have, give your 
informed consent/assent (depending on their age) and be familiarised with the equipment and testing 
procedures that we will use during the next 3 testing visits.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. A child performing exercise testing inside the MR scanner. 
 
Baseline assessments: We will first obtain some information regarding your child’s body 
composition. Their height, sitting height, and weight will be measured. They will also have their skin 
folds measured at the front and back of their arm, just below their shoulder blade and at the front of 
their hip. This is done by very gently pinching the skin and measuring the width of the fold of skin 
between the thumb and index finger. They will then have their resting lung function measured. This 
will involve your child taking a big breath and breathing into a plastic tube and is no different to the 
lung function tests they routinely perform in clinics.  
Participant 
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Familiarisation session: Your child will then be familiarised with exercising within an MR scanner 
environment, using a purpose build replica of the real machine. They will perform the identical task 
that they will undergo during the next 2 sessions. Exercise testing involves them performing single-
legged (right leg), leg exercise whilst lying on their front inside the scanner. Their right foot will be 
fastened to a Velcro rest, which is connected to the ergometer load basket via a rope and pulley system 
(see Figure 1). This system means that there will be some resistance when your child moves their leg 
up and down. They will do this in time with some instructions.  
 
Your child’s first task will be to practice exercising at different intensities at the required speed. They 
will then complete at least 3 practice tests to exhaustion, separated with sufficient rest. This protocol 
will be exactly the same as the one they will perform in the real MR scanner during visit 2. The test 
will then be changed slightly to one with more rest periods, which will be a modified test used during 
visits 3 and 4. The amount of familiarisation required will depend on how fast your child becomes 
used to the exercise test and is happy, but will typically be at least 3 trials.  
 
The aim of this first session is to make sure that 1) your child is happy exercising within the scanner 
environment, 2) your child can competently complete the testing under our instruction and, 3) to 
provide you and your child with an opportunity to ask any questions to the research staff regarding 
the requirements of the next exercise testing sessions.  
 
This session (visit 1) will typically last ~2 hours.  
 
 
Visits 2-4 – Exercise testing within the MR scanner 
 
During visits 2-4 your child will perform the same exercise tests they learnt during the familiarisation 
session, however we will be collecting measurements this time. Visits 2 and 3 will each typically last 
~1 hour.  
Visit 2:  
Overview: At the start of visit 2, we will obtain baseline measurements relating to the size of your 
child’s thigh muscles. Whilst we are measuring these things, your child will simply need to relax and 
lie still within the scanner. As the scanner is a little noisy, they can wear headphones if they like. The 
exercise test itself will simply require your child to move their leg (attached to the pulley system) up 
and down in time with the instructions for 24 seconds and, following enough rest, they will do this 
undergo the incremental test practiced during familiarisation until they are too tired to continue. Your 
child will not feel anything when we take the measurements in their legs. The amount of oxygen 
present in your child’s blood (oxygen sats.) will also be monitored throughout all exercise via the 
fingertip as will muscle oxygenation via near-infrared spectroscopy.  
 
Visits 3 and 4:  
Overview: At the start of visits 3 and 4, we will obtain baseline measurements relating your child’s 
thigh muscles at rest. This should not take as long as during visit 2. During these visits your child will 
not need to perform the 24 second exercise with rest, they will simply complete an intermittent test 
to exhaustion. These visits will therefore be shorter than visit 2. Again, the amount of oxygen present 
in your child’s blood (oxygen sats.) will also be monitored throughout all exercise via the fingertip 
and on the thigh.  
 
Post-testing 
 
 
Page 385 of 403 
 
We also need to know your child’s maturation (growth and development). This will require them to 
self-assess their pubertal stage by selecting from 5 options on a chart which shows different pictures 
of pubic hair through the stages of maturation. Self-assessment will take place at home and you will 
be asked to return the scale in a sealed envelope you will be provided with. We are also interested in 
assessing how physically active your child is during a typical week, if you and they agree to do so. 
This will be assessed by wearing a small wrist-mounted plastic box (like a watch) for 7 days, whilst 
completing a brief diary of the physical activities they perform from the time they wake up to the 
time they go to bed. The monitor would be removed if they swim or take a bath/shower and when in 
bed. You will also complete an on-off log in consultation with your child to log the wear time of the 
monitor.   
 
7. What else will my child have to do? 
 
If your child wishes to take part in the study and he/she has your permission we would like them to 
attend all 3 visits at the exercise laboratory. We ask that they be in a rested state on arrival, and have 
performed no exhaustive exercise in the 2-3 days prior to visits (other than involvement in this study). 
Any specific questions regarding any exercise training or sport your child may be doing prior to 
testing sessions can be discussed with the research team prior to any involvement in this research 
study.  
 
On each visit to the laboratory we also ask that your child has had sufficient food and drink before 
he/she arrives, and that they wear the same or similar clothes for each exercise test (that is sports kit, 
usually shorts, t-shirt and trainers). We also ask that they don’t consume any caffeine 3 hours prior 
to each visit (ask a member of the research team if you are unsure at all what they can and cannot 
have). However, it is important that they do eat a light meal or snack before each visit (i.e. sandwich, 
cereal etc.). 
 
We may ask your child if we can take photographs during their exercise tests. The purpose of these 
photographs is to possibly be used within University of Exeter publicity materials, in Miss Saynor’s 
and Mr Tomlinson’s PhD theses and in conference or teaching presentations, such as posters and 
PowerPoint presentation. This is entirely voluntary and will in no way affect any subsequent 
involvement in the study if you and/or your child should decline. Permission to take any photographs 
will be obtained in writing prior to involvement in the study. Your child’s face will not be identifiable 
from any photographs used in future presentation materials. 
 
8. What are the possible risks of my child taking part? 
 
The exercise testing is very safe. An assessment of your child’s health will be made before they start 
the exercise tests to see if it is safe for them to take part. During the exercise tests your child will be 
carefully monitored and observed to ensure their safety and well-being. Due to the fact that the leg 
exercise in this study is exhaustive, your child will experience tired heavy legs following exercise 
and this may continue for the next 24-48 hours. This study will also require a certain time commitment 
from you and your child, as they will need to attend 3 testing visits. 
 
Measures will be taken to minimise the possible risk of cross-infection. Segregation of patients will 
be observed in testing places. In addition, both equipment and the testing environment will be 
thoroughly cleaned using appropriate bacteriocidal wipes and solutions between patients and at least 
2 hours will separate testing sessions during which time period the laboratory will be ventilated. N.B. 
It will be rare that 2 patients are tested within the same 12 hour period.  
 
9. What are the potential benefits of my child taking part?  
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This research is intended to enhance our understanding of how children with chronic chest disease 
tolerate exercise and, more specifically, why they may find it more tiring that their healthy 
counterparts.  
 
Hopefully, your child will take away a positive and enjoyable experience from their involvement in 
the exercise testing and research study as a whole. They will be tested on equipment that is used to 
monitor the fitness of both sports people and patient groups, and they will get to see how fit they 
currently are and what intensity of leg exercise they can tolerate. Sessions will also act as supervised 
leg exercise sessions for your child. They will be given the results of their exercise tests and talked 
through them by a member of the research team. This will hopefully prove an interesting and 
constructive exercise, particularly if they have a strong interest or involvement in sport and may wish 
to increase the amount of physical activity in which they participate.  
 
10. What happens if my child does not want to continue in the study? 
 
Your child is free to withdraw from the study at any point without giving a reason. Dropping out of 
the study will not affect their clinical care in any way or your relationship with the paediatric staff.  
 
If your child does decide not to continue with the study then they will not be required to complete 
any additional exercise tests, or attend any additional visits to the centre that are associated with the 
research. Results from any tests that they have previously completed will still be available to 
them/you. 
 
11. What if something goes wrong? 
 
If taking part in this study harms your child, compensation arrangements are under the directive of 
the University of Exeter.  Your rights are the same as any person undergoing research, i.e. if your 
child is harmed due to someone’s negligence, then you may have grounds for legal action, but you 
may have to pay for it.  If you wish to complain, or have any concerns about any aspect of the way 
you have been approached or treated during the course of this study, the normal University complaints 
procedures will be available to you. In any such case, complaints should be directed to Professor 
Craig Williams, Director of Research for Sport and Health Sciences, University of Exeter [+44 (0) 
1392 724890; c.a.williams@exeter.ac.uk].  
 
12. Will my child’s involvement in this study be kept confidential? 
 
We have a responsibility to inform you of how we will collect, store and use your child’s information 
gathered during this study. The primary concern is that any information that we collect about your 
child will be confidential. All information collected, such as their name, date of birth, contact details, 
details of their health and test results will be transferred to a paper study file, which will be kept in a 
secure room in a locked filing cabinet. Members of the research team will be outside your child’s 
direct standard care team and will have access to their data. However, your child’s exercise results 
will be kept anonymous by assigning them a unique study code and participant number. Only your 
child’s date of birth will be used to identify the results. The results from the exercise tests are collected 
on paper and stored in a locked filing cabinet. The exercise results are then transferred from paper 
and stored on a computer. The only personal information stored on computer will be your child’s date 
of birth and participant number. Their exercise results will be password protected, as will the 
computer used to store the information. All the paper and computer files will be stored for 15 years, 
after this period paper files will be destroyed and computer files erased. Only the researchers directly 
involved in the study will have access to your child’s medical records and exercise results. 
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13. What will happen to the results of the study? 
 
Once the study is completed, which is targeted to be September 2014, the results will be analysed and 
interpreted and you will subsequently be sent a summary of our research findings. It is the intention 
to submit the results of the research to relevant journals for publication, and to inform our colleagues 
of the findings at scientific meetings. In publishing and talking about the study your child will not be 
identifiable. Some of the data will also be used to form Miss Paschoal-Vicente’s MSc degree 
dissertation.  
 
You and your child will be given the opportunity to comment on the research protocol and testing 
procedure. This information will be collated and may inform future studies. You and your child will 
also receive the results and conclusions from the research and are free to request information 
regarding your child’s individual data.  
 
14. Who is organising and funding the research? 
 
The study is a collaboration between the Paediatric Unit of the Royal Devon and Exeter (RD&E) 
NHS Foundation Trust Hospital, Children’s Health and Exercise Research Centre and Medical School 
(Dr. Jon Fulford) at the University of Exeter. The study is sponsored by the RD&E NHS Foundation 
Trust and has been supported financially by internal funding from the University of Exeter. A 
monetary contribution will be provided to go some way towards covering your travel expenses and/or 
parking costs, bus or rail fares when attending testing sessions.  
 
 
15. Who has reviewed the study? 
 
The scientific content of the study has been reviewed by the Peninsula Research and Development 
Support Unit. All research within the National Health Service (NHS) is looked at by an independent 
group of people, called a Research Ethics Committee (REC). RECs safeguard the rights, safety, 
dignity and well-being of people participating in research in the NHS. They review applications for 
research and give an opinion about the proposed participant involvement and whether the research is 
ethical. The present study has been reviewed and given favourable opinion by the NRES Committee 
South West – Exeter. 
 
 
16. What should I do if my child would like to take part? 
 
If your child would like to take part in the study you must give your permission by completing the 
consent form and your child must also complete their assent (<16 y) / consent (16-18 y) form 
(depending on their age). You should then return the two forms to a member of the research team.  
 
17. What if my child or I have a question? 
 
If you or your child have any questions please do not hesitate to get in touch with a member of the 
research team using the details provided on page 7 and at the top of page 1. 
18. Contact for further information 
 
If you need further information please contact the research time using the details presented on page 
7 and at the top of page 1. For more information regarding participation in research you can access 
the public information pack published by INVOLVE (a non-profit organization promoting public 
 
 
Page 388 of 403 
 
involvement in the NHS, public health and social care research). Visit their website 
www.involve.org.uk/ or obtain a paper copy by writing to: Involve, Royal London House, 22-25 
Finsbury Square, London, EC2A 1DX.  
 
More specialised information regarding participation in clinical research is published by the UK 
Clinical Research Collaboration (UKCRC). For further information visit www.ukcrc.org or request a 
printed copy from: UKCRC, 20 Park Crescent, London, W1B 1AL.  
 
The Research Team 
Primary contact:  
Mr Owen W Tomlinson (Children’s Health & Exercise Research Centre, University of Exeter) 
Tel (work): +44 (0)1392 264721 
E-mail: o.w.tomlinson@exeter.ac.uk  
 
Miss Zoe L. Saynor (Children’s Health & Exercise Research Centre, University of Exeter) 
Tel (work): +44 (0)1392 724759 
E-mail: z.l.saynor@exeter.ac.uk 
 
Dr. Jon Fulford (Exeter Medical School MRI Unit, University of Exeter) 
E-mail: j.fulford@exeter.ac.uk 
 
Dr. Alan Barker (Children’s Health & Exercise Research Centre, University of Exeter) 
Tel (work): +44 (0)1392 722766 
E-mail: a.r.barker@exeter.ac.uk  
 
Dr. Patrick Oades (Consultant Paediatrician, Royal Devon and Exeter Healthcare NHS Trust) 
Tel (work): +44 (0)1392 402665 
E-mail: patrick.oades@nhs.net 
 
Prof. Craig Williams (Children’s Health & Exercise Research Centre, University of Exeter) 
Tel (work): +44 (0)1392 724809 
E-mail: c.a.williams@exeter.ac.uk 
 
Miss Jamille Paschoal-Vicente 
(Children’s Health & Exercise Research Centre, University of Exeter) 
E-mail: jp446@exeter.ac.uk 
 
N.B. Contact outside of office hours should be made to Mr Owen Tomlinson.  
 
 
 
 
 
 
 
 
 
Thank you for considering taking part in this study. Please read this information carefully, before 
you sign the consent form. Please take this leaflet home for reference. 
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Appendix J 
 
 
 
 
Study Number: 14/SW/0061 
Patient Identification Number for this trial: 
 
 
ASSENT FORM FOR PATIENTS (10-15 y) 
(To be completed by the patient and their parent/guardian) 
The effects of chronic chest disease on the leg muscle response to exercise 
Child (or if unable, parent on their behalf) /young person to circle all they agree with please: 
Have you read (or had read to you) about this project [Version 3 dated 26/06/14]     Yes/No 
Has somebody else explained this project to you?         Yes/No 
Do you understand what this project is about?                Yes/No 
Have you asked all the questions you want?       Yes/No 
Have you had your questions answered in a way you understand? Yes/No 
Do you understand that you will be working with people different to your usual care team at the hospital? 
                                                                                                          Yes/No 
Do you understand that people different to your usual care team at the hospital will have access to parts of 
your medical notes to get information needed for the study and give permission for this to happen? 
                                                                                                          Yes/No 
Do you understand that people from your usual care team at the hospital and people in the study team will 
have access to your study data and give permission for this to happen? 
                                                                                                          Yes/No 
 
 
Page 390 of 403 
 
Do you understand it’s OK to stop taking part at any time?  Yes/No 
Are you happy to take part?                                    Yes/No 
If any answers are ‘no’ or you don’t want to take part, don’t sign your name! 
 
If you do want to take part, please write your name and today’s date  
 
 Your name       ___________________________ 
   
 Date              ___________________________ 
 
Your parent or guardian must write their name here too if they are happy for you to do the project 
 
 Print Name  ___________________________ 
 
 Sign               ___________________________ 
 
 Date              ___________________________ 
 
The person from the research team who explained this project to you needs to sign too: 
 
Print Name    ___________________________ 
 
Sign               ___________________________ 
 
Date              ___________________________ 
 
Thank you for your help. 
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Appendix K 
 
 
 
 
Study Number: 14/SW/0061 
Patient Identification Number for this trial: 
PATIENT (16-18 y) CONSENT FORM 
Title of Project: The effects of chronic chest disease on the leg muscle response during 
exercise 
Name of Researchers: Miss Zoe L. Saynor, Dr. Jon Fulford, Dr. Alan R. Barker, Dr. Patrick J. 
Oades, Miss Jamille Paschoal-Vicente and Prof. Craig A. Williams 
 Please initial box 
1 I have read and understand the information sheet [Version 3 dated 26/06/14] for the above 
study and have had the opportunity to ask questions. 
 
2 I understand that taking part is voluntary and I am free to withdraw at any time, without giving 
any reason and without my medical care or legal rights being affected. 
 
3 I understand that sections of my medical records may be looked at by the researchers (who 
are outside my usual direct clinical care team at the hospital) in the study where it is relevant 
to my participation, and that this information will be kept secure. 
 
4 I understand that during the period of my participation that hard exercise is to be avoided but 
that I should eat and drink normally. 
 
5 
 
 
6 
I am aware that my exercise results will be kept anonymous by giving them a unique study 
code and participant number, only my date of birth will be used to identify the results. I give 
consent for my medical records and exercise results to be used as indicated in the patient (16-
18 y) information sheet [Version 3 dated 26/06/14]. I understand that my exercise results will 
be stored for 15 years after which they will be destroyed. 
I understand that relevant sections of my medical notes and data collected during the study 
may be looked at by individuals from regulatory authorities or from the NHS Trust where it is 
relevant to my taking part in this research. I give permission for these individuals to have 
access to my child’s records and data. 
 
7 I give my consent to take part in the above study.  
____________________  ______________  ____________________ 
Name of participant    Date     Signature 
_____________________  ______________  ____________________ 
Name of parent/guardian   Date    Signature  
_____________________  ______________  ____________________ 
Researcher     Date     Signature 
CHILDREN’S HEALTH AND EXERCISE 
RESEARCH CENTRE 
 
Sport and Health Sciences 
St. Luke’s Campus 
Heavitree Road 
Exeter 
EX1 2LU 
 
Tel: +44 (0) 1392 264889 
Email: z.l.saynor@exeter.ac.uk 
Web: www.sshs.ex.ac.uk 
 
EX1 2LU 
 
Tel: +44 (0) 1392 264889 
Email: zls202@ex.ac.uk 
Web: www.sshs.ex.ac.uk 
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Appendix L 
 
 
 
Study Number: 14/SW/0061 
Patient Identification Number for this trial: 
PARENT/GUARDIAN CONSENT FORM 
Title of Project: The effects of chronic chest disease on the leg muscle response during 
exercise  
Name of Researchers: Miss Zoe L. Saynor, Dr. Jon Fulford, Dr. Alan. R. Barker, Dr. Patrick J. 
Oades, Miss Jamille Paschoal-Vicente and Prof. Craig A. Williams 
 Please initial box 
1 I have read and understand the information sheet [Version 3 dated 26/06/14] for the above 
study and have had the opportunity to ask questions. 
 
2 I understand that my child’s taking part is voluntary and they are free to withdraw at any time, 
without giving any reason and without his/her medical care or legal rights being affected. 
 
3 I understand that sections of any of my child’s medical records may be looked at by the 
researchers (who are outside their usual direct clinical care team at the hospital) in the study 
where it is relevant to his/her participation, and that this information will be kept secure. 
 
4 I understand that during the period of his/her participation that hard exercise is to be avoided 
but that he/she should eat and drink normally. 
 
5 
 
 
 
6 
 
I am aware that my child’s exercise results will be kept anonymous by giving them a unique 
study code and participant number, only my child’s date of birth will be used to identify the 
results. I give consent for his/her medical records and exercise results to be used as indicated 
in the parent/guardian information sheet [Version 3 dated 26/06/14]. I understand that my 
child’s exercise results will be stored for 15 years after which they will be destroyed. 
I understand that relevant sections of my medical notes and data collected during the study 
may be looked at by individuals from regulatory authorities or from the NHS Trust where it is 
relevant to my taking part in this research. I give permission for these individuals to have 
access to my child’s records and data. 
 
7 I give my consent for my child to take part in the above study.  
____________________  ______________  ____________________ 
Name of participant    Date     Signature 
_____________________  ______________  ____________________ 
Name of parent/guardian   Date    Signature  
_____________________  ______________  ____________________ 
Researcher     Date     Signature
CHILDREN’S HEALTH AND EXERCISE 
RESEARCH CENTRE 
 
Sport and Health Sciences 
St. Luke’s Campus 
Heavitree Road 
Exeter 
EX1 2LU 
 
Tel: +44 (0) 1392 264889 
Email: z.l.saynor@exeter.ac.uk 
Web: www.sshs.ex.ac.uk 
 
EX1 2LU 
 
Tel: +44 (0) 1392 264889 
Email: zls202@ex.ac. k 
Web: www.sshs.ex.ac.uk 
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Appendix M 
 
MATURATION ASSESSMENT  
PROCEDURES (MALES) – PARENT/GUARDIAN 
 
The assessment of physiological and physical change during growth is essential for the valid 
interpretation of human performance.  
 
 
Pubertal maturity will be self-assessed at home following completion of the exercise 
testing protocol. 
 
Drawings of male and female pubic hair developed by Morris and Udry (1980) made from 
photographs by Tanner (1975) will be used. A written description of each of the 5 stages 
of male and female pubic hair development will be given on the chart as how to select the 
correct pubertal stage.  
 
The most practical approach to assess maturation was developed by Tanner (1962). Tanner 
developed a 5-point scale to assess ‘biological maturity’ through observation of secondary 
sexual characteristics. The scales depicted five or more stages of breast and pubic hair (girls), 
pubic hair and genitalia development (boys). A limitation is that trained health professionals 
such as paediatricians and school nurses are typically employed to assess the scales. 
Subsequently Morris and Udry (1980) developed a self-assessment scale based on Tanner 
stages and found that children were able to accurately assess their own stage of maturation with 
correlation coefficients in the range of 60-70% (Matsudo & Matsudo, 1993).  
 
The secondary sex characteristics described by Tanner (1962) will be used to assess 
pubertal maturity. Pubertal stage 1 will be identified as pre-pubertal, stages 2, 3 and 4 
circum-pubertal, and stage 5 post-pubertal.  
 
(Please find these below and circle the drawing which you feel best represents you) 
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Appendix N 
 
 
MATURATION ASSESSMENT  PROCEDURES (FEMALES) – 
PARENT/GUARDIAN 
 
The assessment of physiological and physical change during growth is essential for the valid 
interpretation of human performance.  
 
 
Pubertal maturity will be self-assessed at home following completion of the exercise 
testing protocol. 
 
Drawings of male and female pubic hair developed by Morris and Udry (1980) made from 
photographs by Tanner (1975) will be used. A written description of each of the 5 stages 
of male and female pubic hair development will be given on the chart as how to select the 
correct pubertal stage.  
 
The most practical approach to assess maturation was developed by Tanner (1962). Tanner 
developed a 5-point scale to assess ‘biological maturity’ through observation of secondary 
sexual characteristics. The scales depicted five or more stages of breast and pubic hair (girls), 
pubic hair and genitalia development (boys). A limitation is that trained health professionals 
such as paediatricians and school nurses are typically employed to assess the scales. 
Subsequently Morris and Udry (1980) developed a self-assessment scale based on Tanner 
stages and found that children were able to accurately assess their own stage of maturation with 
correlation coefficients in the range of 60-70% (Matsudo & Matsudo, 1993).  
 
The secondary sex characteristics described by Tanner (1962) will be used to assess 
pubertal maturity. Pubertal stage 1 will be identified as pre-pubertal, stages 2, 3 and 4 
circum-pubertal, and stage 5 post-pubertal.  
 
(Please find these below and circle the drawing which you feel best represents you) 
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Appendix O 
Activity Log Book 
DAY 1: 
Time Activity 
06:00 – 07:00  
07:00 – 08:00 
 
 
08:00 – 09:00 
 
 
09:00 – 10:00 
 
 
10:00 – 11:00 
 
 
11:00 – 12:00  
 
 
12:00 – 13:00  
 
 
13:00 – 14:00  
 
 
14:00 – 15:00 
 
 
15:00 – 16:00 
 
 
16:00 – 17:00  
 
 
17:00 – 18:00 
 
 
18:00 – 19:00 
 
 
19:00 – 20:00  
 
 
20:00 – 21:00 
 
 
21:00 – 22:00  
22:00 – 23:00  
23:00 – 00:00  
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Appendix P 
Physical Activity Assessment – Parent/Guardian On-Off Log 
Dear Parent,  
Your child is currently wearing a physical activity monitor. Please ensure that monitors are removed prior to swimming, 
bathing, showering and before bedtime. Could you please make a note of the time your child puts the monitor on each morning and the time it 
is taken off at night. It would also be helpful if any times the monitor is removed during the day could be recorded. Thank you.  
Day Time put on in morning Time taken off at night Times removed during the day 
Day 1 
 
   
Day 2 
 
   
Day 3 
 
   
Day 4 
 
   
Day 5 
 
   
Day 6 
 
   
Day 7 
 
   
Please return the monitor in the envelope provided following the 7-day assessment.  
PLEASE ENSURE THE MONITOR IS RETURNED ON: ASAP FOLLOWING 7-DAY ASSESSMENT 
Thank you 
Owen Tomlinson 
01392 264721 
o.w.tomlinson@exeter.ac.uk
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Appendix R 
 
 
0 Nothing at all 
0.5 Very, very slight (just 
noticeable) 
1 Very slight 
2 Slight (light) 
3 Moderate 
4 Somewhat severe 
5 Severe (heavy) 
6  
7 Very severe 
8  
9  
10 Very, very severe (almost 
maximum) 
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Appendix T 
 
